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A B S T R A C T
Background
Decision aids are interventions that support patients by making their decisions explicit, providing information about options and
associated benefits/harms, and helping clarify congruence between decisions and personal values.
Objectives
To assess the effects of decision aids in people facing treatment or screening decisions.
Search methods
Updated search (2012 to April 2015) in CENTRAL; MEDLINE; Embase; PsycINFO; and grey literature; includes CINAHL to
September 2008.
Selection criteria
We included published randomized controlled trials comparing decision aids to usual care and/or alternative interventions. For this
update, we excluded studies comparing detailed versus simple decision aids.
Data collection and analysis
Two reviewers independently screened citations for inclusion, extracted data, and assessed risk of bias. Primary outcomes, based on the
International Patient Decision Aid Standards (IPDAS), were attributes related to the choice made and the decision-making process.
Secondary outcomes were behavioural, health, and health system effects.
We pooled results using mean differences (MDs) and risk ratios (RRs), applying a random-effects model. We conducted a subgroup
analysis of studies that used the patient decision aid to prepare for the consultation and of those that used it in the consultation. We
used GRADE to assess the strength of the evidence.
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Main results
We included 105 studies involving 31,043 participants. This update added 18 studies and removed 28 previously included studies
comparing detailed versus simple decision aids. During the ’Risk of bias’ assessment, we rated two items (selective reporting and blinding
of participants/personnel) as mostly unclear due to inadequate reporting. Twelve of 105 studies were at high risk of bias.
With regard to the attributes of the choice made, decision aids increased participants’ knowledge (MD 13.27/100; 95% confidence
interval (CI) 11.32 to 15.23; 52 studies; N = 13,316; high-quality evidence), accuracy of risk perceptions (RR 2.10; 95% CI 1.66 to
2.66; 17 studies; N = 5096; moderate-quality evidence), and congruency between informed values and care choices (RR 2.06; 95% CI
1.46 to 2.91; 10 studies; N = 4626; low-quality evidence) compared to usual care.
Regarding attributes related to the decision-making process and compared to usual care, decision aids decreased decisional conflict
related to feeling uninformed (MD −9.28/100; 95% CI −12.20 to −6.36; 27 studies; N = 5707; high-quality evidence), indecision
about personal values (MD −8.81/100; 95% CI −11.99 to −5.63; 23 studies; N = 5068; high-quality evidence), and the proportion
of people who were passive in decision making (RR 0.68; 95% CI 0.55 to 0.83; 16 studies; N = 3180; moderate-quality evidence).
Decision aids reduced the proportion of undecided participants and appeared to have a positive effect on patient-clinician communi-
cation. Moreover, those exposed to a decision aid were either equally or more satisfied with their decision, the decision-making process,
and/or the preparation for decision making compared to usual care.
Decision aids also reduced the number of people choosing major elective invasive surgery in favour of more conservative options (RR
0.86; 95% CI 0.75 to 1.00; 18 studies; N = 3844), but this reduction reached statistical significance only after removing the study on
prophylactic mastectomy for breast cancer gene carriers (RR 0.84; 95% CI 0.73 to 0.97; 17 studies; N = 3108). Compared to usual
care, decision aids reduced the number of people choosing prostate-specific antigen screening (RR 0.88; 95% CI 0.80 to 0.98; 10
studies; N = 3996) and increased those choosing to start new medications for diabetes (RR 1.65; 95% CI 1.06 to 2.56; 4 studies; N =
447). For other testing and screening choices, mostly there were no differences between decision aids and usual care.
The median effect of decision aids on length of consultation was 2.6 minutes longer (24 versus 21; 7.5% increase). The costs of the
decision aid group were lower in two studies and similar to usual care in four studies. People receiving decision aids do not appear to
differ from those receiving usual care in terms of anxiety, general health outcomes, and condition-specific health outcomes. Studies did
not report adverse events associated with the use of decision aids.
In subgroup analysis, we compared results for decision aids used in preparation for the consultation versus during the consultation,
finding similar improvements in pooled analysis for knowledge and accurate risk perception. For other outcomes, we could not conduct
formal subgroup analyses because there were too few studies in each subgroup.
Authors’ conclusions
Compared to usual care across a wide variety of decision contexts, people exposed to decision aids feel more knowledgeable, better
informed, and clearer about their values, and they probably have amore active role in decisionmaking andmore accurate risk perceptions.
There is growing evidence that decision aids may improve values-congruent choices. There are no adverse effects on health outcomes
or satisfaction. New for this updated is evidence indicating improved knowledge and accurate risk perceptions when decision aids are
used either within or in preparation for the consultation. Further research is needed on the effects on adherence with the chosen option,
cost-effectiveness, and use with lower literacy populations.
P L A I N L A N G U A G E S U M M A R Y
Decision aids to help people who are facing health treatment or screening decisions
Review question
We reviewed the effects of decision aids on people facing health treatment or screening decisions. In this update, we added 18 new
studies for a total of 105.
Background
Making a decision about the best treatment or screening option can be hard. People can use decision aids when there is more than
one option and neither is clearly better, or when options have benefits and harms that people value differently. Decision aids may be
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pamphlets, videos, or web-based tools. They state the decision, describe the options, and help people think about the options from a
personal view (e.g. how important are possible benefits and harms).
Study characteristics
For research published up to April 2015, there were 105 studies involving 31,043 people. The decision aids focused on 50 different
decisions. The common decisions were about: surgery, screening (e.g. prostate cancer, colon cancer, prenatal), genetic testing, and
medication treatments (e.g. diabetes, atrial fibrillation).The decision aids were compared to usual care that may have included general
information or no intervention. In the 105 studies, 89 evaluated a patient decision aid used by people in preparation for the visit with
the clinician, and 16 evaluated its use during the visit with the clinician.
Key results with quality of the evidence
When people use decision aids, they improve their knowledge of the options (high-quality evidence) and feel better informed and more
clear about what matters most to them (high-quality evidence). They probably have more accurate expectations of benefits and harms
of options (moderate-quality evidence) and probably participate more in decision making (moderate-quality evidence). People who
use decision aids may achieve decisions that are consistent with their informed values (evidence is not as strong; more research could
change results). People and their clinicians were more likely to talk about the decision when using a decision aid. Decision aids have
a variable effect on the option chosen, depending on the choice being considered. Decision aids do not worsen health outcomes, and
people using them are not less satisfied. More research is needed to assess if people continue with the option they chose and also to
assess what impact decision aids have on healthcare systems.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Patient decision aids compared with usual care for adults considering treatment or screening decisions
Patient or population: adults considering treatment or screening decisions
Settings: all sett ings
Intervention: pat ient decision aid
Comparison: usual care
Outcomes Illustrative comparative benefits* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed benefit Corresponding benefit
Usual care Patient decision aid
Knowledge - all studies
Standardized on score
f rom 0 (no knowledge)
to 100 (perfect knowl-
edge), soon af ter expo-
sure to the decision aid
The mean knowl-
edge score was 56.9%
across control groups,
ranging f rom 27.0% to
85.2%
The mean knowledge
score in the interven-
t ion groups was 13.27
higher (11.32 to 15.23
higher)
- 13,316
(52 studies)
⊕⊕⊕⊕
Higha,b
Higher scores indi-
cate better knowledge.
46 out of 52 stud-
ies showed a stat is-
t ically signif icant im-
provement in knowl-
edge
Accurate risk percep-
tions - all studies
Assessed soon af ter
exposure to the deci-
sion aid
269 per 1000c 565 per 1000 (447 to
716 per 1000)
RR 2.10 (1.66 to 2.66) 5096
(17 studies)
⊕⊕⊕©
M oderatea,d
-
Congruence between
the chosen option and
informed values - all
studies
Assessed soon af ter
exposure to the deci-
sion aid
289 per 1000c 595 per 1000 (422 to
841 per 1000)
RR 2.06 (1.46 to 2.91) 4626
(10 studies)
⊕⊕©©
Lowa,d,e,f
-
4
D
e
c
isio
n
a
id
s
fo
r
p
e
o
p
le
fa
c
in
g
h
e
a
lth
tre
a
tm
e
n
t
o
r
sc
re
e
n
in
g
d
e
c
isio
n
s
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Decisional conflict: un-
informed subscale - all
studies
Standardized on score
f rom 0 (not unin-
formed) to 100 (un-
informed) Assessed
soon af ter exposure to
the decision aid
The mean for out-
come ’feeling unin-
formed’ ranged across
control groups f rom 11.
1 to 61.1
Scores≤ 25 associated
with following through
on decisions.
Scores > 38 associated
with delay in decision
making
The mean feeling un-
informed in the inter-
vent ion groups was 9.
28 lower (12.20 to 6.36
lower)
- 5707
(27 studies)
⊕⊕⊕⊕
Higha,b
Lower scores indicate
feeling more informed
Decisional conflict: un-
clear about personal
values subscale - all
studies
Standardized on score
f rom 0 (not unclear) to
100 (unclear)
Assessed soon af ter
exposure to the deci-
sion aid
The mean for outcome
’feeling unclear about
personal values’ ranged
across control groups
f rom 15.5 to 53.2
Scores ≤ 25 as-
sociated with follow-
through with decisions.
Scores > 38 associated
with delay in decision
making
The mean feeling un-
clear values in the inter-
vent ion groups was 8.
81 lower (11.99 to 5.63
lower)
- 5068
(23 studies)
⊕⊕⊕⊕
Higha,b
Lower scores indicate
feeling clearer about
values
Participation in de-
cision making: clin-
ician-controlled deci-
sion making - all stud-
ies
Assessed soon af ter
consultat ion with clini-
cian
228 per 1000c 155 per 1000 (125 to
189 per 1000)
RR 0.68 (0.55 to 0.83) 3180
(16 studies)
⊕⊕⊕©
M oderatea,e
Patient decision aids
aim to increase pat ient
involvement in making
decisions; lower pro-
port ion of clinician-con-
trolled decision making
is better
Adverse events There were no adverse ef fects on health outcomes or sat isfact ion, and no other adverse ef fects reported
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
aThe vast majority of studies measuring this outcome were not at high risk of bias.
bThe GRADE rat ings for these outcomes were not downgraded for heterogeneity given the generally consistent direct ion of
ef fects across studies for the decision aid compared to usual care groups.
cThe data source for the assumed risk was the mean control event rate.
dThe GRADE rat ing was downgraded given the lack of precision.
eThe GRADE rat ing was downgraded given the lack of consistency.
f The GRADE rat ing was downgraded given the lack of directness. As well, the outcome was measured using various
approaches with no gold standard approach.
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B A C K G R O U N D
Many health treatment and screening decisions have no single
’best’ choice. These types of decisions are considered ’preference-
sensitive’ because there is insufficient evidence about outcomes or
there is a need to trade off known benefits and harms. Clinical
Evidence analyzed 3000 treatments, classifying 50% as having in-
sufficient evidence, 24% as likely to be beneficial, 7% as requiring
trade-offs between benefits and harms, 5% as unlikely to be ben-
eficial, 3% as likely to be ineffective or harmful, and only 11% as
being clearly beneficial (Clinical Evidence 2013). Not only does
one have to take into account the strength of the evidence, but
even for the 11%of treatments that showbeneficial effects for pop-
ulations, physicians need to translate the probabilistic nature of
the evidence for individual patients to help them reach a decision
based on informed values. Patient decision aids are an intervention
that can be used to present such evidence (Brouwers 2010). This
review is an update of the review last published in 2014 of the
comparisons between patient decision aids and usual care (Stacey
2014b). To provide a more focused review, we removed 28 studies
that compared detailed versus simple decision aids.
Description of the intervention
According to the International Patient Decision Aids Standards
(IPDAS) Collaboration (Elwyn 2006; IPDAS 2005a; Joseph-
Williams 2013), decision aids are evidence-based tools designed to
help patients make specific and deliberated choices among health-
care options. Patient decision aids supplement (rather than re-
place) clinicians’ counselling about options. The specific aims of
decision aids and the type of decision support they provide may
vary slightly, but in general they:
1. explicitly state the decision that needs to be considered;
2. provide evidence-based information about a health
condition, the options, associated benefits, harms, probabilities,
and scientific uncertainties;
3. help patients to recognize the values-sensitive nature of the
decision and to clarify, either implicitly or explicitly, the value
they place on the benefits and harms. (To accomplish this,
patient decision aids may describe the options in enough detail
that clients can imagine what it is like to experience the physical,
emotional, and social effects, or they may guide clients to
consider which benefits and harms are most important to them.)
Decision aids differ from usual health education materials. Deci-
sion aids make the decision being considered explicit, providing
a detailed, specific, and personalized focus on options and out-
comes for the purpose of preparing people for decision making.
In contrast, health education materials help people to understand
their diagnosis, treatment, and management in general terms, but
given their broader perspective, these materials are not focused on
decision points and thus do not necessarily help them to partici-
pate in decision making. Many decision aids are based on a con-
ceptual model or theoretical framework (Durand 2008; Mulley
1995; O’Connor 1998b; Rothert 1987).
In response to concerns about variability in the quality of patient
decision aids, the IPDAS Collaboration reached agreement on cri-
teria for judging their quality (Elwyn 2006). More than 100 re-
searchers, clinicians, patients, and policymakers from 14 coun-
tries participated. Participants addressed three domains of quality:
clinical content, development process, and evaluation of a patient
decision aid’s effectiveness. A series of background papers inform-
ing the original IPDAS criteria were updated in 2013 (IPDAS
2013). Subsequently, an international team of researchers reached
consensus on a shorter set of qualifying and certifying criteria
(Joseph-Williams 2013). Informed by IPDAS, the Washington
State Health Authority launched the first programme for certify-
ing patient decision aids in 2016 (Washington State 2016).
How the intervention might work
Decision aids can be used before, during, or after a clinical en-
counter to enable patients to become active, informed partici-
pants. Providing the patient decision aid in preparation for the
consultation allows people more time to digest the information
and be ready to discuss the decision, but this may not be feasi-
ble in some health decisions (e.g. antibiotics for upper respiratory
infections). Decision aids can also facilitate shared decision mak-
ing. Shared decision making is defined as a process through which
clinicians and patients make healthcare choices together (Charles
1997;Makoul 2006), representing the crux of people-centred care
(Weston 2001). However, the way the clinician provides infor-
mation may strongly affect people’s preferences (Hibbard 1997),
prompting the need for standardized information such as patient
decision aids. Patients who are more active in making decisions
about their health have better health outcomes and healthcare ex-
periences (Hibbard 2013; Kiesler 2006). In summary, patient de-
cision aids may help clinicians and patients come to quality de-
cisions, grounded in patients’ values and taking into account the
potential trade-offs in benefits and risks of different options.
Why it is important to do this review
Given the broad range of stakeholders interested in patient deci-
sion aids and the rapidly expanding field of research, there was a
need to update this review to identify studies on new decisions
or conducted in new countries and to strengthen the synthesized
evidence supporting use of patient decision aids for outcomes that
do not yet have high-quality evidence. In fact, the 2014 publica-
tion was the most cited Cochrane Review in 2015 based on 1888
reviews published in 2013 and 2014. With growing development
of patient decision aids for use in the consultation, we wanted
to conduct a subgroup analysis of patient decision aids used in
preparation for versus within the consultation.
7Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Results from previous reviews were used to inform clinical practice
guidelines such as Patient Experience in Adult NHS Services (
NCGC/NICE2012) andDecisionSupport forAdults Livingwith
Chronic Kidney Disease (RNAO 2009). Subgroup analyses of
included studies have focused on anxiety (Bekker 2003), adherence
(Trenaman 2016), values congruence (Munro 2016), participant
trial identity (Brown 2015), and heterogeneity (Gentles 2013).
Other systematic reviews have been conducted on the use of pa-
tient decision aids as one type of intervention to facilitate shared
decision making in clinical practice (Coyne 2013; Duncan 2010;
Elwyn 2013; Legare 2010; Legare 2014).
O B J E C T I V E S
To assess the effects of decision aids in people facing treatment or
screening decisions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all published studies that used a randomized con-
trolled trial (RCT) design evaluating patient decision aids.
Types of participants
We included studies involving adults aged 18 years or older who
were making decisions about screening or treatment options for
themselves, a child, or an incapacitated significant other. We ex-
cluded studies in which participants were making hypothetical
choices.
Types of interventions
We included studies that evaluated a patient decision aid as part
of the intervention. Decision aids were defined as interventions
designed to help people make specific and deliberated choices
among options (including the status quo), by making the deci-
sion explicit and by providing (at the minimum) information on
the options and outcomes relevant to a person’s health status as
well as implicit methods to clarify values. The aid also may have
included: information on the disease/condition; costs associated
with options; probabilities of outcomes tailored to personal health
risk factors; an explicit values clarification exercise; information
on others’ opinions; a personalized recommendation on the basis
of clinical characteristics and expressed preferences; and guidance
or coaching in the steps of making and communicating decisions
with others.
We excluded studies if interventions focused on: decisions about
lifestyle changes, clinical trial entry, or general advance directives
(e.g. do not resuscitate); education programmes not geared to a
specific decision; and interventions designed to promote adher-
ence or elicit informed consent regarding a recommended option.
We also excluded studies when the relevant decision aid(s) were not
available to us and not adequately described in the article(s), be-
cause we could not determine the aids’ characteristics and whether
or not theymet theminimum criteria to qualify as patient decision
aids.
Types of comparisons
We included studies that compared patients exposed to a patient
decision aid to patients in comparison groups that were exposed to
usual care, general information, clinical practice guideline, placebo
intervention, or no intervention. For the purposes of this review,
we refer to all such control comparisons as ’usual care’.
We excluded studies that compared two different types of patient
decision aids.
Types of outcome measures
To ascertainwhether the decision aids achieved their objectives, we
examined a broad range of outcomes. Although the decision aids
focused on diverse clinical decisions, many had similar objectives
such as improving knowledge scores, the accuracy of risk percep-
tions, and participation in decision making. Many of these eval-
uation criteria mapped onto the International Patient Decision
Aids Standards (IPDAS) criteria for evaluating the effectiveness of
decision aids (Elwyn 2006; IPDAS 2005b; Sepucha 2013). The
IPDAS criteria were attributes related to the choice (e.g. match
between the chosen option and the features thatmattermost to the
informed patient) and to the decision-making process (e.g. helps
patients to recognize that a decision needs to be made; know the
options and their features; understand that values affect the deci-
sion; be clear about the features that matter most; discuss values
with their clinician; and become involved in their preferred ways).
A complete list of outcomes, specified in advance of the review,
included primary and secondary outcomes.
Primary outcomes
Evaluation criteria that map onto the IPDAS criteria
• Attributes of the choice made: does the patient decision aid
improve the match between the chosen option and the features
that matter most to the informed patient (demonstrated by
outcomes such as knowledge, accurate risk perceptions, values-
choice congruence)?
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• Attributes of the decision-making process: does the patient
decision aid help patients to recognize that a decision needs to be
made, feel informed about the options and their features, be
clear about the option features that matter most, discuss values
with their clinician, and become involved in decision making?
Other decision-making process variables
• Decisional conflict
• Patient-clinician communication
• Participation in decision making
• Proportion undecided
• Satisfaction with the choice, with the process of decision
making, and with the preparation for decision making
Secondary outcomes
Behaviour
• Choice (the actual choice implemented; if not reported, the
participants’ preferred option was used as a surrogate measure)
• Adherence to chosen option
Health outcomes
• Health status and quality of life (generic and condition-
specific)
• Anxiety, depression, emotional distress, regret, confidence
Healthcare system
• Costs, cost-effectiveness
• Consultation length
• Litigation rates
Search methods for identification of studies
Our search strategy for the review included:
1. searching electronic medical and social science databases;
and
2. searching other resources.
Electronic searches
For this update, we used the same search strategy that was revised
by the Trials Search Coordinator at the Cochrane Consumers and
Communication Group in the last update (Stacey 2014b).
Therefore, the cumulative search of electronic databases is as fol-
lows.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2015, Issue 6) in the Cochrane Library (searched
to 24 April 2015).
• MEDLINE Ovid (1966 to 24 April 2015).
• Embase Ovid (1980 to 24 April 2015).
• PsycINFO Ovid (1806 to 24 April 2015).
• CINAHL Ovid (1982 to September 2008), then in Ebsco
(to 24 April 2015).
We present the search strategies in Appendix 1 and Appendix 2.
Searching other resources
On 18 December 2015 we also searched trial registries (World
Health Organization, ClinicalTrials.gov), the Internet using
Google and Google Scholar, and the Decision Aid Library Inven-
tory (decisionaid.ohri.ca). Finally, reference lists of all newly in-
cluded trials were searched.
Data collection and analysis
For this current update, we focused only on new publications
that had appeared since the previous publication (Stacey 2014b),
and we limited the inclusion to patient decision aids versus usual
care. As such, we removed studies from the previous reviews that
compared detailed versus simple patient decision aids to provide
a more focused review.
Selection of studies
Pairs of eight review authors (CB, DS, RT, MB, MHR, KE, NC,
DR) screened all identified citations. We retrieved the full text of
any papers identified as potentially relevant by at least one au-
thor, listing all papers excluded from the review at this stage, with
reasons, in the ’Characteristics of excluded studies’ table. We also
provided citation details and any available information about on-
going studies, and we collated and reported details of additional
publications, so that each study (rather than each report) was the
unit of interest. We report the screening and selection process in
Figure 1.
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Figure 1. Study flow diagram.
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Data extraction and management
Two research assistants extracted data independently (KL, IS). We
compared findings and resolved inconsistencies through discus-
sionwith the principal investigator (DS) and, when necessary, with
a co-author (CB). No review authors extracted data for their own
studies in this update nor in any other versions of this review.
One review author entered all extracted data into ReviewManager
5 (RevMan 5), and a second one worked independently to check
for accuracy against the data extraction sheets (RevMan 2014).
Assessment of risk of bias in included studies
Two research assistants independently appraised studies using the
Cochrane ’Risk of bias’ tool (current update: KL, IS) (Higgins
2011, Chapter 8). We judged each item as conferring high, low,
or unclear risk of bias as set out in the criteria provided by Higgins
2011, and we provided a quote from the study report and a justi-
fication for our judgement for each item in the ’Risk of bias’ table.
For the item on ’other’ potential sources of bias, the assessment in-
cluded: whether the same clinician provided consultation to both
the intervention and usual care groups with measures taken post-
consultation, whether clustering was accounted for in the analysis;
and potential sources of bias reported by the authors in the study
limitations.
We resolved inconsistencies by discussion with the principal in-
vestigator (DS) and, when necessary, with a co-author (CB). No
review authors appraised risk of bias for their own studies in this
update nor in any other versions of this review.
Studies were deemed to be at the highest risk of bias if they were
scored as at high risk on any of the items of the risk of bias tool
(Higgins 2011).
Measures of treatment effect
For dichotomous outcomes, we analyzed data based on the num-
ber of events and the number of people assessed in the interven-
tion and comparison groups. We will use these to calculate the
risk ratio (RR) and 95% confidence interval (CI). For continuous
measures, we analyzed data based on the mean, standard deviation
(SD) and number of people assessed for both the intervention and
comparison groups to calculate mean difference (MD) and 95%
CI.
First, we described study characteristics individually. The a pri-
ori comparison was usual care versus decision aids. For studies in
which there were more than one intervention group, we extracted
data from the groups that provided the strongest contrast between
the intervention and control groups.We pooled results across stud-
ies in cases where investigators used similar outcome measures and
the effects were expected to be independent of the type of deci-
sion studied. For example, we expected decision aids to improve
knowledge and create accurate percetions of options, benefits, and
harms; to reduce decisional conflict; and to enhance active partic-
ipation in decision making. Therefore, we pooled data from in-
cluded RCTs for these outcomes if trials used comparable mea-
sures. To facilitate pooling of data for some outcomes (e.g. knowl-
edge, decisional conflict), we standardized the scores to range from
0 to 100 points. When analysing the effects of decision aids on
choices, we pooled outcomes on more homogeneous subgroups
of decisions (choice of major surgery versus conservative options;
screening test or not, etc.).
Unit of analysis issues
We checked for unit-of-analysis errors. Where we found errors
and sufficient information was available, we re-analyzed the data
using the appropriate unit of analysis by taking account of the
intracluster correlation (ICC). We obtained estimates of the ICC
by contacting authors of included studies, or we imputed them us-
ing estimates from external sources. For two studies (Kupke 2013;
Lewis 2010), it was not possible to obtain sufficient information
to re-analyze the data, and we reported these studies as being at
high risk for ’other’ bias based on these unit-of-analysis errors. We
made no adjustments to the data based on these two studies that
were included in meta-analysis for knowledge only.
Dealing with missing data
We contacted authors to obtain missing data. Where possible, we
conducted analysis on an intention-to-treat basis; otherwise, we
analyzed data as reported. We reported on the levels of loss to
follow-up and assessed this as a source of potential bias.
Assessment of heterogeneity
For this update and in previous versions of the review, we grouped
studies together across populations and settings. The aim was to
enable an assessment of the effectiveness of decision aids across
conditions, rather than to focus on disease-specific contexts. Given
that decision aids are a well-defined and clearly delineated type of
intervention, we decided that this approach was defensible. On
the basis of grouping studies across populations and decision aid
elements, we anticipated that there would be a substantial degree
of heterogeneity in our pooled effect estimates. However, we de-
cided that we would consider the direction of effects and variabil-
ity in these rather than variability in the size of effects, as the ma-
jor basis for our interpretation of heterogeneity. This meant that
for those pooled effect estimates where the direction of effect was
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consistent across studies, we did not downgrade for inconsistency,
despite some variability in the size of effects across individual stud-
ies. We did downgrade for inconsistency for one outcome: con-
gruence between the chosen option and informed values. This was
because there is no accepted gold standard measure for assessing
this outcome, and we considered that variability in measurement
by the included studies added further uncertainty about the effects
of decision aids for this outcome.
Where heterogeneity was present in pooled effect estimates, we
explored possible reasons for variability by conducting subgroup
analysis in the 2009 update (O’Connor 2009b). The post hoc
analysis included the IPDAS effectiveness criteria to explore het-
erogeneity according to the following factors: the type of decision
(treatment versus screening), the type of media of the decision aid
(video/computer versus audio booklet/pamphlet), and the possi-
bility of a ceiling effect based on usual-care scores (resulting in the
removal of studies with lower scores for knowledge and accurate
risk perception and higher scores for decisional conflict using the
subscales measuring levels of informedness and clarity of values).
We analyzed the effect of removing the biggest outlier(s) (defined
by visual inspection of forest plots). Given that the post hoc analy-
sis did not alter the findings from the 2009 update, we did not re-
conduct the post hoc analysis for the IPDAS effectiveness criteria.
Assessment of reporting biases
We used funnel plots to assess publication bias.
Data synthesis
We used RevMan 5 software to estimate a weighted intervention
effect with 95% confidence intervals (RevMan 2014). For contin-
uous measures, we used mean differences (MD); for dichotomous
outcomes, we calculated pooled relative risks (RR).We analyzed all
data with a random-effects model because of the diverse nature of
the studies being combined and then anticipated variability in the
populations and interventions of the included studies. We sum-
marized all of the results for the primary outcomes and rated the
strength of evidence using GRADE (Andrews 2013), presenting
these in a ’Summary of findings’ table (Higgins 2011).
Subgroup analysis and investigation of heterogeneity
For this update, we conducted a subgroup analysis to compare
the effects of the intervention when used in preparation for the
consultation with the effects of those used during the consultation
to usual care.
Sensitivity analysis
We performed post hoc sensitivity analyses to examine the effect
of excluding studies of lower methodological quality. The analysis
excluded studies that were at high risk of bias for any of the cate-
gories in the ’Risk of bias’ assessment (Higgins 2011).
’Summary of findings’ table
We prepared a ’Summary of findings’ table to present the results
of meta-analysis, based on the methods described in Chapter 11
of the Cochrane Handbook for Systematic Reviews of Interventions
(Schünemann 2011). We presented the results of meta-analysis
for the major comparison of the review for each of the key out-
comes. We provided a source and rationale for each assumed risk
cited in the table and used the GRADE criteria to rank the quality
of the evidence for each outcome on each of the following do-
mains: risk of bias, inconsistency, imprecision, indirectness, and
publication bias. Two authors independently assessed the quality
of the evidence using the GRADEprofiler (GRADEpro) software
(GRADEpro GDT).
R E S U L T S
Description of studies
The current version of our reviewupdates our 2014 version, Stacey
2014b, with 18 new studies (Bozic 2013; Brazell 2014; Chabrera
2015; Fraenkel 2012; Knops 2014; Köpke 2014; Kuppermann
2014; Lam 2013; LeBlanc 2015; Legare 2012; Lepore 2012;
Mathers 2012; Mott 2014; Sawka 2012; Shourie 2013; Stacey
2014a; Taylor 2006;Williams 2013). For this update, we excluded
28 previously included studies due to the comparisons being lim-
ited to detailed versus simple patient decision aids (Deschamps
2004; Deyo 2000; Dodin 2001; Goel 2001; Green 2004; Hunter
2005; Kuppermann 2009; Labrecque 2010; Lalonde 2006; Legare
2003; Leung 2004; Myers 2005a; Myers 2011; O’Connor 1998a;
O’Connor 1999a; Raynes-Greenow 2010; Rostom 2002; Rothert
1997; Schapira 2000; Schapira 2007; Solberg 2010; Street 1995;
Tiller 2006; Van Roosmalen 2004; Volk 2008; Wakefield 2008a;
Wakefield 2008b; Wakefield 2008c).
Results of the search
In total, we identified 46,054 citations from the electronic database
searches and258 citations fromother sources.Of these, we assessed
504 citations for eligibility using the full text (see Figure 1).
Included studies
The remaining 151 citations provided data on 105 studies that
met our inclusion criteria, 18 of which are new for this update. The
105 RCTs, involving 31,043 participants, presented results from
10 countries: Australia (10 studies), Canada (15 studies), China (1
study), Finland (2 studies), Germany (6 studies), Netherlands (2
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studies), Spain (1 study), Sweden (1 study), the UK (16 studies),
the USA (50 studies), and Australia plus Canada (1 study). We
present study details below and in the Characteristics of included
studies table.
Unit of randomization
Ninety studies randomized individual patients, and 15 random-
ized clusters. For cluster trials, Allen 2010 randomized 12 com-
pany worksites; Fraenkel 2012, 2 groups of primary care physi-
cians; Hamann 2006, 12 inpatient psychiatric units; Kupke 2013,
49 dental students; Legare 2011, 4 family medicine group prac-
tices; Legare 2012, 12 family medicine group practices; Lewis
2010, 32 family medicine group practices; Loh 2007, 30 gen-
eral practitioners; Mathers 2012, 49 general medicine practices;
McAlister 2005, 102 primary care practices;Mullan 2009, 40 clin-
icians; Nagle 2008, 60 general practitioners; Shourie 2013, 50
general medicine practices; Weymiller 2007, 21 endocrinologists;
and Whelan 2004, 27 surgeons.
For 10 studies (Allen 2010; Legare 2011; Legare 2012; Loh
2007; Mathers 2012; Mullan 2009; Nagle 2008; Shourie 2013;
Weymiller 2007; Whelan 2004), the cluster effect was taken into
account in the published outcome data, and themeta-analysis used
published results. Although Hamann 2006 did not account for
the cluster effect in the published outcome data, the way this study
was reported did not allow us to include it in the meta-analysis,
so we did not re-analyze the data and report the study separately.
For McAlister 2005, meta-analysis was done applying the design
effect (based on the published intracluster correlation coefficient
(ICC)). For Fraenkel 2012, the authors stated that adding a ran-
dom effect for physician clusters did not contribute to better-fit-
ting regression models, and we removed it from the analysis. The
analysis by Kupke 2013 and Lewis 2010 did not account for clus-
tering.
Decision aids and comparisons
The 105 included studies evaluated decision aids that focused on
50 different decisions (Table 1). Themost common decisions were
about prostate cancer screening (14 studies), colon cancer screen-
ing (10 studies), medication for diabetes (4 studies), breast cancer
genetic testing (4 studies), prenatal screening (4 studies), medi-
cation for atrial fibrillation (4 studies), and surgery (mastectomy
for breast cancer, 4 studies; hysterectomy, 3 studies; prostate can-
cer treatment, 4 studies). New decision topics added in this up-
date included surgery for prolapsed pelvic organs (1 study) and
asymptomatic aortic abdominal aneurysm (1 study); restoration
for tooth decay (1 study); measles, mumps, and rubella vaccine
for infants (1 study); treatment of post-traumatic stress disorder
(1 study); and radioactive iodine treatment for thyroid cancer (1
study).
The decision aids used different formats and were compared to a
variety of control interventions (e.g. usual care, general informa-
tion, no intervention, guideline, placebo intervention). We noted
the nature of usual care when reported (see Characteristics of
included studies table). For this review, we have grouped control
interventions and refer to them as ’usual care’.
According to the definition of a patient decision aid, all of the
studies evaluated patient decision aids that included information
about the options and outcomes and provided at least implicit
clarification of values. Most patient decision aids included infor-
mation on the clinical problem (90.5%) as well as outcome proba-
bilities (89.5%). Fewer patient decision aids provided guidance in
the steps of decision making (65.7%), explicit methods to clarify
values (57.1%), and/or examples of others’ experiences (41.0%)
(see table Characteristics of included studies).
Excluded studies
We excluded 302 studies upon close perusal of the relevant papers
(see Characteristics of excluded studies). The reasons for exclusion
were: the study was not a randomized controlled trial; the deci-
sion was hypothetical, with participants not actually at a point of
decision making; the intervention was not focused on making a
choice; the intervention offered no decision support in the form
of a decision aid or did not provide enough information about
the decision aid; no comparison outcome data were provided; the
study did not evaluate the decision aid; the study was a protocol;
the decision aid was about clinical trial entry, lifestyle choice, or
advanced care planning; the study involved testing the presenta-
tion of the decision aid, but with no difference in the content of
the decision aid between study groups; or the study compared a
detailed versus simple decision aid.
We also identified 61 ongoing RCTs through trial registration
databases, personal contact, and published protocols in the elec-
tronic database searches (see references to Ongoing studies and
table Characteristics of ongoing studies).
Risk of bias in included studies
Details on the ratings and rationale for risk of bias are in the
Characteristics of included studies table and displayed in Figure 2
and Figure 3.
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Figure 2. Risk of bias summary as percentages across all included studies.
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Figure 3. Risk of bias summary for each included study.
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Allocation
When assessing risk of selection bias, we rated all 105 studies
as being at low or unclear risk of bias. Allocation concealment
methods prompted a rating of low or unclear risk of bias in 104
studies and high risk of bias in 1 study (Kupke 2013).
Blinding
We judged 102 studies to be at low or unclear risk of performance
and detection bias for the blinding of participants and personnel,
while 3 (2.9%) studies were at high risk of bias. High risk of
bias was due to lack of blinding of physicians to the status of
patients randomized to the patient decision aid and alternative
interventions (Auvinen 2004; Krist 2007; Man-Son-Hing 1999).
We rated the blinding of outcome assessment as leading to low or
unclear risk of bias in all 105 studies.
Incomplete outcome data
For 103 studies, aspects related to incomplete outcome data con-
ferred low or unclear risk of bias. In two (1.9%) studies (Chambers
2012;Mott 2014), there was high risk of bias due to high attrition
rates.
Selective reporting
We rated all 105 studies as being at either low risk of bias because
the protocol was registered publicly or at unclear risk of bias be-
cause we could not assess the extent or the impact of any reporting
bias.
Other potential sources of bias
Of 105 studies, we rated 98 as being at low or unclear risk of
other potential sources of bias. The other seven (6.7%) discussed
other potential risks of bias (Brazell 2014; Clancy 1988; Hamann
2006; Knops 2014; Kupke 2013; LeBlanc 2015; Lewis 2010).
We rated Brazell 2014 and LeBlanc 2015 as being at high risk
of bias given that the same physicians provided consultation to
both intervention and control groups, and measures were taken
after physician consultation. Clancy 1988 describes a potential
for selection bias because non-randomized medical residents were
added to the decision aid group, and there was a low response rate
among those offered decision aid.We ratedKnops 2014 as being at
high risk of bias given that a large number of potential participants
did not participate in the study. Hamann 2006, Kupke 2013, and
Lewis 2010 did not account for clustering in their analyses.
Effects of interventions
See: Summary of findings for the main comparison
In addition to Summary of findings for the main comparison,
see the Data and analyses figures for pooled data and Additional
tables for outcome data that we did not pool. This section presents
the attributes of the choice made, the attributes of the decision
process, and secondary outcomes.
Primary outcomes
Attributes of the choice made: does the patient decision aid
improve the match between the chosen option and the
features that matter most to the informed patient?
The randomized controlled trials used three measures that corre-
spond to this outcome: knowledge scores, accuracy of risk percep-
tions, and congruence between the chosen option and the patient’s
values.
Knowledge
Seventy-one of the 105 studies (67.6%) assessed the effects of de-
cision aids on knowledge. The studies’ knowledge tests were based
on information contained in the decision aid. The proportion of
accurate responses was transformed to a percentage scale ranging
from 0% (no correct responses) to 100% (fully correct responses).
There is high-quality evidence that patient decision aids weremore
effective than usual care (52 studies) on knowledge scores (MD
13.27, 95% CI 11.32 to 15.23; Analysis 1.1). In absolute terms
the group receiving usual care had, on average, 57 of 100 answers
correct. Those in the decision aid group scored better, with 70 of
100 answers correct on average (from 68 to 72 correct).
Nineteen additional studies presented knowledge scores that could
not be included in the pooled outcome (see Table 2).Most of these
other studies reported statistically-significantly higher knowledge
scores for those exposed to the decision aid compared to usual care.
The funnel plot for knowledge as an outcome in studies comparing
decision aid to usual care shows that these studies are at low risk
for publication bias (Figure 4).
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Figure 4. Funnel plot of comparison: 1 Knowledge, outcome: 1.1 Knowledge - all studies.
Accurate risk perceptions (i.e. perceived probabilities of
outcomes)
Of 105 studies, 25 (23.8%) examined the effects of patient de-
cision aids on the accuracy of patients’ perceived probabilities of
outcomes (see Analysis 2.1; Table 3). We classified the accuracy of
perceived outcome probabilities according to the percentage of in-
dividuals whose judgments corresponded to the scientific evidence
about the chances of an outcome for similar people. For studies
that elicited risk perceptions using multiple items, we averaged the
proportion of accurate risk perceptions.
There is moderate-quality evidence that patient decision aids were
more effective than usual care for transmitting accurate risk per-
ceptions (risk ratio (RR) 2.10, 95% CI 1.66 to 2.66, 17 studies;
Analysis 2.1). This means that for every 1000 people receiving
usual care, 269 were likely to accurately interpret risk, whereas far
more people (565 people per 1000; from 447 to 716) accurately
interpreted risk after using a decision aid.
Eight studies reported results that were not amenable to pooling
(see Table 3). Fraenkel 2012; Hanson 2011; Kuppermann 2014;
Mathieu 2010; and Smith 2010 reported a statistically significant
improvement in accurate perceptions of outcomes for the decision
aid group compared to usual care, andMiller 2005 reported no ef-
fect on risk perception. In another study,Weymiller 2007 reported
participants allocated to the decision aid had a significantly more
accurate perception of their estimated cardiovascular risk without
statin therapy compared to the usual care group; this effect was
greater when the clinician used the decision aid during the con-
sultation rather than when the researcher used the decision aid in
preparation for the consultation (Pinteraction= 0.03). For the final
study by Mann E 2010, three of eight knowledge test items mea-
sured accurate risk perceptions, but results were presented for total
knowledge and not individual items.The funnel plot for accurate
risk perception as an outcome in studies comparing decision aid
to usual care shows low risk for publication bias.
Congruence between chosen option and values
Of 105 studies, 16 (15.3%) measured congruence between the
chosen options and the patients’ values. Six measured values-
choice congruence without considering knowledge (Arterburn
2011; Berry 2013; Frosch 2008a; Legare 2008a; Lerman 1997;
Vandemheen 2009).Of 10 studies thatmeasured informed values-
choice congruence, eight used the Multi-Dimensional Measure
of Informed Choice (Bjorklund 2012; Fagerlin 2011; Mathieu
2007;Mathieu 2010; Nagle 2008; Smith 2010; Steckelberg 2011;
Trevena 2008), which assesses the extent to which the choice is
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based on relevant knowledge, is consistent with a person’s values/
attitudes, and is behaviourally implemented (Michie 2002). These
studies operationalized the measure in terms of knowledge scores
higher than the mid-point of the scale, attitude scale scores higher
than themid-point, and choice being congruentwith attitude.Two
other studies measured informed values-based choice: Schwalm
2012 assessed the extent to which the choice was based on knowl-
edge score ≥ 60% and a score for three values-importance ratings
that matched the choice; and Stacey 2014a assessed the extent to
which the choice was based on knowledge score ≥ 66% and mea-
sured values-choice congruence using a logistic regression model.
For the 10 studies that measured informed values-choice congru-
ence, two used preferred choice (Mathieu 2010; Trevena 2008),
and the other eight used actual choice.
There is low quality evidence that patient decision aids were more
effective than usual care for selecting an option that was congruent
with their informed values (RR 2.06, 95% CI 1.46 to 2.91, 10
studies; Analysis 3.1). Of the 10 studies, 8 individually showed
statistically higher congruence scores for the patient decision aid
compared to usual care, and 2 showed no difference (Bjorklund
2012; Mathieu 2010). Repeating this analysis using the studies
that measured actual choice and not preferred choice revealed a
pooled RR of 2.13 (95% CI 1.44 to 3.14; 8 studies). A sub-anal-
ysis of studies using the Multi-Dimensional Measure of Informed
Choice revealed a pooled RR of 2.08 (95% CI 1.40 to 3.08, 8
studies; Analysis 3.3).
There was no difference between patient decision aid and usual
care for the six studies that measured values-choice congruence
without considering knowledge scores (Arterburn 2011; Berry
2013; Frosch 2008a; Legare 2008a; Lerman 1997; Vandemheen
2009; see Table 4). We did not pool these studies because of how
they reported results. Arterburn 2011 reported that, compared to
the control group, those exposed to the decision aid experienced a
more rapid early improvement of value-choice concordance imme-
diately after exposure. Legare 2008a reported that women’s valu-
ing of the non-chemical aspect of natural health products was
positively associated with their choice of natural health products
in managing menopausal symptoms (P = 0.006). The other four
studies reported no differences between groups. However, Frosch
2008a observed that men exposed to the decision aid who chose
not to have a prostate-specific antigen (PSA) test rated their con-
cern about prostate cancer lower than men who requested a PSA
test, while men assigned to the usual care group provided similar
ratings of concern regardless of their PSA choice.
Attributes of the decision process: does the decision aid help
patients to recognize that a decision needs to be made,
know the options and their features, understand that values
affect the decision, be clear about the features that matter
most to them, discuss values with their clinician, and
become involved in their preferred ways?
In relation to the International Patient Decision Aids Standards
(IPDAS) decision process criteria, no studies evaluated the extent
towhich patient decision aids helped participants to recognize that
a decision needed to be made or understand that values affect the
decision. Some studies measured participants’ self-reports about
feeling informed and clear about personal values. The measures
used to evaluate these criteria were two subscales of the previously
validated Decisional Conflict Scale (DCS) (O’Connor 1995).
Decisional conflict
Of 105 studies, 63 (60.0%) evaluated decisional conflict using
the DCS (O’Connor 1995). The DCS is reliable, discriminates
between those who make or delay decisions, is sensitive to change,
and discriminates between different decision support interven-
tions (Morgan 2000; O’Connor 1995; O’Connor 1998b). The
scale measures the constructs of overall decisional conflict and the
particular factors contributing to uncertainty (e.g. feeling uncer-
tain, uninformed, unclear about values, and unsupported in de-
cision making). A final subscale measures perceived effective de-
cision making. The scores were standardized to range from 0 (no
decisional conflict) to 100 points (extreme decisional conflict).
Scores of 25 or lower are associated with follow-through with de-
cisions, whereas scores that exceed 38 are associated with delay
in decision making (O’Connor 1998b). When decision aids are
compared to usual care, a negative score indicates a reduction in
decisional conflict, favouring the decision aid.
Analysis 4.1.1 summarizes the decisional conflict results for the 42
studies that compared decision aids to usual care. We report on
21 studies that were not amenable to pooling in Table 5 (original
DCS), Table 6 (low literacy version), and Table 7 (SURE test
version).
Themean difference (MD) for total DCS scores was−7.22 points
out of 100, favouring the patient decision aid over usual care
groups (95% CI −9.12 to −5.31; see Analysis 4.1.1). Sixteen
studies that could not be pooled (Table 5) reported mixed results
on the original DCS. Of four studies that used the low literacy ver-
sion (Fraenkel 2012; Smith 2010; Taylor 2006; Williams 2013),
all reported statistically significant improvement (i.e. reduced) in
total (or subscale) decisional conflict scores in the decision aid
group, compared to usual care (Table 6). Stacey 2014a reported
no difference between groups using the SURE test version.
The ’feeling uninformed’ subscale of the DCS measures self-re-
ported comfort with knowledge, not actual knowledge.We elected
to consider this as a process measure and to reserve the gold stan-
dard of objective knowledge tests for assessing decision quality.
There was high-quality evidence that patient decision aids were
more effective than usual care in reducing patients’ ’feeling unin-
formed’ about options, benefits, and harms (MD−9.28, 95% CI
−12.20 to−6.36; 27 studies; Analysis 4.1.2). The funnel plot for
’feeling uninformed’ as an outcome in studies comparing decision
aid to usual care shows low risk for publication bias (Figure 5).
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Figure 5. Funnel plot of comparison: 4.1 Decisional conflict: DA vs usual care - all studies, outcome: 4.1.2
Uninformed subscale
There was high-quality evidence that patient decision aids were
more effective thanusual care for reducingpatients’ ’feeling unclear
about values’ subscale of the DCS (MD −8.81; 95% CI −11.99
to −5.63; 23 studies; Analysis 4.1.3). The funnel plot for using
’feeling unclear about values’ as an outcome in studies comparing
decision aid tousual care shows low risk for publicationbias (Figure
6).
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Figure 6. Funnel plot of comparison: 4.1 Decisional conflict: DA vs usual care - all studies, outcome: 4.1.3
Unclear subscale
Patient-clinician communication
Of 105 studies, 10 (9.5%) measured the effect of decision aids on
patient-clinician communication. Of these 10 studies, 5 evaluated
a patient decision aid used primarily within the consultation with
the clinician, and 5 evaluated a patient decision aid used in prepa-
ration for the consultation.
Five studies compared the effect of usual care versus a decision aid
used within the clinical encounter (or, inWeymiller 2007, half the
decision aid participants were exposed just prior to the encounter),
evaluating the extent of shared decision making communication
by analyzing the audio recordings using the OPTION scale (Hess
2012; LeBlanc 2015; Montori 2011; Mullan 2009; Weymiller
2007). The OPTION scale measures the extent to which health-
care providers use behaviours that involve patients in decision
making (Elwyn 2005). All five studies reported statistically higher
meanOPTION scores in the patient decision aid group compared
to usual care (see Table 8).
Four of five studies reported that compared to those in the usual
care group, significantly higher proportions of participants ex-
posed to the patient decision aid in preparation for the consulta-
tion reported that they discussed the decision with their clinician
(Fraenkel 2012; Hanson 2011; Lepore 2012; Sheridan 2011; see
Table 8). The fifth study showed no between-group difference in
discussion of cardiovascular disease with the clinician (Sheridan
2006; see Table 8).
Participation in decision making
Of 105 studies, 24 (22.9%) measured the effect of decision aids
on patients’ perceived participation in decision making (Analysis
5.1; Table 9). Davison 1997 used the Control Preferences Scale
(Degner 1992). This scale uses five response statements tomeasure
the role in decisionmaking: two represent an active or patient-con-
trolled role; one a shared or collaborative role; and two response
statements represent a passive or clinician-controlled role. Most
other studies used comparable response statements that could be
classified within each of the three groupings of the Control Pref-
erences Scale, except for Hamann 2006, which used the COM-
RADE instrument to measure patient perception of involvement,
and two others that used other measures of perceived involvement
(Hanson 2011; Loh 2007; see Table 9).
Using the groupings of the Control Preferences Scale, 16 of 24
studies reported on clinician-controlled decision making. Consis-
tent with the hypothesis that patient decision aids increase patient
participation in decision making, there was moderate-quality ev-
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idence that patient decision aids were more effective than usual
care for reducing clinician-controlled decision making (RR 0.68;
95% CI 0.55 to 0.83; Analysis 5.1.1). In this field, there is no
consensus on the hypothesized effects of decision aids onmeasures
of patient-controlled decision making or shared decision making.
Of 24 studies, 15 reported on participants assuming an active
(patient-controlled) role in decision making and were pooled for
analysis. Compared to usual care, decision aid use increased pa-
tient-controlled decision making (RR 1.28, 95% CI 1.05 to 1.55;
Analysis 5.1.2). The 15 studies that reported on a shared decision-
making role showed no difference between decision aid and usual
care (RR 0.95; 95% CI 0.83 to 1.10; Analysis 5.1.3).
Of eight studies that could not be pooled, Allen 2010, Leighl 2011,
Rubel 2010, and Van Peperstraten 2010 reported no between-
group differences in these roles (Table 9). Three studies reported
that a statistically significant proportion of patients exposed to
the decision aid either participated (Sheridan 2011) - or at least
felt involved - in decision making (Hamann 2006; Loh 2007).
However, Hamann 2006 did not analyze results accounting for
the use of design clusters. Hanson 2011 reported that a higher
proportion described feeling involved (83% vs. 77%), but the
difference between groups was not statistically significant.
Proportion undecided
Of 105 studies, 24 (22.9%) measured the proportion of partici-
pants remaining undecided: of these, 22 studies could be pooled.
A significantly lower proportion of people remained undecided
after exposure to a decision aid (RR 0.64; 95% CI 0.52 to 0.79;
Analysis 6.1).
Kasper 2008 measured progress in decision making using a single
item ranging from ’0 = completely undecided’ to ’100 = made my
decision’. Given the difference in the measure Kasper used, these
results were not included in the meta-analysis. In this study, both
the patients exposed to a decision aid and the usual care group
progressed in their decision making, with no difference between
the groups (Table 10). Sawka 2012 reported that 10.8% in the
patient decision aid group versus 21.6% in the usual care group
reported not knowing if they preferred taking adjuvant radioactive
iodine.
Satisfaction
Nineteen included studies (18.1%) measured satisfaction as it re-
lates to the choice and the preparation for and the process of deci-
sion making. When possible, we standardized the scores to a 0 to
100 point scale, with higher scores reflecting greater satisfaction.
Nineteen studies (18.1%) measured satisfaction with the choice.
Of these 19 studies, 4 reported that people exposed to the decision
aid had higher satisfaction with their choice compared to usual
care, and the other 15 reported no statistically significant differ-
ences (Chabrera 2015; Heller 2008; Laupacis 2006; Montgomery
2007; see Analysis 7.1 and Table 11). For results that used a sim-
ilar measure (Analysis 7.1), there was high satisfaction for all par-
ticipants, with a median score of 82.5% for the decision aid and
80.0% for the usual care groups.
Of 105 total studies, 11 (10.5%) measured satisfaction with the
decision, 11 (10.5%)measured satisfactionwith the decision-mak-
ing process (see Analysis 7.6; plusHess 2012 andVodermaier 2009
in Table 12), 4 measured satisfaction with information provided
(LeBlanc 2015; Laupacis 2006; Montori 2011; Oakley 2006), 3
measured satisfaction with the clinician (Laupacis 2006; Miller
2005; Vodermaier 2009), and 1 measured satisfaction with par-
ticipating in decision making (Kennedy 2002). There were mixed
results, but no studies reported that those exposed to patient de-
cision aids were significantly less satisfied compared to usual care.
For results that used a similar measure of satisfaction with the de-
cision-making process (Analysis 7.4), there was high satisfaction
for all participants, with median scores of 83.8% for the decision
aid and 77.8% for the usual care groups. Although there were no
differences between participant groups in satisfaction with the in-
formation in the Montori 2011, clinicians using the decision aid
had higher satisfaction.
Three studies (2.9%) measured satisfaction with preparation for
decision making using the Preparation for Decision Making Scale
(Bennett 2010) (Table 13). Compared to usual care, two stud-
ies reported significant improvements in people’s satisfaction with
their preparation for making decisions: in Fraenkel 2007 after us-
ing decision aids about management of knee osteoarthritis, and in
Vandemheen 2009 regarding referral to a lung transplant centre.
The third study found no statistically significant difference on this
subscale’s four items (Stacey 2014a).
Secondary outcomes
Behaviour
Choice
Choice was defined as the actual choice implemented. However,
when studies did not report the actual choice, we used the patients’
preferred option as a surrogate measure. Actual choices or prefer-
ences were reported as the percentage of individuals actually im-
plementing or stating a preference for the most intensive or most
invasive option.
In summary, patient decision aids decreased the number of pa-
tients choosing elective surgical procedures (excluding prophy-
lactic mastectomy) and PSA testing in multiple studies. Single
studies showed that decision aids increased the number of people
choosing hepatitis B vaccination, psycho-educational therapies for
mental health conditions, and medication for cardiovascular dis-
ease prevention. In contrast, decision aids decreased the rate of
cardiac stress testing, the number of embryos being transplanted,
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and the rate of antibiotic use for upper respiratory infections. The
effect on patients’ choice in other situations was more variable.
There were mixed results for the choice of colon cancer screening,
genetic testing, prenatal testing, anti-thrombosis therapy, breast
screening, and diabetes medications. There was no difference be-
tween groups for choices about natural health products, hyperten-
sion therapy, breast cancer chemotherapy, schizophraenia medi-
cation, immunotherapy for multiple sclerosis, vaccines (for flu or
measles, mumps, rubella), diabetes screening, birth control, osteo-
porosis treatment, chemotherapy for advanced cancer, chemopre-
ventive medications, use of blood transfusions, childbirth proce-
dures, treatment of prolapsed pelvic organs, or radioactive iodine
treatment for thyroid cancer.
Choice for major elective surgery
Eighteen studies (17.1%) focused on choices regarding major elec-
tive surgery (Analysis 8.1).
Using intention-to-treat analysis, there was a non-significant re-
duction in the number of patients choosing major elective surgery
in the group receiving the decision aid compared to usual care (RR
0.86; 95% CI 0.75 to 1.00, 18 studies; Analysis 8.1.2). Schwartz
2009a reported a statistically significant uptake of prophylactic
mastectomy for women who are BRCA1/2 gene carriers (114%).
And after removing this study from the pooled results, there was a
statistically significant reduction in the number of patients choos-
ing major elective surgery (RR 0.84 95% CI 0.73 to 0.97; 17
studies; Analysis 8.1.3).
Four other studies showed statistically significant reductions in
surgery rates: −29% for cardiac revascularization and bariatric
surgery (Arterburn 2011; Morgan 2000),−33% for orchiectomy
(Auvinen 2004), and−74% for mastectomy (Whelan 2004). The
other 15 studies showed no difference between the decision aid or
usual care groups.
Choice for other elective surgery
Two studies evaluated the effect of decision aids versus usual care
on other elective surgical decisions. Decision aids did not signifi-
cantly influence surgical abortion rates in Wong 2006 or feeding
tube insertions in Hanson 2011 (Table 14).
Choice for prostate-specific antigen screening
The effects of decision aids on prostate-specific antigen (PSA)
screening decisions were variable in 13 studies (12.4%) that com-
pared decision aids to usual care. The pooled RR for 10 studies
was 0.88 (95% CI 0.80 to 0.98; Analysis 8.2.1); Frosch 2008a,
Lepore 2012, and Williams 2013 could not be included in the
pooled data (Table 14). Frosch reported a reduction in screening
rates and the other two reported no difference.
Choice for colon cancer screening
Of 10 studies (9.5%) on colon cancer screening, 3 reported sta-
tistically significant differences in choices, and 7 showed no dif-
ference. Two studies reported that compared to usual care, the
decision aid significantly increased the screening rates by 64%
and 70% (Pignone 2000; Ruffin 2007). The other study reported
a statistically significant reduction of 21% for screening (Smith
2010). There was an increase in screening rates in five studies,
by 6% to 39%, but the difference was not statistically significant
(Lewis 2010; Miller 2011; Schroy 2011; Steckelberg 2011; Wolf
2000). In two studies (Dolan 2002; Trevena 2008), there was a
73% and 4% decrease in screening rates that was not statistically
significant. The pooled RR was 1.12 (95% CI 0.95 to 1.31, 10
studies; Analysis 8.2.2).
Choice for cancer genetic screening
Four studies reported preferences or uptake rates for breast cancer
genetic screening (3.8%). The decision aid did not significantly
affect preferences for breast cancer genetic screening when com-
pared to usual care. The pooled RR was 0.99 (95% CI 0.71 to
1.38, 3 studies; Analysis 8.2.3). One study reported an increase in
screening rates by 14% (Lerman 1997), a second study reported
an increase of 18% (Green 2001), and a third study reported a de-
crease of 29% (Schwartz 2001). Miller 2005 reported that women
exposed to the decision aid who were at higher risk of breast cancer
increased their intention to obtain genetic testing, while those at
average risk decreased their intention (Table 14).
Choice for breast screening
There were lower mammography screening rates among women
aged 38 to 45 years of age (Mathieu 2010), but no between-group
difference in women aged 70 or older who were exposed to a
decision aid versus usual care (Mathieu 2007; Table 14).
Choice for prenatal screening
In all four studies focusing on decisions around prenatal screening,
prenatal testing rates were not affected by a decision aid compared
to usual care (Bekker 2004; Bjorklund 2012; Kuppermann 2014;
Nagle 2008). Meta-analysis included two studies, showing no ef-
fect (RR 0.99, 95% CI 0.91 to 1.09, 2 studies; Bjorklund 2012;
Kuppermann 2014; Analysis 8.2.4).
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Choice for stress test for chest pain
Compared to usual care, adults presenting with chest pain in the
emergency department who received the decision aid had signifi-
cantly lower rates of stress testing (58% versus 77%) (Hess 2012;
Table 14).
Choice for screening for diabetes
Compared to usual care, there was no difference in diabetes screen-
ing rates in Marteau 2010 or preferences for screening in Mann E
2010 in adults exposed to a decision aid (Table 14).
Choice to take antibiotics for upper respiratory infection
Compared to usual care, using a decision aid in the consultation
decreased prescriptions for antibiotics for upper respiratory infec-
tions in Legare 2012, although this difference was not statistically
significant in Legare 2011 (Table 14).
Choice for atrial fibrillation treatment
Three studies evaluated the effect of a decision aid on the use
of anti-thrombotic therapy for atrial fibrillation versus usual care
(Table 14). One study demonstrated a non-significant reduction
in warfarin use of 25% (Man-Son-Hing 1999). The second study
evaluated the proportions of patients choosing the option that was
appropriate relative to their level of risk, and found no significant
difference between the groups (McAlister 2005). Thomson 2007
reported that patients in the usual care group (guided by practice
recommendations) were much more likely to start warfarin (15/
16; 93.8%) compared to the decision aid group (4/16; 25%; RR
0.27; 95% CI: 011 to 0.63).
Choice to take breast cancer prevention medication
There was no difference in medication use among women at risk
of breast cancer who were exposed to the decision aid versus usual
care (Fagerlin 2011; Table 14).
Choice for cardiovascular disease prevention
There was an increase in patient preferences for any effective car-
diovascular disease risk-reducing strategy (including medication)
when using a decision aid versus usual care (63% versus 42%)
(Sheridan 2011; Table 14).
Choice for chemotherapy for cancer
There was no statistically significant difference in the rates of che-
motherapy for adults with advanced colorectal cancer (77% ver-
sus 71%) (Leighl 2011; Table 14). Whelan 2003 also found no
significant effect on preferences for adjuvant chemotherapy versus
no chemotherapy for early stage breast cancer.
Choice for diabetes treatment with new medications
Four studies evaluated patient decision aids compared to usual care
on decisions about starting newmedications for diabetes (MannD
2010; Mathers 2012; Mullan 2009; Weymiller 2007). Although
there was no statistically significant difference between groups for
individual studies, pooled results indicated a significant increase in
starting newmedications (RR 1.65, 95%CI 1.06 to 2.56; Analysis
8.3).
Choice to take hypertension medication
Montgomery 2003 found no significant effect for decision aids
over usual care on the initiation of medication for hypertension
(Table 14).
Choice for menopausal symptom treatment
In a study comparing a decision aid to usual care (Murray 2001b),
there was a non-significant decrease of 8% in hormone therapy
(Table 14). Preferences for natural health products in women ex-
periencing menopausal symptoms were no different for women
exposed to the decision aid compared to women exposed to the
usual education materials (Legare 2008a).
Choice for multiple sclerosis immunotherapy
Kasper 2008 reported no difference in the uptake of immunother-
apy in people with multiple sclerosis who were exposed to a deci-
sion aid compared to usual care based on practice guidelines (Table
14).
Choice to take osteoporosis treatment
There was no difference in prescriptions for bisphosphonates for
osteoporosis treatment (LeBlanc 2015; Table 14). Montori 2011
found no significant effect of decision aids over usual care on the
uptake of medication for osteoporosis treatment.
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Mental health
Hamann 2006 found no difference in prescription rates for an-
tipsychotic medications but reported a statistically significant in-
crease in the uptake in psycho-education (P = 0.003) in people
with schizophraenia exposed to the decision aid compared to usual
care (Table 14). Mott 2014 reported that a higher proportion of
participants in the decision aid group with post-traumatic stress
disorder completed psychotherapy sessions (4 of 9) compared to
usual care (1 of 11).
Obstetrical choices
Childbirth procedures
Three studies focused on childbirth issues, using a decision aid
compared to usual care. There was no difference in preference for
vaginal birth in Shorten 2005 or actual vaginal mode of delivery
in Montgomery 2007 following a previous cesarean section. An-
other study found no difference in actual choice to undergo exter-
nal cephalic version for women with breech presentation (Nassar
2007).
Birth control approaches
There was no difference in the birth control methods chosen for
those in the decision aid versus usual care groups (Langston 2010).
Embryo transplantation
Compared to usual care, those in the decision aid group were
significantlymore likely to choose a single embryo transplant (43%
versus 32%) (Van Peperstraten 2010).
Vaccines
Compared to usual care, there was a non-significant increase in
intentions to get the flu vaccine in those exposed to the decision
aid (46% versus 27%) (Chambers 2012), a statistically significant
increase in uptake of hepatitis B vaccination with decision aids
(Clancy 1988), and no difference in uptake of measles, mumps,
rubella vaccine in infants (Shourie 2013).
Other choices
Blood transfusions
There was no difference in the uptake of preoperative autologous
blood donation when a decision aid was compared to usual care
(Laupacis 2006).
Lung transplant referral
There was no difference in referral rates for consideration of lung
transplant in people with advanced cystic fibrosis exposed to a
decision aid versus usual care (Vandemheen 2009).
Pelvic organ prolapse treatment
There was no difference in treatment rates for prolapsed pelvic
organs (Brazell 2014).
Thyroid cancer radioactive iodine treatment
There was no difference in the rates of adjuvant radioactive iodine
treatment for thyroid cancer (Sawka 2012).
Adherence (continuance/compliance) with chosen option
Of 105 studies, 16 (15.2%) measured adherence using various
approaches (Table 15).
Based on the measurement framework by Trenaman 2016, we
grouped adherence according to adherence to the baseline choice
and adherence to the treatment. Six studies measured only adher-
ence to the baseline choice (Langston 2010; Legare 2012; Lepore
2012; Man-Son-Hing 1999; Mathers 2012; Trevena 2008), 6
studies measured only adherence to treatment (Loh 2007; Mann
D 2010;Mott 2014;Mullan 2009; Oakley 2006; Sheridan 2011),
and 4 studies measured both (LeBlanc 2015; Montgomery 2003;
Montori 2011; Weymiller 2007).
For the 10 studies that measured adherence to choice, two studies
reported that patients exposed to decision aids had higher adher-
ence compared to usual care (Mathers 2012; Montori 2011), and
8 reported no difference between groups. For example, Mathers
2012 asked participants, 6 months after their decision, whether or
not they had changed their initial choice about starting insulin for
type II diabetes (decision aid 68.1% versus 56.3% usual care; P
= 0.041). Montori used pharmacy records to determine if partici-
pants who chose bisphosphonates actually took their medication
on more than 80% of the days for which it was prescribed (100%
decision aid versus 74% usual care; P = 0.009).
For the 10 studies that measured adherence to treatment, 2 studies
reported that patients exposed to decision aids had higher adher-
ence compared to usual care (Mott 2014; Sheridan 2011), 1 study
reported that patients exposed to decision aids had lower adher-
ence (Mullan 2009), and 7 reported no difference. Mott reported
the percentage of participants at four months who engaged in nine
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or more psychotherapy sessions (4 of 4 decision aid group partic-
ipants versus 1 of 5 usual care). Sheridan measured the percent-
age of participants who, 3 months after initiating therapy, were
continuing (59% decision aid versus 34% usual care; P < 0.01).
Mullan used pharmacy records to determine the days covered by
medication use (97.5% decision aid versus 100% usual care).
Health outcomes
General health outcomes
Eleven studies (10.5%) compared a decision aid to usual care in
terms of general health outcomes (Table 16). Ten of these used
either the previously validated Medical Outcomes Study 36-item
Short-Form Health Survey (SF-36) or the 12-item Short-Form
Health Survey (SF-12) (Stewart 1992), while Vuorma 2003 used
the RAND-36 (Hays 1993). As shown in Table 16, there were no
significant differences for mental health function or social func-
tion in any of the seven studies. In one study (Barry 1997), general
health andphysical functionoutcome scoreswere significantly bet-
ter in the decision aid group compared to usual care for men con-
sidering treatments for benign prostatic disease. Of the two stud-
ies evaluating the effect of a decision aid for women considering
treatment for abnormal uterine bleeding, Kennedy 2002 found
a statistically significant improvement in role physical function,
and Vuorma 2003 found a statistically significant improvement in
emotional role functioning for women.
In two studies measuring health utilities using the Euroqol EQ-
5D (Murray 2001a; Murray 2001b), there was no difference be-
tween the decision aid and usual care groups. There was also no
between-group difference in the LeBlanc 2015 study, which used
the Euroqol 5D health thermometer.
Condition-specific health outcomes
Seven studies (6.7%) used various measures to assess condition-
specific health outcomes (Table 17). Outcomes included uri-
nary symptoms (Barry 1997; Murray 2001a), angina (Bernstein
1998), functional assessment of cancer therapy (Leighl 2011),
menopausal symptoms (Murray 2001b), and menstrual symp-
toms (Protheroe 2007; Vuorma 2003). Five studies found no sig-
nificant effects on condition-specific health outcomes (Bernstein
1998; Leighl 2011;Murray 2001a;Murray 2001b;Vuorma 2003).
Protheroe 2007 reported significantly higher menorrhagia-related
quality of life scores in women exposed to the decision aid com-
pared to usual care. Barry 1997 showed an improvement in uri-
nary symptoms in favour of the decision aid group, but it was not
statistically significant.
Other health outcomes
Seven studies (6.7%) reported on other health outcomes (Table
18), including death (Auvinen 2004; Knops 2014), glycated
haemoglobin (Mathers 2012), angina (Morgan 2000), stroke
(Thomson 2007), successful pregnancy (Van Peperstraten 2010),
and pain (Vuorma 2003). There were no statistically significant
differences between groups.
Preference-linked health outcomes
None of the 105 studies measured preference-linked health out-
comes - that is, whether the patients experienced the outcomes
they preferred and avoided the outcomes they wanted to avoid.
Anxiety
Of 105 studies, 31 (29.5%) measured anxiety, with 24 using the
previously validated State Trait Anxiety Inventory (Spielberger
1970), 2 using the anxiety subscale of the Hospital Anxiety and
Depression Scale (Knops 2014; Lam 2013), 2 using questions
about worry (Fraenkel 2012; Smith 2010), 2 measuring intrusive
thoughts (Lewis 2010;McCaffery 2010), and1using a single ques-
tion on a seven-point Likert scale (Johnson 2006; see Table 19).
Of 18 studies that used the State Trait Anxiety inventory within
1 month postintervention, 2 (11.1%) reported that the decision
aid group had significantly lower anxiety scores for people con-
sidering birthing options after a previous caesarean (Montgomery
2007) and for women considering options for the treatment of
menorrhagia (Protheroe 2007). None of the studies demonstrated
significant differences in effects on people’s state anxiety at one
month (2 studies), three months (6 studies), six months (4 stud-
ies), or one year (2 studies). There was no significant difference
between groups for the other instruments that measured anxiety.
Depression
Of 105 studies, 6 (5.7%) measured the effect of decision aids on
depression using various instruments (Table 20).None of the stud-
ies reported a statistically significant difference between groups for
decisions about cancer treatment (Davison 1997; Whelan 2004),
depression (Loh 2007), prenatal genetic testing (Nagle 2008), or
for women considering the number of embryos to transplant (Van
Peperstraten 2010). At 10 months’ postintervention, there were
lower levels of depression in women deciding about breast cancer
surgery who were exposed to the patient decision aid versus the
usual care, but no differences at 1 week, 1 month, or 4 months
postintervention (Lam 2013).
Regret
Of105 studies, 7 (6.7%)measured the effect of decision aids onde-
cision regret, using the five-item Decisional Regret scale (Brehaut
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2003; see Table 21). At 4 and 10months postintervention, women
with breast cancer who were considering surgery and used a deci-
sion aid reported lower regret scores compared to women receiv-
ing usual care (Lam 2013). There was no statistically significant
between-group difference in the other six studies.
Confidence
Of 105 studies, 8 (7.8%) measured the effect of decision aids on
confidence levels (see Table 22). Four of these studies used theDe-
cisional Self-efficacy Scale (Allen 2010; Arterburn 2011; Fraenkel
2007; Smith 2010). Four studies reported a statistically significant
improvement in confidence or self-efficacy with decision making
in the decision aid compared to the usual care groups (Chambers
2012; Fraenkel 2007; Gattellari 2003; McBride 2002), and the
other studies reported no difference between groups.
Healthcare system effects
Cost and resource use
Of eight studies (7.6%) examining cost and resource use, one
conducted a cost-effectiveness analysis (Kennedy 2002), five eval-
uated the effect of decision aids compared to usual care on to-
tal costs (Montgomery 2007; Murray 2001a; Murray 2001b; Van
Peperstraten 2010; Vuorma 2003), and twomeasured resource use
(Legare 2012; Thomson 2007) (see Table 23).
The cost-effectiveness analysis (Kennedy 2002) was conducted
from the healthcare system perspective, using USD values from
1999 to 2000 and calculating costs over two years. The decision
aid with nurse coaching demonstrated the lowest mean cost (USD
1566) compared to decision aid alone (USD 2026) or usual care
(USD 2751).
Of the five studies that evaluated total costs, two reported no statis-
tically significant difference in the patient decision aid compared
to usual care (Montgomery 2007; Vuorma 2003). Two studies re-
ported higher costs for the patient decision aid group when in-
cluding the cost of the interactive video disc equipment (USD216
at 1999 prices) and no statistically significant difference between
groups when removing this cost (Murray 2001a; Murray 2001b).
The fifth study reported that the mean total savings in the deci-
sion aid group versus usual care was EUR 169.75 per couple (Van
Peperstraten 2010).
For healthcare resource use in upper respiratory infection, Legare
2012 reported no difference in the rates of repeat consultations
for the same reason, and Thomson 2007 reported no difference
in the rates of general clinician consultations in the three months
following the intervention. Both studies used the patient decision
aid in the consultation.
Consultation length
Of 105 studies, 10 (9.5%) evaluated the effect of a decision aid
compared to usual care on consultation length (see Table 23).
The median consultation length was 24 minutes (range 3.8 to
68.3) for patient decision aid compared to 21 minutes (range 4.2
to 65.7) for usual care. The difference was 2.6 minutes longer
(7.5% increase) than usual care consultations (range 0.4 minutes
shorter to 23 minutes longer). The length of consultation was
significantly longer for the patient decision aid group in two studies
(Bekker 2004; Thomson 2007), and eight studies reported no
difference. Bekker 2004 reported that consultations about prenatal
diagnostic testing were 5.9 minutes longer, and Thomson 2007
reported consultations about treatment for atrial fibrillation were
23 minutes longer when using a computerized decision aid with
standard gamble method within the consultation.
Litigation rates
None of the 105 studies examined the effect of decision aids on
litigation.
Adverse events
There were no adverse effects on health outcomes or satisfaction,
and no other adverse events reported.
Subgroup analysis - in preparation for versus during
the consultation
Of 105 studies, 89 (84.8%) primarily evaluated the patient deci-
sion aid when used by the patient in preparation for the consulta-
tion, and 16 (15.2%) primarily evaluated the patient decision aid
when used within the consultation. The patient decision aids used
during the consultation focused on prenatal screening (Bekker
2004); cardiac stress testing (Hess 2012); dental surgery (Johnson
2006); restorationof tooth decay (Kupke 2013); antibiotics for up-
per respiratory infection (Legare 2011; Legare 2012); medication
use for depression (Loh 2007), diabetes (Mann D 2010; Mullan
2009; Weymiller 2007), osteoporosis (LeBlanc 2015; Montori
2011), preventionof breast cancer (Ozanne 2007), and atrial fibril-
lation (Thomson 2007); surgery for breast cancer (Whelan 2004);
and chemotherapy for breast cancer (Whelan 2003).
Knowledge
When considered separately by subgroups, there was no differ-
ence between knowledge scores for those exposed to the decision
aid in preparation for the consultation compared to those used in
the consultation itself (Analysis 1.2: MD 13.77% versus 10.57%,
test for subgroup difference P = 0.31, I2: 3%). Weymiller 2007
reported a higher mean difference when the decision aid was ad-
ministered during the consultation but not if it was administered
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by research staff in preparation for the consultation. For the stud-
ies evaluating decision aids used in the consultation not included
in the pooled outcome, two showed a statistically significant im-
provement in knowledge (LeBlanc 2015; Ozanne 2007), and two
showed no difference (Mann D 2010; Thomson 2007).
Accurate risk perceptions
When analyzing pre-consultation and in-consultation decision
aids further, accurate risk perceptions were not different between
studies that used the decision aid in preparation for the consulta-
tion and those where the intervention occurred during the con-
sultation (Analysis 2.2: RR 2.25 versus RR 1.79, test for subgroup
differences: P = 0.33, I2: 0%). The only study evaluating a de-
cision aid within the consultation that was not included in the
meta-analysis, Weymiller 2007, reported a higher proportion with
accurate risk perception when the decision aid was administered
during the consultation, but found no difference between groups
when administered by research staff in preparation for the consul-
tation.
Decisional conflict uninformed subscale
Too few studies measured the uninformed subscale in those ex-
posed to decision aid within the consultation to be able to com-
pare with those who used decision aids in preparation for the
consultation. Weymiller 2007 reported that participants felt less
uninformed when the decision aid was administered during the
consultation, but not if it was administered by research staff in
preparation for the consultation.
Decisional conflict unclear values subscale
Too few studies measured the unclear values subscale in those ex-
posed to decision aidwithin the consultation to be able to compare
with those who used decision aids in preparation for the consul-
tation. Weymiller 2007 reported that participants felt less unclear
about values when the decision aid was administered during the
consultation, but not if it was administered by research staff in
preparation for the consultation.
Patient-clinician communication
Due to variation in the reporting of data for this outcome, we were
unable to investigate the effect of intervention timing on the vari-
ation in the effect on communication. Five studies evaluated a pa-
tient decision aid primarily used within the consultation with the
clinician, and five evaluated a patient decision aid used in prepa-
ration for the consultation (see Table 8). All five studies that used
the decision aid during consultations reported statistically higher
meanOPTION scores in the patient decision aid group compared
to usual care (Hess 2012; LeBlanc 2015; Montori 2011; Mullan
2009; Weymiller 2007). Four of five studies assessing the effects
of pre-consultation decision aid delivery (Fraenkel 2012; Hanson
2011; Lepore 2012; Sheridan 2011) reported that, compared to
those in the usual care group, significantly higher proportions of
participants exposed to the patient decision aid in preparation for
the consultation reported that they discussed the decision with
their clinician, and the fifth study showed no between-group dif-
ference (Sheridan 2006).
Participation in decision making
There were too few studies on decision aids used during the con-
sultation to interpret findings from the subgroup analysis (Analysis
5.2; Analysis 5.3).
Length of the consultation
Due to variation in the reporting of data for this outcome, we
were unable to investigate the effects of intervention timing on
the length of consultation. Of seven studies that evaluated de-
cision aids used within the consultation (Bekker 2004; LeBlanc
2015; Loh 2007; Ozanne 2007; Thomson 2007;Weymiller 2007;
Whelan 2003), two reported that the length of the consultation
was significantly longer for the patient decision aid group (Bekker
2004; Thomson 2007). There was no difference for the other
studies. The three studies that evaluated decision aids used in
preparation for the consultation reported no between group dif-
ference in the length of the consultation (Bozic 2013; Krist 2007;
Vodermaier 2009).
Other outcomes
For values-choice congruence and proportion undecided, none of
the studies of patient decision aids used during the consultation
measured these outcomes. For satisfaction, there were a range of
different approaches tomeasuring this outcome withmixed results
and too few studies to make any descriptive comparisons. For
choice, there were too few studies to conduct a subgroup analysis
of pooled comparisons.
Post hoc analysis
Effects of study quality
To examine the potential bias arising from including studies of low
methodological quality, we excluded 12 studies with a high risk
of bias for any of the seven risk of bias criteria from the analysis
(Auvinen 2004; Brazell 2014; Chambers 2012; Clancy 1988;
Hamann 2006; Knops 2014; Krist 2007; Kupke 2013; LeBlanc
2015; Lewis 2010; Man-Son-Hing 1999; Mott 2014; see Figure
3). Overall, the results remained the same (Table 24; Analysis 1.3;
Analysis 2.3; Analysis 3.5; Analysis 4.4).
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Heterogeneity
When comparing patient decision aids to usual care, there was
statistically significant heterogeneity in five of six of the IPDAS
effectiveness criteria: knowledge scores, accurate risk perceptions,
congruence between values and choice; feeling uninformed, and
feeling unclear regarding personal values. There was no statistically
significant heterogeneity for participation in decision making. It
should be noted that the heterogeneity of the effect was not man-
ifested in its direction but only in its size. For the 2009 update
(O’Connor 2009b), we explored the potential factors contributing
to heterogeneity (Table 25). Overall, regardless of the subgroup
analyses conducted, scores for outcomes were similar to the overall
effect, as indicated by overlapping confidence intervals.
D I S C U S S I O N
Summary of main results
In this updated review, we added 18 new studies for a total of 105
studies comparing patient decision aids to usual care. This up-
date also removed 28 studies that compared detailed versus simple
patient decision aids that were included in the previous update.
Based on the GRADE assessment (Summary of findings for the
main comparison), there is high-quality evidence that compared
to usual care, decision aids improve people’s knowledge regarding
options and reduce the decisional conflict stemming from feel-
ing uninformed and unclear about their personal values. There is
moderate-quality evidence that decision aids stimulate people to
take a more active role in decision making and increase the accu-
racy of their risk perceptions. There is lower-quality evidence that
decision aids improve congruence between the chosen option and
personal values. This outcome ismeasured using a variety of differ-
ent approaches, and the evidence could be strengthened by more
standardized measurement. Moreover, decision aids decreased the
proportion of people remaining undecided.
Although not a primary outcome of the review, the effect of de-
cision aids on patients’ choosing particular options continues to
be variable. The numbers of patients choosing to have major elec-
tive surgery continues to decrease in favour of more conservative
options, except when the baseline rates are low (e.g. surgery for
benign prostate hyperplasia, prophylactic mastectomy for women
who are carriers of the BRCA gene). The numbers of men choos-
ing prostate-specific antigen (PSA) testing were fewer after expo-
sure to decision aids.
Decision aids do no better than usual care in terms of their effects
on people’s satisfaction with decision making or health outcomes
such as general quality of life or condition-specific quality of life.
However, no studies measured preference-linked health outcomes,
nor were adverse events reported. There was also no difference in
anxiety. For length of consultation, eight studies found no differ-
ence, while two studies found a median increase of 2.6 minutes
(7.5%) in the decision aid group compared to usual care consulta-
tions.There continue to be too few studies to determine the effects
of decision aids on costs/resource use (Trenaman 2014). Although
there may be additional costs involved in delivering decision aids,
an independent review of decision aid studies with economic out-
comes concluded that “this was likely to be small relative to the
benefit to patients in terms of improved decision quality when
effective decision aids are used” (NCGC/NICE 2012). Given the
variability in measurement strategies, it difficult to determine the
effect of patient decision aids on adherence to the chosen option
or treatment.
New for this update, we analyzed the pooled data for decision aids
used in preparation for the consultation separately from decision
aids used in the consultation, and we found that there were sim-
ilar improvements in knowledge, accurate risk perceptions, and
patient-clinician communication.
Overall completeness and applicability of
evidence
Main effects of decision aids
The largest and most consistent benefits of decision aids, relative
to usual care, are better knowledge of options and outcomes, and
more accurate perceptions of outcome probabilities. These ob-
servations are clinically important because the usual care groups’
scores for knowledge and perception of outcome probabilities were
lower than the intervention groups’; both knowledge and percep-
tion of outcome probabilities are important for ensuring informed
decisionmaking.These effects suggest that current ’usual care’may
not be good enough when informing people about these complex,
values-sensitive decisions. People need to comprehend the options
and outcome probabilities in order to consider and communicate
to their clinicians the personal value they place on the benefits ver-
sus the harms. Likewise, pooling results from additional studies in
this update shows a significant increase in informed values-based
choice when decision aids were compared to usual care, and the
results appear to be similar across subgroup analyses of studies that
used the same composite measure.
Decision aids also help people feel more comfortable with their
choices than usual care. This is revealed by the reduced scores for
overall decisional conflict and for the decisional conflict subscales.
People who use decision aids generally feel more informed about
options and clearer regarding their personal values.
Compared to usual care strategies, decision aids improve individ-
uals’ perception of involvement in decision making. This obser-
vation suggests that the International Patient Decision Aids Stan-
dards criterion of helping patients participate ’in ways that they
prefer’ needs to be assessed after a patient has adequate informa-
tion about what involvement means using interventions such as
patient decision aids. People may have a mistaken preference for
28Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
passivity because they believe that the best choice relies on the
expertise of the clinician (which option is medically reasonable?)
rather than understand the importance of their own preferences
for outcomes of options (which outcomes matter most to me?).
Evidence continues to build that decision aids have a positive ef-
fect on the patient-clinician consultation (in 9 of the 10 studies
that assessed this effect). Of the studies that measured patient-
clinician communication, five involved using decision aids within
the consultation and five in preparation for the consultation. At
the same time, evidence on length of consultation indicates either
no difference (8 studies) or slightly longer (2 studies) consultations
in the decision aid group compared to usual care consultations.
However, few studies have reported on the impact of the context
in which the patient decision aids are used. A previous subgroup
analysis of 29 studies evaluating patient decision aids for treatment
decisions reported greater improvement in knowledge scores (P
= 0.03) when the patient decision aid was evaluated within the
clinical pathway of care, compared to when patients volunteered
to participate in the study independent of their clinician (Brown
2015).
Variable effects of decision aids
There may be several reasons for the variable effect of decision aids
on the outcome of choices. First, most studies were under-powered
to detect important differences in the outcome of choices. Second,
not enough is knownabout baseline rates for optimal use of specific
options. Third, in the studies reporting the outcome ’choices’ at
baseline and postdecision aid, some options may have been under-
used andothers over-used, relative to the choices individualswould
make if theyweremore fully informed.Under these circumstances,
one could expect to observe directional effects on choices once
people become better informed and more involved in decision
making.
Relatively under-used options at baseline were prostate surgery
for benign prostatic hyperplasia and prophylactic mastectomy for
breast cancer gene carriers. In this prostate-related example, there
was a shortage of urologists and low referral rates for benign pro-
static hyperplasia, whereas the breast-related example reflects the
growing number of women who test gene positive and become
aware of their options for preventing breast cancer. Hence, under-
use of an option may be corrected with exposure to a decision aid.
In the other surgical decision aid studies, there were higher num-
bers of people choosing surgery in the control group (e.g. cardiac
revascularization, back surgery, hysterectomy, orchiectomy, mas-
tectomy). The procedure may have been chosen due to people’s
inflated perceptions of the probabilities of benefits, lack of appre-
ciation of the probabilities of harms, and lack of awareness of al-
ternatives (Hoffman 2015). Exposure to the decision aid reduced
the number of people choosing elective surgery in favour of more
conservative alternatives.
Limited effects of decision aids
The limited effects of decision aids on reported satisfaction with
the decision-making process and with the actual choice made may
indicate that decision aids have a limited effect on satisfaction.
The null effects may also be due to measurement insensitivity.
This is especially likely when satisfaction with usual care is already
quite high (e.g. ceiling effects) and when choices are inherently
difficult to make because of competing benefits and harms. Fur-
thermore, once the decision is made, people may find it psycho-
logically more comforting to say that they are satisfied rather than
entertain doubts about what they have chosen (Gruppen 1994).
There is a need to establish the ’essential ingredients’ in decision
aids and to identify the people who are most likely to benefit from
them. As the body of available research grows, it will become easier
and more important to assess the usefulness of different compo-
nents of decision support for different clinical contexts, decision
problems, and groups of people. For example, an analysis of deci-
sion aids used in higher versus lower socioeconomic groups indi-
cated greater improvements for those of lower socioeconomic sta-
tus (Durand 2014). Recently, the IPDASCollaboration completed
a set of evidence reviews underlying the IPDAS checklist (IPDAS
2013), proposing criteria for defining the intervention as a pa-
tient decision aid andminimal certifying criteria (Joseph-Williams
2013). These are being used to inform the certification of patient
decision aids in the USA, England, and Norway.
It is not surprising that decision aids had limited effects on health
outcomes. One reason for using a decision aid is that there is of-
ten no option with a clear health outcome advantage. For exam-
ple, whenmen with localized prostate cancer consider active treat-
ment options, their health outcomes can be different, depending
on whether they choose surgery with higher risks of impotence or
radiation therapy with higher risks of longer term bowel irritation.
Therefore, if health outcomes are used in future investigations of
decision aids in situations in which there is clearly no health out-
come advantage, the key question to pose is: do patients experi-
ence the health outcomes they prefer and avoid the outcomes to
which they are averse?
More recently, decision aids are being used in situations in which
there may be a longer-term health advantage, for example, in pre-
ventive decisions about the management of type II diabetes and/
or hypertension, when the longer-term health outcome may be to
avoid stroke (Mann D 2010; Mathers 2012; Montgomery 2003;
Mullan 2009; Weymiller 2007). Interestingly, the pooled results
showed a statistically significant increase in medication initiation
when participants were exposed to the decision aid compared to
usual care.
Unknown effects of decision aids
The effect of patient decision aids on adherence to the chosen
option is an area of uncertainty. The adherence results are difficult
to interpret due to incomplete data, primarily self-reported data,
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varying length of follow-ups, and small sample sizes. Moreover,
studies reporting this outcome such as Man-Son-Hing 1999 had
very little variation in choice (over 90% of long-term aspirin users
decided to stay on aspirin). When examining adherence, it would
be important to do so in the early phase, when presumably the
issue is actually decisional in nature (e.g. filling the prescription,
picking up the prescription, refilling the prescription) rather than
involving the management of side effects and in a manner that
separates those choosing to change versus those remaining with
the status quo.
Despite the positive effects of decision aids on patient-clinician
communication, some authors are concerned about the potential
negative influence that decision aids may have on the relational
aspects of the decision-making process; this concern highlights the
need for further evaluation when decision aids are implemented as
part of the routine process of care (Charles 2010; LeBlanc 2010).
In the context of decision aid use, cost-effectiveness and health
utilities are other secondary outcome measures about which little
is known and further evaluation is required (Trenaman 2014).
We also need to establish ways of measuring preference-linked
health outcomes to better determine the effect on quality of life.
It is unlikely that we will observe the effect of decision aids on
litigation rates in studies of decision aids, given the time delay to
litigation and the rarity of this type of event. There do not appear
to be any adverse events from using decision aids, but this could
be more clearly examined in future studies. In fact, a mock trial
that used a patient decision aid for prostate-specific antigen testing
found that the majority of jurors (94%) would indicate that the
standard of care had been met (Barry 2008). A recent systematic
review concluded that there was insufficient evidence to determine
if patient decision aids could reduce medical malpractice litigation
(Durand 2014).
Quality of the evidence
Risk of bias ratings reveal between-study variability. We rated few
studies as being at low risk of bias for blinding of participants
and personnel and most studies as being at unclear risk of bias.
Likewise, the majority of studies were rated as being at unclear
risk of bias for selective reporting. When we conducted a post
hoc analysis that involved removing studies at high risk of bias
from the meta-analysis, there was no effect on the results. The
conclusions of this review are limited by inadequate power to
detect important between-subgroup differences in effectiveness
and by the wide variability in the decision contexts, the elements
within the patient decision aids, the type of comparison delivered
(collectively referred to as usual care here), the targeted outcomes,
and the evaluation procedures. The small number of studies for
most outcomes did not allow for analysis of publication bias due
to failure to publish negative studies. Moreover, most studies were
at unclear risk of selective outcome reporting, indicating that there
may have been bias arising from a failure to report all negative
findings.
We rated the six primary outcomes in the ’Summary of findings’
table usingGRADE and assessed outcomes as high quality (knowl-
edge, feeling uninformed, feeling unclear values), moderate qual-
ity (accurate risk perception, clinician-controlled role in decision
making), and low quality (values-choice congruence). For values-
choice congruence, the GRADE rating was downgraded for lack
of consistency, directness, and precision. More specifically, con-
gruence was measured using various approaches, as there is no
gold standard measurement approach (Munro 2016). Several of
the outcomes demonstrated statistically significant levels of het-
erogeneity. For the outcome of knowledge, for example, hetero-
geneity would be expected, given that the knowledge tests them-
selves were not standardized. However, we did not downgrade
the ratings for knowledge, feeling uninformed, and feeling un-
clear values based on heterogeneity given the consistent direction
of findings across studies. Moreover, the heterogeneity found in
the various outcomes reflects differences across clinically diverse
studies; therefore, the pooled effect size and confidence intervals
should be interpreted as a range across conditions, which may not
be applicable to a specific condition.
Potential biases in the review process
The strength of this systematic review is that patient decision aids
improve several key primary outcomes across a wide variety of pop-
ulations and decision contexts. The potential biases in the review
process are due to limitations associated with having inadequate
power to detect potentially important differences in effectiveness
between subgroups, to differentiate between the most effective
elements within the patient decision aid, and to investigate any
differences associated with the type of comparison interventions
used in studies. Several of the outcomes demonstrated statistically
significant heterogeneity. This reflects differences across clinically
diverse studies; therefore, the pooled effect size and confidence
intervals should be interpreted as a range across conditions, which
may not be applicable to a specific condition. In the Gentles 2013
subgroup analysis exploring three potential sources of heterogene-
ity (e.g. type of control intervention, decision aid IPDAS quality
score, participants’ baseline accurate risk perception), participants’
baseline accurate risk perception was an important variable for ex-
plaining heterogeneity. Authors reported that when participants’
baseline scores for accurate risk perception were lower, decision
aids led to great improvement. Furthermore, we limited the ex-
tracted study data to only two comparison groups (e.g.most inten-
sive intervention including a patient decision aid and usual care);
therefore, we did not investigate the possibility of intermediate
effects with less intensive decision aid interventions.
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Agreements and disagreements with other
studies or reviews
Our results confirm many of the observations reported in the
previous versions of our review and in a comparative effectiveness
review that focused on studies evaluating oncology-specific patient
decision aids (Trikalinos 2014). We published the first systematic
review of 17 randomized trials of decision aids in 1999 (O’Connor
1999b; O’Connor 2001), followed by updates in 2003 with a total
of 35 studies (O’Connor 2003), in 2009 with a total of 55 studies
(O’Connor 2009b), in 2011 with a total of 86 studies (Stacey
2011), and 2014 with a total of 115 studies (Stacey 2014b).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The positive effects of decision aids on improving people’s knowl-
edge of risks and benefits, feeling informed, and feeling clear about
their values across a wide variety of decision contexts provides suf-
ficient evidence for using them in clinical practice. They proba-
bly also facilitate accurate risk perception and active participation
in decision making. However, several conditions may be neces-
sary for successful implementation, including: good quality deci-
sion aids that meet the needs of the population; clinicians who
are willing to use decision aids in their practice; effective systems
for delivering decision support; and clinicians and healthcare con-
sumers who are skilled in shared decision making. Although there
have been some strides in achieving these conditions (Elwyn 2013;
O’Connor 2007), the use of patient decision aids will not occur
without adequate attention to implementation barriers to imple-
mentation and careful design of effective strategies for introduc-
ing and maintaining their use in routine clinical practice (Elwyn
2013; Gravel 2006; Legare 2008b; Legare 2010; Legare 2014).
New in this update was a subgroup analysis of the findings based
on timing of decision aid used either before or during a consul-
tation. Although knowledge scores and accurate risk perceptions
were significantly higher in the decision aid group compared to
the usual care, there was no difference in these outcomes when
comparing decision aids used in preparation for versus during the
consultation.
Implications for research
Studies are needed to deepen our understanding of interactions
between patient decision aid use and the patterns of patient-clin-
ician communication; format issues such as the web-based deliv-
ery of patient decision aids; and downstream effects on cost, re-
source use, and adherence. Although this update shows new stud-
ies conducted in Spain and China, most studies have taken place
in North America, the UK, Europe, and Australia. There were far
fewer studies of patient decision aids used within the consultation
than those delivered pre-consultation, and this is an area of further
research given the important issue of implementation.
With the addition of more studies in the systematic review, it may
be possible to tease out the reasons for heterogeneity of results,
including variability in: study quality; comparison intervention;
elements within patient decision aids; decision type; setting where
it was used; and format of decision aid (e.g. video, Internet, book-
let). Research should also explore the degree of detail in patient
decision aids that is required for positive effects according to the
IPDAS criteria. In particular, evaluation is needed to compare the
effect of those decision aids that meet the minimal IPDAS criteria
for certification versus those that meet the full roster of IPDAS
quality criteria (Joseph-Williams 2013).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Allen 2010
Methods Cluster-randomized to decision aid vs usual care
Participants 398 + 414 men considering prostate cancer screening in the USA
Interventions DA: computer tailored programme on clinical problem, outcome probabilities, explicit
values clarification, others’ opinion and guidance (step-by-step process for making the
decision; interactive computer programme: inherently guided the patient through the
decision aid and decision making process), tailored printout given to patients to promote
discussion with others (practitioner, significant others)
Comparator: no intervention
Outcomes Primary outcomes: decisional status, knowledge, decision self-efficacy, decisional consis-
tency
Secondary outcomes: desire for involvement in decision making, decisional conflict,
preferred options
Outcomes assessed pre- and postintervention
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Sites were blocked on size and percent of
male employees and randomly assigned by
computer-generated random numbers to
condition within blocks” (p 2173, Setting)
Allocation concealment (selection bias) Unclear risk The study does not address this criterion.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study does not address this criterion.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes measured
were not subjective to interpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data and low rate
of attrition that was consistent between
groups
Selective reporting (reporting bias) Unclear risk No mention of protocol
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Allen 2010 (Continued)
Other bias Low risk Intervention delivery: mention of money
incentive to complete paperwork, but was
judged to have no effect on outcomes mea-
sured (p 2175)
Arterburn 2011
Methods Randomized to decision aid vs usual care
Participants 75 + 77 participants considering bariatric surgery in the USA
Interventions DA: booklet + video on options’ outcomes, clinical problem, outcome probabilities,
others’ opinion, guidance (list of questions to discuss with clinician)
Comparator: usual care (general information pamphlets on clinical problem)
Outcomes Primary outcomes: knowledge, values, values concordance
Secondary outcomes: treatment preference, decisional conflict, decisional self-efficacy,
proportion undecided
Primary outcomes assessed at baseline, postintervention and 3 months follow-up; sec-
ondary outcomes assessed at baseline and postintervention
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[U]sed computer-assisted, block randomi-
sation process to ensure balanced allocation
of participants” (p 1670, Participants and
randomization)
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment and
no mention of impact on study
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “[S]tudy was not blinded” (p 1670, Partic-
ipants and randomization); no mention of
impact on study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subject to interpre-
tation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Measures: mentioned 4 choices for treat-
ment preference (surgery, drug therapy, diet
and/or exercise programme and unsure) but
only reported on surgery andunsure options
(p 1671); minimal attrition that was consis-
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Arterburn 2011 (Continued)
tent between groups
Selective reporting (reporting bias) Unclear risk No mention of study protocol or trial regis-
tration; all pre-specified outcomes included
Other bias Low risk The study appears to be free of other sources
of bias
Auvinen 2004
Methods Randomized to decision aid vs usual care
Participants 103 + 100 men newly diagnosed with prostate cancer in Finland
Interventions DA: pamphlet patient decision aid created for study on options’ outcomes, outcome
probability, guidance
Comparator: usual care by clinical guideline
Outcomes Primary outcome: uptake of options
Secondary outcome: participation in decision making
Other outcomes (from Huang 2014): death (5 years), disease-free survival (10-years),
biochemical failure (serum PSA elevation) (5 years), biochemical failure-free survival (5
years), disease progression (5 years), disease progression-free survival (5 years) (data from
104 + 106 men)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Auvinen 2001, p 2: “randomized centrally,
using software based on a random number
generator”; no blocking used
Auvinen 2004, (primary study), p 1: “ran-
domized using a computer algorithm based
on random numbers”
Allocation concealment (selection bias) Unclear risk Auvinen 2001,p 2, Patients and Methods:
randomized centrally at the Finnish Cancer
Registry
Auvinen 2004, (primary study), p 1: ran-
domized centrally
Comment: central allocation confers low
risk
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Auvinen 2001, p 3: “recognized carry-over
effect because same physician in charge for
intervention and control groups, diminish
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Auvinen 2004 (Continued)
contrast between groups, as these physicians
were more motivated to inform patients
than those physicians not participating”
Auvinen 2004 (primary study): no blind-
ing but primary outcome is choice of treat-
ment for prostate, objectively recorded. But
unsure how physicians may have influenced
decisions
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding but primary outcome is
choice of treatment for prostate, objectively
recorded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Auvinen 2001, p 3: flow-chart
“Imbalance in the numbers of patients be-
tween the arms within two hospitals. Not
expected to affect the results in any way”;
“some participants refused to give informed
consent, health deterioration, not seen by
urologist” (p 4)
Auvinen 2004 (primary study), p 2: flow di-
agram and results; low attrition and consis-
tent between groups
Selective reporting (reporting bias) Unclear risk No indication that trial registered in central
trials registry
Auvinen 2001, p 2: “The study protocol was
approved by an ethical committee in each
participating hospital”
Auvinen 2004 (primary study), p 1: “The
study protocol was approved by the insti-
tutional review board at each participating
hospital”
Other bias Low risk Appears to be free of other potential biases
Barry 1997
Methods Randomized to decision aid vs usual care
Participants 104 + 123 patients considering benign prostatic hyperplasia treatment in the USA
Interventions DA: Health Dialog interactive videodisc on options’ outcomes, clinical problem, out-
come probability, others’ opinion
Comparator: usual care using general information on the clinical problem
Outcomes Primary outcome: knowledge
Secondary outcomes: uptake of option, satisfaction with DM process, satisfaction with
decision, interest in DM, general health outcomes, condition specific health outcomes
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Barry 1997 (Continued)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Stratified by study site in concealed blocks
of 10” (p 2)
Allocation concealment (selection bias) Low risk Study coordinator opening serially num-
bered, opaque, sealed envelopes (p 2)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding but phase 1 eliminated risk of
contamination
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding but phase 1 eliminated risk of
outcome assessor interfering with decision
Incomplete outcome data (attrition bias)
All outcomes
Low risk Patient accrual and follow-up reported;
post-randomizationwithdrawals could have
biased the results (more in intervention
group) - however they reported no evidence
of a differential effect of the study group (p
3)
Selective reporting (reporting bias) Unclear risk No indication that trial registered in central
trials registry
Other bias Low risk Appears to be free of other potential biases
Bekker 2004
Methods Randomized to detailed vs routine consultation
Participants 59 + 58 pregnant women who have received a maternal serum screening positive test
result for Down syndrome in the UK
Interventions DA (in consult): decision analysis plus routine consultation onoptions’ outcomes, clinical
problem, outcome probability, values clarification, guidance/coaching
Comparator: routine consultation on options’ outcomes, outcome probability
Outcomes Primary outcome: anxiety
Secondary outcomes: uptake of option, knowledge, decisional conflict, informeddecision
making, satisfaction with consultation, consultation length
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Bekker 2004 (Continued)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Bekker 2003, p 2 - section 2.3 Sample
and Procedure: “randomly allocated... us-
ing previously numbered... envelopes”
Bekker 2004 (primary study), p 3: “Partic-
ipants were randomly allocated by previ-
ously numbered envelopes”; does not men-
tion how sequence was generated
Allocation concealment (selection bias) Low risk Bekker 2003, p 2 - section 2.3 Sample and
Procedure: “Using previously numbered,
sealed, opaque envelopes”
Bekker 2004 (primary study), p 3: previ-
ously numbered, sealed, opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants blinded,
personnel not blinded. Same personnel did
control & intervention. Tape recorded ses-
sions to ensure no bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Bekker 2003 flow diagram indicates pos-
trandomization attrition with more attri-
tion in decision aid group; no discussion
on implications of attrition
Bekker 2004 (primary study), p 4: results/
flow diagram; baseline characteristics not
included
Selective reporting (reporting bias) Unclear risk Bekker 2003: the coding frame was devel-
oped from literature. Does not mention
protocol
Bekker 2004 (primary study): no informa-
tion provided about central trials registry
Other bias Unclear risk Bekker 2003: does not directly address
baseline characteristics of participants
Bekker 2004 (primary study): appears to be
free of other potential biases
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Bernstein 1998
Methods Randomized to decision aid vs usual care
Participants 65 + 53 patients with coronary artery disease considering revascularization surgery in
the USA
Interventions DA: Health Dialog video on options’ outcomes, clinical problem, outcome probability,
others’ opinion
Comparator: usual care (no information provided)
Outcomes Primary outcome: satisfaction with decision and decision making process
Secondary outcomes: uptake of option, knowledge, satisfaction with care, general health
outcomes, condition specific health outcomes
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was stratified by study site
in blocks of 10” (p 3)
Allocation concealment (selection bias) Low risk “[R]andomization performed by a study co-
ordinator opening opaque, sealed envelopes
at study headquarters” (p 3)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Neither subjects nor study staff were blinded
to treatment assignment - could lead to dif-
ferent satisfaction ratings based on knowing
the treatment received
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured
Incomplete outcome data (attrition bias)
All outcomes
Low risk Flow diagram (p 3); low attrition of eligible
participants randomized and consistent be-
tween group
Selective reporting (reporting bias) Unclear risk No information provided indicating trial
was included in central trials registry
Other bias Low risk Appears to be free of other potential biases
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Berry 2013
Methods Randomized to decision aid vs usual care
Participants 266 + 228 men considering prostate cancer treatment in the USA
Interventions DA: interactive web based video on options’ outcomes, clinical problem, outcome prob-
abilities, others’ opinion, guidance (list of questions to ask doctor and automated sum-
mary)
Comparator: usual care
Outcomes Primary outcome: decisional conflict
Secondary outcome: preferred/actual treatment choice (pre- and post-DA), proportion
undecided
Other outcomes (Bosco 2012): choice concordance (6 months post-DA). (Data from
239 + 209 men)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Methods section- second paragraph, p 3:
“Participants were randomized automati-
cally by the P3P application to study groups
(1:1 using a simple randomization scheme
with no blocking)”
Allocation concealment (selection bias) Low risk Methods section, p 3: “Participants were
randomized automatically by the P3P ap-
plication to study groups”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants were not blinded and study
does not address the effect on the results
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear whether outcome assessors are
blinded, but outcomes are not subject to in-
terpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used intention-to-treat analysis and low
dropout (p 4)
Selective reporting (reporting bias) Low risk Protocol made available
Other bias Unclear risk Was a multicentre trial which could have
lead to contamination, protocol violation
and biased questionnaire completion
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Bjorklund 2012
Methods Randomized to decision aid vs usual care
Participants 236 + 247 women less than 11 weeks pregnant considering Down syndrome screening
in Sweden
Interventions DA: linear video on options’ outcomes, clinical problem, outcome probabilities, others’
opinion, and guidance (step-by-step process for making the decision)
Comparator: usual care using pamphlet
Outcomes Primary outcomes: knowledge (post-DA), attitude (post-DA), uptake of combined ul-
trasound and biochemical screening (post-DA)
Secondary outcomes: values congruent with chosen option (post-DA)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Themidwife allocated the participants ran-
domly by sealed envelopes” (p 391) but
does not state the actual sequence genera-
tion method
Allocation concealment (selection bias) Low risk Used sealed envelopes, “prepared, sequen-
tially coded and distributed to thematernity
units by the research group” (p 391)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “It was not possible to blind neither [sic]
themidwives nor the participants due to the
characteristics of the intervention” (p 395)
. The study does not address the effects of
this on the results
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding but outcomes were objectively
measured and not subjective to interpreta-
tion
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No mention of why some participants’ data
were excluded in Tables 2, 3 and 4
Selective reporting (reporting bias) Unclear risk No mention of study protocol
Other bias Low risk Appears to be free of other sources of bias
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Bozic 2013
Methods Randomized to decision aid vs usual care
Participants 95 + 103 participants with hip and/or knee osteoarthritis considering hip/knee surgery
Interventions DA: DVD and booklet on options’ outcomes, clinical problem, outcome probabilities,
explicit values clarification, others’ opinions, and guidance/coaching with health coach
Comparator: usual care using pamphlet
Outcomes Primary outcomes: informed decision/knowledge (pre, immediately post, and 6 weeks
follow-up)
Secondary outcomes: preferred treatment choice (pre and immediately post), patient and
provider satisfaction (immediately post), length of consultation time
Notes Trial registration: NCT01492257
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization was blocked with use
of random permuted blocks in groups of
four, six, or eight to help ensure that the
groups were balanced” (p 1634)
Allocation concealment (selection bias) Low risk “Patients were randomized to either the in-
tervention group or the control group with
use of the sealed envelop method” (p 1634)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “[S]urgeons were not blinded to the inter-
vention” (p 1635). Knowing the allocation
of participants, surgeons’ favourable scoring
could be due to greater investment in de-
cision-making. Insufficient information to
make a judgment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes are objectively measured and not
subject to interpretation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 62% (123/198) retention rate therefore
high attrition rate - however the attrition
was balanced between groups
Selective reporting (reporting bias) Low risk Protocol available
Other bias Low risk Appears to be free of other sources of bias
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Brazell 2014
Methods Randomized to DA + standard counselling vs usual care + standard counselling
Participants 53 + 51 women presenting for the management and treatment of pelvic organ prolapse
Interventions DA: paper-based or web-based DA on clinical problem, options’ outcomes, outcome
probabilities, patient stories and standard counselling
Comparator: standard counselling alone
Outcomes Primary outcomes: decisional conflict (immediately postconsultation)
Secondary outcomes: choice (3 months after making decision), decisional regret (3
months after making decision)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomized 1:1 using a ran-
dom numbers table in blocks of 6” (p 231)
Allocation concealment (selection bias) Unclear risk Insufficient information provided to make
judgment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information provided to make
judgment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided to make
judgment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk High attrition but balanced between
groups: “39 randomized subjects were ei-
thermissed by the research assistant at their
new patient visit and thus did not receive
a DCS questionnaire to complete or they
canceled their appointments and did not
reschedule a new one” (p 233). There was a
48% (50/104) attrition rate for Decisional
Regret measures
Selective reporting (reporting bias) Low risk Trial registered
Other bias High risk Risk of contamination due to same physi-
cians in both groups. Also, outcomes mea-
sured after the PtDA and physician consult
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Chabrera 2015
Methods Randomized to DA vs usual care
Participants 73 + 74 men recently diagnosed with prostate cancer considering treatment options
Interventions DA: 2-part decision support booklet with clinical problem, options’ outcomes, outcome
probabilities, patient stories, explicit values clarification, and guidance
Comparator: usual care
Outcomes Primary outcomes: knowledge, decisional conflict, satisfaction with decision-making
process
Secondary outcome: coping
Outcomes assessed at 3 months postintervention
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[S]tudy participants were randomized into 1 of 2
arms using a computer-generated random list with
unequal blocks” (p E44)
Allocation concealment (selection bias) Unclear risk Insufficient information provided to make judg-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information provided to make judg-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided to make judg-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Balanced attrition in both groups
Selective reporting (reporting bias) Unclear risk No protocol provided; trial not registered
Other bias Unclear risk Prostate cancer in Catalonia is common; however,
only 147 were recruited for this trial (p E44)
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Chambers 2012
Methods Randomized to DA vs usual care
Participants 74 + 77 healthcare workers who did not receive the influenza vaccine considering receiv-
ing the vaccine in Canada
Interventions DA: web-based DA on options’ outcomes, clinical problem, outcome probabilities, ex-
plicit values clarification and guidance
Comparator: usual care using pamphlet
Outcomes Primary outcomes: confidence in decision (post-DA)
Secondary outcomes: impact on immunization intent (post-DA), proportion undecided
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization list was generated using the
randomization function in Excel 2002 (version 10.
6856.6856 SP3)” (p 199)
Allocation concealment (selection bias) Low risk “The list was imported from Excel into a Microsoft
SQL Server database. The online application would
sequentially assign a random identification number
and their decision aid status (seeing the decision
aid or not) from the randomization list when users
logged into the survey.” (p 199)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported whether or not they were blinded dur-
ing the course of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Questionnaire scores are objective and not subject
to interpretation
Incomplete outcome data (attrition bias)
All outcomes
High risk 65% completion rate in intervention arm and 77%
completion rate in control arm: attrition could be
different where the respondents and non-respon-
dents are different
Selective reporting (reporting bias) Low risk Protocol available
Other bias Unclear risk Figure 1 numbers for exclusion are not logical
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Clancy 1988
Methods Randomized to decision aid vs usual care
Participants 753 + 263 health physicians considering Hep B vaccine in the USA
Interventions DA: pamphlet on options’ outcomes, clinical problem, outcome probability, explicit
values clarification (personal decision analysis), guidance/coaching
Comparator: usual care (no information provided)
Outcomes Uptake of option
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers table; all incoming resi-
dents were assigned to Group 2 (non-ran-
domized residents identified as subgroup)
(p 2)
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No blinding of participants or personnel.
Did not report on how this may affect their
findings
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but decisions for screen-
ing were retrieved from health records (ob-
jective data)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Flow chart not included. Insufficient infor-
mation to make a judgment
Selective reporting (reporting bias) Unclear risk No information provided
Other bias High risk Potential selection bias - non-randomized
residents were added to group 2 and there-
fore potential unbalanced distribution (p
287)
Low response rate among those offered de-
cision analysis
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Davison 1997
Methods Randomized to decision aid + audio-taped consultation vs usual care
Participants 30 + 30 men with prostate cancer considering treatment in Canada
Interventions DA: written + audiotape consultation of options’ outcomes, clinical problem, outcome
probability, others’ opinion
Comparator: usual care (general information pamphlets on clinical problem)
Outcomes Primary outcomes: role in decision making
Secondary outcomes: anxiety, depression
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The group towhich subjects were assigned
was predetermined by a block randomiza-
tion procedure. This ensured there were an
equal number of subjects in both groups
for each physician.” (p 5, Data collection)
Allocation concealment (selection bias) Unclear risk Not mentioned; group assignment prede-
termined by block randomization proce-
dure (p 5)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No blinding; study does not report on how
the results could be influenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear blinding and whether outcomes
could be affected by unblinded assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk Noflow diagram; p 12 explains why certain
men did not listen to audiotape. All men
approached by study investigator agreed to
participate; only 1man refused to complete
the second set of questionnaires
Selective reporting (reporting bias) Unclear risk Protocol not mentioned
Other bias Low risk Appears to be free of other sources of bias;
similar baseline characteristics
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De Achaval 2012
Methods Randomized to detailed vs simple vs usual care
Participants 70 + 70 + 71 patients diagnosed with knee osteoarthritis considering treatment in the
USA
Interventions Complex DA: video booklet + interactive joint analysis on options’ outcomes, clinical
problem, outcome probabilities, explicit values clarification, others’ opinion and guid-
ance (list of questions)
Comparator DA: video booklet on options’ outcomes, clinical problem, outcome prob-
abilities, others’ opinion and guidance (list of questions)
Comparator: usual care receiving generic booklet
Outcomes Decisional conflict (baseline and postintervention)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated list with uneven
blocks (p 231)
Allocation concealment (selection bias) Low risk Numbered, sealed and opaque envelopes (p
231)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Likely not blinded, but low threat of bias
in study (p 231)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants were not blinded but outcome
was objectively measured (p 231)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 dropouts; missing data effect size unlikely
to have significant impact on study out-
come
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk Appears to be free of other sources of bias
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Dolan 2002
Methods Randomized to decision aid vs usual care
Participants 50 + 47 average risk for colorectal cancer considering screening in the USA
Interventions DA: computer with analytic hierarchy process on options’ outcomes, clinical problem,
outcome probability, explicit values clarification, guidance/coaching
Comparator: usual care with information on options, clinical problem
Outcomes Primary outcomes: uptake of option, decisional conflict
Secondary outcomes: role in decision making
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[R]andomization schedules were created
using a computer random number genera-
tor” (p 2, Study interventions)
Allocation concealment (selection bias) Low risk Computer-based (p 2, Study interventions)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear blinding of participants. All pa-
tient interviews in both the experimental
and control groups were done by the same
investigator, unclear on how this could con-
tribute to risk of bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk See flow diagram - low attrition
Selective reporting (reporting bias) Unclear risk Nothing specifically mentioned re study
protocol
Other bias Low risk Appears to be free of other sources of bias
Evans 2010
Methods Randomized to online decision aid vs paper decision aid vs questionnaire vs usual care
Participants 129 + 126 + 127 + 132 men considering PSA screening in Wales
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Evans 2010 (Continued)
Interventions DA: online programme on options’ outcomes, clinical problem, outcome probabilities,
explicit values clarification, others’ opinion, guidance (interactive computer programme;
summary)
Comparator: paper version of online DA on options’ outcomes, clinical problem, out-
come probabilities, explicit values clarification, others’ opinion, guidance (interactive
computer programme; summary)
Comparator: received a questionnaire
Comparator: received nothing
Outcomes Primary outcomes: knowledge (post-DA)
Secondary outcomes: attitude (post-DA), intention to undergo PSA testing (post-DA),
anxiety (post-DA), uptake of PSA test (post-DA), total decisional conflict
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “[A] random sample of 100 men was se-
lected from the list.” “The process ensured
individual level randomization” (p 4, Re-
cruitment process)
Allocation concealment (selection bias) Low risk “[A]ffirmative consent forms from each
practice were transferred to the research of-
ficer who allocated each participant with
a number provided remotely by the trial
statistician to ensure concealment” (p 4,
Recruitment process)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study does not address this outcome
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk See flow diagram indicating high attrition
consistently across groups
Selective reporting (reporting bias) Low risk Registered as a trial
Other bias Low risk The study appears free of other sources of
bias
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Fagerlin 2011
Methods Decision aid vs delayed intervention vs control
Participants 382 + 159 + 100 women with an elevated 5-year risk of breast cancer considering breast
cancer prevention medication in the USA
Interventions DA: tailored DA on options’ outcomes, clinical problem, outcome probabilities, and
explicit values clarification
Comparator 1: given DA after 3-month follow-up
Comparator 2: given DA after all outcome measures were taken
Outcomes Decisional conflict (post-DA), behavioural intent (post-DA), actual behaviour (post-
DA), proportion undecided, perception of benefits (post-DA), perception of risk (post-
DA)
Other outcomes:
• Banegas 2013: decisional conflict (post-DA) (data from 690 + 160 + 162 women)
, proportion undecided (3 months)
• Korfage 2013: knowledge (immediately post and 3 months post-DA), attitudes
(immediately post and 3 months post-DA), behavioural intent (post-DA), actual
behaviour (3 months post-DA), informed decision defined as “participants with
sufficient knowledge about chemoprevention behavior, whose attitudes were
concordant with their intentions or decisions to engage in chemoprevention behavior”
(data from 383 + 102 + 100 women).
Notes Primary outcome was not specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random sequence generationwas provided
by the author
Allocation concealment (selection bias) Low risk Central and web-based allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear blinding - using an online deci-
sion aid would have avoided control par-
ticipants accessing the decision aid
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Does not report exclusions; inadequate re-
porting on participant flow through the
study to determine risk for attrition bias or
incomplete outcome data
Selective reporting (reporting bias) Unclear risk No mention of study protocol
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Fagerlin 2011 (Continued)
Other bias Low risk Appears to be free of other sources of bias
Fraenkel 2007
Methods Randomized to decision aid vs usual care
Participants 47 + 40 patients with knee pain considering treatment options in the USA
Interventions DA: interactive computer tool options’ outcomes, outcome probability, explicit values
clarification
Comparator: usual care using the Arthritis Foundation information pamphlet
Outcomes Decisional self-efficacy, preparation for decision making
Notes Primary outcome was not specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomization se-
quence (p 2)
Allocation concealment (selection bias) Unclear risk No information provided; computer gener-
ated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No blinding but study does not report if it
had an impact on the outcomes measured
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low risk of attrition bias - outcome data for
all 40 controls and 44 of 47 intervention (p
3, Results)
Selective reporting (reporting bias) Unclear risk No information provided; no indication of
trial was registered centrally
Other bias Low risk Appears to be free of other potential biases
80Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fraenkel 2012
Methods Cluster-randomized control trial of clinics to decision aid versus usual care
Participants 69 + 66 patients with nonvalvular atrial fibrillation considering anticoagulation with
aspirin or warfarin
Interventions DA: computer-based tool on options’ outcomes, clinical problem, options’ probabilities,
guidance, explicit values clarification
Comparator: control arm (no further information provided)
Outcomes Primary outcomes: feeling informed and having clear values (baseline, immediately post)
Secondary outcomes: knowledge (baseline, immediately post), accuracy of risk (baseline,
immediately post), anxiety (baseline, immediately post), worry (baseline, immediately
post), rationale for preferred treatment (during the encounter - DA group only), discus-
sion of related outcomes (during the encounter as captured on audiotape), change in
treatment plan (post intervention), anxiety, accurate risk expectations (stroke, bleeding)
Notes Trial registration NCT00829478
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Inadequate information on random se-
quence generation
Allocation concealment (selection bias) Unclear risk inadequate information on allocation con-
cealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “To avoid contamination, participantswere
randomized at the level of the firm so that
all participants in one firm received the in-
tervention, and all participants in the sec-
ond firm were included in the control arm”
(p 1435)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “An interviewer blinded to the participant’s
group assignment reassessed the primary
and secondary outcomes after participant’s
primary care visit” (p 1436)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Does not appear to be incomplete outcome
data; flow diagram does not report partici-
pation beyond randomization
Selective reporting (reporting bias) Low risk Protocol available
Other bias Low risk Does not appear to be any other potential
sources of bias
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Frosch 2008a
Methods Randomized to decision aid vs. decision aid + chronic disease trajectory vs chronic disease
trajectory vs usual care (Internet information)
Participants 155 + 152 + 153 + 151 men considering prostate cancer screening
Interventions DA: information on options’ outcomes, clinical problem, outcome probabilities, others’
opinions
Comparator 1: information on options’ outcomes, clinical problem, outcome probabil-
ities, others’ opinions, explicit values clarification (utilities for outcomes associated with
prostate cancer)
Comparator 2: explicit values clarification (utilities for outcomes associated with prostate
cancer)
Comparator 3: usual care using public information on prostate cancer screening on
AmericanCancer Society andCenters forDisease Control and Preventionwebsites 2005-
2006
Outcomes Primary outcomes: knowledge, actual option, decisional conflict
Secondary outcomes: concern about prostate cancer, treatment preference if prostate
cancer diagnosed
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer algorithm randomly assigned
participants to the 4 study groups
Allocation concealment (selection bias) Low risk Revealed after signed consent and com-
pleted baseline measures
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Accessed a secure Internet site that hosted
all study materials; participants had unlim-
ited access to assigned intervention, unclear
blinding of personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were mea-
sured via questionnaires and not subjective
to interpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used intention-to-treat analysis; imputed
missing data for participants who did not
complete follow-up assessments; minimal
attrition
Selective reporting (reporting bias) Unclear risk No indication of published protocol
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Frosch 2008a (Continued)
Other bias Low risk Appears to be free of other potential biases
Gattellari 2003
Methods Randomized to decision aid vs usual care
Participants 126 + 122 men considering PSA testing in Australia
Interventions DA: pamphlet on options’ outcomes, clinical problem, outcome probability, explicit
values clarification
Comparator: usual care using brief information on screening test and chances of false-
positive results
Outcomes Preferred option, knowledge, decisional conflict, accurate risk perceptions, perceived
ability to make an informed choice
Notes Primary outcome was not specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Pre-randomized code - no further informa-
tion (p 1)
Allocation concealment (selection bias) Low risk Pre-randomized code unobtrusivelymarked
on envelopes (p 1)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Consenting menwere blinded to allocation,
but unclear if personnel were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Pre-test characteristics included. Flow chart
not included and reasons for attrition not
mentioned; some attrition but balanced be-
tween groups
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Low risk Appears to be free of other potential biases
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Gattellari 2005
Methods Randomized to decision aid booklet vs decision aid video vs usual care
Participants 140 + 141 + 140 men considering PSA testing in Australia
Interventions DA: pamphlet on options’ outcomes, clinical problem, outcome probability, explicit
values clarification
Comparator 1: video on clinical problem, outcome probability, others’ opinion
Comparator 2: usual care using brief information on screening test and chances of false-
positive results
Outcomes Preferred option, knowledge, decisional conflict, perceived ability to make an informed
choice
Notes Primary outcome was not specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Unique identification codes assigned to
participants according to date and time en-
rolled into the interventional component
of the study. Block randomization of iden-
tification codes then performed via com-
puter software (p 2 - 2.3.1)
Allocation concealment (selection bias) Low risk “Allocation concealment was ensured as the
interviewers, responsible for enrolling par-
ticipants onto the trial, were blinded to the
randomized study design while one of the
authors (MG)was responsible for randomi-
sation. Hence, it was not possible for either
participants or interviewers to be aware of
the randomisation sequence.” (p 2 - 2.3.1)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and interviewers were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk At post-test, it was not possible to blind the
interviewers but outcomes were objectively
measured and not subjective to interpreta-
tion
Incomplete outcome data (attrition bias)
All outcomes
Low risk Minimal attrition that is consistent across
groups (figure 1)
Selective reporting (reporting bias) Unclear risk “[S]uccess of study protocol” limitation to
protocol: men not confronted with actual
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Gattellari 2005 (Continued)
decision to undergo PSA screening; no in-
dication that trial registered in central trials
registry (p 13, paragraph 5)
Other bias Low risk “[H]igh follow-up rate and allocation con-
cealment; study not subjected to selection
bias” (p 13, paragraph 5). Appears to be free
of other sources of bias
Green 2001
Methods Randomized to decision aid + counselling vs counselling alone vs usual care
Participants 29 + 14 women with a first degree relative with breast cancer interested in learning about
genetic testing in the USA
Interventions DA: CD-ROM plus counselling on options’ outcomes, clinical problem, others’ opin-
ions, guidance/coaching
Comparator: counselling
Comparator: usual care
Outcomes Primary outcome: preferred options
Secondary outcome: knowledge
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[B]lock randomization schedule to one of
three groups in a 2:2:1 ratio” (p 2)
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “[G]enetic counsellor blinded to random-
ization until just prior to the session” (p 2)
, unclear if participants were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to to in-
terpretation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Values do not always add up to the num-
ber of participants due to missing data”;
reasons not mentioned (p 4). “Participants’
baseline knowledge was reflected in the
control group’s answers”; participants bal-
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Green 2001 (Continued)
anced in study groups
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Low risk Appears to be free of other sources of bias
Hamann 2006
Methods Cluster-randomized trial of decision aid vs usual care
Participants 54 + 59 patients with schizophraenia considering treatment options (cluster-RCT with
12 wards paired and randomized) in Germany
Interventions DA: 16-page booklet on options’ outcomes, outcome probabilities, explicit values clari-
fication, coaching/guidance
Comparator: usual care
Outcomes Knowledge, participation in decision making (COMRADE - doctor gave me a chance
to decided which treatment I thought was best for me), uptake of psycho-education,
rehospitalization, adherence, satisfaction with care, severity of illness (baseline only),
attitudes about drug use, decision making preference
Notes Primary outcome was not specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “[O]ne member of each pair being ran-
domly assigned to the control or to the in-
terventional condition” (p 266). Sequence
generation method was not stated
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for attrition mentioned
Selective reporting (reporting bias) Unclear risk No information provided
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Hamann 2006 (Continued)
Other bias High risk Clustering was not accounted for in the
analysis
Hanson 2011
Methods Randomized to decision aid vs usual care
Participants 127 + 129 patients diagnosed with advanced dementia and eating problems considering
long-term feeding tube placement in the USA
Interventions DA: booklet or audio recording on options’ outcomes, clinical problem, outcome proba-
bilities, explicit values clarification, others’ opinion, guidance (steps in decision making,
worksheet, summary)
Comparator: usual care
Outcomes Primary outcomes: decisional conflict (3 months post-DA)
Secondary outcomes: surrogate knowledge, risk perceptions, frequency of communica-
tion with providers (3 months post-DA), feeding treatment use (3, 6 and 9 months post-
DA), participation in decision making, satisfaction with the decision, decisional regret
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerized random number generation
(p 2010, Randomization)
Allocation concealment (selection bias) Unclear risk No description of method used to conceal
allocation (p 2010, Randomization)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Cluster randomization prevented double
blinding and may have introduced bias due
to site effects” (p 2014, Discussion); study
authors unsure of effect on study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “[B]ecause of cluster randomization, data
collectors were not blinded to group assign-
ment” (p 2010, Randomization); authors
believe has little impact on study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Intervention group missing data for 1 par-
ticipant, reason for omission not reported
(table 1)
No explanation for number of participants
in each group (n = 127) given numbers vary
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Hanson 2011 (Continued)
from those in ’recruitment and retention’
figure (table 4)
Selective reporting (reporting bias) Low risk Registered with clinicaltrials.gov, protocol
on website
Other bias Low risk Appears to be free of other potential biases
Heller 2008
Methods Randomized to decision aid vs usual care
Participants 66 + 67 breast cancer patients eligible for breast reconstruction in the USA
Interventions DA: interactive software programme on options’ outcomes, others’ opinions
Comparator: standard patient education
Outcomes Knowledge, anxiety, satisfaction with treatment choice, satisfaction with decision-mak-
ing ability
Notes Primary outcome was not specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “upon study entry, the participants were
randomized (computer generated) to one of
two groups” (p 2)
Allocation concealment (selection bias) Unclear risk Not enough information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Baseline anxiety and knowledge included in
graphs. Participant numbers between study
groups balanced (p 3). Reasons for incom-
plete questionnaires and study withdrawals
mentioned
Selective reporting (reporting bias) Unclear risk No information provided re protocol
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Heller 2008 (Continued)
Other bias Low risk Appears to be free of other potential biases
Hess 2012
Methods Randomized to decision aid vs usual care
Participants 103 + 105 patients in the the emergency department with primary symptoms of nontrau-
matic chest pain and were being considered of admission to the emergency department
observation unit for monitoring and cardiac stress testing within 24 hours
Interventions DA (in consultation): 1-page printout on options’ outcomes, clinical problem, and out-
come probabilities
Comparator: usual care
Outcomes Primary outcomes: knowledge
Secondary outcomes: risk perceptions, decisional conflict, actual choice, satisfaction with
decision making process, patient-practitioner communication
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomized to either usual
care or shared decision making through a
Web-based, computer-generated allocation
sequence in a 1:1 concealed fashion” (p 253)
Allocation concealment (selection bias) Low risk “Patients were randomized to either usual
care or shared decision making through a
Web-based, computer-generated allocation
sequence in a 1:1 concealed fashion” (p 253)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Personnel were blinded, but unclear if pa-
tients were blinded (p 253, Outcome mea-
sures). However, the primary outcome is
unlikely to be biased
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators assessing outcomes were
blinded (p 253, Outcome measures).
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Some of the numbers of patients reported
in the results did not match the flow chart
Selective reporting (reporting bias) Low risk Protocol is available
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Hess 2012 (Continued)
Other bias Low risk Appears to be free of other biases
Jibaja-Weiss 2011
Methods Randomized to decision aid vs usual care
Participants 51 + 49 women diagnosed with breast cancer considering surgical treatment in the USA
Interventions DA: computer programme on options’ outcomes, clinical problem, outcome probabili-
ties, explicit values clarification, others’ opinion and guidance (step-by-step process for
making the decision)
Comparator: usual care + breast cancer treatment educational materials normally pro-
vided to patients
Outcomes Surgical treatment preference (post-DA), breast cancer knowledge (pre, post-DA, post-
DA and consult), satisfactionwith surgical decision (post-DA), satisfactionwith decision-
making process (post-DA), decisional conflict (pre, post-DA, post-DA and consult),
proportion undecided
Notes Primary outcome was not specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients at each hospital were randomized
using permuted blocks” (p 42,Methods sec-
tion)
Allocation concealment (selection bias) Unclear risk Not addressed in the study
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not addressed in the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There is no way to know if the plots include
all of the participants’ data since they do
not specify what was the number of patients
used to obtain these mean scores
Selective reporting (reporting bias) Unclear risk No mention of protocol
Other bias Low risk Appears to be free of other potential biases
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Johnson 2006
Methods Randomized to decision aid vs usual care
Participants 32 + 35 patients considering endodontic treatment options in the USA
Interventions DA (in consultation): decision board on options’ outcomes, clinical problem, outcome
probability, guidance
Comparator: usual care
Outcomes Primary outcomes: knowledge, satisfaction with decision making process, anxiety
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[F]our computerized random generation
lists to assign to one of two groups” (p 3)
Allocation concealment (selection bias) Unclear risk Not for residents: computer-generated ran-
domization lists (1 for each resident) were
prepared by the PI (p 3-4); therefore resi-
dents would have had pre-generated lists;
Unclear for patients: “allocation was con-
cealed from patients” (p 3) but does not ex-
plain how
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding not mentioned. Allocation was
concealed from patients only (p 3)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to to in-
terpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Flow diagram (p 6); all 40 patients agreed to
participate in the study, but only 32 ques-
tionnaires were useable several residents did
not understand need for entering data on
the envelope and placingmatched question-
naire in it (p 5)
Selective reporting (reporting bias) Unclear risk No indication that the trial was registered
in a central trials registry
Other bias Unclear risk “[B]aseline data obtained because possi-
ble that clinicians training in the EndoDB
would alter usual care discussions” (p 5)
. Mentions taking baseline characteristics,
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Johnson 2006 (Continued)
but not included in article
Kasper 2008
Methods Randomized to decision aid vs usual care
Participants 150 + 147 multiple sclerosis patients considering immunotherapy in Germany
Interventions DA: booklet and worksheet on options’ outcomes, clinical problem, outcome probabil-
ities, explicit values clarification (based on IPDAS)
Comparator: information material on immunotherapy (80 pages)
Outcomes Primary outcomes: role in decision making
Secondary outcomes: choice, feeling undecided, helpfulness with making a decision,
attitudes toward immunotherapy, expectations of side effects realized at 6 months
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[A]llocation using computer generated
random numbers” (p 5)
Allocation concealment (selection bias) Unclear risk Randomization was carried out by con-
cealed allocation, but method of conceal-
ment was not described (p 2, Assignment)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were not told whether the in-
formation they received was standard infor-
mation or the newly developed DA (p 3,
Masking)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were not told whether the infor-
mation they received was standard informa-
tion or the newly developedDA (p 3,Mask-
ing)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Flow of participants (p 2, Fig 1); baseline
data/characteristics included
Selective reporting (reporting bias) Low risk “The protocol of this study has been pub-
lished with the trial registration at http://
controlled-trials.com/ ISRCTN25267500”
(p 2)
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Kasper 2008 (Continued)
Other bias Unclear risk Difference in preferred interaction style be-
tween groups at baseline (P value 0.04) (p
5)
Kennedy 2002
Methods Randomized to decision aid + coaching vs decision aid only vs usual care
Participants 215 + 206 + 204 women considering treatment for menorrhagia in the UK
Interventions DA: video + booklet on options’ outcomes, clinical problem, outcome probabilities,
explicit values clarification, others’ opinions, guidance/coaching
Coaching: ~ 20 minute coaching with explicit values clarification by a registered nurse
prior to seeing physician
Comparator: usual care
Outcomes Primary outcomes: general quality of life
Secondary outcomes: uptake of option, satisfaction, menorrhagia severity, cost-effective-
ness
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation sequence was generated by com-
puter and stratified by consultant and the
age at which the woman left full-time edu-
cation (p 3)
Allocation concealment (selection bias) Low risk “Secure randomization ensured by using
a central telephone randomization system”
(p 3)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Possibility of contamination bias; clinicians
could have applied the experience gained
from consultations with the interventions
groups in their consultations with the con-
trol group (p 6)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear if blinding used but most out-
comes were objectively measured and not
subjective to interpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Table 1 and Figure 1 flow diagram (p 4-5)
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Kennedy 2002 (Continued)
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Low risk Appears to be free from other risks of bias
Knops 2014
Methods Randomized to decision aid vs usual care
Participants 91 + 87 patients with asymptomatic abdominal aortic aneurysm considering elective
surgery vs watchful waiting
Interventions DA: interactive CD-ROM on options’ outcomes, clinical problem, outcome probabili-
ties, explicit values clarification
Comparator: usual care with regular information
Outcomes Primary outcomes: decisional conflict (baseline, 1, 4, and 10 months)
Secondary outcomes: patient knowledge (baseline and 1 month), anxiety (baseline, 1, 4,
and 10 months), satisfaction with conversation with the surgeon (baseline and 1 month)
, final treatment choice (10 months), aneurysm rupture (10 months), possible date
of surgery (10 months), postoperative morbidity and mortality (10 months), physical
quality of life (baseline, 1, 4, and 10 months)
Notes Trial registration: NTR1524
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated
randomisation ALEA v.2.2, NKI-AVL, the
Netherlands) was performed by the investi-
gators” (p 2)
Allocation concealment (selection bias) Low risk “Computer-generated
randomisation ALEA v.2.2, NKI-AVL, the
Netherlands) was performed by the investi-
gators” (p 2)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Patients and investigators could not be
blinded after group assignment, a factor
which is inherent to the decision aid and the
design of the study. Surgeons and nurses in-
volved in the outpatient care of the partic-
ipants were blinded to the patient’s alloca-
tion group, although patients were not pro-
hibited from sharing their allocation with
them.” (p 3)
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Knops 2014 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome measurement is not likely to be
influenced by lack of blinding as all out-
comes were measured objectively using val-
idated scales and data retrieved frommedial
records
Incomplete outcome data (attrition bias)
All outcomes
Low risk Appears to have similar attrition between
groups. The proportion of values missing
varied from 2% to 9% per outcome mea-
sure. Missing values were completed by
multiple imputation analysis. If one of the
outcome measures had more than 25%
missing values, that outcome measure for
that patient was excluded from analysis.
Therefore, missing data have been handled
appropriately (p 3)
Selective reporting (reporting bias) Unclear risk Insufficient information to make judgment
Other bias High risk “Considerable number of patients could not
be included, were not asked to participa-
tion, or declined to participate. Selection
bias may have occured in patients that were
not included” (p 6)
“Both patients and surgeons were aware of
the aim and subject of the study and could
not be blinded to the allocation. It is pos-
sible that surgeons in the contributing cen-
tres offered more than average information
to their patients” (p 6). Performance bias
may have been introduced in terms of al-
tered communication style
Krist 2007
Methods Randomized to decision aid booklet vs decision aid web-based vs usual care
Participants 196 + 226 + 75 patients considering prostate cancer screening in the USA
Interventions DA: 4 page pamphlet with options’ outcomes, clinical problem, outcome probability
Comparator: web-site with same information as paper based DA
Comparator: usual care
Outcomes Primary outcomes: role in decision making
Secondary outcomes: knowledge, decisional conflict, time spent discussing screening,
choice (PSA test ordered)
Notes -
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Krist 2007 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[C]oordinator referred to pre-generated
randomisation tables to inform the partic-
ipant to which arm he was randomised” (p
2)
Allocation concealment (selection bias) Low risk At the time of enrolment, the allocationwas
concealed from the coordinator (p 2)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Physicians were not blinded - could af-
fect decision making process and uptake of
screening
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk p 3, Results; p 4, Flow diagram
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Unclear risk Uneven groups but done intentionally, ra-
tion of 1:3:3 but appears to be free of other
potential biases
Kupke 2013
Methods Cluster-randomized trial of 2 groups of dental students to decision board group and
non-decision board group. Patients randomized to students in either group
Participants 57 + 36 patients with defect in posterior tooth (Class II defect) considering 6 treatment
options, including no therapy
Interventions DA (in consultation): options’ outcomes, outcome probabilities
Comparator: usual care with discussion of the treatment options
Outcomes Knowledge (costs/self-payment, survival rate, characteristics and treatment time) (postin-
tervention); overall satisfaction with consultation (postintervention)
Notes Primary outcome not specified
Risk of bias Risk of bias
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Kupke 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned by a dice (selection of
students and patient allocation) (p 20)
Allocation concealment (selection bias) High risk “The patients were assigned to the students
according to common standards of the uni-
versity independently and without know-
ing which group the student belonged to.”
(p 20)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Patients were assigned to the students in-
dependently and without knowing which
group the students belonged to” (p 20)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to judge if blind-
ing of outcome assessment occurred
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar attribution in both groups; “miss-
ing answers were treated as incorrect an-
swers, while illegible answers were treated
as missing values” (p 22)
Selective reporting (reporting bias) Unclear risk No mention of study protocol or trial reg-
istration. No way to ensure the outcomes
they intended to measure are fully reported
Other bias High risk Did not adjust for clustering in analysis
Kuppermann 2014
Methods Randomized to decision aid vs usual care
Participants 375 + 369 11-week pregnant women who had not yet undergone prenatal screening or
diagnostic testing
Interventions DA: describes clinical condition, options, outcome probabilities, values clarification
Comparator: usual care
Outcomes Primary outcomes: invasive prenatal diagnostic testing (3 to 6 months)
Secondary outcomes: testing strategy undergone (3 to 6 months), knowledge (3 to 6
months), accurate risk perception (procedure related miscarriage, DS affected fetus) (3
to 6 months), decisional conflict (3 to 6 months), decisional regret (3 to 6 months)
Notes -
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Kuppermann 2014 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computer generated random allocation
sequence assigned participants to experi-
mental groups within permuted blocks of
random size, with a 1:1 allocation ratio,
stratified by age, clinical site, parity, and in-
terviewer” (p 1211)
Allocation concealment (selection bias) Low risk “The randomization code was not available
to any study-related personnel until data
analysis was complete” (p 1211)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Different research associates facilitated
baseline and follow-up interviews and med-
ical record review to ensure blinding to the
randomization assignment” (p 1211)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Different research associates facilitated
baseline and follow-up interviews and med-
ical record review to ensure blinding to the
randomization assignment” (p 1211)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar attrition in both groups. “[A]ll re-
ported analyses were based on a modified
intention-to-treat sample” (p 1211)
Selective reporting (reporting bias) Low risk Trial registered
Other bias Low risk Appears to be free of other sources of bias
Lam 2013
Methods Randomized to decision aid or standard information booklet after initial consultation
Participants 138 + 138 women considering breast cancer surgery for early-stage breast cancer
Interventions DA: take-home booklet on clinical problem, options’ outcomes, outcome probabilities,
guidance, explicit values clarification
Comparator: standard information booklet
Outcomes Primary outcomes: treatment decision making difficulties and decisional conflict scale
at 1 week post consultation, knowledge at 1-week postconsultation, decision regret at 1
month after surgery
Secondary outcomes: postoperative psychological distress (anxiety and depression) at
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Lam 2013 (Continued)
1, 4, and 10 months after surgery, decision regret at 4 and 10 months after surgery,
treatment decision
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patient assignment to treatment and con-
trol arms was performed using a prior
computer-generated random-number se-
quence” (p 2880)
Allocation concealment (selection bias) Low risk “A serially labeled, opaque, sealed-envelope
method was used for block randomization”
(p 2880)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Two research staff members - one respon-
sible for preintervention assessment and
block allocation and the other for postinter-
vention assessments - ensured that the re-
searcher performing follow-up assessments
was blinded regarding women’s allocation
status.” “Blinding surgeons to allocation
status proved impractical.” (p 2880)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk 1 research staff member was responsible for
postintervention assessments to ensure that
the researcher performing follow-up assess-
ments was blinded regarding women’s allo-
cation status (p 2880)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Does not appear to bemissing any outcome
data; similar attrition in both groups
Selective reporting (reporting bias) Low risk Study protocol available online with pub-
lished study
Other bias Low risk Does not appear to be subject to other
sources of bias
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Langston 2010
Methods Randomized to decision aid + coaching vs usual care
Participants 114 + 108 women pregnant women in their first trimester considering use of contracep-
tives in the USA
Interventions DA: double-sided flip chart on clinical problem, outcome probabilities, guidance (ad-
ministered by a research assistant), coaching (structured, standardized, non-directive
contraceptive counselling) + usual care
Comparator: usual care
Outcomes Primary outcomes: proportion of participants choosing very effective contraceptive
method (post-DA and consult)
Secondary outcomes: actual choice on day of procedure (post-DA and consult), adher-
ence of very effective and/or effective methods at 3 months and at 6 months (post-DA
and consult)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Using a random-number table, we deter-
mined the sequence for 1:1 allocation con-
strained by blocks of 10” (p 363, Methods-
study procedures)
Allocation concealment (selection bias) Low risk “Randomization assignments were sealed
inside numbered, opaque envelopes” (p
363, Methods-study procedures)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “No blinding of participants or coordina-
tors was feasible due to the nature of the
intervention. Physician-providers did not
know the participant’s allocation group, did
not discuss the study with patients, and
were asked not to change their counselling”
(p 363, Methods-study procedures)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk For “method initiation on the day of
the procedure” it is only said that the
“[p]articipants in the intervention group
were not more likely to initiate the re-
quested method immediately compared to
those in the usual care group”; possible that
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Langston 2010 (Continued)
the results contradicted the hypothesis and
were excluded for this reason
Selective reporting (reporting bias) Unclear risk Nomention of study protocol; not enough
information to permit judgement
Other bias Low risk Appears to be free of other potential biases
Laupacis 2006
Methods Randomized to decision aid vs usual care
Participants 60 + 60 patients undergoing elective open heart surgery considering pre-operative au-
tologous blood donation in Canada
Interventions DA: audiotape booklet on options’ outcomes, clinical problem, outcome probability,
explicit values clarification, guidance (Ottawa Decision Support Framework)
Comparator: usual care
Outcomes Primary outcomes: knowledge, decisional conflict
Secondary outcomes: uptake of option, satisfaction with decision making process, satis-
faction with decision, accurate risk perceptions
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization envelopes were prepared
centrally by a statistician” (p 2)
Allocation concealment (selection bias) Low risk “The envelopes were labeled with identifi-
cation numbers and contained a card spec-
ifying the patient’s group assignment. The
envelopes were opened by the interviewer
after completion of the baseline interview.”
(p 2)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
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Laupacis 2006 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Results, p 4; fig 1, flow diagram
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Low risk Appears to be free of other potential biases
LeBlanc 2015
Methods Randomized to decision aid vs individualized score only vs usual care
Participants 32 + 33 + 14 women over 50 years diagnosed with osteopenia or osteoporosis not taking
biphosphonates or other prescription medication
Interventions DA (in consultation): clinical problem, individualized risk of condition, options’ out-
comes, guidance
Comparator 1: individualized risk
Comparator 2: usual care
Outcomes Primary outcomes: knowledge (immediately post), decisional conflict (immediately post)
, participation in decision-making process (immediately post), decision to start (immedi-
ately post), adherence (6 months), acceptability (timing not specified), satisfaction with
the decision-making process (not specified), quality of life (not specified), time (review
of video consultation)
Secondary outcome: decision quality (not reported)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were allocated using a computer-
generated sequence that randomized them
1:1:1 in a concealed fashion” (p 5)
Allocation concealment (selection bias) Low risk “Patients were allocated using a computer-
generated sequence that randomized them
1:1:1 in a concealed fashion” (p 5)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Patients and clinicians were aware of
the overall objective, presented as im-
provement in communication between pa-
tients and clinicians during the clinical en-
counter, but remained blinded to the spe-
cific aims” (p 5)
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LeBlanc 2015 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “After randomization, only data analysts re-
mained blind to allocation” (p 5)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used intention-to-treat analysis; similar at-
trition in both groups
Selective reporting (reporting bias) Unclear risk Trial registered; Checklists available for
CONSORT and protocol. Sample size
originally calculated based on adherence
but re-calculated for decisional conflict
given inability to reach original target
Other bias High risk “Possible contamination at the clinician
level (i.e. clinician who, having used the
decision aid with a prior patient, recreates
elements of the decision aid with a sub-
sequent patient allocated to receive FRAX
alone or usual care) was monitored by a de-
tailed review of the available video recorded
encounters” (p 5)
Legare 2008a
Methods Randomized to decision aid vs usual care
Participants 45 + 45 women considering use of natural health products for managing menopausal
symptoms
Interventions DA: booklet with worksheet on options’ outcomes, clinical problem, explicit values
clarification, guidance/coaching (Ottawa Decision Support Framework)
Comparator: general information brochure on the clinical problem (did not address risks
and benefits)
Outcomes Primary outcomes: decisional conflict
Secondary outcomes: knowledge of natural health products in general (not specific option
outcomes), preferred choice, values-choice agreement, proportion undecided
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomization scheme was carried out
by a biostatistician using computer-gener-
ated unequal blocks
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Legare 2008a (Continued)
Allocation concealment (selection bias) Low risk Sealed opaque envelopes containing 1 or the
other documents (a PDA in the intervention
group and a general information brochure
in the control group) were prepared by an-
other individual, external to the study
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The investigators were blinded but no men-
tion of blinding of participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to to in-
terpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk See Figure 1 for flow diagram, reason for
loss to follow-up was described
Selective reporting (reporting bias) Low risk Trial registration identifier is
NCT00325923
Other bias Low risk No statistically significant difference in
women’s characteristics between groups (Ta-
ble 1)
Legare 2011
Methods Cluster-randomized to decision aid vs usual care
Participants 245 + 214 patients with non-emergent acute respiratory infections considering using
antibiotics in Canada
Interventions DA (in consultation): pamphlet on options’ outcomes, clinical problem, outcome prob-
abilities, explicit values clarification, guidance and coaching
Comparator: delayed intervention
Outcomes Primary outcomes:
• Patient outcomes: actual choice (pre and post-DA), perceived decision quality
(pre and post-DA), decisional conflict (pre and post-DA), decision regret (pre and
post-DA), general health outcomes
• Practitioner outcomes: decision, perceived decision quality, decisional conflict
Secondary outcomes:
• Patient outcomes: intention to engage in future SDM (pre and post-DA),
participation in decision making
• Practitioner outcomes: intention to engage in future SDM and comply with
clinical practice guidelines
Notes -
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Legare 2011 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A biostatistician simultaneously ran-
domised all FMGs and allocated them to
groups using Internet-based software” (p
99)
Allocation concealment (selection bias) Low risk “Using Internet-based software” (p 99)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear blinding of participants and per-
sonnel: only biostatistician was blinded (p
99)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biostatistician who assesses the outcomes
is blinded, outcomes were objectively mea-
sured (p 99)
Incomplete outcome data (attrition bias)
All outcomes
Low risk There appear to be no missing data
Selective reporting (reporting bias) Low risk No missing pre-specified outcomes
Other bias Low risk Appears to be free of other sources of bias
Legare 2012
Methods Cluster-randomized controlled trial to decision aid vs usual care
Participants 239+210 adults and children with with a diagnosis of acute respiratory infection (e.g.,
bronchitis, otitis media, pharyngitis, rhinosinusitis)
Interventions DA (in consultation): pamphlet on options’ outcomes, clinical problem, outcome proba-
bilities, explicit values clarification, guidance and coaching (participating physicians also
received training in the form of a 2-hour online tutorial and a 2-hour on-site interactive
workshop)
Comparator: usual care
Outcomes Primary outcome: use of antibiotics (immediately post consultation)
Secondary outcomes: decisional conflict (immediately post), control preference scale
(immediately post), quality of decision (immediately post), adherence to the decision (2
weeks post), repeat consultation (2 weeks post), decisional regret (2 weeks post), quality
of life (2 weeks post) and intention to engage in SDM in future consultations regarding
antibiotics for acute respiratory infections (2 weeks post)
Notes -
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Legare 2012 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A biostatistician used internet-based soft-
ware to simultaneously randomize all 12
family practice teaching units to either the
intervention group or control group. The
teaching units were stratified according to
rural or urban location” (p E728)
Allocation concealment (selection bias) Low risk “A biostatistician used internet-based soft-
ware to simultaneously randomize all 12
family practice teaching units to either the
intervention group or control group. The
teaching units were stratified according to
rural or urban location” (p E728)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Patients with symptoms suggestive of an
acute respiratory infection were initially re-
cruited by a RA in the waiting room before
consultation with a physician” (p E728)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The biostatistician was unaware of group
allocation, the researchers and research as-
sistants who recruited patients and col-
lected data were not” and “Statistical analy-
sis was performed by a statistician who was
unaware of the teaching unit allocations”
(p E729)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Protocol registered and published
Other bias Low risk “To avoid contamination bias, access to the
online tutorial was denied to providers in
the control groupduring the trial” (pE728)
Leighl 2011
Methods Randomized to DA + usual care vs usual care
Participants 107 + 100 patients diagnosed with metastatic CRC considering advanced chemotherapy
in Australia and Canada
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Leighl 2011 (Continued)
Interventions DA: booklet and audiotape on option’ outcomes, clinical problem, outcome probabili-
ties, explicit values clarification and guidance (steps in decision making + worksheet)
Comparator: usual care
Outcomes Primary outcomes: knowledge (post-DA), satisfaction with decision (post-DA)
Secondary outcomes: anxiety (pre and post-DA), satisfaction with consultation (post-
DA), choice leaning (post-DA), decisional conflict (post-DA). achievement of their in-
formation preference (post-DA), participation in decision making (post-DA), accept-
ability (post-DA), quality of life (post-DA)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomized lists (p
2078, Study design)
Allocation concealment (selection bias) Low risk Code concealed in sealed envelopes until
time of random assignment (p 2078, Study
design)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Patients not blinded and subjective out-
comes may be affected by them knowing
their assignment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All outcomes are not subjected to interpre-
tation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 31% dropout rate, but similar losses across
all groups
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk Appears to be free of other sources of bias
Lepore 2012
Methods Randomized to decision support intervention (decision coaching by telephone + educa-
tional pamphlet) vs control
Participants 244 + 246 African American men aged 45-70 in the USA
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Lepore 2012 (Continued)
Interventions DA: condition-specific educational pamphlet on prostate cancer screening and tailored
telephone education on options’ outcomes, explicit values clarification, others’ opinions,
and guidance (decision coaching)
Comparator: attention control (education on fruit and vegetable consumption)
Outcomes Primary outcomes: knowledge (pretest and post-test at 8 months postrandomization),
decisional conflict (posttest), physician visit to discuss testing (post-test), adherence as
congruence between testing intentions and behaviors (post-test)
Secondary outcomes: testing intention (post-test), benefit-to-risk ratio of testing (post-
test), PSA screening (post-test), anxiety (pretest and post-test)
Notes Trial registration NCT01415375
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The principal investigator used a com-
puter-generated randomization
schedule to randomize the participant.” (p
322)
Allocation concealment (selection bias) Unclear risk “The principal investigator used a com-
puter-generated randomization schedule to
randomize the participant and emailed the
randomization assignment to the interven-
tionist.” (p 322)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Interventionists were not blind to condi-
tion. We can assume that patients were
blinded as the study design was a tele-
phone call for both intervention and con-
trol groups (p 322)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Data collectors were blind to condition
but the interventionists were not” (p 322)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Does not appear to bemissing any outcome
data
Selective reporting (reporting bias) Low risk Appears to have reported on all pre-speci-
fied outcomes (protocol)
Other bias Low risk Appears to be free of other potential sources
of bias
108Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lerman 1997
Methods Randomized to decision aid vs waiting list control
Participants 122 + 114 + 164 women considering BRCA1 gene testing in the USA
Interventions DA: education and counselling on options’ outcomes, clinical problem, outcome prob-
ability, explicit values clarification, others’ opinions, guidance/coaching
Comparator: no intervention
Outcomes Primary outcome: preferred option
Secondary outcomes: knowledge, accurate risk perceptions, perceived personal risk/ben-
efits/limitations, agreement between values and choice
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Of 440 women, 400 completed 1-month
follow-up interviews; no reasons provided;
baseline data/characteristics included (p 2)
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Low risk Appears to be free of other potential biases
Lewis 2010
Methods Cluster-randomized to decision aid vs usual care
Participants 211 + 232 patients considering colorectal cancer screening in the USA
Interventions DA: web-based, DVD and VHS videotape formats + stage targeted brochures (and
booster kit if patients had not been screened) on options’ outcomes, clinical problem,
outcome probabilities, others’ opinion, guidance (encouraged patients to communicate
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Lewis 2010 (Continued)
with their practitioners by asking questions and sharing preferences; summary)
Comparator: usual care using Aetna annual reminders to obtain CRC screening
Outcomes Knowledge of the age at which screening should begin (post-DA), completion of col-
orectal cancer screening (pre, post-DA), intrusive thoughts (pre, post-DA), interest in
CRC screening (pre, post-DA), intent to ask provider about screening (pre, post-DA),
readiness to be screened (pre, post-DA), perceived risk of colon cancer (pre, post-DA),
general beliefs about colon cancer (pre, post-DA), fears about colorectal cancer screening
(pre, post-DA), perceptions about whether participants had enough information (post-
DA), whether participants had enough information about specific screening tests (post-
DA), willingness to pay for screening tests (post), desire to participate inmedical decision
(post)
Practice level measures: assess CRC screening practices (pre, post-DA), referrals (pre,
post-DA), quality improvement initiatives
Notes Primary outcome was not specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation was done using matched
pairs and a blocking procedure.” (p 2, Prac-
tice recruitment and randomization sec-
tion)
Allocation concealment (selection bias) Unclear risk “Thus, purposive assignment to treatment
group was used, resulting in a hybrid ran-
domisation” (p 3, Practice recruitment and
randomization section). There is no men-
tion of the effect of this purposive assign-
ment on the study
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk As mentioned above, staff used purposive
assignment and were therefore not blinded,
but there is no mention of the effect on the
study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The study did not address this outcome,
but outcomes were objectively measured
Incomplete outcome data (attrition bias)
All outcomes
Low risk There appear to be no missing outcome
data
Selective reporting (reporting bias) Unclear risk No mention of study protocol
Other bias High risk Unadjusted cluster analysis
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Loh 2007
Methods Cluster-randomized to decision aid vs usual care
Participants 263 + 142 patients with physician diagnosed depression (cluster RCT with 30 general
practitioners randomized) in Germany
Interventions DA (in consultation): options’ outcomes, clinical problem, explicit values clarification,
guidance/coaching
Comparator: usual care
Outcomes Participation in decision making, adherence, satisfaction with clinical care, depression
severity, consultation length
Notes Primary outcome was not specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[T]wo-thirds of the general practitioners
were randomly assigned to the intervention
groupby drawingblinded lots under the su-
pervision of the principal investigator and
two researchers” (p 3)
Allocation concealment (selection bias) Low risk Drawing blinded lots (p 3 - 2.1)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear blinding, not enough information
provided to assess whether this contributes
to bias on outcomes not measured by us-
ing a scale (e.g. consultation time was doc-
umented in minutes by the physicians fol-
lowing each consultation)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Further results resting on the baseline
phase of this trial were already presented
elsewhere” (p 5, fig); “unequal distribu-
tion of physicians was due to possibility of
higher dropout rate in intervention group
because of additional time and effort” (p 3)
Selective reporting (reporting bias) Unclear risk No indication that the trial was registered
in a central trials registry
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Loh 2007 (Continued)
Other bias Low risk Appears to be free of other potential bi-
ases (p 5-6, details pt and physician base-
line characteristics). Statistically significant
differences were controlled for in outcome
analyses
Man-Son-Hing 1999
Methods Randomized to decision aid vs usual care
Participants 139 + 148 patients on atrial fibrillation trial considering continuing on aspirin vs change
to Warfarin in Canada
Interventions DA: audiotape booklet on options’ outcomes, clinical problem, outcome probability, ex-
plicit values clarification, others’ opinions, guidance (Ottawa Decision Support Frame-
work)
Comparator: usual care
Outcomes Primary outcomes: uptake of options, adherence
Secondary outcomes: help with making a decision, knowledge, accurate risk perceptions,
decisional conflict, satisfaction with decision making process, role in decision making
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated scheme (p 2)
Allocation concealment (selection bias) Low risk Administered from a central location (p 2)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unclear blinding however, “contamination,
physicians may have provided DA informa-
tion to patients receiving usual care” (p 7)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk P 4, fig 2 flow chart. Reasons for attrition
not mentioned. Baseline data not included
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Low risk No other potential risks of bias
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Mann D 2010
Methods Randomized to decision aid vs usual care
Participants 80 + 70 participants diagnosed with diabetes considering the use of statins to reduce
coronary risk
Interventions DA (in consultation): healthcare provider led discussion using developed tool (Statin
Choice) on options’ outcomes,outcome probabilities, guidance (step-by-step process for
making the decision; administered by the physician in the consultation)
Comparator: usual primary care visit + pamphlet
Outcomes Knowledge (postconsult and post-DA), decisional conflict (postconsult and post-DA),
risk estimation (postconsult and post-DA), beliefs (postconsult and post-DA), adherence
(3 and 6 months postconsult and post-DA)
Notes Primary outcome was not specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participantswere randomized but there is no
mention of method used (p 138, Methods
section)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were not
subjective to interpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Baseline data was provided
Selective reporting (reporting bias) Unclear risk Only reports on improvement (i.e. deci-
sional conflict scale); does not present out-
come data to fullest (no numerical data on
knowledge results between groups, only de-
scribes in words)
Other bias Unclear risk “We did not adjust the clustering of effects
given that few participants received care by
the same clinicians” (p 139, Analysis sec-
tion). No mention of magnitude in change
of data due to this choice
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Mann E 2010
Methods Randomized to decision aid vs usual care
Participants 278 + 139 participants considering diabetes screening in the UK
Interventions DA: screening invitation on clinical problem, outcome probabilities and explicit values
clarification
Comparator: usual care using screening invitation on clinical problem
Outcomes Primary outcomes: preferred option (post-DA)
Secondary outcomes: whether invitation type impacts on intention (post-DA), impact
on knowledge (post-DA), impact on attitude (post-DA), risk perception
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Invitation taken from the top of a ran-
domly ordered pile (either standard or one
of two versions of an informed decision
choice invitation). The materials were or-
dered in a way that the invitation type was
hidden until the recruitment process was
completed” (p 2-3, Methods, Participants
section). Unclear how invitation type was
hidden
Allocation concealment (selection bias) Low risk “Invitation taken from the top of a ran-
domly ordered pile; materials were ordered
in a way that the invitation type was hid-
den until the recruitment process was com-
pleted” (p 2-3, Methods, Participants sec-
tion)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Interviewers were not aware of the direction
of anticipated effect of materials, and ma-
terials were dummy-coded so that no sense
of intervention or control would have been
communicated to interviewers or partici-
pants (p 3, Methods, Participants section)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study didnot address this outcome, but out-
comes were objectively measured and not
subject to interpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
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Mann E 2010 (Continued)
Selective reporting (reporting bias) Unclear risk No mention of protocol; insufficient infor-
mation to permit judgment
Other bias Unclear risk “Present sample was … not necessarily rep-
resentative of the highest risk individuals
in this age group”; “£5 incentive might
have also added a selection bias”; “Lack of
anonymitywith verbally delivered question-
naire might encourage socially desirable re-
sponding” (p 6, Discussion section)
Marteau 2010
Methods Randomized to decision aid vs usual care
Participants 633 + 639 patients considering diabetes screening in England
Interventions DA: screening invitation on clinical problem, outcome probabilities and explicit values
clarification
Comparator: usual care using screening invitation on clinical problem
Outcomes Primary outcome: attendance for screening (post-DA and consult)
Secondary outcomes: intention to make changes to lifestyle (post-DA and consult),
satisfaction with decisions made among attenders (post-DA and consult)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[G]enerated simultaneously in a batch by
random numbers using Excel spreadsheet
software, stratifying by number of partici-
pants in household” (p 2, Randomization
section)
Allocation concealment (selection bias) Low risk “Randomisation … was undertaken by the
study statistician from a central site” (p 2,
Randomization section)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Personnel were blinded and appears that pa-
tients were unaware which arm they were in
(members of the same household received
the same intervention) (p 2, Randomization
section)
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Marteau 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Clinical and trial staff taking measurements
and entering data were unaware of the study
arm towhich participants had been assigned
(p 2, Randomization section)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Published protocol (p 2, Methods)
Other bias Low risk Appears free of other potential biases
Mathers 2012
Methods Cluster-randomized controlled trial of 49 general practices in the UK to decision aid,
healthcare professional training workshop and use of PDA in consultation, or usual care
Participants 95 + 80 participants with type 2 diabetes considering adding or changing to insulin
therapy
Interventions DA: booklet about clinical problem, treatment options, options’ outcomes, outcome
probabilities, explicit values clarification, structured guidance
Comparator: usual care
Outcomes Primary outcomes: decisional conflict (immediately postintervention), glycaemic control
(glycosolated haemoglobin, HbA1c) at 6 months
Secondary outcomes: knowledge (immediately post), realistic expectations (immediately
post), preference option (immediately post), proportion undecided (immediately post),
participation in decision-making (immediately post), regret (6 months), adherence with
chosen option (6 months)
Notes Trial registration: ISRCTN14842077
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “All eligible and willing practices were ran-
domly allocated by a computer” (p 3)
Allocation concealment (selection bias) Low risk “A statistician generated the random allo-
cation sequence while a secretary who was
not involved in the research study assigned
participants to either the intervention or
control groups” (p 3)
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Mathers 2012 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Blinding of the intervention and assess-
ment of the process measures were not fea-
sible in view of the nature of the interven-
tion studied” (p 3)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Blinding of the intervention and assess-
ment of the process measures were not fea-
sible in view of the nature of the interven-
tion studied” (p 3)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Does not appear to bemissing any outcome
data
Selective reporting (reporting bias) Low risk Trial registered
Other bias Unclear risk Cannot make a judgment with informa-
tion provided regarding cessation of re-
cruitment at 175 (yet 320 required to allow
detection of 0.5% difference in HbA1c)
Mathieu 2007
Methods Randomized to decision aid versus usual care
Participants 367 + 367 women aged 70 to 71 years and considering a subsequent screening mam-
mography in Australia
Interventions DA: booklet on options’ outcomes, clinical problem, outcome probability, explicit val-
ues clarification, others’ opinions, guidance with worksheet (Ottawa Decision Support
Framework)
Comparator: BreastScreen NSW brochure - includes information for women 70 + but
no numeric information about the outcomes of screening
Outcomes Primary outcomes: actual decision, informed choice
Secondary outcomes: knowledge (includes 5 questions about risk perceptions), anxiety,
decisional conflict, breast cancer worry, preference/intension, attitudes about screening,
relationship between objective and perceived risk of breast cancer
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer programme, which assigned al-
locations in accordance with a simple ran-
domization schedule (p 2, Methods)
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Mathieu 2007 (Continued)
Allocation concealment (selection bias) Low risk Randomized by interview staff who ac-
cessed a previously concealed computer
programme (p 2, Methods)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Interviewers [at follow-up] were blinded,
outcomes were objectively measured and
not subjective to to interpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Fig 1 flow diagram (p 2)
Selective reporting (reporting bias) Low risk “The trial was registeredwith theAustralian
Clinical TrialsRegistry and theClinical Tri-
als Registration System” (p 5)
Other bias Low risk Appears to be free of other potential biases
Mathieu 2010
Methods Randomized to decision aid vs usual care
Participants 189 + 223 women considering mammography screening
Interventions DA: Internet programme + worksheet on options’ outcomes, clinical problem, outcome
probabilities, explicit values clarification, others’ opinions, guidance (worksheet with
questions relevant to decision making process; one or more questions that asked patients
to clarify their preferences; summary)
Comparator: delayed intervention
Outcomes Primary outcomes: knowledge (post-DA), risk perception
Secondary outcomes: intention (post-DA), values (post-DA), informed choice (post-
DA), proportion undecided
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[C]omputer generated simple randomiza-
tion schedule” (p 66, Randomization and
baseline questions section)
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Mathieu 2010 (Continued)
Allocation concealment (selection bias) Unclear risk “[R]andomization was conducted in a con-
cealed manner” (p 66). Method of alloca-
tion concealment not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were not
subjective to interpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcomes mentioned in Outcome mea-
sures sectionwere reported in the results sec-
tion (p 68, Table 2; information for inten-
tion as well as anxiety and acceptability can
be found in text format in the secondary
outcomes section on pg.67-68)
Selective reporting (reporting bias) Unclear risk No mention of protocol
Other bias Low risk Appears to be free of other potential sources
of bias
McAlister 2005
Methods Cluster-randomized to decision aid vs usual care
Participants 219 + 215 patients considering antithrombotic therapy for nonvalvular atrial fibrillation
(cluster-RCT with 102 primary care practices randomized) in Canada
Interventions DA: audiotape booklet on options’ outcomes, clinical problem, outcome probabilities,
explicit values clarification, others’ opinions, guidance (OttawaDecision Support Frame-
work)
Comparator: usual care
Outcomes Primary outcomes: uptake of (appropriate) option
Secondary outcomes: knowledge, decisional conflict, accurate risk perceptions
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[C]luster randomization at level of pri-
mary care practice to minimize contami-
nation; randomization was done centrally
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McAlister 2005 (Continued)
to preserve allocation concealment using a
computer generated sequence” (p 2)
Allocation concealment (selection bias) Low risk Randomization was done centrally to pre-
serve allocation concealment (p 2, Meth-
ods)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not blinded, but not sure whether the lack
of blinding would affect the outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Results and Fig 1 - flow diagram (p 3)
Selective reporting (reporting bias) Low risk DAAFI trial protocol, including copies of
the various questionnaires we employed,
has been published (p 1, Methods)
Other bias Low risk Appears to be free of other potential biases
McBride 2002
Methods Randomized to decision aid vs usual care
Participants 289 + 292 perimenopausal women considering hormone replacement therapy in the
USA
Interventions DA: options’ outcomes, clinical problem, outcome probability, values clarification, oth-
ers’ opinions, guidance/coaching
Comparator: delayed intervention
Outcomes Primary outcome: accurate risk perceptions
Secondary outcomes: satisfactionwith decision, confidence with knowledge andmaking/
discussing decision
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided; Bastian 2002, no
information provided - Study design is de-
scribed elsewhere (p 4)
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McBride 2002 (Continued)
Allocation concealment (selection bias) Unclear risk No information provided; Bastian 2002, no
information provided - Study design is de-
scribed elsewhere (p 4)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Complete data are available for 520 (90%)
of the women (p 2). Reasons why not men-
tioned (Bastian 2002, p 5,Results; p 6, Base-
line characteristics/data included)
Selective reporting (reporting bias) Unclear risk No indication that the trial was registered
in a central trials registry
Other bias Low risk Appears to be free of other potential bi-
ases; Bastian 2002, p 8 -Eligible participants
were willing to consider HRT and this may
have favoured recruitment of women with
higher SES and those who had prior expe-
rience with HRT
McCaffery 2010
Methods Randomized to decision aid + informed choice vs HPV testing vs repeat smear
Participants 104 + 104 + 106 women screened as HPV indeterminate considering HPV testing in
Australia
Interventions DA: pamphlet on options’ outcomes, clinical problem, outcome probabilities, explicit
values clarification, others’ opinion and guidance (worksheet)
Comparator 1: no decision support, received immediate HPV testing
Comparator 2: no decision support, received a repeat cervical smear at 6 months
Outcomes Primary outcomes: quality of life (post-DA)
Secondary outcomes: waiting time anxiety (post-DA), , perceived risk (post-DA), per-
ceived seriousness of cancer (post-DA), worriedness (post-DA), intrusive thoughts (post-
DA), satisfaction with care (post-DA), anxiety (post-DA), distress and concerns (post-
DA), self-esteem (post-DA), effect on sexual behaviour (post-DA), help seeking be-
haviour (post-DA), knowledge (post-DA)
Notes -
121Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
McCaffery 2010 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Participants were randomised centrally by
the research team within each clinic in
blocks of three” (p 2, Design)
Allocation concealment (selection bias) Low risk “Participants were randomised centrally by
the research team within each clinic in
blocks of three” (p 2, Design)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Patients and staff were unblinded, but ob-
jective outcomes were used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All outcomes are on questionnaires; not
subject to interpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Figure 3: sensitivity analysis was done to
include most of the patients
Selective reporting (reporting bias) Low risk Protocol available
Other bias Low risk Appears to be free of other sources of bias
Miller 2005
Methods Randomized to decision aid vs usual care
Participants 279 women considering BRCA1-BRCA2 gene testing in the USA
Interventions DA: educational intervention on options’ outcomes, personal family cancer history; clin-
ical problem, outcome probability, explicit values clarification, others’ opinions, guid-
ance/coaching
Comparator: provision of general information about cancer risk
Outcomes Preferred option, knowledge, perceived risk, satisfaction
Notes Primary outcome was not specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Miller 2005 (Continued)
Random sequence generation (selection
bias)
Low risk “[R]andomized by the CATI system” (p 4)
after self-initiated telephone contact
Allocation concealment (selection bias) Low risk “[C]omputerized assisted telephone inter-
view system (CATI)” (p 4)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding was not addressed
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons stated for initial drop-out of study
participants (p 8). Patients contacted of-
fered reasons for dropping out. Study pro-
tocol allowed patients to be reached up to
13 times at follow-up; but still not able to
be reached
Selective reporting (reporting bias) Unclear risk No indication that the trial was registered
in a central trials registry
Other bias Low risk Appears to be free of other sources of bias
Miller 2011
Methods Decision aid vs attention placebo
Participants 132 + 132 participants considering colon cancer screening in the USA
Interventions DA: computer-based web programme on options’ outcomes, clinical problem, outcome
probabilities, others’ opinion, guidance (encourages patient-practitioner communica-
tion, summary)
Comparator: computer-based web programme on prescription drug refills and safety
Outcomes Primary outcomes: receipt of CRC screening (post-DA)
Secondary outcomes: ability to state a preference, change in readiness to receive screening
(pre and post-DA), CRC test ordering (post-DA), proportion undecided
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Miller 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Block-randomized, stratified by literacy level (p
609, Methods)
Allocation concealment (selection bias) Unclear risk Study does not address this domain
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Health care providers were not notified of patients’
enrolment in the study at any time (p 609,Methods)
RAs that administered post-DA questionnaire were
not blinded but believed to be a low risk of bias (p
613, Discussion)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “[C]linical outcome assessors were [blinded]” (p
613, Discussion)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Protocol on ClinicalTrials.gov
Other bias Unclear risk USD 10 gift card for participation could affect par-
ticipant pool
Montgomery 2003
Methods Randomized to decision aid + decision analysis vs decision analysis vs decision aid vs
usual care
Participants 51 + 52 + 55 + 59 newly diagnosed hypertensive patients considering drug therapy for
blood pressure in the UK
Interventions DA: decision analysis plus information video and leaflet on options’ outcomes, clinical
problem, outcome probability, explicit values clarification
Comparator: decision analysis on options’ outcomes, outcome probability, explicit values
clarification
Comparator: video and leaflet on options’ outcomes, clinical problem
Comparator: usual care
Outcomes Primary outcomes: decisional conflict
Secondary outcomes: uptake of option, knowledge, anxiety
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Montgomery 2003 (Continued)
Random sequence generation (selection
bias)
Low risk Allocation schedule was computer-gener-
ated by an individual not involved in the
study (p 2)
Allocation concealment (selection bias) Low risk “[A]llocation was concealed to the author
in advance by the nature of the minimiza-
tion procedure” (p 2)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not blinded - unclear if this would intro-
duce bias to outcome assessed
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Flow diagram (p 5)
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Low risk Appears to be free of other potential biases
Montgomery 2007
Methods Randomized to decision aid with values clarification vs decision aid without values
clarification vs usual care
Participants 245 + 250 + 247 women with previous caesarean section in the UK
Interventions DA: options’ outcomes, clinical problem, outcome probability, explicit values clarifica-
tion
Comparator: options’ outcomes, clinical problem, outcome probability
Comparator: usual care
Outcomes Primary outcomes: decisional conflict
Secondary outcomes: choice, anxiety, knowledge, satisfaction with decision
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Blocked by using randomly permuted and
selected blocks of sizes 6, 9, 12, and 15
generated by computer (p 2Methods, Ran-
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Montgomery 2007 (Continued)
domization)
Allocation concealment (selection bias) Low risk 1 member of the study team generated the
randomization sequence by computer, and
another member of staff with no other in-
volvement in the trial performed the allo-
cation (p 2 Methods, Randomization)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to to in-
terpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk See flow of women through the study
Selective reporting (reporting bias) Low risk Trials registry ISRCTN84367722
Other bias Low risk Recruited more than planned to account
for lost data (p 4, Sample size); baseline
characteristics were balanced
Montori 2011
Methods Randomized to decision aid vs usual care + booklet
Participants 52 + 48 women with low bone mass or osteoporosis considering taking bisphosphonates
in the USA
Interventions DA (in consultation): worksheet on options’ outcomes, clinical problem, outcome prob-
abilities, guidance (administered by physician)
Comparator: usual care + general information booklet on osteoporosis
Outcomes Patient knowledge (post-DA), satisfactionwith knowledge transfer (post-DA), decisional
conflict (post-DA), patient-clinician communication (OPTION), trust with physician
(during intervention), clinician’s perception of decision quality (post-DA), clinician’s
satisfaction with knowledge transfer (post-DA), uptake (post-DA), adherence (post-DA)
, fidelity (post-DA), contamination (post-DA), risk perception
Notes Primary outcome was not specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Montori 2011 (Continued)
Random sequence generation (selection
bias)
Low risk “computer generated allocation” (p 551,
Randomization)
Allocation concealment (selection bias) Low risk Patients randomized “in a concealed fash-
ion (using a secure study website)” (p 551,
Randomization)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No mention of participants being blinded
to their allocation; only mention of data
collectors and analysts blinding (p 551,
Randomization)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “After randomization, data collectors and
data analysts were blind to allocation” (p
551, Randomization); Outcomes were not
subject to interpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk “The protocol for this trial has been re-
ported in full” (p 550, Design)
Other bias Unclear risk Appears to be free of other potential biases
Morgan 2000
Methods Randomized to decision aid vs usual care
Participants 120 + 120 patients with ischaemic heart disease considering revascularization surgery in
Canada
Interventions DA: Health Dialog interactive videodisc on options’ outcomes, clinical problem, out-
come probability, others’ opinions
Comparator: usual care
Outcomes Primary outcome: satisfaction with the decision making process
Secondary outcomes: uptake of option, knowledge
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Morgan 1997, p 29: all randomization en-
rolment was performed by telephone at
which time the participant was assigned
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Morgan 2000 (Continued)
Morgan 2000 (primary study), p 2, Meth-
ods, Patient Population: “Only the statis-
tician was privy to the two randomisation
schedules and blocking factor used”
Allocation concealment (selection bias) Low risk Morgan 1997, p 29: only the statisticianwas
privy to the two randomization schedules
and blocking factor;
Morgan 2000, (primary study), p 2, Meth-
ods, Patient Population: “only the statisti-
cian was privy to the two randomisation
schedules and blocking factor used. All ran-
domization enrolment was performed by
telephone”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “[D]ue to nature of trial, neither patients
or investigators were blinded to the study” -
may introduce bias to subjective outcomes
such as satisfaction
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Morgan 1997, p 39, Patient accrual and fol-
low-up: baseline characteristics included
Morgan 2000 (primary study): 78% com-
pleted follow-up (90 of 120 in the interven-
tion; 97 of 120 in the control). reasons for
attrition were provided
Selective reporting (reporting bias) Unclear risk No indication that the trial was registered
in a central trials registry
Other bias Unclear risk Morgan 1997, p 56: significant number of
patients were lost to follow-up (25%); Mor-
gan 2000 (primary study): baseline data im-
balance (high school grad, income, no. of
diseased arteries). Dropout group reported
lower incomes, may have affected results.
(discussion par. 6) “Selection bias was mini-
mized by enrolling available consecutive pa-
tients”
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Mott 2014
Methods Randomized to shared decision-making process with DA versus usual care
Participants 13 +14 military veterans in USA diagnosed with PTSD and had served in Iraq or
Afghanistan
Interventions DA: booklet on clinical problem, options’ outcomes, structured guidance
Comparator: usual care
Outcomes Satisfaction with SDM qualitatively (postintervention), perceived advantages and dis-
advantages of SDM qualitative (postintervention), treatment preferences (4 months),
adherence using treatment engagement (4 months)
Notes Not reported as registered in trials database; no primary outcome reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Participants were randomized to SDM or
UC using a computer-generated random-
ization sequence” (p 146)
Allocation concealment (selection bias) Low risk “[R]andomization envelopeswere prepared
by the study statistician to ensure that study
staff remainedmasked to randomization se-
quence” (p 146)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information provided to make
judgment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study staff not blinded but because out-
comes were taken from medical records.
“At 4-month follow-up, study staff re-
viewed participants’ medical records to ex-
tract information on treatment preferences
and engagement. Medical-record reviews
were conducted by a single rater trained in
use of the dataextraction form. A second
rater, masked to initial ratings, reextracted
data from 20% of patients” (p 146)
Incomplete outcome data (attrition bias)
All outcomes
High risk 27 participants were consented and en-
rolled , yet only 20 (UC = 11; SMD = 9)
completed the study (p 146-147). Only 5
participants in the SDM arm completed
the exit interview. No mention of missing
data
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Mott 2014 (Continued)
Selective reporting (reporting bias) Low risk No protocol available but all expected out-
comes reported on
Other bias Low risk Does not appear to be any other sources of
bias
Mullan 2009
Methods Cluster-randomized to decision aid vs usual care
Participants 48 + 37 patients with type 2 diabetes considering treatment options (cluster RCT with
40 clinicians randomized) in the USA
Interventions DA (in consultation): decision cards with information on options, outcomes, outcome
probability, explicit values clarification
Compare: 12-page pamphlet on oral antihyperglycaemic medications
Outcomes Knowledge, decisional conflict, participation in decision making, acceptability of the
information, change in medication, adherence, HbA1C levels, trust in physician, OP-
TION to analyse audio-taped encounters
Notes Primary outcome was not specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Patients were blinded, the clinicians were
not, but each session was recorded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reasons for attrition not included
Selective reporting (reporting bias) Low risk Trial registration no. at clinicaltrials.gov re-
ported
Other bias Low risk Appears to be free of other sources of bias
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Murray 2001a
Methods Randomized to decision aid vs usual care
Participants 57 + 55 men considering treatment for benign prostatic hypertrophy in the UK
Interventions DA: Health Dialog interactive videodisc on options, outcomes, clinical problem, out-
come probability, others’ opinions
Comparator: usual care
Outcomes Primary outcomes: uptake of option, prostate symptoms, costs, anxiety
Secondary outcomes: decisional conflict, role in decision making, general health status,
utility
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[R]andomisation schedule, stratified ac-
cording to recruitment centre, was gener-
ated by computer” (p 4)
Allocation concealment (selection bias) Low risk “Allocation were sealed in opaque num-
bered envelopes, opened by the study nurse”
(p 4)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not blinded but not sure how this would
introduce bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to to in-
terpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Flow diagram (p 5); baseline data/charac-
teristics included and balanced
Selective reporting (reporting bias) Unclear risk No indication that the trial was registered
in a central trials registry
Other bias Low risk Appears to be free of other sources of bias
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Murray 2001b
Methods Randomized to decision aid vs usual care
Participants 102 + 102 women considering hormone replacement therapy in the UK
Interventions DA:HealthDialog interactive videodisc on options outcomes, clinical problem, outcome
probability, other’s opinion
Comparator: usual care
Outcomes Primary outcomes: preferred option
Secondary outcomes: help with making a decision, decisional conflict, role in decision
making
anxiety, menopausal symptoms, costs, utility, general health status
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[R]andomisation schedule, stratified ac-
cording to recruitment centre, was gener-
ated by computer” (p 3 Methods, Random-
ization)
Allocation concealment (selection bias) Low risk “Allocations were sealed in opaque num-
bered envelopes, opened by the study nurse
after collection of the baseline data” (p 3
Methods, Randomization)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to to in-
terpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk See page 3 figure for Progress of patients
through trial
Selective reporting (reporting bias) Unclear risk Protocol is not mentioned
Other bias Low risk Similar baseline characteristics, appears to
be free of other potential biases. Educational
achievement was higher in control group.
Quote “Subsequent analysis showed that
educational level not related to use of HRT
nor was there an interaction between edu-
cational attainment and the intervention”
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Nagle 2008
Methods Cluster-randomized to decision aid vs usual care
Participants 167 + 172 women in early pregnancy considering genetic testing (26 + 29 general
physicians) (cluster RCT with 60 general practitioners randomized) in Australia
Interventions DA: 24-page booklet and worksheet on options, benefits and risks, test limitations,
outcomes; clinical problem, outcome probability, explicit values clarification, opinions
of others’, guidance (Ottawa Decision Support Framework)
Comparator: standard pamphlet on prenatal testing
Outcomes Primary outcomes: informed choice, decisional conflict
Secondary outcomes: anxiety, depression, attitudes toward pregnancy, acceptability of
the intervention, choice
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers (p
3)
Allocation concealment (selection bias) Low risk Computer-generated random numbers by
an independent statistician; allocation con-
cealment was achieved (p 3)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Due to the nature of the intervention, it
was not possible to blind women, GP’s or
researchers” (p 3); unclear if this would in-
troduce bias to outcome assessed
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Researchers were not blinded but outcomes
were objectively measured and not subjec-
tive to interpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Results, p 4; Fig 1 - flow diagram, p 5
Selective reporting (reporting bias) Low risk Trial Registration - The ADEPT trial was
registered in the UK with Current Con-
trolled Trials [ISRCTN22532458] and
with the Australian Clinical Trials Registry
(No: 012606000234516) (p 4)
Other bias Low risk Appears to be free of other potential biases
(p 8); selection bias but was adjusted for in
analysis
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Nassar 2007
Methods Randomized to decision aid vs usual care
Participants 102 + 98 women diagnosed with a breech presentation from 34 weeks gestation consid-
ering external cephalic version in Australia
Interventions DA: 24-page booklet, 30-minute audio-CD and worksheet; clinical problem, outcome
probability, explicit values clarification, opinions of others’, guidance (Ottawa Decision
Support Framework)
Comparator: usual care counselling and information on the management of breech
presentation
Outcomes Primary outcomes: knowledge, decisional conflict, anxiety, satisfaction with the decision,
Secondary outcomes: preferred role in decision making, preferred choice
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[R]andomly generated using computer
and stratified by parity and center using ran-
dom variable block sizes” (p 2)
Allocation concealment (selection bias) Low risk “[P]articipants were randomized by tele-
phoning a remote, central location” (p 2)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Womens were not blinded - unclear if this
would introduce bias to outcome assessed
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up because of onset of labour
or incomplete data forms (p 3). Baseline
characteristics are included and equal. Min-
imumof 84participants in each study group
achieved; p 4 - flow diagram
Selective reporting (reporting bias) Low risk ISRCTN14570598
Other bias Low risk “Maternal characteristics and baseline mea-
sures of cognitive and affective outcomes
were comparable between groups” (p 3 Re-
sults, Table 1)
“Blinding clinicians and employment of a
research midwife to interact with women”
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Nassar 2007 (Continued)
(p 6)
Oakley 2006
Methods Randomized to decision aid vs usual care
Participants 16 + 17 postmenopausal women with osteoporosis considering treatment options to
prevent further bone loss in the UK
Interventions DA: audiotape booklet on options’ outcomes, clinical problem, outcome probability, ex-
plicit values clarification, others’ opinions, guidance (Ottawa Decision Support Frame-
work)
Comparator: usual care
Outcomes Satisfaction with information, decisional conflict (intervention group only), improve-
ment in adherence
Notes Primary outcome was not specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Low risk Group allocation was done by a third party,
unconnected to the study and blinded to
the identity of the patients (p 1)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear blinding, some outcomes were as-
sessed by open-ended questions, do not
knowwhether this contributes to risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Sample characteristics not included; base-
line satisfaction score included. “No evalu-
ation was carried out to determine the rea-
sons for non-participation” (p 2)
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Unclear risk No baseline characteristics (p 2). Only 16
patients in intervention group and 17 in
control group; small sample size
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Ozanne 2007
Methods Randomized to decision aid + standard counselling vs usual care (standard counselling)
Participants 15 + 15 women considering breast cancer prevention in the USA
Interventions DA (in consultation): interactive computer decision aid on options outcomes, outcome
probability
Comparator: standard counselling
Outcomes Primary outcomes: consultation length
Secondary outcomes: knowledge, decisional conflict, satisfaction with the decision, ac-
ceptability of the decision aid, physician satisfaction with the consultation
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomized evenly between
groups; no information provided about
generation (p 149)
Allocation concealment (selection bias) Unclear risk No information provided (p 149)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to to in-
terpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Demographic data included; reasons for at-
trition mentioned
Selective reporting (reporting bias) Unclear risk No reference to study protocol
Other bias Unclear risk Small sample size, does not say how many
physicians participated in study, mentions
that there were observed changes in physi-
cian behaviour (based on doing both inter-
vention and control)
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Partin 2004
Methods Randomized todecision aidwith others’ opinions vs decision aidwithout others’ opinions
vs usual care
Participants 384 + 384 + 384 men considering PSA testing in the USA
Interventions DA: Health Dialog video on options’ outcomes, clinical problem, outcome probability,
others’ opinions
Comparator 1: pamphlet on options’ outcomes, clinical problem, outcome probability
Comparator 2: usual care
Outcomes Primary outcomes: knowledge
Secondary outcomes: preferred option, help with making a decision, decisional conflict
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Using a computer-generated algorithm (p
2)
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “[P]roviders were blinded to the fact that
their patients were participating in a trial”
“coordinator did not have direct contact
with subjects” (p 5)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “[F]ollow-up interviewers blinded, statisti-
cians were not”.Outcomeswere objectively
measured and not subjective to to interpre-
tation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Flow diagram (p 2); reasons for attri-
tion mentioned and participants balanced
across study groups. Sample characteristics
included
Selective reporting (reporting bias) Unclear risk No indication that the trial was registered
in a central trials registry
Other bias Low risk Appears to be free of other potential biases
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Pignone 2000
Methods Randomized to decision aid vs usual care
Participants 125 + 124 adults considering colon cancer screening in the USA
Interventions DA: video of options’ outcomes, clinical problem, others’ opinion
Comparator: video on car safety
Outcomes Primary outcome: uptake of options
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[C]omputerized random number genera-
tor” (p 2, Methods, Group assignment)
Allocation concealment (selection bias) Low risk “[R]andomization was performed centrally
and was not balanced among centers. As-
signments were placed in sealed, opaque,
sequentially numbered envelopes and were
distributed to the three sites” (p 2,Methods,
Group assignment)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The providers and staff were not blinded
to intervention status” “3 to 6 months af-
ter, different RA blinded to participant in-
tervention examined clinic records” (p 2)
Does not mention whether patients were
blinded; unclear if lack of blinding con-
tributed to potential risk of bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A different research assistant who was
blinded to participants’ intervention status
examined participants’ clinic records in a
standardized and validatedmanner to deter-
mine whether colon cancer screening tests
were actually completed within 3months of
the index visit
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Because of an administrative error, 18 con-
trols did not complete the second and third
questionnaires (p 4)
Selective reporting (reporting bias) Unclear risk Protocol was not mentioned
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Pignone 2000 (Continued)
Other bias Low risk Baseline characteristics similar, appear to be
no other potential sources of biases. Mini-
mized bias from repeated measurements by
administering the same questionnaires to
the intervention and control participants
Protheroe 2007
Methods Randomized to decision aid vs usual care
Participants 60 + 56 women considering treatment options for menorrhagia in the UK
Interventions DA: interactive computerized DA on options’ outcomes, clinical problem, outcome
probability, explicit values clarification, guidance
Comparator: information leaflet
Outcomes Primary outcomes: decisional conflict
Secondary outcomes: knowledge, anxiety, condition specific health outcomes, treatment
preference, undecided
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomization, strat-
ified by practice and minimized according
to age (p 2, Methods)
Allocation concealment (selection bias) Unclear risk Random allocation was concealed from the
individual who was making judgments of
eligibility, but the method of concealment
was not stated (p 2, Methods)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to to in-
terpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Fig 6 flow diagram (p 5); baseline data/char-
acteristics included and balanced (p 4)
Selective reporting (reporting bias) Low risk ISRCTN72253427
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Protheroe 2007 (Continued)
Other bias Low risk Appears to be free of other potential biases
Rubel 2010
Methods Randomized to pretest + decision aid + post-test vs decision aid + post-test vs pretest +
posttest vs posttest
Participants 50 + 50 + 50 + 50 men considering prostate cancer screening in the USA
Interventions DA: booklet on options’ outcomes, clinical problem, outcome probabilities, others’ opin-
ions + pretest and post-test
Comparator : booklet on options’ outcomes, clinical problem, outcome probabilities,
others’ opinions + post-test
Comparator: pretest + post-test
Comparator: post-test
Outcomes Knowledge (pre, post-DA), decisional anxiety (post-DA), decisional conflict (post-DA),
participation in decision making (pre, post-DA), schema for PSA testing (pre, post-DA)
, perception of quality and interpretation of recommendation (post-DA)
Notes Primary outcome was not specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Electronically generated random number
sequence (p 309, Study design section)
Allocation concealment (selection bias) Low risk They were given sealed, sequentially num-
bered packets (p 309, Study design section)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No mention of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding, but the outcomes were
objectively measured and not subject to in-
terpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Protocol followed CONSORT checklist (p
310, Study design section)
Other bias Low risk Appears to be free of other potential biases
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Ruffin 2007
Methods Randomized to decision aid vs usual care
Participants 87 + 87 community dwelling adults not previously screened for CRC in the USA
Interventions DA: interactive website with information on options’ outcomes, clinical problem, out-
come probability, explicit values clarification, others’ opinion, guidance
Comparator: non-interactive website with information on clinical problem
Outcomes Primary outcome: uptake of option
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A block randomisation process pro-
grammed by the study computer support
staff and verified by a statistician was used
including two strata, race and gender” (p 3)
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The investigators, data collectors, data en-
try, and data analyst were all blinded to
study arm assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Flow diagram (p 3)
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Low risk Appears to be free of other potential biases
Sawka 2012
Methods Randomized to decision aid vs usual care
Participants 37 + 37 individuals with early-stage papillary thyroid cancer
Interventions DA: web-based decision aid with clinical problem, options’ outcomes, outcome proba-
bilities, guidance, printout summary
Comparator: usual care (consultation with a specialized head and neck surgeon, and with
1 or more medical specialist)
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Sawka 2012 (Continued)
Outcomes Primary outcomes: knowledge (baseline and immediately post intervention)
Secondary outcomes: decisional conflict, undecided, treatment decision (baseline, im-
mediately post intervention, 6 to12 months), individual primarily responsible for the
treatment decision (6 to 12 months)
Notes Trial registration: NCT01083550
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Central computerized randomization in a
1:1 ratio was performed at a patient level by
using variable block sizes of 2 and 4 (allo-
cation designed by a study statistician)” (p
2908)
Allocation concealment (selection bias) Low risk “Before the random assignment/testing
visit, neither the participant, study staff,
investigators, nor treating physicians were
aware of the allocation, because it had not
yet been assigned” (p 2908)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “There was no blinding of participants,
study staff, or treating physicians after ran-
dom assignment was completed” (p 2908)
, yet it is unlikely that the outcomes are af-
fected by the lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “There was no blinding of participants,
study staff, or treating physicians after ran-
dom assignment was completed. However,
the statistician was blinded to the allocation
of groups at the time of data analysis.” (p
2908)
Incomplete outcome data (attrition bias)
All outcomes
Low risk There does not appear to be any missing
outcome data
Selective reporting (reporting bias) Unclear risk Authors state the trial is registered, but no
link to trial number
Other bias Low risk Appears to be free of other potential sources
of bias
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Schroy 2011
Methods Randomized to detailed vs simple decision aid vs control
Participants 223 + 212 + 231 average-risk patients considering CRC screening in the USA
Interventions Detailed DA: CRC risk assessment + web-based interactive audio-visual DA on options’
outcomes, clinical problem, outcome probabilities, others’ opinion and guidance
Comparator 1: web-based decision aid only
Comparator 2: usual care using pamphlet
Outcomes Knowledge (pre and post-DA), satisfaction with decision making process (pre and post-
DA), preferred choice (pre and post-DA)
Notes Primary outcome was not specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No mention of randomization process
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Providers were not blinded, subjective out-
comes such as satisfaction with decision-
making process could have been affected,
unclear if participants were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors not blinded but outcome mea-
sures not believed to be influenced by it
Incomplete outcome data (attrition bias)
All outcomes
Low risk No data appears to be missing
Selective reporting (reporting bias) Unclear risk No mention of examination of selective
outcome reporting or study protocol
Other bias Low risk Appears to be free of other sources of bias
Schwalm 2012
Methods Randomized to decision aid vs usual care
Participants 76 + 74 patients undergoing coronary angiography
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Schwalm 2012 (Continued)
Interventions DA: booklet on options’ outcomes, clinical problem, outcome probabilities, explicit
values clarification and guidance
Comparator: usual care
Outcomes Primary outcomes: decisional conflict
Secondary outcomes: knowledge, risk perception, value congruent with chosen option
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerized random number generator
(p 261, Study design)
Allocation concealment (selection bias) Low risk Sealed envelopes (p 261, Study design)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Patients and physicians were not blinded to
the allocation (p 261, Study design)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear if DCS score assessed by unblinded
individuals, but outcomes were objectively
measured and not subjective to interpreta-
tion
Incomplete outcome data (attrition bias)
All outcomes
Low risk Did not seem to have incomplete data
Selective reporting (reporting bias) Low risk Protocol is available
Other bias Low risk Appeared to be free of other biases
Schwartz 2001
Methods Randomized to decision aid vs usual care
Participants 181 + 190 Ashkenazi Jewish women considering genetic testing in the USA
Interventions DA: 16-page booklet on genetic testing with options’ outcomes, clinical problem
Comparator: general information on breast cancer, Understanding Breast Changes: A
Health Guide for all Women, published by the National Cancer Institute
Outcomes Primary outcome: preferred option
Secondary outcomes: knowledge, accurate risk perceptions
Notes -
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Schwartz 2001 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated (p 3)
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk High retention rate, baseline data and rea-
sons for lost to follow-up were provided (p
2, Participants section)
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Low risk Appears to be free of other potential biases
Schwartz 2009a
Methods Randomized to decision aid + genetic counselling vs genetic counselling alone
Participants 100 + 114 women considering prophylactic mastectomy for being BRCA1/2 mutation
carriers in the USA
Interventions DA: CD-Rom on options’ outcomes, clinical problem, risk communication with in-
dividually tailored risk graphs, explicit values clarification, others’ opinion; guidance/
counselling - genetic counselling as usual care (Ottawa Decision Support Framework)
Comparator: genetic counselling on benefits and risks of testing, clinical problem (risk
assessment, cancer risks associated with mutations, process of testing and interpretation
of results) plus written letter outlining all guidelines and recommendations
Outcomes Primary outcomes: decisional conflict, satisfaction with decision, actual choice (risk
reduction mastectomy)
Secondary outcomes: remaining undecided
Notes -
Risk of bias Risk of bias
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Schwartz 2009a (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomized via computer-generated ran-
dom number in a 1:1 ratio (p 3, Procedure)
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Fig. 1 - flow diagram (p 3)
Selective reporting (reporting bias) Unclear risk Protocol not mentioned
Other bias Low risk Appears to be free of other sources of bias (p
8) “when variable for not watching DA cd
was considered in multivariate models, the
results did not change substantively (data
not shown)”
Sheridan 2006
Methods Randomized to decision aid vs usual care (list of risk factors)
Participants 49 + 38 adults with no history of cardiovascular disease in the USA
Interventions DA: computerized decision aid on options’ outcomes, outcome probabilities
Comparator: list of CHD risk factors to present to doctor
Outcomes Patient-practitioner communication (e.g. discussion with doctor, specific plan to reduce
risk discussed with doctor)
Notes Primary outcome was not specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[C]omputerized random number genera-
tor” (p 2)
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Sheridan 2006 (Continued)
Allocation concealment (selection bias) Low risk “[S]ealed in security envelopes” (p 2)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants were blinded but the doctors
who saw both groups were not
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcome was patient
reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Results (p 5); Flowdiagram (p 10); Baseline
characteristics/data included
Selective reporting (reporting bias) Low risk ClinicalTrials.gov NCT00315978
Other bias Low risk Appears to have no other potential risk of
bias
Sheridan 2011
Methods Randomized to decision aid + tailored messages vs usual care
Participants 81 + 79 patients with moderate or high risk for CHD considering CHD prevention
strategies in the USA
Interventions DA: web-based decision aid on options’ outcomes, clinical problem, outcome probabil-
ities, explicit values clarification and guidance
Comparator: usual care using computer programme
Outcomes Preferred choice (post-DA), adherence
Other outcomes (Sheridan 2014): patient-provider communication (post-DA), patient
participation (post-DA), patients perceptions of discussions and the health care visit
(post-DA), preferred choice (baseline and post-DA) (data from 81 +79 patients)
Notes Primary outcome was not specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomised by study staff
who accessed an online randomised sched-
ule” (p 2). Sequence generationmethodnot
stated
Allocation concealment (selection bias) Low risk “Patients were randomised by study staff
who accessed an online randomised sched-
ule” (p 2)
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Sheridan 2011 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients blinded and physicians unblinded
but objective outcomes are not likely af-
fected by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes deemed objective therefore lack
of blinding did not influence assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk There appears to be no missing data
Selective reporting (reporting bias) Low risk Protocol made available
Other bias Low risk Appears to be free of other sources of bias
Shorten 2005
Methods Randomized to decision aid vs usual care
Participants 85 + 84 pregnant women who have experienced previous cesarean section considering
birthing options in Australia
Interventions DA: decision aid booklet on options’ outcomes, clinical problem, outcome probabilities,
explicit values clarification, guidance (Ottawa Decision Support Framework)
Comparator: usual care
Outcomes Primary outcomes: knowledge, decisional conflict
Secondary outcomes: preferred option, help with making a decision
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-based randomized generation (p
3, Procedure)
Allocation concealment (selection bias) Low risk “[O]paque envelopes containing a random
allocation for each participant code num-
ber” (p 3)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants/midwives/
doctors were blinded to patients’ allocation.
However, women who used the decision aid
as specified and in a process of consultation
with their midwife or doctor would have
negated the blinding of their clinicians, and
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Shorten 2005 (Continued)
perhaps of the women themselves. For the
intervention group, this may have affected
the level and type of information exchanged
between them and their caregivers
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to to in-
terpretation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 16 women were lost to follow-up from the
intervention group and 18 from the control
group (no reasons listed) (p 4, Results)
Selective reporting (reporting bias) Low risk Reference to published protocol
Other bias Low risk Appears to be free of other potential biases
Shourie 2013
Methods Cluster-randomized controlled trial of GP practices to web-based MMR DA + usual
care, MMR leaflet + usual care, versus usual care
Participants 50 + 93 + 77 parents’ of children facing their first dose MMR vaccination
Interventions Web-based DA: clinical problem, options’ outcomes, explicit values clarification, guid-
ance
MMR leaflet: Health Scotland leaflet, ’MMR: your questions answered’
Comparator: usual care
Outcomes Primary outcomes: decisional conflict (baseline and 2 weeks postintervention)
Secondary outcomes: choice uptake of first dose MMR (when child was 15 months),
knowledge (baseline and 2 weeks; results not provided), MMR immunization cognitions
(baseline and 2weeks post; results not provided), immunization trade-off beliefs (baseline
and 2 weeks post; results not provided), anxiety (baseline and 2 weeks post; results not
provided), use of the intervention (baseline and 2 weeks post)
Notes Trial registration: UK Clinical Research Network - UKCRN ID 4811
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Simple randomisation using a computer-
generated random list allocated GP prac-
tices on a 1:1:1 basis” (p 3)
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Shourie 2013 (Continued)
Allocation concealment (selection bias) Low risk “An independent researcher who had no
contact with participants generated the al-
location sequence and assigned the GP
practices to their allocated arm” (p 3)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “On receipt of the completed baseline ques-
tionnaire and consent form, the appropri-
ate interventionwas delivered. At this point
the researchers and participants were no
longer blind to allocation” (p 3). We don’t
know if receiving the intervention had an
effect on the ultimate decision that was
made
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome data assessment does not depend
on the assessor. It is an objective question-
naire
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing primary outcome data.
Selective reporting (reporting bias) Unclear risk Protocol registered. Primary outcome re-
ported as stated. Secondary outcomes are
not reported (p 3)
Other bias Unclear risk Difference in allocation to groups (50 + 93
+ 77). Unclear what effect this difference
had on the results
Smith 2010
Methods Randomized to detailed vs simple decision aid vs usual care
Participants 196 + 188 + 188 socioeconomically disadvantaged participants diagnosed with average
or slightly above average risk of bowel cancer considering bowel cancer screening in
Australia
Interventions DA: booklet + DVD + worksheet + question prompt list on options’ outcomes, clini-
cal problem, outcome probabilities, explicit values clarification, guidance (step-by-step
process for making the decision; worksheet; encourages patients to communicate with
practitioners by asking questions; summary)
Comparator: booklet + DVD + worksheet on options’ outcomes, clinical problem, out-
come probabilities, explicit values clarification, guidance (step-by-step process for mak-
ing the decision; worksheet; encourages patients to communicate with practitioners by
asking questions; summary)
Comparator: usual care using standard information booklet
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Smith 2010 (Continued)
Outcomes Primary outcomes: values congruent with chosen option (post-DA), participation in
decision making (pre, post-DA)
Secondary outcomes: knowledge (pre, post-DA), attitude, actual choice (post-DA), de-
cisional conflict (post-DA), decision satisfaction (post-DA), confidence in decision mak-
ing (post-DA), general anxiety (post-DA), worry about developing bowel cancer (pre,
post-DA), risk perception
Other outcomes (Smith 2014): screening participation (357 + 173 participants)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Participants who verbally consented to
take part were then randomised to one of
the three groups using random permutated
blocks of size 6 and 9 for each sex stratum”
(p 3, Participants and recruitment section)
Allocation concealment (selection bias) Low risk Central allocation; “interviewers respon-
sible for recruiting participants were not
aware of the randomization sequence or al-
location and therefore did not know which
intervention respondents would receive” (p
3, Participants and recruitment section)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “It was not possible for the reviewers to
be blinded to the group allocation. How-
ever, all questions used standardised word-
ing with pre-coded responses and were
asked within a supervised environment,
where interviewer performances were regu-
larly monitored to ensure scripts were read
as written” (p 3, Outcome measures sec-
tion)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “[A]nalyses were by intention to treat and
carried out blinded to intervention” (p 5,
Statistical analysis section); outcomes mea-
sured were not subject to interpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Explanation for the missing data reported
at base of tables
Selective reporting (reporting bias) Low risk Study protocol available (ClinicalTri-
als.gov NCT00765869 and Australian
New Zealand Clinical Trials Registry
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Smith 2010 (Continued)
12608000011381)
Other bias Low risk Appears to be free of other potential sources
of bias
Stacey 2014a
Methods Randomized to decision aid vs usual care
Participants 71 + 71 adults diagnosed with knee osteoarthritis considering joint replacement in
Canada
Interventions DA: DVD + booklet + worksheet on options’ outcomes, clinical problem, outcome
probabilities, explicit values clarification, others’ opinion, guidance (1 page summary for
the surgeon)
Comparator: usual care
Outcomes Primary outcomes: feasibility (including recruitment, data collection), preliminary ef-
fectiveness
Secondary outcomes: knowledge (post-DA, pre-surgeon consult), informed values-con-
gruent with chosen option (post-DA, pre-surgeon consult), uptake of chosen option at
1 year; decisional conflict (SURE test), preparation for decision making (4 items), wait
times
Notes Trial registration: NCT00743951
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The allocation schedule was computer-
generated centrally by a statistician using a
permuted block design with randomly vary-
ing block lengths of 4, 6, or 8.” (p 3)
Allocation concealment (selection bias) Low risk “Allocations were concealed in numbered
opaque sealed envelopes” (p 3)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Patients were not informed of the interven-
tion characteristics” (p 3)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Although the research assistant was not
blinded to group allocation, study outcomes
for effectivenesswere objective andobtained
from clinic data (e.g. date of surgery or wait
list status)” (p 3)
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Stacey 2014a (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Protocol registered on ClinicalTrials.gov
Other bias Low risk Appears to be free of other potential sources
of bias
Steckelberg 2011
Methods Randomized to decision aid vs usual care
Participants 785 + 792 patients with no CRC history considering CRC screening in Germany
Interventions DA: brochure on options’ outcomes, clinical problem, and outcome probabilities
Comparator: usual care using pamphlet
Outcomes Primary outcomes: values congruent with chosen option (post-DA)
Secondary outcomes: knowledge (post-DA), combination of actual and planned uptake
(post-DA), risk perception
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated sequence (p 2, Ran-
domization and blinding)
Allocation concealment (selection bias) Low risk Allocation was concealed. Identity numbers
were independent of allocation, and study
members did not have access to the data. (p
2, Randomization and blinding)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial staff who sent out questionnaires and
reminders were not aware of study arm, un-
clear if participants were blinded (p 2, Ran-
domization and blinding)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial staff and statistician who entered data
were blinded (p 2, Randomization and
blinding)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12% missing one or both questionnaires
in intervention group vs 9.2% in control;
judged to have low impact on study out-
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Steckelberg 2011 (Continued)
come (p 2)
Selective reporting (reporting bias) Low risk Protocol available
Other bias Unclear risk Participants who completed the trial do not
add up
Taylor 2006
Methods Randomized to print DA versus video DA versus wait list control
Participants 98 + 95 + 92 African American men with no history of prostate cancer to consider
prostate cancer screening
Interventions Print DA: clinical problem; outcome probabilities; guidance (list of questions to ask at
next appointment); others’ opinions
Video DA: clinical problem; others’ opinions
Wait list comparator: no information provided until 1 month postrandomization (base-
line assessment for this group coincided with 1-month assessment of print and video
arms)
Outcomes Prostate cancer screening intention (baseline and 1month; not reported), prostate screen-
ing uptake (1 year; not included because wait list received intervention before 1 year)
process variables including use and perception of the intervention materials (1 month)
, prostate cancer knowledge (baseline and 1 month post), decisional conflict (baseline
and 1 month post), satisfaction with screening decision (baseline and 1 month post)
Notes No primary outcome reported; not found in trials registry
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information related to random
sequence generation
Allocation concealment (selection bias) Unclear risk Insufficient information to judge allocation
concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to judge blinding;
however, participants were requested to not
share intervention materials with others to
prevent contamination between groups (p
2180)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to judge blinding
of outcome assessment
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Taylor 2006 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Does not appear to bemissing any outcome
data
Selective reporting (reporting bias) Unclear risk No protocol registered or published
Other bias Unclear risk “All participants were mailed $25 for their
participation following completion of the
1-month interview” (p 2181)
“Men who reported that they had not yet
had a chance to read/watch the materials
were given an additional week to do so and
called again to complete the follow-up as-
sessment” (p 2181)
Thomson 2007
Methods Randomized to decision aid vs usual care by clinical guidelines
Participants 69 + 67 patients with atrial fibrillation considering treatment options in the UK
Interventions DA (in consultation): computerized decision on options’ outcomes, clinical problem,
outcome probabilities, explicit values clarification, guidance/coaching by physician
Comparator: guidelines applied as direct advice
Outcomes Primary outcome: decisional conflict
Secondary outcomes: anxiety, knowledge, resource use, choice, health outcomes (stroke,
transient ischaemic attack, bleeding events)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[E]lectronically-generated random per-
muted blocks via a web-based randomisa-
tion service” (p 2, Recruitment and ran-
domization)
Allocation concealment (selection bias) Low risk “[E]lectronically-generated random per-
muted blocks via a web-based randomisa-
tion service” (p 2, Recruitment and ran-
domization)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Physicianswere blinded.Unclear if patients
are blinded and how that may affect the
outcome
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Thomson 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk See flow diagram
Selective reporting (reporting bias) Low risk ISRCTN24808514
Other bias Low risk Baseline characteristics similar, sample size
similar, not stopped early
Trevena 2008
Methods Randomized to decision aid vs usual care by consumer guidelines
Participants 157 + 157 patients not previously screened for colorectal cancer in Australia
Interventions DA: age-gender-family history specific DA booklet with information on options, out-
come probabilities, explicit values clarification, guidance (personal worksheet with steps
in decision making) (Theory of planned behaviour)
Comparator: consumer guidelines recommending faecal occult blood testing
Outcomes Primary outcome: informed choice
Secondary outcomes: knowledge, values, screening intention (choice); test uptake, anx-
iety, acceptability of the intervention, satisfaction with the decision
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Sequential ID numbers were randomly
assigned by computer program to DA or
Guidelines (G) in blocks of four” (p 3)
Allocation concealment (selection bias) Low risk “Allocation was concealed via the pass-
word-protected program” (p 3)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants were blinded to the interven-
tion type - not sure about GPs
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Researchers were blinded to allocation for
all telephone interviews, outcomes were
objectively measured
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Trevena 2008 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Baseline characteristics included (p 3). Fig 2
flow chart (p 5). Reasons for loss to follow-
up not mentioned
Selective reporting (reporting bias) Low risk ClinicalTrials.gov - NCT00148226
Other bias Low risk Appears to be free of other potential biases
Van Peperstraten 2010
Methods Randomized to decision aid vs usual care
Participants 152 + 156 infertile women on wait list for in vitro fertilization in the Netherlands
Interventions DA: self-administered booklet on options’ outcomes, clinical problem, outcome prob-
abilities, explicit values clarification, guidance (step-by-step process for making deci-
sion, worksheet with questions relevant to decision-making process; 1 or more questions
that asked patients to clarify their preferences; summary to be shared with practitioner)
, coaching (by trained in vitro fertilization nurse) + standard in vitro fertilization care
Comparator: standard in vitro fertilization care, including a session in which the number
of embryos transferred was discussed
Outcomes Primary outcomes: actual choice (postintervention and consult)
Secondary outcomes: knowledge (pre, post-DA and consult), empowerment (pre, post-
DA and consult), participation in decision making, decisional conflict (post-DA and
consult), levels of anxiety (pre, post-DA and consult), depression (pre, post-DA and
consult), cost evaluation of empowerment strategy (post-DA and consult), condition-
specific health outcomes (pregnancies) (post-DA and consult)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated list (p 2, Methods sec-
tion)
Allocation concealment (selection bias) Low risk Central allocation (p 2, Methods section)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Because of the nature of the intervention
it was not possible to blind the participants
or in vitro fertilisation doctors to the al-
location. Participation in our trial did not
change the normal in vitro routine.” (p 2,
Methods section)
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Van Peperstraten 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes assessed
were not subjective to interpretation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There are categories in each column of ta-
ble 1 (p 3) where the denominators do not
match the number of people in the group
and no reason was given to explain why this
would be or if this affects the study
Selective reporting (reporting bias) Low risk Outcomes same as those registered with
ClinicalTrials.gov
Other bias Low risk The study appear to be free of other sources
of bias
Vandemheen 2009
Methods Randomized to decision aid vs usual care
Participants 70 + 79 patients with cystic fibrosis considering referral for lung transplantation in
Canada
Interventions DA: self-administered booklet with clinical problem, outcome probability, explicit values
clarification, guidance (Ottawa Decision Support Framework)
Comparator: blank pages
Outcomes Primary outcomes: knowledge, accurate risk perceptions, decisional conflict
Secondary outcomes: preparation for decision making, choice, durability of decision,
undecided
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[C]omputer-generated random listing of
two treatment allocations blocked in blocks
of 2 or 4, stratified by site and infection sta-
tus of Burkholderia cepacia” (p 2)
Allocation concealment (selection bias) Low risk Central allocation (p 2)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Single blinded RCT; patients and re-
searchers were blinded but physicians were
not because theywere involvedwith patients
before being randomized
158Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Vandemheen 2009 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Research staff, who were blinded to treat-
ment allocation, telephoned each patient
and had them complete a follow-up ques-
tionnaire; other outcomes reported are ob-
jectively measured
Incomplete outcome data (attrition bias)
All outcomes
Low risk Baseline characteristics included (Flow dia-
gram, p 2)
Selective reporting (reporting bias) Low risk Clinical trial registered with www.clinical-
trials.gov (NCT00345449)
Other bias Low risk Appears to be free of other potential biases
Vodermaier 2009
Methods Randomized to decision aid vs usual care
Participants 74 + 78 women with breast cancer considering treatment options in Germany
Interventions DA: Decision board administered by research psychologists and booklet on options’
outcomes, clinical problem, outcome probability
Comparator: booklet on clinical problem
Outcomes Primary outcome: decisional conflict
Secondary outcomes: choice, length of consultation, satisfaction with decision making,
participation in decision making
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomisation after the patient gave writ-
ten informed consent” “Random assign-
ment was performed bymeans of numbered
cards in envelopes” “stratified by age group”
(p 2)
Allocation concealment (selection bias) Low risk “[N]umbered cards in envelopes” (p 2)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not blinded - unclear if this would intro-
duce bias to outcome assessed
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Vodermaier 2009 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not blinded but outcomes were objectively
measured and not subjective to interpreta-
tion
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Flow diagram, p 5; baseline characteristics
not included
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Low risk Appears to be free of other potential biases
Volk 1999
Methods Randomized to decision aid vs usual care
Participants 80 + 80 men considering PSA testing in the USA
Interventions DA: Health Dialog videotape and brochure on options’ outcomes, clinical problem,
outcome probability, others’ opinion
Comparator: usual care
Outcomes Primary outcomes: knowledge, preferred/uptake of option
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Volk 1999 (primary
study), p 3: “[r]andomization by permuted
blocks” “Each block included the numbers
1 through 4”;
Volk 2003, p 2, Methods: Randomization
by permuted blocks was used to balance the
number of subjects in each arm of the study
Allocation concealment (selection bias) Unclear risk Volk 1999 (primary study): no information
provided
Volk 2003, p 2: “[d]etails of the study pro-
cedures, subjects, and 2-week follow-up re-
sults can be found elsewhere”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were not blinded to the treat-
ment assignment, but the physicians were;
therefore outcomes were unlikely to be bi-
ased
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Volk 1999 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Interviewers were not blinded but outcomes
were objectively measured and not subjec-
tive to interpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Volk 1999 (primary study), p 2, Procedures:
baseline values included
Volk 2003, p 4 Fig 1 - flowdiagram; baseline
data not included
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Low risk Volk 1999 (primary study): appears to be
free of other potential biases
Volk 2003: appears to be free of other
sources of bias
Vuorma 2003
Methods Randomized to decision aid vs usual care
Participants 184 + 179 women considering treatment for menorrhagia in Finland
Interventions DA: booklet on options’ outcomes, clinical problem, outcome probability
Comparator: usual care
Outcomes Primary outcomes: uptake of option
Secondary outcomes: knowledge, proportion remaining undecided, anxiety, satisfaction,
health outcomes, use and cost of healthcare services
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Vuorma 2003 (primary study), p 2, Ran-
domization: computer-generated; done by
a researcher who did not participate in the
planning or concealment procedures
“[D]one in STAKES, by researcher sepa-
rately for each hospital in computer-gener-
ated varying clusters”(p 2)
Vuorma 2004: no information provided
Allocation concealment (selection bias) Low risk Vuorma 2003 (primary study), p 2 “se-
quentially numbered, opaque and sealed en-
velopes”
Vuorma 2004, p 2 “sequentially numbered,
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Vuorma 2003 (Continued)
opaque, sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Noblinding, unclear if measurements could
be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study staff were not blinded but outcomes
were objectively measured and not subjec-
tive to interpretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Vuorma 2003 (primary study): flow chart
balanced.
Reasons for non-eligibility. “Onewomenon
HRT was randomized by mistake and in-
cluded in analyses.” Baseline characteristics
included and balanced across groups (p 4-
5)
Vuorma 2004, flow diagram (p 3)
Selective reporting (reporting bias) Unclear risk Vuorma 2003 (primary study): no mention
of study protocol
Vuorma 2004: no information provided
Other bias Low risk Vuorma 2003 (primary study), p 7: “in-
crease in knowledge in both study groups,
carry-over effect; change in decision-mak-
ing process of intervention group may
have altered physician’s negotiation with pa-
tients” appears to be free of other potential
biases
Vuorma 2004, p 5: “comparison of the base-
line characteristics presented elsewhere” In
the pre-trial group compared with the con-
trol group, there was a greater increase in the
dimensions of physical role functioning and
emotional role functioning of the RAND-
36
Watson 2006
Methods Randomized to decision aid vs usual care
Participants 475 + 522 men considering prostate cancer screening in the UK
Interventions DA: leaflet on options’ outcomes, clinical problem, outcome probability
Comparator: usual care
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Watson 2006 (Continued)
Outcomes Primary outcomes: knowledge, screening intention, attitudes
Secondary outcomes: preferred role in decision making
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[R]andom numbers generated centrally by
Stata v8.2” (p 3)
Allocation concealment (selection bias) Low risk “[R]andom numbers generated centrally by
Stata v8.2” (p 3)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Flow diagram (p 2); reason for exclusion
from analysis mentioned. Sample character-
istics of risk included
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Unclear risk “Adjustment for multiple testing was not
accounted for and hence a degree of caution
with interpretation is required, particularly
in relation to findings with a P-value close
to 0.05” (p 3)
Weymiller 2007
Methods Cluster-randomized to decision aid vs usual care
Participants 51 + 46 patients with type 2 diabetes in the USA
Interventions DA (in consultation): 1-page decision aid options’ outcomes, clinical problem, tailored
outcome probability, guidance/coaching
Comparator: booklet on cholesterol management
Outcomes Primary outcomes: knowledge, decisional conflict
Secondary outcomes: consultation length, acceptability of the intervention, adherence,
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Weymiller 2007 (Continued)
estimated personal risk, trust, patient participation (OPTION), choice
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated allocation sequence
(p 2)
Nannenga 2009: no information provided
Allocation concealment (selection bias) Low risk Computer-generated allocation sequence,
unavailable to personnel enrolling patients.
“[W]ith concealed allocation” (Abstract);
“maintained allocation concealment” (p 5)
; randomized by concealed central alloca-
tion (Nannenga 2009, p 2)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and clinicians blinded to the
study objectives, providers and patients
were naive to this study objective
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Data analysts and statisticians blinded to
allocation; intervention and outcomes; ad-
equate blinding wherever possible
Incomplete outcome data (attrition bias)
All outcomes
Low risk Flow diagram (p 3); reasons for attrition
mentioned (p 4); baseline characteristics in-
cluded; flow diagram
Nannenga 2009, p 3: reasons for attri-
tionmentioned and study groups balanced;
baseline characteristics included
Selective reporting (reporting bias) Low risk ClinicalTrials.gov identifier:
NCT00217061
Other bias Low risk Enrollment of patients already receiving
statin therapy and limited statin uptake de-
creased the precision of our results; results
should best be interpreted as preliminary
and requiring verification
Nannenga 2009: appears to be free of other
potential biases
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Whelan 2003
Methods Randomized to decision aid vs usual care
Participants 82 + 93 women with node negative breast cancer considering adjuvant chemotherapy
in Canada
Interventions DA: decision board and booklet on options’ outcomes, clinical problem, outcome prob-
ability, guidance/coaching
Comparator: booklet on clinical problem
Outcomes Primary outcomes: knowledge, satisfaction of participant
Secondary outcomes: preferred option, anxiety, accurate risk perceptions, participation
in decision making
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Low risk Randomization, which was performed at a
central location (p 3)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unable to blind participants in our trial for
practical reasons, measures were taken to
minimize bias in the design of the study and
the assessment of outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Flow diagram not included. “[O]ne pa-
tient excluded from analysis, determined by
physician not to be candidate for chemo-
therapy” (p 4). Baseline data/characteristics
included
Selective reporting (reporting bias) Unclear risk Unclear if lack of blinding contributed to
potential risk of bias
Other bias Low risk Appears to be free of other potential biases
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Whelan 2004
Methods Cluster-randomized to decision aid vs usual care
Participants 94 + 107 women with Stage 1 or 2 breast cancer considering surgery (cluster-RCT with
27 surgeons randomized) in Canada
Interventions DA: decision board on options’ outcomes, outcome probability, guidance/coaching
Comparator: usual care
Outcomes Primary outcomes: preferred option, knowledge, decisional conflict, satisfaction
Secondary outcomes: accurate risk perceptions, anxiety
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Does not specify how the sequencewas gen-
erated; a paired cluster randomization pro-
cess was used (p 2, Study design and pro-
cedures)
Allocation concealment (selection bias) Unclear risk Randomly assigned in a concealed fashion,
but method of concealment was not stated
(p 2, Study design and procedures)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “[C]hose cluster randomization method to
avoid contamination that might have oc-
curred if surgeons used decision board for
some patients and not others” (p 6); un-
clear if this would introduce bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Baseline characteristics not included; rea-
sons given for loss of participants
Selective reporting (reporting bias) Unclear risk No indication that the trial was registered
in a central trials registry
Other bias Low risk Appears to be free of other potential biases
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Williams 2013
Methods Randomized to decision aid at home or in clinic versus usual care at home or in clinic
Participants 134 + 138 + 134 +137 men aged 40-70 years with no history of prostate cancer who
had pre-registered for screening
Interventions DA: content adapted from the Centers for Disease Control and Prevention’s PCS educa-
tional tool. Includes clinical problem, treatment options, outcome probabilities, explicit
values clarification, others’ stories, summary worksheet
Comparator: information booklet. A 3-page fact sheet requiring 5 minutes to read.
Information presented in a Q&A format on who is recommended for testing, how to
interpret results, and the limitations of testing
Outcomes Knowledge, decisional conflict, screening outcomes, satisfaction with decision
Outcomes assessed at baseline, 2 months, 13 months, except satisfaction with decision
(2 months and 13 months)
Notes No primary outcome reported; trial registration not provided
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to judge random
sequence generation
Allocation concealment (selection bias) Unclear risk Insufficient information to judge allocation
concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to judge blinding
of participants and personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to judge blinding
of outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk There does not appear to be any outcome
data missing
Selective reporting (reporting bias) Unclear risk No registered or published protocol
Other bias Low risk Appears to be free of other potential biases
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Wolf 1996
Methods Randomized to decision aid vs usual care
Participants 103 + 102 men considering PSA testing in the USA
Interventions DA: script of options’ outcomes, clinical problem, outcome probability, others’ opinions
Comparator: usual care (single sentence)
Outcomes Preferred option
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Wolf 1996 (primary study): no information
provided
Wolf 1998, p 2: “the methodology of the
randomized trial has been reported previ-
ously”
Allocation concealment (selection bias) Unclear risk Wolf 1996 (primary study): no information
provided
Wolf 1998, p 2: “The methodology of the
randomized trial has been reported previ-
ously”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Wolf 1996 (primary study), p 2: needed a
minimum sample size of 150 participants,
and was achieved with total sample size of
205. Reasons for attrition mentioned; base-
line characteristics included
Wolf 1998: no information provided except
that methodology of the randomized trial
and the content of the informational inter-
vention reported previously (p 2). Baseline
characteristics included; flowof participants
not included
Selective reporting (reporting bias) Unclear risk No indication that the trial was registered
in a central trials registry
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Wolf 1996 (Continued)
Other bias Low risk Wolf 1996 (primary study): participant
population had lower SES therefore external
validity of the findings limited, but overall
appears to be free of other potential biases
Wolf 1998: appears to be free of other po-
tential biases
Wolf 2000
Methods Randomized to decision aid vs usual care
Participants 266 + 133 elderly (≥ 65 years) considering CRC screening in the USA
Interventions DA: script of options’ outcomes, clinical problem, outcome probabilities
Comparator: usual care (5 sentences)
Outcomes Primary outcome: preferred option
Secondary outcomes: accurate risk perceptions
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “[P]atients were randomised” (p 2); does
not indicate how
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Baseline data not included (p 2, Results)
Selective reporting (reporting bias) Unclear risk Protocol not mentioned
Other bias Low risk Appears to be free of other potential biases
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Wong 2006
Methods Randomized to decision aid vs placebo control leaflet
Participants 162 + 164 women referred for pregnancy termination in the UK
Interventions DA: decision aid leaflet on options’ outcomes, clinical problem, outcome probability,
explicit values clarification
Comparator: placebo leaflet on contraception use post pregnancy termination
Outcomes Primary outcomes: uptake of option, knowledge, decisional conflict, anxiety
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “1:1 ratio, balanced block of 10”; “enve-
lope preparation by drawing slips of pa-
per labelled either control or intervention”;
“the slip determined leaflet placed into en-
velope” (p 2)
Allocation concealment (selection bias) Low risk Consecutive numbered, opaque trial enve-
lope (p 2, Methods)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear blinding but outcomes were objec-
tively measured and not subjective to inter-
pretation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Baseline characteristics not included (p 3)
; reasons for attrition and incompletion
mentioned
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Low risk Appears to be free of other potential biases
CHD: coronary heart disease; CRC: colorectal cancer; DA: decision aid; HPV: human papilloma virus; HRT: hormone replacement
therapy; NSW: New South Wales; OA: osteoarthritis; PSA: prostate-specific antigen; PTSD: post-traumatic stress disorder; RCT:
randomized controlled trial; SES: socioeconomic status.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abadie 2009 Study did not evaluate the decision aid (evaluated clinician use of the decision aid in one arm of a study
only)
Adab 2003 Hypothetical choice, not at a point of decision making
Al Saffar 2008 Study not focused on making a choice; adhering to medications only
Alegría 2014 Not a patient decision aid
Altiner 2007 Not a patient decision aid
Anderson 2011 Not a randomized controlled trial
Arimori 2006 Not a patient decision aid (not including benefits and harms)
Armstrong 2005 Unable to ascertain whether intervention meets criteria to qualify as a patient decision aid; additional
information requested from author but not provided
Arterburn 2013 Not evaluating a patient decision aid
Au 2011 Not a randomized controlled trial
Bakken 2014 Not a patient decision aid; related to lifestyle choices
Becker 2009 Hypothetical choice; not at the point of decision making
Belkora 2012 Not a patient decision aid
Bellmunt 2010 Not a patient decision aid
Bennett 2011 Compares 3 versions of the same patient decision aid
Bieber 2006 Study did not evaluate the patient decision aid (evaluated shared decision-making process); not a patient
decision aid
Branda 2013 2 patient decision aids with findings aggregated
Brenner 2014 Not a patient decision aid
Breslin 2008 Not a randomized controlled trial
Brown 2004 Not focused on making a choice (no specific decision to be made)
Brundage 2001 Not a randomized controlled trial
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Burton 2007 Not a patient decision aid (general patient education only)
Buzhardt 2011 Not evaluating patient decision making
Campbell 2014 Not evaluating a patient decision aid
Carling 2008 Hypothetical choice, not at point of decision making
Causarano 2015 Not a patient decision aid
Chadwick 1991 Not a randomized controlled trial
Chan 2011 Not a patient decision aid
Chewning 1999 Not a randomized controlled trial
Chiew 2008 Not a randomized controlled trial
Clouston 2014 Not a patient decision aid
Col 2007 Unable to ascertain characteristics of the patient decision aid. Additional information requested from
author but not provided (e.g. values clarification)
Colella 2004 Not a patient decision aid (describes model of care)
Costanza 2011 Not a randomized controlled trial
Coulter 2003 Not a randomized controlled trial (editorial)
Cox 2012 Not a randomized controlled trial
Crang-Svalenius 1996 Not a randomized controlled trial
Davison 1999 Unable to ascertain whether intervention meets criteria (values clarification) to qualify as a patient
decision aid
Davison 2007 Not a patient decision aid
De Boer 2012 Not a randomized controlled trial
De Haan 2013 Not a randomized controlled trial of a patient decision aid
Deen 2012 Not a patient decision aid
Deinzer 2009 Not a patient decision aid
Denig 2014 not a patient decision aid
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Deschamps 2004 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Deyo 2000 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Diefenbach 2012 Not a patient decision aid
Dobke 2008 Not focused on making a choice
Dodin 2001 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Donovan 2012 Does not report results of the randomized controlled trial; descriptive article offering techniques of
provision of information
Driscoll 2008 Not a patient decision aid
Dunn 1998 Quasi-RCT: randomization was by days of the week
Eaton 2011 Not a decision aid (no decision support)
Eden 2009 Hypothetical choice, not at point of decision making
Eden 2014 The educational brochure (control group) provided information about the options, benefits, and harms
making it a simple patient decision aid
Eden 2015 Not a treatment or screening decision
Edwards 2012 Hypothetical choice, not a randomized controlled trial
El-Jawahri 2010 End of life decision
Ellison 2008 Not a randomized controlled trial (Quasi-experimental design); unclear whether at point of decision
making
Elwyn 2004 No difference in intervention between arms; risk communication did not have values clarification
Emery 2007 Not a patient decision aid
Emmett 2007 Not a randomized controlled trial
Feldman-Stewart 2006 Hypothetical choice, not at point of decision making
Feldman-Stewart 2012 Same patient decision aid with vs without values clarification
Fiks 2013a Not patient decision making (uptake of vaccine)
Flood 1996 Non-randomized allocation; wait list control
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Francis 2009 Not a patient decision aid
Fraval 2015 Not a patient decision aid; general education material to obtain informed consent for surgery
Frosch 2001 Not a randomized controlled trial
Frosch 2003 Same decision aid delivered on the Internet versus on DVD plus booklet
Frosch 2008b Not a randomized controlled trial
Frosch 2011 Not a patient decision aid
Frost 2009 Qualitative study for an included RCT
Fujiwara 2015 Not a patient decision aid and aims to increase screening rates
Garvelink 2013 Hypothetical decision
Genz 2012 Not a patient decision aid
Giordano 2014 Not a patient decision aid
Goel 2001 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Graham 2000 Not a patient decision aid (general information)
Gray 2009 Hypothetical choice, not at the point of decision making
Green 2001b Not a patient decision aid (educational intervention)
Green 2004 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Greenfield 1985 Not focused on making a choice (intervention to increase patient involvement in care)
Griffith 2008a Hypothetical choice, not at the point of decision making
Griffith 2008b Not a randomized controlled trial
Gruppen 1994 Not a patient decision aid
Gummersbach 2015 Not a patient decision aid and a hypothetical decision
Hacking 2013 Not a patient decision aid
Hall 2007 Not about evaluating a patient decision aid
Hall 2011 Not a patient decision aid
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Hamann 2014 not a patient decision aid
Harmsen 2014 Not a patient decision aid
Harwood 2011 Not a randomized controlled trial
Healton 1999 Not a patient decision aid (education to promote compliance)
Henderson 2013 Not a treatment or screening decision
Herrera 1983 Quasi-RCT: assigned to 1 of 2 alternating groups
Hess 2015 Conjoint analysis for values clarification without information on options, pros and cons
Hewison 2001 Not a patient decision aid; no values clarification
Heyn 2013 Not a randomized controlled trial
Hickish 1995 Not a randomized controlled trial (letter)
Hochlehnert 2006 Not a patient decision aid (general information; no values clarification)
Hofbauer 2008 Not a randomized controlled trial
Hoffman 2009 Not a patient decision aid
Holbrook 2007 Hypothetical choice, not at the point of decision making
Hollen 2013 Not a treatment or screening decision
Holloway 2003 Not focused on making a choice (promotes complying with a recommended option)
Holmes-Rovner 2011 Not a randomized controlled trial
Holt 2009 Study does not evaluate a decision aid; evaluation of spiritual versus non-spiritual framework
Hope 2010 Same content
Huijbregts 2013 Not a patient decision aid
Hunt 2005 Not focused on making a choice (promotes complying with a recommended option)
Hunter 1999 Not focused on making a choice (no specific decision)
Hunter 2005 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Huyghe 2009 Hypothetical choice, not at point of decision making for all participants
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Ilic 2008 No difference in content of interventions - testing mode of delivery
Isebaert 2007 Not a randomized controlled trial (English paper published in 2008 Urologia Internationalis)
Jackson 2011 Not a patient decision aid
Jerant 2007 Not focused on making a choice - adherence to screening
Jibaja-Weiss 2006 No comparison outcome data provided (only presents data for intervention group)
Joosten 2009 Not a patient decision aid
Joosten 2011 Not a patient decision aid
Jorm 2003 Hypothetical choice, not at point of decision making - community sample asked to evaluate information
booklet on depression
Kakkilaya 2011 Hypothetical choice, not at point of decision making
Kaplan 2014a Not a patient decision aid
Kaplan 2014b Not randomized controlled trial results; cross-sectional analysis of baseline data
Kassan 2012 Web arm only, not a randomized controlled trial
Kellar 2008 Hypothetical choice, not at point of decision making
Kiatpongsan 2014 No specific decision to be made and not a true randomized controlled trial
Kobelka 2009 Not a randomized controlled trial; not a patient decision aid
Koelewijn-van Loon 2009 Lifestyle only
Krawczyk 2012 Uptake of a recommended option
Kripalani 2007 Not a patient decision aid
Krones 2008 Not a patient decision aid - no benefits and harms
Kuppermann 2009 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Kurian 2009 Not a randomized controlled trial; not a patient decision aid
Köpke 2009 Not a patient decision aid
Köpke 2014 Not a patient decision aid
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Labrecque 2010 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
LaCroix 1999 Inadequate comparison outcome data provided, secondary report of pilot study
Lairson 2011 Not a patient decision aid (to increase uptake of screening)
Lalonde 2006 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Lancaster 2009 Not a patient decision aid
Landrey 2013 Not a patient decision aid
Lazcano Ponce 2000 Not a patient decision aid (no values clarification)
Legare 2003 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Leung 2004 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Levin 2011 Not a patient decision aid
Lewis 2003 Hypothetical choice, not at the point of decision making
Lewis 2012 Uptake of a recommended option
Lopez-Jornet 2012 Not a patient decision aid/not at point of decision-making
Lukens 2013 Not a patient decision aid. Results in response to clinical vignettes (hypothetical scenarios)
Lurie 2011 Not a randomized controlled trial (all patients received DA)
Maisels 1983 Not a patient decision aid (no values clarification)
Mancini 2006 Not about evaluating a patient decision aid
Manne 2009 Not focused on making a choice (about adherence not decision making)
Manns 2005 Not focused on making a choice (Promotes complying with a recommended option)
Markham 2003 Not a patient decision aid (review of patient information pamphlets on pre-operative fasting)
Martin 2012 Hypothetical choice, not at the point of decision making
Maslin 1998 Insufficient outcome data provided in publication; requested from author but not provided
Matlock 2014 End of life
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Matloff 2006 Not a patient decision aid - genetic counselling only
Mazur 1994 Hypothetical choice, not at the point of decision making
McCaffery 2007 Not a patient decision aid
McGinley 2002 Not a patient decision aid (no values clarification)
McGowan 2008 Not a patient decision aid
McInerney-Leo 2004 Not a patient decision aid (no risk/benefit information; no values clarification)
Mclaren 2012 Not a patient decision aid; hypothetical choice, not at point of decision making
Meropol 2013 Not a patient decision aid
Michie 1997 Unable to ascertain whether intervention meets criteria (values clarification) to qualify as a patient
decision aid; additional information requested but author was unable to provide the intervention
Miller 2014a No specific decision; related to increasing visits to healthcare provider
Miller 2014b Aims to increase visits to healthcare providers; intervention targeted to partners
Mishel 2009 Not a patient decision aid (information only)
Mohammad 2012 Not a patient decision aid; presents only benefits, not harms
Molenaar 2001 Not a randomized controlled trial
Mulley 2006 Not a randomized controlled trial (editorial)
Myers 2005a Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Myers 2005b Not a randomized controlled trial (editorial)
Myers 2007 Not a patient decision aid
Myers 2011 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Myers 2013 Uptake of screening
Neubeck 2008 Study protocol, does not appear to be patient decision aid
Newton 2001 Not a randomized controlled trial
O’Cathain 2002 Suite of 8 decision aids (not an efficacy trial)
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O’Connor 1999a Simple versus detailed patient decision aid (excluded in update after 2014 publication)
O’Connor 1996 No patient decision aid - framing effects
O’Connor 1998a Simple versus detailed patient decision aid (excluded in update after 2014 publication)
O’Connor 2009a Not a patient decision aid
O’Connor 2011 Not a patient decision aid
Owens 2014A Not an RCT; doctoral dissertation
Patanwala 2011 Not a patient decision aid
Patel 2014 Not an RCT
Pearson 2005 Not a patient decision aid (focus on provision of information)
Peele 2005 Not a patient decision aid (decision aid only supplies mortality risk information; no risk info; no values
clarification)
Petty 2014 Not a randomized controlled trial and not a patient decision aid
Philip 2010 Not a randomized controlled trial, not a patient decision aid (promotes complying with a recommended
option)
Phillips 1995 Quasi-RCT: alternating order based on patients’ initial appointment sequence
Pignone 2013 Not a patient decision aid; compared the effect of 3 different values clarification methods
Pinto 2008 About clinical trial entry
Powers 2011 Not a patient decision aid
Proctor 2006 Not a patient decision aid (general patient education resource)
Prunty 2008 About a lifestyle choice - whether or not to have a child or have another child if I have multiple sclerosis
Ranta 2015 Not a patient decision aid; intended to increase guideline adherence for transient ischaemic attack/stroke
Rapley 2006 Not a randomized controlled trial
Raynes-Greenow 2009 No difference in intervention content; comparison of presentation formats; audio-guided decision aid
versus booklet only
Raynes-Greenow 2010 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
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Rimer 2001 Not focused on making a choice (promotes complying with a recommended option)
Rimer 2002 Not focused on making a choice (promotes complying with a recommended option)
Robinson 2013 Not a patient decision aid
Ronda 2014 Benefits or harms of self-testing are not provided as information on the website; values clarification
exercise asks users to qualify value statements as benefits or harms
Rostom 2002 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Roter 2012 Not a patient decision aid
Rothert 1997 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Rovner 2004 Not a randomized controlled trial
Rubinstein 2011 Not a patient decision aid
Ruddy 2009 Not a patient decision aid
Ruehlman 2012 Not a patient decision aid
Ruland 2013 No specific decision to be made
Ryser 2004 Not focused on making a choice (promotes complying with a recommended option)
Sassen 2014 Not a patient decision aid evaluation study; healthcare professionals were recruited, not patients
Saver 2007 Not a patient decision aid - general information; not a specific decision
Sawka 2011 Not a randomized controlled trial
Scaffidi 2014 Not an RCT
Schapira 2000 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Schapira 2007 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Schwartz 2009b Hypothetical choice, not at the point of decision making
Sears 2007 About do not resuscitate versus initiating cardiopulmonary resuscitation decision
Sequist 2011 Not a patient decision aid (promotes complying with a recommended option)
Shah 2012 Not a patient decision aid, lifestyle choices
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Sheppard 2012 Not a randomized controlled trial
Sheridan 2004 Not a randomized controlled trial
Sheridan 2010 Hypothetical choice, not at point of decision making
Sheridan 2012 Not a patient decision aid - no benefits and harms
Sherman 2014 Not a randomized controlled trial
Shirai 2012 Not a patient decision aid
Silver 2012 Hypothetical choice, not at point of decision making
Siminoff 2006 Not a patient decision aid (no discussion of harms)
Simon 2012a Not a patient decision aid
Simon 2012b Not a patient decision aid
Smith 2011a No decision regarding treatment or screening to be made (decision regarding full disclosure)
Smith 2011b Not a patient decision aid, not an RCT
Solberg 2010 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Sorenson 2004 Not a randomized controlled trial
Sparano 2006 Not a patient decision aid
Stalmeier 2009 Not a randomized controlled trial (about instrument development)
Starosta 2015 Not a patient decision aid - benefits and harms of screening are missing
Stein 2013 End of life
Steiner 2003 Not a patient decision aid (only effectiveness not cons of options; not at point of decision making)
Stephens 2008 Not a randomized controlled trial
Stiggelbout 2008 Not a patient decision aid
Stirling 2012 Not a treatment or screening decision
Street 1995 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Street 1998 Not focused on making a choice (promotes complying with a recommended option)
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Sundaresan 2011 Hypothetical choice, not at the point of decision making, not a randomized controlled trial
Tabak 1995 Not a randomized controlled trial
Taylor 2013 Not a patient decision aid - benefits and harms of screening not included
Ten 2008 Not a patient decision aid; about stopping medication use
Thomas 2013 Not a patient decision aid
Thomson 2006 Not a randomized controlled trial; not at point of decision making
Thornton 1995 Unable to ascertain whether intervention meets criteria to qualify as a patient decision aid; additional
information requested from author but not provided
Tiller 2006 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Tinsel 2013 Not a patient decision aid
Tomko 2015 Not a patient decision aid - benefits and harms of screening are missing
Ukoli 2013 Not an RCT
Valdez 2001 Not a randomized controlled trial; not focused on making a choice (complying with a recommended
option)
Van der Krieke 2013 Not a patient decision aid, no benefits/harms
Van Roosmalen 2004 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Van Steenkiste 2008 Not a randomized controlled trial
Van Til 2009 Hypothetical choice, not at the point of decision making
Van Tol-Geerdink 2013 Not a randomized controlled trial; insufficient information to judge random sequence generation,
allocation concealment, and blinding
Veroff 2012 Not a patient decision aid
Volandes 2009 Advanced care planning options
Volandes 2011 Hypothetical choice, end-of-life decision
Volandes 2013 Advanced care planning
Volk 2008 Simple versus detailed patient decision aid (excluded in update after 2014 publication)
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Von Wagner 2011 Not a randomized controlled trial (commentary)
Wagner 1995 Not a randomized controlled trial
Wakefield 2008a Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Wakefield 2008b Simple versus detailed patient decision aid (excluded in update after 2014 publication)
Wakefield 2008c simple versus detailed patient decision aid (excluded in update after 2014 publication)
Wallston 1991 Not a patient decision aid - patient preference study
Wang 2004 Not a patient decision aid - intent of intervention to facilitate genetic counselling process, no focused
decision
Warner 2015 Not a treatment or screening decision
Watts 2014 Simple versus detailed patient decision aid
Welschen 2012 Not a patient decision aid
Wennberg 2010 Same decision aid in both groups
Westermann 2013 Not a patient decision aid
Weymann 2015 Patients not at the point of decision making
Wilhelm 2009 Not a patient decision aid
Wilkes 2013 Unable to ascertain characteristics of the patient decision aid. Additional information requested from
author but not provided (e.g. values clarification)
Wilkie 2013 Not treatment or screening decision
Wilkins 2006 Not a randomized controlled trial
Willemsen 2006 Lifestyle change
Williams-Piehota 2008 Not a randomized controlled trial
Williamson 2014 Lifestyle decision - not treatment or screening
Woltmann 2011 Not a patient decision aid
Wroe 2005 Not focused on making a choice - promotes complying with a recommended option
Yee 2014 Not a patient decision aid
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Yun 2011 End-of-life decision
Zajac 2012 Hypothetical
Zapka 2004 Not focused on making a choice - promotes complying with a recommendation
Zikmund-Fisher 2008 No difference in intervention content - comparison of presentation of probabilities
Zoffman 2012 Not a randomized controlled trial, not a patient decision aid
Characteristics of ongoing studies [ordered by study ID]
ACTRN12615000523505
Trial name or title The motherhood choices decision aid for women with rheumatoid arthritis increases knowledge and reduces
decisional conflict: a randomized controlled study
Methods RCT
Participants 130 women diagnosed with rheumatoid arthritis and currently under the care of a rheumatologist
Interventions Patient decision aid vs usual care
Outcomes Decisional conflict, knowledge, anxiety, depression, self-efficacy
Starting date May 2015
Contact information Tanya Meade; School of Social Science and Psychology University of Western Sydney; Sydney, Australia
Notes Trial #: ACTRN12615000523505
ACTRN12615000843550
Trial name or title Evaluation of decision aids for parents about the benefits and harms of antibiotic use for coughs and colds in
children
Methods Pilot RCT
Participants 108 adult parents or primary caregivers of a child
Interventions Patient decision aid vs usual care
Outcomes Informed choice, knowledge, attitudes towards antibiotic use, intention to use antibiotic, decisional conflict,
confidence in decision-making, usability and accessibility of the written materials
Starting date August 2015
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ACTRN12615000843550 (Continued)
Contact information Mr Peter D Coxeter; pcoxeter@bond.edu.au; Bond University, Queensland, Australia
Notes ACTRN12615000843550
Al-Itejawi 2015
Trial name or title (Cost-)effectiveness and implementation of a decision aid for patients with prostate cancer
Methods Stepped wedge cluster RCT
Participants Newly diagnosed adult participants with localized prostate cancer
Interventions Patient decision aid vs usual care
Outcomes Decisional conflict, quality of life, treatment preferences, participation indecisionmaking, knowledge, patient-
provider communication
Starting date May 2015
Contact information Hoda Al-Itejawi; Afdeling Urologie, Amsterdam, the Netherlands
Notes Trial #: NTR5177
Anderson 2014
Trial name or title Shared decision making in the emergency department: Chest Pain Choice Trial (CPC)
Methods RCT
Participants Presenting to the emergency department with chest pain
Interventions Chest Pain Choice decision aid vs usual care
Outcomes Knowledge, patient engagement, decisional conflict, satisfaction, adverse events, admissions, healthcare uti-
lization
Starting date October 2013
Contact information Erik P Hess, Mayo Clinic
Notes NCT01969240; verified September 2014, estimated study completion March 2016
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Aslani 2014
Trial name or title Computerized decision aid on mode of delivery
Methods Cluster RCT
Participants Pregnant Iranian women
Interventions Computerized decision aid
Outcomes Decisional conflict, knowledge
Starting date Not reported
Contact information Azam Aslani, Mashhad University, Iran
Notes -
Buhse 2013
Trial name or title Efficacy of an evidence-based informed shared decision making program for prevention of myocardial infarc-
tion in type 2 diabetes
Methods RCT
Participants 154 patients with type 2 diabetes
Interventions Shared decision-making programme consisting of a decision aid booklet and a curriculum for group coun-
selling vs placebo counselling
Outcomes Knowledge, sustainability of knowledge, achievement of individual treatment goals, achievement of treatment
goals prioritized by individual patients, medication uptake
Starting date March 2013
Contact information Matthias Lenz, University of Hamburg
Notes ISRCTN84636255
Carroll 2012
Trial name or title Development of and feasibility testing of decision support for patients who are candidates for an implantable
defibrillator
Methods RCT
Participants Referred for consideration of an implantable cardioverter-defibrillators (non-cardiac resynchronization ther-
apy) for a primary prevention indication
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Carroll 2012 (Continued)
Interventions Patient decision aid provided prior to the consultation with the physician, which provides a lay summary that
outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator
or the option of medical management vs usual care
Outcomes Decision aid development and evaluation, decisional conflict and decision quality, sure test, reparation for
decision-making scale, medical outcomes trust short form (SF-36v2)
Starting date June 2012
Contact information Sandra Carroll, McMaster University
Notes Trial #: NCT01876173
Chambers 2008
Trial name or title ProsCan for Men: randomized controlled trial of a decision support intervention for men with localised
prostate cancer
Methods RCT
Participants 700 men newly diagnosed with localized prostate cancer
Interventions A tele-based nurse delivered 5-session decision support/psychosocial intervention vs usual care
Outcomes Cancer threat appraisal; decision-related distress and bother from treatment side effects; involvement in
decision making; satisfaction with health care; heathcare utilization; use of healthcare resources; and a return
to previous activities
Starting date Not yet assessed
Contact information Suzanne K Chambers, Griffith University
Notes Trials #: ACTRN012607000233426
Coylewright 2012
Trial name or title Shared decision making in patients with stable coronary artery disease: PCI Choice
Methods RCT
Participants -
Interventions -
Outcomes -
Starting date -
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Coylewright 2012 (Continued)
Contact information Megan Coylewright, Mayo Clinic
Notes Upcoming RCT
Cuypers 2015
Trial name or title Prostate cancer patient-centered care: impact of a treatment decision aid in a pragmatic, cluster randomized
controlled trial
Methods Pragmatic RCT
Participants 400 men newly diagnosed with early stage prostate cancer
Interventions Decision aid (online) vs usual care
Outcomes Decisional conflict, decisional regret, treatment satisfaction, decision making role, knowledge, satisfaction
with decision-making process, preparation for decision-making, health-related quality of life, personality
(anxiety, depression, optimism), skills measures (self-efficacy, health literacy, numeracy)
Starting date May 2014
Contact information M Cuypers; M.Cuypers@uvt.nl; Tilburg University Social and Behavioral Sciences
Tilburg, the Netherlands
Notes NTR4554
Den Ouden 2015
Trial name or title Shared decision-making in type 2 diabetes with a support decision tool that takes into account clinical factors,
the intensity of treatment and patient preferences
Methods Cluster RCT
Participants 150 adults with type 2 diabetes mellitus for 8-15 years
Interventions Patient decision aid with training vs usual care
Outcomes Achievement of diabetes-specific health goals, satisfaction with treatment, quality of life, well-being, coping,
evidence of shared decision-making
Starting date March 2012
Contact information h.denouden@umcutrecht.nl;Henk denOuden; JuliusCntre forHealth Sciences and PrimaryCare, University
Medical Centre, Utrecht, the Netherlands
Notes Trial #: NCT02285881
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Dirmaier 2013
Trial name or title Tailored, dialogue-based health communication application for patients with chronic low back pain
Methods RCT
Participants 414 patients with self-reported chronic low back pain
Interventions Web-based interactive health communication application (IHCA) vs control (standard info)
Outcomes Knowledge, patient empowerment, website usage, preparation for decision making, decisional conflict
Starting date 2012
Contact information Martin Härter, University Medical Center Hamburg-Eppendorf
Notes International Clinical Trials Registry DRKS00003322
Geiger 2011
Trial name or title Investigating a training supporting Shared Decision Making (IT’S SDM 2011): study protocol for a random-
ized controlled trial
Methods RCT
Participants 40 physicians that contribute a sequence of 4 medical consultations including a diagnostic or treatment
decision
Interventions A training curriculum for the doctors - intend to stimulate efforts to involve their patients in the decision-
making process
Outcomes Physician-patient communication, effect of SDM on perceived quality of the decision process and on the
elaboration of the decision, decisional conflict
Starting date Not yet assessed
Contact information Friedemann Geiger, University Medical Center Schleswig - Holstein
Notes Trials #: ISRCTN78716079
Hersch 2014
Trial name or title Effect of information about over detection of breast cancer onwomen’s decision-making aboutmammography
screening
Methods RCT
Participants 970 women aged 48-50
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Hersch 2014 (Continued)
Interventions Intervention (evidence-based information booklet including over detection, breast cancer mortality reduction
and false positives) vs control information booklet (including mortality reduction and false positives only)
Outcomes Knowledge, consistency between attitudes and intentions, decision conflict, confidence, regret, anxiety, per-
ceived risk, quality of life
Starting date June 2014
Contact information Kirsten McCaffery, University of Sydney
Notes Australian New Zealand Clinical Trials Registry ACTRN12613001035718
Hess 2014
Trial name or title Shared decision making in parents of children with head trauma: head CT choice
Methods RCT
Participants 1004 parent-child dyad, seeking care for a child who had blunt trauma above the eyebrows and is positive for
at least 1 PECARN clinical prediction rules
Interventions Patient decision aid vs usual care
Outcomes Knowledge, engagement in decision-making process, decisional conflict, trust in the physician, satisfaction
with the decision-making process, choice, healthcare utilization 7-days post ER visit, rate of clinically impor-
tant traumatic brain injury
Starting date April 2014
Contact information Erik Hess; Mayo Clinic; Rochester, MN
Notes Trial #: NCT02063087
Jimbo 2012
Trial name or title Decision aid to technologically enhance shared decision making
Methods RCT
Participants Patients who are not current with colorectal cancer screening
Interventions Web based decision aid + interactive component (preferences and risk assessment) vs web based decision aid
only
Outcomes Uptake of screening on patient determinants/preference/intention before the patient-physician encounter, and
on shared decision making, concordance and patient intention during/after the patient-physician encounter
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Jimbo 2012 (Continued)
Starting date May 2012
Contact information Masahito Jimbo, University of Michigan
Notes Trial # :NCT01514786; last updated December 2013, estimated study completion October 2014
Layton 2012
Trial name or title Effects of a web-based decision aid on African American men’s prostate screening knowledge and behavior
Methods -
Participants 128 African American men
Interventions -
Outcomes -
Starting date -
Contact information Beverly Layton, Walden University
Notes Unpublished thesis
LeBlanc 2013
Trial name or title Translating comparative effectiveness of depression medications into practice by comparing the depression
medication choice decision aid to usual care: study protocol for a randomized controlled trial
Methods RCT
Participants 300 patients
Interventions Use of the Depression Medication Choice decision aid by patients and their primary care clinician during the
clinical encounter vs usual care
Outcomes Decisional conflict, knowledge, satisfaction, preference in decision making style, patient involvement in
decision making, depression outcomes, medication adherence
Starting date December 2011
Contact information Victor Montori, Mayo Clinic, USA
Notes NCT01502891
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Mann 2012
Trial name or title Increasing efficacy of primary care-based counselling for diabetes prevention: rationale and design of the
ADAPT (Avoiding Diabetes Thru Action Plan Targeting) trial
Methods RCT
Participants Primary care providers
Interventions Using the ADAPT (Avoiding Diabetes Thru Action Plan Targeting) system to enhance providers’ effectiveness
to counsel about lifestyle behaviour changes
Outcomes Outcome measurements are designed to detect changes in patient behaviours that are most likely to result
from the use of ADAPT tool: difference between intervention and control patients in the change in mean
steps per day at baseline and after 6 months, and 6 month difference of differences in haemoglobin A1C and
self-reported diet between the 2 groups
Starting date Not yet assessed
Contact information Devin Mann, Boston University School of Medicine
Notes Trial #: NCT01473654
NCT00813033
Trial name or title Use of a patient decision aid for gastrologic endoscopy in a paediatric setting
Methods Interventional efficacy study
Participants 80 parents considering gastro-endoscopy for child
Interventions Not yet assessed
Outcomes Knowledge, expectations of outcomes, clarity of values, decision, decision conflict
Starting date December 2008
Contact information Nancy Neilan, Children’s Mercy Hospital, Kansas City
Notes Trials #: NCT00813033; completed March 2011
NCT01077037
Trial name or title Shared decision making in the emergency department: the Chest Pain Choice Trial
Methods RCT
Participants 1500 adults admitted to the emergency department for chest pain, being considered by the treating clinical
for admission for cardiac testing
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NCT01077037 (Continued)
Interventions Patient decision aid vs usual care
Outcomes Knowledge, healthcare utilization (rate of hospital admission, rate of cardiac testing, etc), patient engagement
in decision-making process, decisional conflict, trust in the physician, satisfaction with decision, safety (major
adverse cardiac events within 30 days)
Starting date October 2013
Contact information hess.erik@mayo.edu; Mayo Clinic, Rochester, Minnesota, USA
Notes Trial #: NCT01969240
NCT01152294
Trial name or title Measuring quality of decisions about treatment of menopausal symptoms
Methods RCT
Participants Patients talked with healthcare provider about ways to manage menopause or seriously considered taking
medicine or supplement to manage menopause
Interventions Decision aid (DVD/booklet) vs usual care
Outcomes Knowledge, value concordance
Starting date June 2010
Contact information Karen R Sepucha, Massachusetts General Hospital
Notes NCT01152294; completed, study results on clinicaltrials.gov
NCT01152307
Trial name or title Measuring quality of decisions about treatment of depression
Methods RCT
Participants Patients that talked to a healthcare provider about starting or stopping a treatment (prescription medicine for
depression or counselling)
Interventions Decision aid (DVD/booklet) vs usual care
Outcomes Knowledge, value concordance
Starting date June 2010
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NCT01152307 (Continued)
Contact information Karen R Sepucha, Massachusetts General Hospital
Notes NCT01152307; completed, study results on clinicaltrials.gov
NCT01447186
Trial name or title Informed decisions about lung cancer screening
Methods RCT
Participants 500 adults between 55 and 77 years olds who are currently smoking or quit within the past 15 years
Interventions Patient decision aid vs standard educational information
Outcomes Decisional conflict: value subscale and informed subscale
Starting date March 2015
Contact information MD Anderson Cancer Center; USA
Notes Trial #: NCT02286713
NCT01618097
Trial name or title Evaluation of DVD and Internet decision aids for hip and knee osteoarthritis: focus on health literacy
Methods RCT
Participants Osteoarthritis patients
Interventions DVD decision aid vs Internet-based decision aid
Outcomes Decisional conflict, decision self-efficacy, knowledge
Starting date January 2012
Contact information Kelli D Allen, Duke University
Notes Trial #: NCT01618097; last updated March 2014, study completion date January 2014
194Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT01713894
Trial name or title Utility of a clinically relevant decision aid, for parents facing extremely premature delivery
Methods RCT
Participants 300 women who are receiving counselling at the limits of viability
Interventions Decision aid vs usual care
Outcomes Decisional conflict, knowledge
Starting date May 2013
Contact information uguillen@christianacare.org; Ursula Guillen, Christiana Care Health Systems; University of Michigan
Notes Trial # NCT01713894
NCT01771536
Trial name or title Study to test use of a decision aid in a clinical visit to help patients choose a diabetes medication. Translating
Information on Comparative Effectiveness Into Practice (TRICEP)
Methods RCT
Participants Type 2 diabetes mellitus patients
Interventions Diabetes medication decision aid vs usual care
Outcomes Patient satisfaction and knowledge. Physician adoption and satisfaction with the decision aid
Starting date January 2011
Contact information Nilay D Shah, Mayo Clinic
Notes NCT01293578; estimated completion date December 2014
NCT01851785
Trial name or title Behavioral and social science research on understanding and reducing health disparities: African American
preference for knee replacement: a patient-centred intervention (ACTION)
Methods RCT
Participants African-American participants referred to orthopaedic doctor with presence of knee OA
Interventions Decision aid video + communication, skill-building intervention vs educational programme (an NIH-devel-
oped booklet) that summarizes how to live with knee OA but does not mention joint replacement
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NCT01851785 (Continued)
Outcomes Recommendation and receipt of knee joint replacement
Starting date July 2010
Contact information Said A Ibrahim, University of Pennsylvania
Notes Trial #: NCT01851785; last verified May 2013, estimated completion date June 2015
NCT01941186
Trial name or title A family centered intervention to promote optimal child development
Methods RCT
Participants 64 parent-child dyad in which the child is aged 0-36 months screening positive for developmental concern
Interventions Patient decision aid vs usual care
Outcomes Evaluation by early intervention specialist, attitudes, knowledge, uncertainty, intervention acceptability, in-
tervention feasibility
Starting date December 2013
Contact information Children’s Hospital of Philadelphia
Philadelphia, PN, USA, 19104
Notes Trial #: NCT01941186
NCT01976325
Trial name or title Incorporation of the ’Ottawa Malaria Decision Aid’ into the pre-travel consultation process
Methods RCT
Participants 100 adults attending a travel clinic before travelling to an area with known chloroquine-resistant malaria
Interventions Decision aid vs usual care
Outcomes Knowledge, decisional conflict, preparation for decision-making, medication adherence
Starting date January 2014
Contact information amccarthy@toh.on.ca; Anne E McCarthy; Ottawa Hospital Research Institute
Notes Trial # NCT01976325
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NCT02026102
Trial name or title A pilot trial of patient decision aids for implantable cardioverter-defibrillators (ICDs)
Methods RCT
Participants 60 patients with heart failure referred for primary prevention implantable cardioverter-defibrillators
Interventions Decision aid toolkit vs usual care
Outcomes Intervention acceptability, decision quality (knowledge and values concordance), quality of life, depressive
symptoms, health status, spiritual well-being
Starting date September 2014
Contact information amy.jenkins@ucdenver.edu; University of Colorado Hospital (UCH)
Notes Trial #: NCT02026102
NCT02084290
Trial name or title Evaluating a prediction tool and decision aid for patients with Crohn’s disease
Methods RCT
Participants 300 adults with Crohn’s disease
Interventions Patient decision aid and SDM programme vs usual care
Outcomes Preferred choice, actual choice, adherence, cost of care, remission, patient on steroids, surgeries, Crohn’s
disease related hospitalizations
Starting date March 2014
Contact information corey.a.siegel@hitchcock.org; Corey A Siegel; Dartmouth-Hitchcock Medical Center
Notes Trial #: NCT02084290
NCT02110979
Trial name or title Validation of a patient decision aid for type 2 diabetes
Methods RCT
Participants 200 type 2 diabetes patients
Interventions Patient decision aid vs usual care
Outcomes Knowledge, decisional conflict
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NCT02110979 (Continued)
Starting date April 2014
Contact information EPI-Q Inc, Oak Brook, IL, USA, 60523
www.epi-q.com/our-approach
Notes Trial #: NCT02110979
NCT02145481
Trial name or title Decisional quality for patients with stable coronary artery disease
Methods RCT
Participants 846 adults with stable coronary artery disease
Interventions Patient decision aid vs standard education
Outcomes Quality of the decision-making process, knowledge, communication, involvement, treatment preferences
Starting date May 2014
Contact information R. Adams Dudley; University of California, San Francisco
Notes Trial # NCT02145481
NCT02198690
Trial name or title Randomized trial of a mammography decision aid for women aged 75 and older
Methods RCT
Participants 550 women aged 75-89 years
Interventions Decision aid vs usual care
Outcomes Receipt of mammography screening, acceptability, anxiety, decision-making role, decisional conflict, home
safety, home safety discussions, knowledge, preparation for decision-making, screening discussions, screening
intentions
Starting date September 2014
Contact information Mara A Schonberg, MD, MPH; mschonbe@bidmc.harvard.edu; Beth Israel Deaconess Medical Center;
Boston, MA, USA
Notes NCT02198690
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NCT02235571
Trial name or title iChoose kidney decision aid for treatment options among end-stage renal disease (ESRD) patients
Methods RCT
Participants 450 adults with end-stage renal disease on dialysis for < 1 year and being evaluated for kidney transplant
Interventions Patient decision aid vs usual care
Outcomes Knowledge, evidence of shared decision-making, access to transplant, treatment preferences
Starting date September 2014
Contact information Rachel Patzer; Emory Transplant Center; Atlanta, GA, USA
Notes Trial # NCT02235571
NCT02248974
Trial name or title Development and user testing of a decision aid for left ventricular assist device (LVAD) placement
Methods RCT
Participants 144 adults who are candidates for a left ventricular assist device
Interventions Patient decision aid vs. standard education
Outcomes Knowledge, decisional conflict, control preferences scale, CollaboRATE score, perceived quality of care,
satisfaction with decision-making process, decisional regret, satisfaction with life, preparation for decision-
making, usability and acceptability of the intervention
Starting date February 2014
Contact information Jennifer Blumenthal-Barby; Baylor College of Medicine; Houston, TX
Notes Trial #: NCT02248974
NCT02259699
Trial name or title Ovarian cancer patient-centered decision aid
Methods RCT
Participants 221 women with stage III optimally debulked advanced ovarian cancer
Interventions Patient decision aid vs usual care
Outcomes Satisfaction with decision, evidence of shared decision-making, quality of life, satisfaction with care and
satisfaction with cancer treatment
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NCT02259699 (Continued)
Starting date December 2014
Contact information lwenzel@uci.edu; Lari Wenzel; University of California, Irvine, USA
Notes Trial #: NCT02259699
NCT02308592
Trial name or title Patient decision aid for antidepressant use in pregnancy
Methods RCT
Participants 50 women aged 18 years or older planning a pregnancy or <30 weeks pregnant
Interventions Patient decision aid vs standard resource sheet
Outcomes depression, anxiety, decisional conflict, knowledge, intervention acceptability, choice, satisfaction with DA
Starting date January 2015
Contact information simone.vigod@wchospital.ca
Women’s College Hospital, Toronto, Ontario, Canada
Notes Trial #: NCT02308592
NCT02319525
Trial name or title
Methods
Participants
Interventions
Outcomes
Starting date
Contact information
Notes
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NCT02326597
Trial name or title Decision aid for therapeutic options in sickle cell disease
Methods RCT
Participants 120 individuals with sickle cell disease ages 8 to 80 years
Interventions Decision aid vs usual care
Outcomes Knowledge, self-efficacy, decisional conflict, values, realistic expectations, preparation for decision-making,
choice predisposition, stage of decision-making, decisional regret
Starting date September 2014
Contact information diana.ross@emory.edu; principal investigator Lakshmanan Krishnamurti; Emory University, Atlanta, GA,
USA
Notes Trial # NCT02326597
NCT02344576
Trial name or title Amulticenter trial of a shared decision support intervention for patients and their caregivers offered destination
therapy for end-stage heart failure
Methods RCT
Participants 400 adults advanced heart failure and are being evaluated for destination left ventricular assist device
Interventions Patient decision aid vs usual care
Outcomes Knowledge, values, decisional conflict, decisional regret, stress, anxiety, depression, quality of life, control
preferences scale, illness acceptance, health status
Starting date May 2015
Contact information jocelyn.thompson@ucdenver.edu; University of Colorado, Denver
Notes Trial #: NCT02344576
NCT02488317
Trial name or title Empowering patients on choices for renal replacement therapy
Methods RCT
Participants 150 adults with kidney disease
Interventions Patient decision aid vs usual care
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NCT02488317 (Continued)
Outcomes Preference for shared decision-making (CPS), decisional conflict, decision self-efficacy, knowledge, preparation
for decision making
Starting date May 2015
Contact information Francesca Tentori; Arbor Research Collaborative for Health; Ann Arbor, MI
Notes Trial #: NCT02488317
NCT02488603
Trial name or title Utilization of decision aids for tamoxifen treatment in breast cancer patients
Methods RCT
Participants 360 breast cancer patients referred for tamoxifen treatment
Interventions Patient decision aid vs usual care
Outcomes Knowledge, decisional conflict scale, satisfaction with decision, quality of life
Starting date August 2015
Contact information Eun Sook Lee; National Cancer Center, Korea
Notes Trial # NCT02488603
NCT02492009
Trial name or title Patient decision aid for antidepressant use in pregnancy
Methods RCT
Participants 50 women aged 18 years or older planning a pregnancy or < 30 weeks pregnant
Interventions Patient decision aid vs standard resource sheet
Outcomes Depression, anxiety, decisional conflict, knowledge, intervention acceptability, choice
Starting date June 2015
Contact information hind.khalifeh@kcl.ac.uk or ruth.brauer@kcl.ac.uk
Section of Women’s Mental Health, King’s College London
Notes Trial #: NCT02492009
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NCT02503553
Trial name or title Decision aids in cerebral aneurysm treatment
Methods RCT
Participants 60 patients undergoing treatment for cerebral aneurysm
Interventions Patient decision aid vs usual care
Outcomes Participation in the shared-decision making process; stress levels, patient satisfaction level
Starting date August 2015
Contact information Kimon Bekelis; Dartmouth-Hitchcock Medical Center; New Hampshire, USA
Notes Trial #: NCT02503553
NCT02516449
Trial name or title Assessment of shared decision making aids in asthma
Methods RCT
Participants 51 adults with mild to severe asthma
Interventions Patient decision aid vs usual care
Outcomes Knowledge, decisional conflict, treatment adherence, asthma control
Starting date March 2013
Contact information Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Canada,
G1V 4G5
Notes Trial # NCT02516449
NCT02540044
Trial name or title Supporting patient care with electronic resource (SuPER): efficacy of an online decision aid for patients
considering biologic therapy for rheumatoid arthritis
Methods RCT
Participants 144 adults with rheumatoid arthritis whose rheumatologists have recommended initiating a biologic/subse-
quent entry biologic or switching to another biologic agent
Interventions Online patient decision aid vs online standard information
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NCT02540044 (Continued)
Outcomes Decisional conflict, knowledge, self-efficacy, self-management behaviours, health resource utilization, choice,
evidence of shared decision-making
Starting date January 2016
Contact information Linda Li; University of British Columbia; Vancouver, Canada
Notes Trial #: NCT02540044
NCT02611050
Trial name or title Treatment decisions for multi-vessel CAD
Methods RCT
Participants 160 adults with stable multi-vessel CAD at relative equipoise for at least 2 potential treatment options
Interventions Option grid decision aid vs usual care
Outcomes Decisional conflict, CollaboRATE score, knowledge, patient experience, treatment received
Starting date December 2015
Contact information Elizabeth L Nichols; the Dartmouth Institute
Notes Trial #: NCT02611050
Oostendorp 2011
Trial name or title Assessing the information desire of patients with advanced cancer by providing information with a decision
aid, which is evaluated in a randomized trial: a study protocol
Methods RCT
Participants Patients with advanced colorectal, breast, or ovarian cancer and have started treatment with first-line palliative
chemotherapy
Interventions Patients are randomized to receive either usual care or usual care + decision aid
Outcomes Not yet assessed
Starting date Not yet assessed
Contact information Linda JM Oostendorp, Radbound University
Notes Netherlands Trial Register (NTR): NTR1113
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Yu 2015
Trial name or title Impact of an interprofessional shared decision-making and goal setting decision aid for patients with diabetes
Methods Cluster-randomized controlled trial
Participants 112 patients with diabetes
Interventions Multicomponent patient decision aid toolkit vs patient education pamphlet
Outcomes Decisional conflict, diabetes distress, health-related quality of life, chronic illness care, intention to engage in
SDM
Starting date April 2015
Contact information yuca@smh.ca
Notes Trial # NCT02379078
CA-125: cancer antigen 125;CAD: coronary artery disease;CT: computerized tomography;NIH: National Institutes of Health;NSW:
New South Wales; OA: osteoarthritis; RCT: randomized controlled trial; SDM: shared decision making.
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D A T A A N D A N A L Y S E S
Comparison 1. Knowledge
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Knowledge - all studies 52 13316 Mean Difference (IV, Random, 95% CI) 13.27 [11.32, 15.23]
2 Knowledge - subgroup by timing
of intervention (in consultation
versus in preparation for
consultation)
52 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 In consultation 8 922 Mean Difference (IV, Random, 95% CI) 10.57 [4.79, 16.36]
2.2 In preparation for
consultation
44 12394 Mean Difference (IV, Random, 95% CI) 13.77 [11.61, 15.93]
3 Knowledge - studies without
high risk of bias
47 12327 Mean Difference (IV, Random, 95% CI) 13.43 [11.37, 15.49]
Comparison 2. Accurate risk perceptions
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Accurate risk perceptions - all
studies
17 5096 Risk Ratio (M-H, Random, 95% CI) 2.10 [1.66, 2.66]
2 Accurate risk perceptions
- subgroup by timing of
intervention (in consultation
versus in preparation for
consultation)
17 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 In consultation 6 898 Risk Ratio (M-H, Random, 95% CI) 1.79 [1.28, 2.52]
2.2 In preparation for
consultation
11 4198 Risk Ratio (M-H, Random, 95% CI) 2.25 [1.65, 3.07]
3 Accurate risk perceptions -
studies without high risk of bias
15 4732 Risk Ratio (M-H, Random, 95% CI) 2.02 [1.57, 2.59]
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Comparison 3. Informed values-choice congruence
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Informed values-choice
congruence - all studies
10 4626 Risk Ratio (M-H, Random, 95% CI) 2.06 [1.46, 2.91]
2 Informed values-choice
congruence - actual choice only
8 4154 Risk Ratio (M-H, Random, 95% CI) 2.13 [1.44, 3.14]
3 Informed values-chose
congruence -using MMIC
8 4365 Risk Ratio (M-H, Random, 95% CI) 2.08 [1.40, 3.08]
4 Informed values-chose
congruence - heterogeneous
measures
2 261 Risk Ratio (M-H, Random, 95% CI) 2.02 [1.44, 2.83]
5 Informed values-choice
congruence - without studies of
high risk of bias
10 4626 Risk Ratio (M-H, Random, 95% CI) 2.06 [1.46, 2.91]
Comparison 4. Decisional conflict
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Decisional conflict - all studies 42 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Total decisional conflict
score
38 8785 Mean Difference (IV, Random, 95% CI) -7.22 [-9.12, -5.31]
1.2 Uninformed subscale 27 5707 Mean Difference (IV, Random, 95% CI) -9.28 [-12.20, -6.36]
1.3 Unclear values subscale 23 5068 Mean Difference (IV, Random, 95% CI) -8.81 [-11.99, -5.63]
1.4 Uncertainty subscale 28 6200 Mean Difference (IV, Random, 95% CI) -4.04 [-6.27, -1.81]
1.5 Unsupported subscale 24 5214 Mean Difference (IV, Random, 95% CI) -6.27 [-8.86, -3.68]
1.6 Ineffective choice subscale 24 5241 Mean Difference (IV, Random, 95% CI) -6.31 [-8.93, -3.70]
2 Decisional conflict - in
consultation
6 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Uncertainty subscale 2 310 Mean Difference (IV, Random, 95% CI) -6.45 [-18.29, 5.38]
2.2 Uninformed subscale 4 545 Mean Difference (IV, Random, 95% CI) -6.37 [-14.58, 1.85]
2.3 Unclear values subscale 1 204 Mean Difference (IV, Random, 95% CI) -17.2 [-23.77, -10.
63]
2.4 Unsupported subscale 2 354 Mean Difference (IV, Random, 95% CI) -7.16 [-13.28, -1.03]
2.5 Ineffective choice subscale 2 307 Mean Difference (IV, Random, 95% CI) -2.37 [-7.31, 2.58]
2.6 Total decisional conflict
score
5 735 Mean Difference (IV, Random, 95% CI) -6.46 [-12.78, -0.14]
3 Decisional conflict - in
preparation for consultation
36 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Uncertainty subscale 26 5890 Mean Difference (IV, Random, 95% CI) -3.83 [-6.12, -1.55]
3.2 Uninformed subscale 23 5162 Mean Difference (IV, Random, 95% CI) -9.81 [-13.00, -6.61]
3.3 Unclear values subscale 22 4864 Mean Difference (IV, Random, 95% CI) -8.40 [-11.59, -5.21]
3.4 Unsupported subscale 22 4860 Mean Difference (IV, Random, 95% CI) -6.18 [-8.96, -3.40]
3.5 Ineffective choice subscale 22 4934 Mean Difference (IV, Random, 95% CI) -6.75 [-9.59, -3.90]
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3.6 Total decisional conflict
score
33 8050 Mean Difference (IV, Random, 95% CI) -7.32 [-9.35, -5.28]
4 Decisional conflict - without
studies having high risk of bias
39 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Uncertainty subscale 26 5809 Mean Difference (IV, Random, 95% CI) -4.53 [-6.87, -2.18]
4.2 Uninformed subscale 25 5316 Mean Difference (IV, Random, 95% CI) -9.96 [-13.13, -6.78]
4.3 Unclear values subscale 21 4677 Mean Difference (IV, Random, 95% CI) -9.55 [-13.08, -6.02]
4.4 Unsupported subscale 22 4823 Mean Difference (IV, Random, 95% CI) -7.00 [-9.76, -4.24]
4.5 Ineffective choice subscale 22 4850 Mean Difference (IV, Random, 95% CI) -6.97 [-9.76, -4.18]
4.6 Total decisional conflict
score
35 8240 Mean Difference (IV, Random, 95% CI) -7.81 [-9.84, -5.77]
Comparison 5. Participation in decision making
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participation in decision making
- all studies
16 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Clinician-controlled
decision making
16 3180 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.55, 0.83]
1.2 Patient-controlled
decision making
15 3009 Risk Ratio (M-H, Random, 95% CI) 1.28 [1.05, 1.55]
1.3 Shared decision making 15 2973 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.10]
2 Participation in decision making
- in consultation
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Clinician-controlled
decision making - in
consultation
3 650 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.70, 1.12]
2.2 Patient-controlled decision
making - in consultation
2 479 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.80, 1.27]
2.3 Shared decision making -
in consultation
2 479 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.84, 1.55]
3 Participation in decision
making - in preparation for
consultation
13 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Clinician-controlled
decision making
13 2530 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.48, 0.75]
3.2 Patient-controlled
decision making
13 2530 Risk Ratio (M-H, Random, 95% CI) 1.37 [1.08, 1.73]
3.3 Shared decision making 13 2494 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.80, 1.09]
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Comparison 6. Proportion undecided
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion undecided - all
studies
22 5256 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.52, 0.79]
Comparison 7. Satisfaction
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Satisfaction with the choice - all
studies
11 Mean Difference (IV, Random, 95% CI) Totals not selected
2 Satisfaction with the choice - in
consultation
1 Mean Difference (IV, Random, 95% CI) Totals not selected
3 Satisfaction with the choice - in
preparation for consultation
10 Mean Difference (IV, Random, 95% CI) Totals not selected
4 Satisfaction with the decision
making process - all studies
9 Mean Difference (IV, Random, 95% CI) Totals not selected
5 Satisfaction with the decision
making process - in
consultation
1 Mean Difference (IV, Random, 95% CI) Totals not selected
6 Satisfaction with the decision
making process - in preparation
for consultation
8 Mean Difference (IV, Random, 95% CI) Totals not selected
Comparison 8. Choice
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Choice: surgery over conservative
option
18 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Per-protocol analysis 18 3286 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.75, 1.01]
1.2 Intention-to-treat analysis 18 3844 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.75, 1.00]
1.3 Per-protocol analysis
without prophylactic
mastectomy
17 3108 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.73, 0.97]
2 Choice for screening 25 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 PSA screening 10 3996 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.80, 0.98]
2.2 Colorectal cancer
screening
10 4529 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.95, 1.31]
2.3 Breast cancer genetic
testing
3 738 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.71, 1.38]
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2.4 Prenatal diagnostic testing 2 1100 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.91, 1.09]
3 Choice: diabetes medication
(uptake new medication)
4 447 Risk Ratio (M-H, Random, 95% CI) 1.65 [1.06, 2.56]
Analysis 1.1. Comparison 1 Knowledge, Outcome 1 Knowledge - all studies.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 1 Knowledge
Outcome: 1 Knowledge - all studies
Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Allen 2010 291 66 (35.48) 334 60 (29.24) 2.0 % 6.00 [ 0.86, 11.14 ]
Arterburn 2011 75 72 (12) 77 65 (17) 2.1 % 7.00 [ 2.33, 11.67 ]
Barry 1997 104 75 (45) 123 54 (45) 1.3 % 21.00 [ 9.25, 32.75 ]
Bekker 2004 50 74 (14.5) 56 71.5 (16) 2.0 % 2.50 [ -3.31, 8.31 ]
Bernstein 1998 61 83 (16) 48 58 (16) 1.9 % 25.00 [ 18.95, 31.05 ]
Bjorklund 2012 182 77 (17) 204 71 (20) 2.2 % 6.00 [ 2.31, 9.69 ]
Chabrera 2015 61 75.7 (19) 61 49.9 (16) 1.9 % 25.80 [ 19.57, 32.03 ]
Frosch 2008a 155 81.4 (18.7) 151 72.4 (19.7) 2.1 % 9.00 [ 4.69, 13.31 ]
Gattellari 2003 106 50 (18.4) 108 45 (15.9) 2.1 % 5.00 [ 0.39, 9.61 ]
Gattellari 2005 131 57.2 (21.3) 136 42.2 (16.7) 2.1 % 15.00 [ 10.40, 19.60 ]
Green 2001 29 95 (7) 14 65 (21) 1.3 % 30.00 [ 18.71, 41.29 ]
Hanson 2011 127 88.4 (21.64) 129 79.5 (21.64) 2.0 % 8.90 [ 3.60, 14.20 ]
Hess 2012 101 51.43 (18.2) 103 42.86 (18.3) 2.0 % 8.57 [ 3.56, 13.58 ]
Jibaja-Weiss 2011 44 61.22 (20.38) 39 43.59 (26.61) 1.4 % 17.63 [ 7.33, 27.93 ]
Johnson 2006 32 92.6 (11) 35 85.2 (15.6) 1.9 % 7.40 [ 0.98, 13.82 ]
Knops 2014 80 76.92 (16.92) 84 72.3 (16.15) 2.0 % 4.62 [ -0.45, 9.69 ]
Krist 2007 196 69 (33.21) 75 54 (33.21) 1.6 % 15.00 [ 6.16, 23.84 ]
Kupke 2013 50 60 (23.3) 31 27 (16.7) 1.6 % 33.00 [ 24.27, 41.73 ]
Kuppermann 2014 357 62.7 (21.3) 353 57.3 (21.3) 2.2 % 5.40 [ 2.27, 8.53 ]
Lam 2013 113 61 (21) 112 59 (21) 2.0 % 2.00 [ -3.49, 7.49 ]
Laupacis 2006 53 83 (19.5) 53 67.4 (17) 1.8 % 15.60 [ 8.64, 22.56 ]
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(. . . Continued)
Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Leighl 2011 100 72.5 (26.86) 100 60 (26.86) 1.8 % 12.50 [ 5.05, 19.95 ]
Lepore 2012 215 61.6 (0.13) 216 54.7 (0.13) 2.4 % 6.90 [ 6.88, 6.92 ]
Lerman 1997 122 68.9 (19) 164 49 (21.7) 2.1 % 19.90 [ 15.17, 24.63 ]
Lewis 2010 93 45.1 (34.01) 107 46.7 (34.01) 1.5 % -1.60 [ -11.05, 7.85 ]
Man-Son-Hing 1999 137 75.91 (15.72) 136 66.46 (16.07) 2.2 % 9.45 [ 5.68, 13.22 ]
Mann E 2010 273 64.14 (21.86) 134 41.29 (21) 2.1 % 22.85 [ 18.45, 27.25 ]
Mathieu 2010 113 73.5 (27.6) 189 62.7 (27.6) 1.9 % 10.80 [ 4.37, 17.23 ]
McCaffery 2010 77 81 (23.51) 71 72 (23.51) 1.7 % 9.00 [ 1.42, 16.58 ]
Montgomery 2003 50 75 (17) 58 60 (18) 1.9 % 15.00 [ 8.39, 21.61 ]
Montgomery 2007 196 69.7 (18) 202 57.5 (18.5) 2.2 % 12.20 [ 8.61, 15.79 ]
Montori 2011 49 63.3 (29.61) 46 43.3 (29.61) 1.3 % 20.00 [ 8.09, 31.91 ]
Morgan 2000 86 75 (32.04) 94 62 (32.04) 1.5 % 13.00 [ 3.63, 22.37 ]
Mullan 2009 48 63.5 (24.4) 37 53 (18.2) 1.6 % 10.50 [ 1.44, 19.56 ]
Nassar 2007 98 88 (19) 90 79 (18) 2.0 % 9.00 [ 3.71, 14.29 ]
Protheroe 2007 54 59.7 (18.4) 54 48.8 (19.6) 1.8 % 10.90 [ 3.73, 18.07 ]
Sawka 2012 37 97 (6) 37 78 (13) 2.1 % 19.00 [ 14.39, 23.61 ]
Schroy 2011 223 89.17 (15) 231 71.67 (22.5) 2.2 % 17.50 [ 13.99, 21.01 ]
Schwalm 2012 76 60 (30) 74 40 (26) 1.6 % 20.00 [ 11.02, 28.98 ]
Schwartz 2001 191 65.71 (14.29) 190 57.14 (15.71) 2.2 % 8.57 [ 5.55, 11.59 ]
Shorten 2005 99 75.33 (15) 92 60.53 (17.07) 2.1 % 14.80 [ 10.23, 19.37 ]
Smith 2010 357 54.17 (27.83) 173 34.17 (14.25) 2.2 % 20.00 [ 16.42, 23.58 ]
Stacey 2014a 66 71.2 (23.7) 66 46.6 (21.4) 1.7 % 24.60 [ 16.90, 32.30 ]
Steckelberg 2011 785 53.75 (28.75) 792 31.25 (15) 2.3 % 22.50 [ 20.23, 24.77 ]
Taylor 2006 80 77.3 (15.5) 74 62.7 (11.8) 2.1 % 14.60 [ 10.27, 18.93 ]
Thomson 2007 53 62.91 (14.26) 56 62.35 (14.1) 2.0 % 0.56 [ -4.77, 5.89 ]
Van Peperstraten 2010 123 62 (28.3) 132 43 (20.5) 1.9 % 19.00 [ 12.90, 25.10 ]
Vandemheen 2009 70 74 (27.07) 79 49 (23.33) 1.7 % 25.00 [ 16.83, 33.17 ]
Volk 1999 78 48 (21.6) 80 31 (18.8) 1.9 % 17.00 [ 10.68, 23.32 ]
Whelan 2003 82 80.2 (14.4) 93 71.7 (13.3) 2.1 % 8.50 [ 4.37, 12.63 ]
Williams 2013 196 64.4 (18.5) 185 61.7 (17.8) 2.2 % 2.70 [ -0.95, 6.35 ]
Wong 2006 154 85 (26.7) 159 60 (21.7) 2.0 % 25.00 [ 19.60, 30.40 ]
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(. . . Continued)
Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Total (95% CI) 6779 6537 100.0 % 13.27 [ 11.32, 15.23 ]
Heterogeneity: Tau2 = 41.98; Chi2 = 717.60, df = 51 (P<0.00001); I2 =93%
Test for overall effect: Z = 13.31 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Knowledge, Outcome 2 Knowledge - subgroup by timing of intervention (in
consultation versus in preparation for consultation).
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 1 Knowledge
Outcome: 2 Knowledge - subgroup by timing of intervention (in consultation versus in preparation for consultation)
Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 In consultation
Bekker 2004 50 74 (14.5) 56 71.5 (16) 13.3 % 2.50 [ -3.31, 8.31 ]
Hess 2012 101 51.43 (18.2) 103 42.86 (18.3) 13.8 % 8.57 [ 3.56, 13.58 ]
Johnson 2006 32 92.6 (11) 35 85.2 (15.6) 13.0 % 7.40 [ 0.98, 13.82 ]
Kupke 2013 50 60 (23.3) 31 27 (16.7) 11.4 % 33.00 [ 24.27, 41.73 ]
Montori 2011 49 63.3 (29.61) 46 43.3 (29.61) 9.3 % 20.00 [ 8.09, 31.91 ]
Mullan 2009 48 63.5 (24.4) 37 53 (18.2) 11.2 % 10.50 [ 1.44, 19.56 ]
Thomson 2007 53 62.91 (14.26) 56 62.35 (14.1) 13.6 % 0.56 [ -4.77, 5.89 ]
Whelan 2003 82 80.2 (14.4) 93 71.7 (13.3) 14.3 % 8.50 [ 4.37, 12.63 ]
Subtotal (95% CI) 465 457 100.0 % 10.57 [ 4.79, 16.36 ]
Heterogeneity: Tau2 = 56.40; Chi2 = 46.70, df = 7 (P<0.00001); I2 =85%
Test for overall effect: Z = 3.58 (P = 0.00034)
2 In preparation for consultation
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(. . . Continued)
Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Allen 2010 291 66 (35.48) 334 60 (29.24) 2.4 % 6.00 [ 0.86, 11.14 ]
Arterburn 2011 75 72 (12) 77 65 (17) 2.4 % 7.00 [ 2.33, 11.67 ]
Barry 1997 104 75 (45) 123 54 (45) 1.5 % 21.00 [ 9.25, 32.75 ]
Bernstein 1998 61 83 (16) 48 58 (16) 2.3 % 25.00 [ 18.95, 31.05 ]
Bjorklund 2012 182 77 (17) 204 71 (20) 2.5 % 6.00 [ 2.31, 9.69 ]
Chabrera 2015 61 75.7 (19) 61 49.9 (16) 2.2 % 25.80 [ 19.57, 32.03 ]
Frosch 2008a 155 81.4 (18.7) 151 72.4 (19.7) 2.5 % 9.00 [ 4.69, 13.31 ]
Gattellari 2003 106 50 (18.4) 108 45 (15.9) 2.4 % 5.00 [ 0.39, 9.61 ]
Gattellari 2005 131 57.2 (21.3) 136 42.2 (16.7) 2.4 % 15.00 [ 10.40, 19.60 ]
Green 2001 29 95 (7) 14 65 (21) 1.6 % 30.00 [ 18.71, 41.29 ]
Hanson 2011 127 88.4 (21.64) 129 79.5 (21.64) 2.4 % 8.90 [ 3.60, 14.20 ]
Jibaja-Weiss 2011 44 61.22 (20.38) 39 43.59 (26.61) 1.7 % 17.63 [ 7.33, 27.93 ]
Knops 2014 80 76.92 (16.92) 84 72.3 (16.15) 2.4 % 4.62 [ -0.45, 9.69 ]
Krist 2007 196 69 (33.21) 75 54 (33.21) 1.9 % 15.00 [ 6.16, 23.84 ]
Kuppermann 2014 357 62.7 (21.3) 353 57.3 (21.3) 2.6 % 5.40 [ 2.27, 8.53 ]
Lam 2013 113 61 (21) 112 59 (21) 2.3 % 2.00 [ -3.49, 7.49 ]
Laupacis 2006 53 83 (19.5) 53 67.4 (17) 2.1 % 15.60 [ 8.64, 22.56 ]
Leighl 2011 100 72.5 (26.86) 100 60 (26.86) 2.1 % 12.50 [ 5.05, 19.95 ]
Lepore 2012 215 61.6 (0.13) 216 54.7 (0.13) 2.7 % 6.90 [ 6.88, 6.92 ]
Lerman 1997 122 68.9 (19) 164 49 (21.7) 2.4 % 19.90 [ 15.17, 24.63 ]
Lewis 2010 93 45.1 (34.01) 107 46.7 (34.01) 1.8 % -1.60 [ -11.05, 7.85 ]
Man-Son-Hing 1999 137 75.91 (15.72) 136 66.46 (16.07) 2.5 % 9.45 [ 5.68, 13.22 ]
Mann E 2010 273 64.14 (21.86) 134 41.29 (21) 2.5 % 22.85 [ 18.45, 27.25 ]
Mathieu 2010 113 73.5 (27.6) 189 62.7 (27.6) 2.2 % 10.80 [ 4.37, 17.23 ]
McCaffery 2010 77 81 (23.51) 71 72 (23.51) 2.1 % 9.00 [ 1.42, 16.58 ]
Montgomery 2003 50 75 (17) 58 60 (18) 2.2 % 15.00 [ 8.39, 21.61 ]
Montgomery 2007 196 69.7 (18) 202 57.5 (18.5) 2.6 % 12.20 [ 8.61, 15.79 ]
Morgan 2000 86 75 (32.04) 94 62 (32.04) 1.8 % 13.00 [ 3.63, 22.37 ]
Nassar 2007 98 88 (19) 90 79 (18) 2.4 % 9.00 [ 3.71, 14.29 ]
Protheroe 2007 54 59.7 (18.4) 54 48.8 (19.6) 2.1 % 10.90 [ 3.73, 18.07 ]
Sawka 2012 37 97 (6) 37 78 (13) 2.4 % 19.00 [ 14.39, 23.61 ]
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Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Schroy 2011 223 89.17 (15) 231 71.67 (22.5) 2.6 % 17.50 [ 13.99, 21.01 ]
Schwalm 2012 76 60 (30) 74 40 (26) 1.9 % 20.00 [ 11.02, 28.98 ]
Schwartz 2001 191 65.71 (14.29) 190 57.14 (15.71) 2.6 % 8.57 [ 5.55, 11.59 ]
Shorten 2005 99 75.33 (15) 92 60.53 (17.07) 2.4 % 14.80 [ 10.23, 19.37 ]
Smith 2010 357 54.17 (27.83) 173 34.17 (14.25) 2.6 % 20.00 [ 16.42, 23.58 ]
Stacey 2014a 66 71.2 (23.7) 66 46.6 (21.4) 2.0 % 24.60 [ 16.90, 32.30 ]
Steckelberg 2011 785 53.75 (28.75) 792 31.25 (15) 2.7 % 22.50 [ 20.23, 24.77 ]
Taylor 2006 80 77.3 (15.5) 74 62.7 (11.8) 2.5 % 14.60 [ 10.27, 18.93 ]
Van Peperstraten 2010 123 62 (28.3) 132 43 (20.5) 2.3 % 19.00 [ 12.90, 25.10 ]
Vandemheen 2009 70 74 (27.07) 79 49 (23.33) 2.0 % 25.00 [ 16.83, 33.17 ]
Volk 1999 78 48 (21.6) 80 31 (18.8) 2.2 % 17.00 [ 10.68, 23.32 ]
Williams 2013 196 64.4 (18.5) 185 61.7 (17.8) 2.5 % 2.70 [ -0.95, 6.35 ]
Wong 2006 154 85 (26.7) 159 60 (21.7) 2.3 % 25.00 [ 19.60, 30.40 ]
Subtotal (95% CI) 6314 6080 100.0 % 13.77 [ 11.61, 15.93 ]
Heterogeneity: Tau2 = 44.14; Chi2 = 669.38, df = 43 (P<0.00001); I2 =94%
Test for overall effect: Z = 12.50 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.03, df = 1 (P = 0.31), I2 =3%
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Analysis 1.3. Comparison 1 Knowledge, Outcome 3 Knowledge - studies without high risk of bias.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 1 Knowledge
Outcome: 3 Knowledge - studies without high risk of bias
Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Allen 2010 291 66 (35.48) 334 60 (29.24) 2.2 % 6.00 [ 0.86, 11.14 ]
Arterburn 2011 75 72 (12) 77 65 (17) 2.3 % 7.00 [ 2.33, 11.67 ]
Barry 1997 104 75 (45) 123 54 (45) 1.4 % 21.00 [ 9.25, 32.75 ]
Bekker 2004 50 74 (14.5) 56 71.5 (16) 2.2 % 2.50 [ -3.31, 8.31 ]
Bernstein 1998 61 83 (16) 48 58 (16) 2.1 % 25.00 [ 18.95, 31.05 ]
Bjorklund 2012 182 77 (17) 204 71 (20) 2.4 % 6.00 [ 2.31, 9.69 ]
Chabrera 2015 61 75.7 (19) 61 49.9 (16) 2.1 % 25.80 [ 19.57, 32.03 ]
Frosch 2008a 155 81.4 (18.7) 151 72.4 (19.7) 2.3 % 9.00 [ 4.69, 13.31 ]
Gattellari 2003 106 50 (18.4) 108 45 (15.9) 2.3 % 5.00 [ 0.39, 9.61 ]
Gattellari 2005 131 57.2 (21.3) 136 42.2 (16.7) 2.3 % 15.00 [ 10.40, 19.60 ]
Green 2001 29 95 (7) 14 65 (21) 1.5 % 30.00 [ 18.71, 41.29 ]
Hanson 2011 127 88.4 (21.64) 129 79.5 (21.64) 2.2 % 8.90 [ 3.60, 14.20 ]
Hess 2012 101 51.43 (18.2) 103 42.86 (18.3) 2.3 % 8.57 [ 3.56, 13.58 ]
Jibaja-Weiss 2011 44 61.22 (20.38) 39 43.59 (26.61) 1.6 % 17.63 [ 7.33, 27.93 ]
Johnson 2006 32 92.6 (11) 35 85.2 (15.6) 2.1 % 7.40 [ 0.98, 13.82 ]
Kuppermann 2014 357 62.7 (21.3) 353 57.3 (21.3) 2.4 % 5.40 [ 2.27, 8.53 ]
Lam 2013 113 61 (21) 112 59 (21) 2.2 % 2.00 [ -3.49, 7.49 ]
Laupacis 2006 53 83 (19.5) 53 67.4 (17) 2.0 % 15.60 [ 8.64, 22.56 ]
Leighl 2011 100 72.5 (26.86) 100 60 (26.86) 1.9 % 12.50 [ 5.05, 19.95 ]
Lepore 2012 215 61.6 (0.13) 216 54.7 (0.13) 2.6 % 6.90 [ 6.88, 6.92 ]
Lerman 1997 122 68.9 (19) 164 49 (21.7) 2.3 % 19.90 [ 15.17, 24.63 ]
Mann E 2010 273 64.14 (21.86) 134 41.29 (21) 2.3 % 22.85 [ 18.45, 27.25 ]
Mathieu 2010 113 73.5 (27.6) 189 62.7 (27.6) 2.1 % 10.80 [ 4.37, 17.23 ]
McCaffery 2010 77 81 (23.51) 71 72 (23.51) 1.9 % 9.00 [ 1.42, 16.58 ]
Montgomery 2003 50 75 (17) 58 60 (18) 2.0 % 15.00 [ 8.39, 21.61 ]
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Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Montgomery 2007 196 69.7 (18) 202 57.5 (18.5) 2.4 % 12.20 [ 8.61, 15.79 ]
Montori 2011 49 63.3 (29.61) 46 43.3 (29.61) 1.4 % 20.00 [ 8.09, 31.91 ]
Morgan 2000 86 75 (32.04) 94 62 (32.04) 1.7 % 13.00 [ 3.63, 22.37 ]
Mullan 2009 48 63.5 (24.4) 37 53 (18.2) 1.7 % 10.50 [ 1.44, 19.56 ]
Nassar 2007 98 88 (19) 90 79 (18) 2.2 % 9.00 [ 3.71, 14.29 ]
Protheroe 2007 54 59.7 (18.4) 54 48.8 (19.6) 2.0 % 10.90 [ 3.73, 18.07 ]
Sawka 2012 37 97 (6) 37 78 (13) 2.3 % 19.00 [ 14.39, 23.61 ]
Schroy 2011 223 89.17 (15) 231 71.67 (22.5) 2.4 % 17.50 [ 13.99, 21.01 ]
Schwalm 2012 76 60 (30) 74 40 (26) 1.7 % 20.00 [ 11.02, 28.98 ]
Schwartz 2001 191 65.71 (14.29) 190 57.14 (15.71) 2.5 % 8.57 [ 5.55, 11.59 ]
Shorten 2005 99 75.33 (15) 92 60.53 (17.07) 2.3 % 14.80 [ 10.23, 19.37 ]
Smith 2010 357 54.17 (27.83) 173 34.17 (14.25) 2.4 % 20.00 [ 16.42, 23.58 ]
Stacey 2014a 66 71.2 (23.7) 66 46.6 (21.4) 1.9 % 24.60 [ 16.90, 32.30 ]
Steckelberg 2011 785 53.75 (28.75) 792 31.25 (15) 2.5 % 22.50 [ 20.23, 24.77 ]
Taylor 2006 80 77.3 (15.5) 74 62.7 (11.8) 2.3 % 14.60 [ 10.27, 18.93 ]
Thomson 2007 53 62.91 (14.26) 56 62.35 (14.1) 2.2 % 0.56 [ -4.77, 5.89 ]
Van Peperstraten 2010 123 62 (28.3) 132 43 (20.5) 2.1 % 19.00 [ 12.90, 25.10 ]
Vandemheen 2009 70 74 (27.07) 79 49 (23.33) 1.8 % 25.00 [ 16.83, 33.17 ]
Volk 1999 78 48 (21.6) 80 31 (18.8) 2.1 % 17.00 [ 10.68, 23.32 ]
Whelan 2003 82 80.2 (14.4) 93 71.7 (13.3) 2.4 % 8.50 [ 4.37, 12.63 ]
Williams 2013 196 64.4 (18.5) 185 61.7 (17.8) 2.4 % 2.70 [ -0.95, 6.35 ]
Wong 2006 154 85 (26.7) 159 60 (21.7) 2.2 % 25.00 [ 19.60, 30.40 ]
Total (95% CI) 6223 6104 100.0 % 13.43 [ 11.37, 15.49 ]
Heterogeneity: Tau2 = 42.59; Chi2 = 674.45, df = 46 (P<0.00001); I2 =93%
Test for overall effect: Z = 12.78 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Accurate risk perceptions, Outcome 1 Accurate risk perceptions - all studies.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 2 Accurate risk perceptions
Outcome: 1 Accurate risk perceptions - all studies
Study or subgroup Decision Aid Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gattellari 2003 57/106 11/108 5.2 % 5.28 [ 2.93, 9.50 ]
Hess 2012 24/101 1/103 1.2 % 24.48 [ 3.37, 177.53 ]
Laupacis 2006 14/47 5/50 3.5 % 2.98 [ 1.16, 7.63 ]
LeBlanc 2015 23/32 12/45 5.6 % 2.70 [ 1.59, 4.58 ]
Lerman 1997 90/122 108/164 7.5 % 1.12 [ 0.96, 1.31 ]
Man-Son-Hing 1999 92/139 35/148 6.8 % 2.80 [ 2.05, 3.83 ]
Mann D 2010 35/80 22/70 6.2 % 1.39 [ 0.91, 2.13 ]
Mathers 2012 67/95 4/75 3.4 % 13.22 [ 5.05, 34.62 ]
McAlister 2005 66/175 25/155 6.3 % 2.34 [ 1.56, 3.51 ]
McBride 2002 109/265 82/274 7.2 % 1.37 [ 1.09, 1.73 ]
Montori 2011 23/49 10/43 5.0 % 2.02 [ 1.09, 3.75 ]
Schwalm 2012 47/76 29/74 6.7 % 1.58 [ 1.13, 2.20 ]
Steckelberg 2011 361/785 141/792 7.5 % 2.58 [ 2.18, 3.05 ]
Vandemheen 2009 46/70 23/79 6.4 % 2.26 [ 1.54, 3.31 ]
Whelan 2003 47/82 34/92 6.7 % 1.55 [ 1.12, 2.15 ]
Whelan 2004 73/94 62/107 7.4 % 1.34 [ 1.10, 1.63 ]
Wolf 2000 189/266 72/133 7.4 % 1.31 [ 1.10, 1.56 ]
Total (95% CI) 2584 2512 100.0 % 2.10 [ 1.66, 2.66 ]
Total events: 1363 (Decision Aid), 676 (Control)
Heterogeneity: Tau2 = 0.19; Chi2 = 151.38, df = 16 (P<0.00001); I2 =89%
Test for overall effect: Z = 6.16 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Accurate risk perceptions, Outcome 2 Accurate risk perceptions - subgroup by
timing of intervention (in consultation versus in preparation for consultation).
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 2 Accurate risk perceptions
Outcome: 2 Accurate risk perceptions - subgroup by timing of intervention (in consultation versus in preparation for consultation)
Study or subgroup Decision Aid Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 In consultation
Hess 2012 24/101 1/103 2.6 % 24.48 [ 3.37, 177.53 ]
LeBlanc 2015 23/32 12/45 16.5 % 2.70 [ 1.59, 4.58 ]
Mann D 2010 35/80 22/70 19.2 % 1.39 [ 0.91, 2.13 ]
Montori 2011 23/49 10/43 14.4 % 2.02 [ 1.09, 3.75 ]
Whelan 2003 47/82 34/92 22.0 % 1.55 [ 1.12, 2.15 ]
Whelan 2004 73/94 62/107 25.3 % 1.34 [ 1.10, 1.63 ]
Subtotal (95% CI) 438 460 100.0 % 1.79 [ 1.28, 2.52 ]
Total events: 225 (Decision Aid), 141 (Control)
Heterogeneity: Tau2 = 0.11; Chi2 = 17.62, df = 5 (P = 0.003); I2 =72%
Test for overall effect: Z = 3.37 (P = 0.00075)
2 In preparation for consultation
Gattellari 2003 57/106 11/108 7.9 % 5.28 [ 2.93, 9.50 ]
Laupacis 2006 14/47 5/50 5.5 % 2.98 [ 1.16, 7.63 ]
Lerman 1997 90/122 108/164 10.8 % 1.12 [ 0.96, 1.31 ]
Man-Son-Hing 1999 92/139 35/148 10.0 % 2.80 [ 2.05, 3.83 ]
Mathers 2012 67/95 4/75 5.4 % 13.22 [ 5.05, 34.62 ]
McAlister 2005 66/175 25/155 9.3 % 2.34 [ 1.56, 3.51 ]
McBride 2002 109/265 82/274 10.4 % 1.37 [ 1.09, 1.73 ]
Schwalm 2012 47/76 29/74 9.8 % 1.58 [ 1.13, 2.20 ]
Steckelberg 2011 361/785 141/792 10.7 % 2.58 [ 2.18, 3.05 ]
Vandemheen 2009 46/70 23/79 9.5 % 2.26 [ 1.54, 3.31 ]
Wolf 2000 189/266 72/133 10.7 % 1.31 [ 1.10, 1.56 ]
Subtotal (95% CI) 2146 2052 100.0 % 2.25 [ 1.65, 3.07 ]
Total events: 1138 (Decision Aid), 535 (Control)
Heterogeneity: Tau2 = 0.23; Chi2 = 130.92, df = 10 (P<0.00001); I2 =92%
Test for overall effect: Z = 5.11 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.94, df = 1 (P = 0.33), I2 =0.0%
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Analysis 2.3. Comparison 2 Accurate risk perceptions, Outcome 3 Accurate risk perceptions - studies
without high risk of bias.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 2 Accurate risk perceptions
Outcome: 3 Accurate risk perceptions - studies without high risk of bias
Study or subgroup Decision Aid Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gattellari 2003 57/106 11/108 6.0 % 5.28 [ 2.93, 9.50 ]
Hess 2012 24/101 1/103 1.3 % 24.48 [ 3.37, 177.53 ]
Laupacis 2006 14/47 5/50 3.9 % 2.98 [ 1.16, 7.63 ]
Lerman 1997 90/122 108/164 8.6 % 1.12 [ 0.96, 1.31 ]
Mann D 2010 35/80 22/70 7.1 % 1.39 [ 0.91, 2.13 ]
Mathers 2012 67/95 4/75 3.8 % 13.22 [ 5.05, 34.62 ]
McAlister 2005 66/175 25/155 7.2 % 2.34 [ 1.56, 3.51 ]
McBride 2002 109/265 82/274 8.2 % 1.37 [ 1.09, 1.73 ]
Montori 2011 23/49 10/43 5.7 % 2.02 [ 1.09, 3.75 ]
Schwalm 2012 47/76 29/74 7.7 % 1.58 [ 1.13, 2.20 ]
Steckelberg 2011 361/785 141/792 8.5 % 2.58 [ 2.18, 3.05 ]
Vandemheen 2009 46/70 23/79 7.3 % 2.26 [ 1.54, 3.31 ]
Whelan 2003 47/82 34/92 7.7 % 1.55 [ 1.12, 2.15 ]
Whelan 2004 73/94 62/107 8.4 % 1.34 [ 1.10, 1.63 ]
Wolf 2000 189/266 72/133 8.5 % 1.31 [ 1.10, 1.56 ]
Total (95% CI) 2413 2319 100.0 % 2.02 [ 1.57, 2.59 ]
Total events: 1248 (Decision Aid), 629 (Control)
Heterogeneity: Tau2 = 0.18; Chi2 = 136.15, df = 14 (P<0.00001); I2 =90%
Test for overall effect: Z = 5.51 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Informed values-choice congruence, Outcome 1 Informed values-choice
congruence - all studies.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 3 Informed values-choice congruence
Outcome: 1 Informed values-choice congruence - all studies
Study or subgroup Decision Aid Comparison Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bjorklund 2012 128/179 123/197 11.9 % 1.15 [ 0.99, 1.32 ]
Fagerlin 2011 202/383 6/102 7.5 % 8.97 [ 4.10, 19.60 ]
Mathieu 2007 227/309 136/279 11.9 % 1.51 [ 1.31, 1.73 ]
Mathieu 2010 65/91 70/110 11.7 % 1.12 [ 0.93, 1.36 ]
Nagle 2008 127/167 111/171 11.9 % 1.17 [ 1.02, 1.35 ]
Schwalm 2012 36/76 19/74 10.0 % 1.84 [ 1.17, 2.91 ]
Smith 2010 121/357 21/172 10.2 % 2.78 [ 1.81, 4.25 ]
Stacey 2014a 31/55 14/56 9.6 % 2.25 [ 1.35, 3.75 ]
Steckelberg 2011 345/785 101/792 11.6 % 3.45 [ 2.83, 4.20 ]
Trevena 2008 14/134 2/137 3.8 % 7.16 [ 1.66, 30.89 ]
Total (95% CI) 2536 2090 100.0 % 2.06 [ 1.46, 2.91 ]
Total events: 1296 (Decision Aid), 603 (Comparison)
Heterogeneity: Tau2 = 0.26; Chi2 = 186.48, df = 9 (P<0.00001); I2 =95%
Test for overall effect: Z = 4.11 (P = 0.000040)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Informed values-choice congruence, Outcome 2 Informed values-choice
congruence - actual choice only.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 3 Informed values-choice congruence
Outcome: 2 Informed values-choice congruence - actual choice only
Study or subgroup Decision Aid Comparison Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bjorklund 2012 128/179 123/197 13.9 % 1.15 [ 0.99, 1.32 ]
Fagerlin 2011 202/383 6/102 9.0 % 8.97 [ 4.10, 19.60 ]
Mathieu 2007 227/309 136/279 14.0 % 1.51 [ 1.31, 1.73 ]
Nagle 2008 127/167 111/171 13.9 % 1.17 [ 1.02, 1.35 ]
Schwalm 2012 36/76 19/74 11.9 % 1.84 [ 1.17, 2.91 ]
Smith 2010 121/357 21/172 12.1 % 2.78 [ 1.81, 4.25 ]
Stacey 2014a 31/55 14/56 11.4 % 2.25 [ 1.35, 3.75 ]
Steckelberg 2011 345/785 101/792 13.7 % 3.45 [ 2.83, 4.20 ]
Total (95% CI) 2311 1843 100.0 % 2.13 [ 1.44, 3.14 ]
Total events: 1217 (Decision Aid), 531 (Comparison)
Heterogeneity: Tau2 = 0.28; Chi2 = 167.61, df = 7 (P<0.00001); I2 =96%
Test for overall effect: Z = 3.80 (P = 0.00014)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Informed values-choice congruence, Outcome 3 Informed values-chose
congruence -using MMIC.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 3 Informed values-choice congruence
Outcome: 3 Informed values-chose congruence -using MMIC
Study or subgroup Decision Aid Comparison Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bjorklund 2012 128/179 123/197 14.7 % 1.15 [ 0.99, 1.32 ]
Fagerlin 2011 202/383 6/102 9.4 % 8.97 [ 4.10, 19.60 ]
Mathieu 2007 227/309 136/279 14.7 % 1.51 [ 1.31, 1.73 ]
Mathieu 2010 65/91 70/110 14.5 % 1.12 [ 0.93, 1.36 ]
Nagle 2008 127/167 111/171 14.7 % 1.17 [ 1.02, 1.35 ]
Smith 2010 121/357 21/172 12.7 % 2.78 [ 1.81, 4.25 ]
Steckelberg 2011 345/785 101/792 14.4 % 3.45 [ 2.83, 4.20 ]
Trevena 2008 14/134 2/137 4.9 % 7.16 [ 1.66, 30.89 ]
Total (95% CI) 2405 1960 100.0 % 2.08 [ 1.40, 3.08 ]
Total events: 1229 (Decision Aid), 570 (Comparison)
Heterogeneity: Tau2 = 0.27; Chi2 = 184.27, df = 7 (P<0.00001); I2 =96%
Test for overall effect: Z = 3.63 (P = 0.00028)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Informed values-choice congruence, Outcome 4 Informed values-chose
congruence - heterogeneous measures.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 3 Informed values-choice congruence
Outcome: 4 Informed values-chose congruence - heterogeneous measures
Study or subgroup Decision Aid Comparison Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Schwalm 2012 36/76 19/74 55.7 % 1.84 [ 1.17, 2.91 ]
Stacey 2014a 31/55 14/56 44.3 % 2.25 [ 1.35, 3.75 ]
Total (95% CI) 131 130 100.0 % 2.02 [ 1.44, 2.83 ]
Total events: 67 (Decision Aid), 33 (Comparison)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 4.05 (P = 0.000051)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Informed values-choice congruence, Outcome 5 Informed values-choice
congruence - without studies of high risk of bias.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 3 Informed values-choice congruence
Outcome: 5 Informed values-choice congruence - without studies of high risk of bias
Study or subgroup Decision Aid Comparison Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bjorklund 2012 128/179 123/197 11.9 % 1.15 [ 0.99, 1.32 ]
Fagerlin 2011 202/383 6/102 7.5 % 8.97 [ 4.10, 19.60 ]
Mathieu 2007 227/309 136/279 11.9 % 1.51 [ 1.31, 1.73 ]
Mathieu 2010 65/91 70/110 11.7 % 1.12 [ 0.93, 1.36 ]
Nagle 2008 127/167 111/171 11.9 % 1.17 [ 1.02, 1.35 ]
Schwalm 2012 36/76 19/74 10.0 % 1.84 [ 1.17, 2.91 ]
Smith 2010 121/357 21/172 10.2 % 2.78 [ 1.81, 4.25 ]
Stacey 2014a 31/55 14/56 9.6 % 2.25 [ 1.35, 3.75 ]
Steckelberg 2011 345/785 101/792 11.6 % 3.45 [ 2.83, 4.20 ]
Trevena 2008 14/134 2/137 3.8 % 7.16 [ 1.66, 30.89 ]
Total (95% CI) 2536 2090 100.0 % 2.06 [ 1.46, 2.91 ]
Total events: 1296 (Decision Aid), 603 (Comparison)
Heterogeneity: Tau2 = 0.26; Chi2 = 186.48, df = 9 (P<0.00001); I2 =95%
Test for overall effect: Z = 4.11 (P = 0.000040)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Decisional conflict, Outcome 1 Decisional conflict - all studies.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 4 Decisional conflict
Outcome: 1 Decisional conflict - all studies
Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Total decisional conflict score
Allen 2010 291 14 (34.29) 334 20 (37.83) 2.6 % -6.00 [ -11.66, -0.34 ]
Brazell 2014 53 15.8 (13.9) 51 14.1 (16.1) 2.6 % 1.70 [ -4.09, 7.49 ]
Chabrera 2015 61 31.2 (10.2) 61 51.7 (13.3) 2.9 % -20.50 [ -24.71, -16.29 ]
De Achaval 2012 69 23.4 (14.95) 69 29.2 (16.61) 2.7 % -5.80 [ -11.07, -0.53 ]
Dolan 2002 41 20.75 (13) 37 25.75 (20.25) 2.2 % -5.00 [ -12.64, 2.64 ]
Evans 2010 89 38.08 (24.15) 103 49.58 (24.15) 2.3 % -11.50 [ -18.35, -4.65 ]
Fagerlin 2011 690 22 (42.2) 160 55.7 (108.4) 0.9 % -33.70 [ -50.79, -16.61 ]
Hanson 2011 118 16.25 (18.55) 115 24.25 (18.55) 2.8 % -8.00 [ -12.76, -3.24 ]
Hess 2012 101 23.3 (20.76) 103 43.3 (18.97) 2.6 % -20.00 [ -25.46, -14.54 ]
Jibaja-Weiss 2011 44 16.53 (19.9) 39 22.16 (25.29) 1.8 % -5.63 [ -15.51, 4.25 ]
Knops 2014 73 22 (17) 81 24 (17) 2.7 % -2.00 [ -7.38, 3.38 ]
Kuppermann 2014 357 12.9 (14.1) 353 13.8 (15.6) 3.2 % -0.90 [ -3.09, 1.29 ]
Lam 2013 113 15.8 (15.5) 112 19.9 (16.3) 2.9 % -4.10 [ -8.26, 0.06 ]
Laupacis 2006 53 17.5 (13.75) 54 25.25 (14.25) 2.7 % -7.75 [ -13.06, -2.44 ]
Legare 2008a 43 23 (14.25) 41 27 (15.25) 2.5 % -4.00 [ -10.32, 2.32 ]
Lepore 2012 215 34.15 (24.03) 216 39.85 (24.04) 2.8 % -5.70 [ -10.24, -1.16 ]
Man-Son-Hing 1999 139 16.25 (11.25) 148 18.5 (13.5) 3.1 % -2.25 [ -5.12, 0.62 ]
Mann D 2010 80 25.5 (11.14) 70 28.5 (11.14) 3.0 % -3.00 [ -6.57, 0.57 ]
Mathers 2012 95 17.4 (12.6) 80 25.2 (14.9) 2.9 % -7.80 [ -11.93, -3.67 ]
Mathieu 2007 315 20.06 (14.51) 295 21.89 (14.51) 3.2 % -1.83 [ -4.13, 0.47 ]
McAlister 2005 205 15 (12.5) 202 17.5 (12.5) 3.2 % -2.50 [ -4.93, -0.07 ]
Montgomery 2003 50 27.1 (10) 58 44.2 (19.3) 2.6 % -17.10 [ -22.79, -11.41 ]
Montgomery 2007 198 23.6 (15.1) 201 27.8 (14.6) 3.1 % -4.20 [ -7.12, -1.28 ]
Montori 2011 49 14.4 (24.92) 46 16.2 (24.92) 1.7 % -1.80 [ -11.83, 8.23 ]
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(. . . Continued)
Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Morgan 2000 86 27.5 (37.5) 94 27.5 (37.5) 1.6 % 0.0 [ -10.97, 10.97 ]
Mullan 2009 48 14.1 (17.89) 37 14.95 (12.68) 2.4 % -0.85 [ -7.35, 5.65 ]
Murray 2001a 57 32.5 (10) 48 40 (12.5) 2.9 % -7.50 [ -11.89, -3.11 ]
Murray 2001b 94 37.5 (12.5) 96 45 (15) 3.0 % -7.50 [ -11.42, -3.58 ]
Nagle 2008 167 17.75 (12.25) 171 16.25 (13.75) 3.1 % 1.50 [ -1.27, 4.27 ]
Nassar 2007 98 4.6 (9) 98 13.5 (19.2) 2.9 % -8.90 [ -13.10, -4.70 ]
Protheroe 2007 69 23.4 (14.3) 69 40.5 (18.3) 2.6 % -17.10 [ -22.58, -11.62 ]
Sawka 2012 37 25.2 (13.4) 37 52.1 (21.9) 2.1 % -26.90 [ -35.17, -18.63 ]
Schwalm 2012 76 14.8 (10.5) 74 19.5 (16.7) 2.8 % -4.70 [ -9.18, -0.22 ]
Shorten 2005 99 23.5 (12.5) 88 29.5 (18.25) 2.8 % -6.00 [ -10.54, -1.46 ]
Shourie 2013 43 14.25 (17.25) 67 37.25 (21.5) 2.3 % -23.00 [ -30.29, -15.71 ]
Vandemheen 2009 70 11.6 (13.6) 79 20.4 (16.9) 2.8 % -8.80 [ -13.70, -3.90 ]
Vodermaier 2009 55 20.5 (14.75) 56 24.75 (15.5) 2.6 % -4.25 [ -9.88, 1.38 ]
Whelan 2004 94 10 (12) 107 15.5 (12.9) 3.0 % -5.50 [ -8.94, -2.06 ]
Subtotal (95% CI) 4635 4150 100.0 % -7.22 [ -9.12, -5.31 ]
Heterogeneity: Tau2 = 28.03; Chi2 = 255.34, df = 37 (P<0.00001); I2 =86%
Test for overall effect: Z = 7.42 (P < 0.00001)
2 Uninformed subscale
Bekker 2004 50 32.5 (15) 56 31.67 (14.17) 3.9 % 0.83 [ -4.74, 6.40 ]
Brazell 2014 53 12.1 (12.7) 51 11.1 (15.2) 3.9 % 1.00 [ -4.39, 6.39 ]
Chabrera 2015 61 39.7 (10.6) 61 61.1 (19.7) 3.8 % -21.40 [ -27.01, -15.79 ]
De Achaval 2012 69 15.9 (15.78) 69 27.3 (16.61) 3.9 % -11.40 [ -16.81, -5.99 ]
Dolan 2002 41 15.75 (13) 37 24.5 (21.25) 3.4 % -8.75 [ -16.67, -0.83 ]
Fagerlin 2011 690 8.7 (43.2) 160 57.4 (110.7) 1.7 % -48.70 [ -66.15, -31.25 ]
Hess 2012 101 22.8 (22.8) 103 40.6 (21.53) 3.8 % -17.80 [ -23.89, -11.71 ]
Jibaja-Weiss 2011 44 15 (22.26) 39 23.42 (28.72) 2.7 % -8.42 [ -19.58, 2.74 ]
Laupacis 2006 54 16.25 (13.75) 54 27.25 (15) 3.9 % -11.00 [ -16.43, -5.57 ]
Legare 2008a 43 29.75 (22.75) 41 34.25 (26) 2.8 % -4.50 [ -14.97, 5.97 ]
Man-Son-Hing 1999 139 15.75 (13.25) 148 21 (14.75) 4.2 % -5.25 [ -8.49, -2.01 ]
Mann D 2010 80 27.1 (17.6) 70 33.8 (17.6) 3.8 % -6.70 [ -12.35, -1.05 ]
Mathers 2012 95 18.1 (13.3) 80 26 (16.6) 4.0 % -7.90 [ -12.41, -3.39 ]
Mathieu 2007 315 20.78 (15.59) 295 23.26 (15.59) 4.3 % -2.48 [ -4.96, 0.00 ]
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(. . . Continued)
Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
McAlister 2005 205 15 (12.5) 202 20 (15) 4.3 % -5.00 [ -7.68, -2.32 ]
Montgomery 2003 50 22.17 (9.47) 58 49.14 (25.4) 3.6 % -26.97 [ -34.01, -19.93 ]
Montgomery 2007 199 35.1 (25.6) 203 35.8 (22.7) 4.0 % -0.70 [ -5.43, 4.03 ]
Morgan 2000 86 20 (21.5) 94 27.5 (21.5) 3.7 % -7.50 [ -13.79, -1.21 ]
Mullan 2009 48 13.65 (19.84) 37 15.28 (15.49) 3.5 % -1.63 [ -9.14, 5.88 ]
Murray 2001a 52 27.56 (10.51) 45 38.88 (20.02) 3.7 % -11.32 [ -17.83, -4.81 ]
Murray 2001b 93 29.93 (17.26) 93 38.89 (22.53) 3.8 % -8.96 [ -14.73, -3.19 ]
Nagle 2008 167 15.25 (14.5) 171 12.75 (14.75) 4.3 % 2.50 [ -0.62, 5.62 ]
Schwalm 2012 76 15.7 (13.5) 74 22.3 (20.5) 3.9 % -6.60 [ -12.17, -1.03 ]
Shourie 2013 44 11.25 (15.25) 69 46.25 (26) 3.4 % -35.00 [ -42.61, -27.39 ]
Vandemheen 2009 70 4.5 (9.6) 79 17.2 (20.6) 3.9 % -12.70 [ -17.77, -7.63 ]
Vodermaier 2009 55 22 (15.75) 56 30 (22.5) 3.5 % -8.00 [ -15.21, -0.79 ]
Wong 2006 136 21.75 (15) 146 25.75 (15) 4.2 % -4.00 [ -7.50, -0.50 ]
Subtotal (95% CI) 3116 2591 100.0 % -9.28 [ -12.20, -6.36 ]
Heterogeneity: Tau2 = 49.45; Chi2 = 231.76, df = 26 (P<0.00001); I2 =89%
Test for overall effect: Z = 6.23 (P < 0.00001)
3 Unclear values subscale
Brazell 2014 53 15.3 (15.5) 51 17.2 (20.1) 4.3 % -1.90 [ -8.82, 5.02 ]
Chabrera 2015 61 28.1 (11.2) 61 53.2 (14.5) 4.8 % -25.10 [ -29.70, -20.50 ]
De Achaval 2012 69 17.9 (14.95) 69 26.1 (19.11) 4.6 % -8.20 [ -13.92, -2.48 ]
Dolan 2002 41 19.75 (15.75) 37 29.25 (24) 3.7 % -9.50 [ -18.61, -0.39 ]
Fagerlin 2011 690 12.6 (50.3) 160 47.7 (128.4) 1.7 % -35.10 [ -55.35, -14.85 ]
Hess 2012 101 24.2 (25.64) 103 41.4 (22.05) 4.4 % -17.20 [ -23.77, -10.63 ]
Jibaja-Weiss 2011 44 14.38 (27.08) 39 29.73 (41.6) 2.4 % -15.35 [ -30.66, -0.04 ]
Laupacis 2006 54 18.75 (16.5) 55 30 (17) 4.4 % -11.25 [ -17.54, -4.96 ]
Legare 2008a 43 19.75 (16.5) 41 23.25 (20) 4.1 % -3.50 [ -11.36, 4.36 ]
Man-Son-Hing 1999 139 16.25 (12.5) 148 19 (14.75) 5.1 % -2.75 [ -5.91, 0.41 ]
Mathers 2012 95 16.7 (13.9) 80 26.7 (18.2) 4.8 % -10.00 [ -14.87, -5.13 ]
Mathieu 2007 315 19.51 (16.3) 295 22.59 (80) 3.7 % -3.08 [ -12.38, 6.22 ]
McAlister 2005 205 15 (12.5) 202 17.5 (15) 5.2 % -2.50 [ -5.18, 0.18 ]
Montgomery 2003 50 28.5 (12.5) 58 51.29 (25.73) 4.1 % -22.79 [ -30.26, -15.32 ]
Montgomery 2007 201 17.6 (13.2) 203 24.1 (15.8) 5.2 % -6.50 [ -9.34, -3.66 ]
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(. . . Continued)
Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Morgan 2000 86 30 (3.25) 94 30 (3.25) 5.4 % 0.0 [ -0.95, 0.95 ]
Murray 2001a 53 35.38 (12.33) 45 40.56 (16.44) 4.6 % -5.18 [ -11.02, 0.66 ]
Murray 2001b 82 37.5 (15) 84 42.85 (16.57) 4.8 % -5.35 [ -10.16, -0.54 ]
Nagle 2008 167 19 (15.25) 171 15.5 (15.75) 5.1 % 3.50 [ 0.20, 6.80 ]
Schwalm 2012 76 18 (15.3) 74 26 (24.2) 4.4 % -8.00 [ -14.50, -1.50 ]
Shourie 2013 44 11.25 (13) 69 37.5 (24.25) 4.3 % -26.25 [ -33.14, -19.36 ]
Vandemheen 2009 70 9.9 (17.7) 79 16.8 (21) 4.5 % -6.90 [ -13.12, -0.68 ]
Vodermaier 2009 55 20.75 (15.5) 56 24.75 (15.5) 4.6 % -4.00 [ -9.77, 1.77 ]
Subtotal (95% CI) 2794 2274 100.0 % -8.81 [ -11.99, -5.63 ]
Heterogeneity: Tau2 = 48.93; Chi2 = 273.77, df = 22 (P<0.00001); I2 =92%
Test for overall effect: Z = 5.43 (P < 0.00001)
4 Uncertainty subscale
Bekker 2004 50 45 (20.83) 56 45 (25.83) 2.9 % 0.0 [ -8.89, 8.89 ]
Brazell 2014 53 21.7 (21.4) 51 18.8 (23.3) 3.0 % 2.90 [ -5.71, 11.51 ]
Chabrera 2015 61 32 (11.4) 61 43.8 (8.82) 4.7 % -11.80 [ -15.42, -8.18 ]
De Achaval 2012 69 33.4 (23.26) 69 35.9 (22.43) 3.3 % -2.50 [ -10.12, 5.12 ]
Dolan 2002 41 27 (19.25) 37 26 (24.25) 2.6 % 1.00 [ -8.79, 10.79 ]
Fagerlin 2011 690 37.4 (62.3) 160 73.2 (159.7) 0.7 % -35.80 [ -60.98, -10.62 ]
Gattellari 2003 106 42.5 (20) 108 42.5 (33.33) 3.4 % 0.0 [ -7.35, 7.35 ]
Gattellari 2005 131 30.83 (19.25) 136 29.17 (15) 4.5 % 1.66 [ -2.49, 5.81 ]
Hanson 2011 118 22 (20) 115 28.75 (20) 4.2 % -6.75 [ -11.89, -1.61 ]
Hess 2012 101 24.7 (23.33) 103 36.8 (23.59) 3.7 % -12.10 [ -18.54, -5.66 ]
Jibaja-Weiss 2011 44 15.38 (32.25) 39 12.83 (22.53) 2.1 % 2.55 [ -9.32, 14.42 ]
Laupacis 2006 54 20.5 (18.75) 55 23 (21) 3.4 % -2.50 [ -9.97, 4.97 ]
Legare 2008a 43 26.5 (23) 41 33.25 (25.25) 2.5 % -6.75 [ -17.09, 3.59 ]
Man-Son-Hing 1999 139 21 (21) 148 19.75 (19) 4.4 % 1.25 [ -3.39, 5.89 ]
Mathers 2012 95 20.1 (16.6) 80 29.4 (20.8) 4.0 % -9.30 [ -14.95, -3.65 ]
Mathieu 2007 315 22.23 (19.46) 295 22.65 (19.46) 4.9 % -0.42 [ -3.51, 2.67 ]
McAlister 2005 205 20 (20) 202 17.5 (17.5) 4.7 % 2.50 [ -1.15, 6.15 ]
Montgomery 2003 50 35.5 (20.47) 58 47.99 (25.14) 3.0 % -12.49 [ -21.10, -3.88 ]
Montgomery 2007 201 22.1 (18.4) 203 27.3 (18.8) 4.7 % -5.20 [ -8.83, -1.57 ]
Morgan 2000 86 35 (13) 94 32.5 (13) 4.7 % 2.50 [ -1.30, 6.30 ]
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Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Murray 2001a 57 35 (20) 48 42.5 (20) 3.3 % -7.50 [ -15.18, 0.18 ]
Murray 2001b 94 52.5 (25) 96 60 (27.5) 3.4 % -7.50 [ -14.97, -0.03 ]
Nagle 2008 167 24 (19.75) 171 24.25 (21.5) 4.5 % -0.25 [ -4.65, 4.15 ]
Schwalm 2012 76 18 (18.8) 74 19.6 (19.9) 3.8 % -1.60 [ -7.80, 4.60 ]
Shourie 2013 44 16.25 (18.25) 68 38.25 (29.5) 2.9 % -22.00 [ -30.85, -13.15 ]
Vandemheen 2009 70 26.4 (25.9) 79 36.4 (27.8) 3.0 % -10.00 [ -18.63, -1.37 ]
Vodermaier 2009 55 27 (24.25) 56 30 (10) 3.5 % -3.00 [ -9.92, 3.92 ]
Wong 2006 136 38.25 (22.5) 146 40 (20.83) 4.2 % -1.75 [ -6.82, 3.32 ]
Subtotal (95% CI) 3351 2849 100.0 % -4.04 [ -6.27, -1.81 ]
Heterogeneity: Tau2 = 24.09; Chi2 = 107.12, df = 27 (P<0.00001); I2 =75%
Test for overall effect: Z = 3.55 (P = 0.00039)
5 Unsupported subscale
Brazell 2014 53 11.5 (14.4) 51 9.5 (13.9) 4.3 % 2.00 [ -3.44, 7.44 ]
Chabrera 2015 61 30.5 (11.6) 61 51.7 (15.3) 4.5 % -21.20 [ -26.02, -16.38 ]
De Achaval 2012 69 20.5 (14.95) 69 25 (15.78) 4.4 % -4.50 [ -9.63, 0.63 ]
Dolan 2002 41 21 (13.5) 37 23.25 (20) 3.6 % -2.25 [ -9.91, 5.41 ]
Fagerlin 2011 690 18.1 (46.9) 160 43.3 (119.4) 1.4 % -25.20 [ -44.03, -6.37 ]
Hess 2012 101 18.5 (22.56) 103 29.2 (22.56) 4.1 % -10.70 [ -16.89, -4.51 ]
Jibaja-Weiss 2011 44 19.17 (26.3) 39 22.07 (28.88) 2.5 % -2.90 [ -14.84, 9.04 ]
Laupacis 2006 53 17.25 (15.75) 55 24 (17.25) 4.1 % -6.75 [ -12.98, -0.52 ]
Legare 2008a 43 24.25 (19.5) 41 23.5 (17.25) 3.6 % 0.75 [ -7.11, 8.61 ]
Man-Son-Hing 1999 139 16.25 (13) 148 16.5 (14) 4.9 % -0.25 [ -3.37, 2.87 ]
Mann D 2010 80 25.2 (13.72) 70 29.6 (13.72) 4.6 % -4.40 [ -8.80, 0.00 ]
Mathers 2012 95 17.4 (13.1) 80 20.8 (15.3) 4.7 % -3.40 [ -7.66, 0.86 ]
Mathieu 2007 315 20.9 (15.58) 295 22.98 (15.58) 5.1 % -2.08 [ -4.55, 0.39 ]
McAlister 2005 205 15 (15) 202 15 (15) 5.0 % 0.0 [ -2.91, 2.91 ]
Montgomery 2003 50 23.67 (10.96) 58 40.52 (19.83) 4.2 % -16.85 [ -22.79, -10.91 ]
Montgomery 2007 200 22.2 (16.5) 201 28.5 (18.7) 4.9 % -6.30 [ -9.75, -2.85 ]
Morgan 2000 86 30 (24.75) 94 32.5 (24.75) 3.8 % -2.50 [ -9.74, 4.74 ]
Murray 2001a 53 32.7 (12.75) 45 40.56 (17.1) 4.1 % -7.86 [ -13.92, -1.80 ]
Murray 2001b 85 36.47 (14.43) 82 48.68 (15.46) 4.6 % -12.21 [ -16.75, -7.67 ]
Nagle 2008 167 15.25 (13.75) 171 14.5 (15.75) 4.9 % 0.75 [ -2.40, 3.90 ]
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Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Schwalm 2012 76 12.2 (15.2) 74 14.9 (16.9) 4.4 % -2.70 [ -7.85, 2.45 ]
Shourie 2013 43 13.25 (17.25) 69 38 (21.75) 3.7 % -24.75 [ -32.02, -17.48 ]
Vandemheen 2009 70 6.9 (12.3) 79 14.5 (17.7) 4.5 % -7.60 [ -12.45, -2.75 ]
Vodermaier 2009 55 16.25 (16.25) 56 21 (15.75) 4.2 % -4.75 [ -10.70, 1.20 ]
Subtotal (95% CI) 2874 2340 100.0 % -6.27 [ -8.86, -3.68 ]
Heterogeneity: Tau2 = 32.67; Chi2 = 155.62, df = 23 (P<0.00001); I2 =85%
Test for overall effect: Z = 4.75 (P < 0.00001)
6 Ineffective choice subscale
Bekker 2004 50 22.5 (13.75) 56 21.88 (14.38) 4.3 % 0.62 [ -4.74, 5.98 ]
Brazell 2014 53 17.8 (19.1) 51 13.8 (18.3) 3.7 % 4.00 [ -3.19, 11.19 ]
Chabrera 2015 61 27.1 (11.7) 61 49.5 (14.3) 4.5 % -22.40 [ -27.04, -17.76 ]
De Achaval 2012 69 27.7 (18.27) 69 31.2 (19.11) 4.0 % -3.50 [ -9.74, 2.74 ]
Dolan 2002 41 20.5 (14.5) 37 25.75 (21) 3.5 % -5.25 [ -13.34, 2.84 ]
Fagerlin 2011 690 30 (52.3) 160 55.5 (133.9) 1.2 % -25.50 [ -46.61, -4.39 ]
Hanson 2011 118 14 (15.55) 115 19.25 (15.55) 4.6 % -5.25 [ -9.24, -1.26 ]
Laupacis 2006 53 15 (14.5) 55 21.25 (16) 4.2 % -6.25 [ -12.00, -0.50 ]
Legare 2008a 43 16.5 (14.75) 41 22.25 (19) 3.7 % -5.75 [ -13.05, 1.55 ]
Man-Son-Hing 1999 139 13.5 (13) 148 15.5 (14.75) 4.8 % -2.00 [ -5.21, 1.21 ]
Mathers 2012 95 16.1 (14.4) 80 23.3 (15.2) 4.5 % -7.20 [ -11.61, -2.79 ]
Mathieu 2007 315 18.41 (14.96) 295 19.19 (14.96) 5.0 % -0.78 [ -3.16, 1.60 ]
McAlister 2005 205 15 (12.5) 202 17.5 (15) 4.9 % -2.50 [ -5.18, 0.18 ]
Montgomery 2003 50 26 (11.11) 58 35.13 (17.2) 4.3 % -9.13 [ -14.52, -3.74 ]
Morgan 2000 86 20 (32) 94 22.5 (32) 3.1 % -2.50 [ -11.86, 6.86 ]
Murray 2001a 57 25 (10) 48 30 (15) 4.4 % -5.00 [ -9.97, -0.03 ]
Murray 2001b 94 30 (15) 96 37.5 (17.5) 4.5 % -7.50 [ -12.13, -2.87 ]
Nagle 2008 167 16.25 (13.75) 171 15 (14.25) 4.9 % 1.25 [ -1.74, 4.24 ]
Schwalm 2012 76 11.3 (11.4) 74 15.9 (15.9) 4.5 % -4.60 [ -9.04, -0.16 ]
Shourie 2013 44 11 (12.25) 68 30.5 (19.5) 4.1 % -19.50 [ -25.38, -13.62 ]
Vandemheen 2009 70 10.4 (16.4) 79 17.9 (20.4) 4.1 % -7.50 [ -13.42, -1.58 ]
Vodermaier 2009 55 28.25 (20.75) 56 35 (20) 3.6 % -6.75 [ -14.33, 0.83 ]
Whelan 2004 94 12.5 (12) 107 17 (13) 4.8 % -4.50 [ -7.96, -1.04 ]
Wong 2006 136 19.38 (13.13) 159 36.67 (19.17) 4.7 % -17.29 [ -21.00, -13.58 ]
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Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 2861 2380 100.0 % -6.31 [ -8.93, -3.70 ]
Heterogeneity: Tau2 = 34.12; Chi2 = 175.19, df = 23 (P<0.00001); I2 =87%
Test for overall effect: Z = 4.73 (P < 0.00001)
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Analysis 4.2. Comparison 4 Decisional conflict, Outcome 2 Decisional conflict - in consultation.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 4 Decisional conflict
Outcome: 2 Decisional conflict - in consultation
Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Uncertainty subscale
Bekker 2004 50 45 (20.83) 56 45 (25.83) 46.7 % 0.0 [ -8.89, 8.89 ]
Hess 2012 101 24.7 (23.33) 103 36.8 (23.59) 53.3 % -12.10 [ -18.54, -5.66 ]
Subtotal (95% CI) 151 159 100.0 % -6.45 [ -18.29, 5.38 ]
Heterogeneity: Tau2 = 57.51; Chi2 = 4.67, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 1.07 (P = 0.28)
2 Uninformed subscale
Bekker 2004 50 32.5 (15) 56 31.67 (14.17) 25.7 % 0.83 [ -4.74, 6.40 ]
Hess 2012 101 22.8 (22.8) 103 40.6 (21.53) 25.2 % -17.80 [ -23.89, -11.71 ]
Mann D 2010 80 27.1 (17.6) 70 33.8 (17.6) 25.7 % -6.70 [ -12.35, -1.05 ]
Mullan 2009 48 13.65 (19.84) 37 15.28 (15.49) 23.5 % -1.63 [ -9.14, 5.88 ]
Subtotal (95% CI) 279 266 100.0 % -6.37 [ -14.58, 1.85 ]
Heterogeneity: Tau2 = 60.19; Chi2 = 21.50, df = 3 (P = 0.00008); I2 =86%
Test for overall effect: Z = 1.52 (P = 0.13)
3 Unclear values subscale
Hess 2012 101 24.2 (25.64) 103 41.4 (22.05) 100.0 % -17.20 [ -23.77, -10.63 ]
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Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 101 103 100.0 % -17.20 [ -23.77, -10.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.13 (P < 0.00001)
4 Unsupported subscale
Hess 2012 101 18.5 (22.56) 103 29.2 (22.56) 43.8 % -10.70 [ -16.89, -4.51 ]
Mann D 2010 80 25.2 (13.72) 70 29.6 (13.72) 56.2 % -4.40 [ -8.80, 0.00 ]
Subtotal (95% CI) 181 173 100.0 % -7.16 [ -13.28, -1.03 ]
Heterogeneity: Tau2 = 12.33; Chi2 = 2.64, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 2.29 (P = 0.022)
5 Ineffective choice subscale
Bekker 2004 50 22.5 (13.75) 56 21.88 (14.38) 41.7 % 0.62 [ -4.74, 5.98 ]
Whelan 2004 94 12.5 (12) 107 17 (13) 58.3 % -4.50 [ -7.96, -1.04 ]
Subtotal (95% CI) 144 163 100.0 % -2.37 [ -7.31, 2.58 ]
Heterogeneity: Tau2 = 7.81; Chi2 = 2.48, df = 1 (P = 0.12); I2 =60%
Test for overall effect: Z = 0.94 (P = 0.35)
6 Total decisional conflict score
Hess 2012 101 23.3 (20.76) 103 43.3 (18.97) 20.5 % -20.00 [ -25.46, -14.54 ]
Mann D 2010 80 25.5 (11.14) 70 28.5 (11.14) 22.5 % -3.00 [ -6.57, 0.57 ]
Montori 2011 49 14.4 (24.92) 46 16.2 (24.92) 15.1 % -1.80 [ -11.83, 8.23 ]
Mullan 2009 48 14.1 (17.89) 37 14.95 (12.68) 19.3 % -0.85 [ -7.35, 5.65 ]
Whelan 2004 94 10 (12) 107 15.5 (12.9) 22.6 % -5.50 [ -8.94, -2.06 ]
Subtotal (95% CI) 372 363 100.0 % -6.46 [ -12.78, -0.14 ]
Heterogeneity: Tau2 = 42.94; Chi2 = 31.11, df = 4 (P<0.00001); I2 =87%
Test for overall effect: Z = 2.00 (P = 0.045)
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Analysis 4.3. Comparison 4 Decisional conflict, Outcome 3 Decisional conflict - in preparation for
consultation.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 4 Decisional conflict
Outcome: 3 Decisional conflict - in preparation for consultation
Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Uncertainty subscale
Brazell 2014 53 21.7 (21.4) 51 18.8 (23.3) 3.2 % 2.90 [ -5.71, 11.51 ]
Chabrera 2015 61 32 (11.4) 61 43.8 (8.82) 5.1 % -11.80 [ -15.42, -8.18 ]
De Achaval 2012 69 33.4 (23.26) 69 35.9 (22.43) 3.5 % -2.50 [ -10.12, 5.12 ]
Dolan 2002 41 27 (19.25) 37 26 (24.25) 2.8 % 1.00 [ -8.79, 10.79 ]
Fagerlin 2011 690 37.4 (62.3) 160 73.2 (159.7) 0.7 % -35.80 [ -60.98, -10.62 ]
Gattellari 2003 106 42.5 (20) 108 42.5 (33.33) 3.6 % 0.0 [ -7.35, 7.35 ]
Gattellari 2005 131 30.83 (19.25) 136 29.17 (15) 4.9 % 1.66 [ -2.49, 5.81 ]
Hanson 2011 118 22 (20) 115 28.75 (20) 4.5 % -6.75 [ -11.89, -1.61 ]
Jibaja-Weiss 2011 44 15.38 (32.25) 39 12.83 (22.53) 2.3 % 2.55 [ -9.32, 14.42 ]
Laupacis 2006 54 20.5 (18.75) 55 23 (21) 3.6 % -2.50 [ -9.97, 4.97 ]
Legare 2008a 43 26.5 (23) 41 33.25 (25.25) 2.7 % -6.75 [ -17.09, 3.59 ]
Man-Son-Hing 1999 139 21 (21) 148 19.75 (19) 4.7 % 1.25 [ -3.39, 5.89 ]
Mathers 2012 95 20.1 (16.6) 80 29.4 (20.8) 4.3 % -9.30 [ -14.95, -3.65 ]
Mathieu 2007 315 22.23 (19.46) 295 22.65 (19.46) 5.3 % -0.42 [ -3.51, 2.67 ]
McAlister 2005 205 20 (20) 202 17.5 (17.5) 5.1 % 2.50 [ -1.15, 6.15 ]
Montgomery 2003 50 35.5 (20.47) 58 47.99 (25.14) 3.2 % -12.49 [ -21.10, -3.88 ]
Montgomery 2007 201 22.1 (18.4) 203 27.3 (18.8) 5.1 % -5.20 [ -8.83, -1.57 ]
Morgan 2000 86 35 (13) 94 32.5 (13) 5.0 % 2.50 [ -1.30, 6.30 ]
Murray 2001a 57 35 (20) 48 42.5 (20) 3.5 % -7.50 [ -15.18, 0.18 ]
Murray 2001b 94 52.5 (25) 96 60 (27.5) 3.6 % -7.50 [ -14.97, -0.03 ]
Nagle 2008 167 24 (19.75) 171 24.25 (21.5) 4.8 % -0.25 [ -4.65, 4.15 ]
Schwalm 2012 76 18 (18.8) 74 19.6 (19.9) 4.1 % -1.60 [ -7.80, 4.60 ]
Shourie 2013 44 16.25 (18.25) 68 38.25 (29.5) 3.1 % -22.00 [ -30.85, -13.15 ]
Vandemheen 2009 70 26.4 (25.9) 79 36.4 (27.8) 3.2 % -10.00 [ -18.63, -1.37 ]
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Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Vodermaier 2009 55 27 (24.25) 56 30 (10) 3.8 % -3.00 [ -9.92, 3.92 ]
Wong 2006 136 38.25 (22.5) 146 40 (20.83) 4.5 % -1.75 [ -6.82, 3.32 ]
Subtotal (95% CI) 3200 2690 100.0 % -3.83 [ -6.12, -1.55 ]
Heterogeneity: Tau2 = 23.28; Chi2 = 98.99, df = 25 (P<0.00001); I2 =75%
Test for overall effect: Z = 3.29 (P = 0.00099)
2 Uninformed subscale
Brazell 2014 53 12.1 (12.7) 51 11.1 (15.2) 4.6 % 1.00 [ -4.39, 6.39 ]
Chabrera 2015 61 39.7 (10.6) 61 61.1 (19.7) 4.5 % -21.40 [ -27.01, -15.79 ]
De Achaval 2012 69 15.9 (15.78) 69 27.3 (16.61) 4.6 % -11.40 [ -16.81, -5.99 ]
Dolan 2002 41 15.75 (13) 37 24.5 (21.25) 4.0 % -8.75 [ -16.67, -0.83 ]
Fagerlin 2011 690 8.7 (43.2) 160 57.4 (110.7) 2.0 % -48.70 [ -66.15, -31.25 ]
Jibaja-Weiss 2011 44 15 (22.26) 39 23.42 (28.72) 3.2 % -8.42 [ -19.58, 2.74 ]
Laupacis 2006 54 16.25 (13.75) 54 27.25 (15) 4.6 % -11.00 [ -16.43, -5.57 ]
Legare 2008a 43 29.75 (22.75) 41 34.25 (26) 3.4 % -4.50 [ -14.97, 5.97 ]
Man-Son-Hing 1999 139 15.75 (13.25) 148 21 (14.75) 5.0 % -5.25 [ -8.49, -2.01 ]
Mathers 2012 95 18.1 (13.3) 80 26 (16.6) 4.8 % -7.90 [ -12.41, -3.39 ]
Mathieu 2007 315 20.78 (15.59) 295 23.26 (15.59) 5.1 % -2.48 [ -4.96, 0.00 ]
McAlister 2005 205 15 (12.5) 202 20 (15) 5.1 % -5.00 [ -7.68, -2.32 ]
Montgomery 2003 50 22.17 (9.47) 58 49.14 (25.4) 4.2 % -26.97 [ -34.01, -19.93 ]
Montgomery 2007 199 35.1 (25.6) 203 35.8 (22.7) 4.7 % -0.70 [ -5.43, 4.03 ]
Morgan 2000 86 20 (21.5) 94 27.5 (21.5) 4.4 % -7.50 [ -13.79, -1.21 ]
Murray 2001a 52 27.56 (10.51) 45 38.88 (20.02) 4.3 % -11.32 [ -17.83, -4.81 ]
Murray 2001b 93 29.93 (17.26) 93 38.89 (22.53) 4.5 % -8.96 [ -14.73, -3.19 ]
Nagle 2008 167 15.25 (14.5) 171 12.75 (14.75) 5.0 % 2.50 [ -0.62, 5.62 ]
Schwalm 2012 76 15.7 (13.5) 74 22.3 (20.5) 4.5 % -6.60 [ -12.17, -1.03 ]
Shourie 2013 44 11.25 (15.25) 69 46.25 (26) 4.0 % -35.00 [ -42.61, -27.39 ]
Vandemheen 2009 70 4.5 (9.6) 79 17.2 (20.6) 4.6 % -12.70 [ -17.77, -7.63 ]
Vodermaier 2009 55 22 (15.75) 56 30 (22.5) 4.1 % -8.00 [ -15.21, -0.79 ]
Wong 2006 136 21.75 (15) 146 25.75 (15) 4.9 % -4.00 [ -7.50, -0.50 ]
Subtotal (95% CI) 2837 2325 100.0 % -9.81 [ -13.00, -6.61 ]
Heterogeneity: Tau2 = 50.54; Chi2 = 210.26, df = 22 (P<0.00001); I2 =90%
Test for overall effect: Z = 6.02 (P < 0.00001)
3 Unclear values subscale
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Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brazell 2014 53 15.3 (15.5) 51 17.2 (20.1) 4.5 % -1.90 [ -8.82, 5.02 ]
Chabrera 2015 61 28.1 (11.2) 61 53.2 (14.5) 5.1 % -25.10 [ -29.70, -20.50 ]
De Achaval 2012 69 17.9 (14.95) 69 26.1 (19.11) 4.8 % -8.20 [ -13.92, -2.48 ]
Dolan 2002 41 19.75 (15.75) 37 29.25 (24) 3.9 % -9.50 [ -18.61, -0.39 ]
Fagerlin 2011 690 12.6 (50.3) 160 47.7 (128.4) 1.7 % -35.10 [ -55.35, -14.85 ]
Jibaja-Weiss 2011 44 14.38 (27.08) 39 29.73 (41.6) 2.5 % -15.35 [ -30.66, -0.04 ]
Laupacis 2006 54 18.75 (16.5) 55 30 (17) 4.6 % -11.25 [ -17.54, -4.96 ]
Legare 2008a 43 19.75 (16.5) 41 23.25 (20) 4.2 % -3.50 [ -11.36, 4.36 ]
Man-Son-Hing 1999 139 16.25 (12.5) 148 19 (14.75) 5.4 % -2.75 [ -5.91, 0.41 ]
Mathers 2012 95 16.7 (13.9) 80 26.7 (18.2) 5.0 % -10.00 [ -14.87, -5.13 ]
Mathieu 2007 315 19.51 (16.3) 295 22.59 (80) 3.8 % -3.08 [ -12.38, 6.22 ]
McAlister 2005 205 15 (12.5) 202 17.5 (15) 5.5 % -2.50 [ -5.18, 0.18 ]
Montgomery 2003 50 28.5 (12.5) 58 51.29 (25.73) 4.3 % -22.79 [ -30.26, -15.32 ]
Montgomery 2007 201 17.6 (13.2) 203 24.1 (15.8) 5.4 % -6.50 [ -9.34, -3.66 ]
Morgan 2000 86 30 (3.25) 94 30 (3.25) 5.6 % 0.0 [ -0.95, 0.95 ]
Murray 2001a 53 35.38 (12.33) 45 40.56 (16.44) 4.8 % -5.18 [ -11.02, 0.66 ]
Murray 2001b 82 37.5 (15) 84 42.85 (16.57) 5.0 % -5.35 [ -10.16, -0.54 ]
Nagle 2008 167 19 (15.25) 171 15.5 (15.75) 5.3 % 3.50 [ 0.20, 6.80 ]
Schwalm 2012 76 18 (15.3) 74 26 (24.2) 4.6 % -8.00 [ -14.50, -1.50 ]
Shourie 2013 44 11.25 (13) 69 37.5 (24.25) 4.5 % -26.25 [ -33.14, -19.36 ]
Vandemheen 2009 70 9.9 (17.7) 79 16.8 (21) 4.7 % -6.90 [ -13.12, -0.68 ]
Vodermaier 2009 55 20.75 (15.5) 56 24.75 (15.5) 4.8 % -4.00 [ -9.77, 1.77 ]
Subtotal (95% CI) 2693 2171 100.0 % -8.40 [ -11.59, -5.21 ]
Heterogeneity: Tau2 = 46.63; Chi2 = 255.50, df = 21 (P<0.00001); I2 =92%
Test for overall effect: Z = 5.17 (P < 0.00001)
4 Unsupported subscale
Brazell 2014 53 11.5 (14.4) 51 9.5 (13.9) 4.7 % 2.00 [ -3.44, 7.44 ]
Chabrera 2015 61 30.5 (11.6) 61 51.7 (15.3) 4.9 % -21.20 [ -26.02, -16.38 ]
De Achaval 2012 69 20.5 (14.95) 69 25 (15.78) 4.8 % -4.50 [ -9.63, 0.63 ]
Dolan 2002 41 21 (13.5) 37 23.25 (20) 4.0 % -2.25 [ -9.91, 5.41 ]
Fagerlin 2011 690 18.1 (46.9) 160 43.3 (119.4) 1.6 % -25.20 [ -44.03, -6.37 ]
Jibaja-Weiss 2011 44 19.17 (26.3) 39 22.07 (28.88) 2.8 % -2.90 [ -14.84, 9.04 ]
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Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Laupacis 2006 53 17.25 (15.75) 55 24 (17.25) 4.5 % -6.75 [ -12.98, -0.52 ]
Legare 2008a 43 24.25 (19.5) 41 23.5 (17.25) 3.9 % 0.75 [ -7.11, 8.61 ]
Man-Son-Hing 1999 139 16.25 (13) 148 16.5 (14) 5.4 % -0.25 [ -3.37, 2.87 ]
Mathers 2012 95 17.4 (13.1) 80 20.8 (15.3) 5.1 % -3.40 [ -7.66, 0.86 ]
Mathieu 2007 315 20.9 (15.58) 295 22.98 (15.58) 5.5 % -2.08 [ -4.55, 0.39 ]
McAlister 2005 205 15 (15) 202 15 (15) 5.4 % 0.0 [ -2.91, 2.91 ]
Montgomery 2003 50 23.67 (10.96) 58 40.52 (19.83) 4.6 % -16.85 [ -22.79, -10.91 ]
Montgomery 2007 200 22.2 (16.5) 201 28.5 (18.7) 5.3 % -6.30 [ -9.75, -2.85 ]
Morgan 2000 86 30 (24.75) 94 32.5 (24.75) 4.1 % -2.50 [ -9.74, 4.74 ]
Murray 2001a 53 32.7 (12.75) 45 40.56 (17.1) 4.5 % -7.86 [ -13.92, -1.80 ]
Murray 2001b 85 36.47 (14.43) 82 48.68 (15.46) 5.0 % -12.21 [ -16.75, -7.67 ]
Nagle 2008 167 15.25 (13.75) 171 14.5 (15.75) 5.4 % 0.75 [ -2.40, 3.90 ]
Schwalm 2012 76 12.2 (15.2) 74 14.9 (16.9) 4.8 % -2.70 [ -7.85, 2.45 ]
Shourie 2013 43 13.25 (17.25) 69 38 (21.75) 4.1 % -24.75 [ -32.02, -17.48 ]
Vandemheen 2009 70 6.9 (12.3) 79 14.5 (17.7) 4.9 % -7.60 [ -12.45, -2.75 ]
Vodermaier 2009 55 16.25 (16.25) 56 21 (15.75) 4.6 % -4.75 [ -10.70, 1.20 ]
Subtotal (95% CI) 2693 2167 100.0 % -6.18 [ -8.96, -3.40 ]
Heterogeneity: Tau2 = 34.85; Chi2 = 151.76, df = 21 (P<0.00001); I2 =86%
Test for overall effect: Z = 4.36 (P = 0.000013)
5 Ineffective choice subscale
Brazell 2014 53 17.8 (19.1) 51 13.8 (18.3) 4.1 % 4.00 [ -3.19, 11.19 ]
Chabrera 2015 61 27.1 (11.7) 61 49.5 (14.3) 4.9 % -22.40 [ -27.04, -17.76 ]
De Achaval 2012 69 27.7 (18.27) 69 31.2 (19.11) 4.4 % -3.50 [ -9.74, 2.74 ]
Dolan 2002 41 20.5 (14.5) 37 25.75 (21) 3.9 % -5.25 [ -13.34, 2.84 ]
Fagerlin 2011 690 30 (52.3) 160 55.5 (133.9) 1.4 % -25.50 [ -46.61, -4.39 ]
Hanson 2011 118 14 (15.55) 115 19.25 (15.55) 5.1 % -5.25 [ -9.24, -1.26 ]
Laupacis 2006 53 15 (14.5) 55 21.25 (16) 4.6 % -6.25 [ -12.00, -0.50 ]
Legare 2008a 43 16.5 (14.75) 41 22.25 (19) 4.1 % -5.75 [ -13.05, 1.55 ]
Man-Son-Hing 1999 139 13.5 (13) 148 15.5 (14.75) 5.3 % -2.00 [ -5.21, 1.21 ]
Mathers 2012 95 16.1 (14.4) 80 23.3 (15.2) 5.0 % -7.20 [ -11.61, -2.79 ]
Mathieu 2007 315 18.41 (14.96) 295 19.19 (14.96) 5.4 % -0.78 [ -3.16, 1.60 ]
McAlister 2005 205 15 (12.5) 202 17.5 (15) 5.4 % -2.50 [ -5.18, 0.18 ]
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Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Montgomery 2003 50 26 (11.11) 58 35.13 (17.2) 4.7 % -9.13 [ -14.52, -3.74 ]
Morgan 2000 86 20 (32) 94 22.5 (32) 3.5 % -2.50 [ -11.86, 6.86 ]
Murray 2001a 57 25 (10) 48 30 (15) 4.8 % -5.00 [ -9.97, -0.03 ]
Murray 2001b 94 30 (15) 96 37.5 (17.5) 4.9 % -7.50 [ -12.13, -2.87 ]
Nagle 2008 167 16.25 (13.75) 171 15 (14.25) 5.3 % 1.25 [ -1.74, 4.24 ]
Schwalm 2012 76 11.3 (11.4) 74 15.9 (15.9) 5.0 % -4.60 [ -9.04, -0.16 ]
Shourie 2013 44 11 (12.25) 68 30.5 (19.5) 4.5 % -19.50 [ -25.38, -13.62 ]
Vandemheen 2009 70 10.4 (16.4) 79 17.9 (20.4) 4.5 % -7.50 [ -13.42, -1.58 ]
Vodermaier 2009 55 28.25 (20.75) 56 35 (20) 4.0 % -6.75 [ -14.33, 0.83 ]
Wong 2006 136 19.38 (13.13) 159 36.67 (19.17) 5.1 % -17.29 [ -21.00, -13.58 ]
Subtotal (95% CI) 2717 2217 100.0 % -6.75 [ -9.59, -3.90 ]
Heterogeneity: Tau2 = 37.39; Chi2 = 170.48, df = 21 (P<0.00001); I2 =88%
Test for overall effect: Z = 4.65 (P < 0.00001)
6 Total decisional conflict score
Allen 2010 291 14 (34.29) 334 20 (37.83) 3.0 % -6.00 [ -11.66, -0.34 ]
Brazell 2014 53 15.8 (13.9) 51 14.1 (16.1) 3.0 % 1.70 [ -4.09, 7.49 ]
Chabrera 2015 61 31.2 (10.2) 61 51.7 (13.3) 3.3 % -20.50 [ -24.71, -16.29 ]
De Achaval 2012 69 23.4 (14.95) 69 29.2 (16.61) 3.1 % -5.80 [ -11.07, -0.53 ]
Dolan 2002 41 20.75 (13) 37 25.75 (20.25) 2.5 % -5.00 [ -12.64, 2.64 ]
Evans 2010 89 38.08 (24.15) 103 49.58 (24.15) 2.7 % -11.50 [ -18.35, -4.65 ]
Fagerlin 2011 690 22 (42.2) 160 55.7 (108.4) 1.0 % -33.70 [ -50.79, -16.61 ]
Hanson 2011 118 16.25 (18.55) 115 24.25 (18.55) 3.2 % -8.00 [ -12.76, -3.24 ]
Jibaja-Weiss 2011 44 16.53 (19.9) 39 22.16 (25.29) 2.0 % -5.63 [ -15.51, 4.25 ]
Knops 2014 73 22 (17) 81 24 (17) 3.1 % -2.00 [ -7.38, 3.38 ]
Kuppermann 2014 357 12.9 (14.1) 353 13.8 (15.6) 3.7 % -0.90 [ -3.09, 1.29 ]
Lam 2013 113 15.8 (15.5) 112 19.9 (16.3) 3.3 % -4.10 [ -8.26, 0.06 ]
Laupacis 2006 53 17.5 (13.75) 54 25.25 (14.25) 3.1 % -7.75 [ -13.06, -2.44 ]
Legare 2008a 43 23 (14.25) 41 27 (15.25) 2.8 % -4.00 [ -10.32, 2.32 ]
Lepore 2012 215 34.15 (24.03) 216 39.85 (24.04) 3.3 % -5.70 [ -10.24, -1.16 ]
Man-Son-Hing 1999 139 16.25 (11.25) 148 18.5 (13.5) 3.6 % -2.25 [ -5.12, 0.62 ]
Mathers 2012 95 17.4 (12.6) 80 25.2 (14.9) 3.3 % -7.80 [ -11.93, -3.67 ]
Mathieu 2007 315 20.06 (14.51) 295 21.89 (14.51) 3.7 % -1.83 [ -4.13, 0.47 ]
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Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
McAlister 2005 205 15 (12.5) 202 17.5 (12.5) 3.7 % -2.50 [ -4.93, -0.07 ]
Montgomery 2003 50 27.1 (10) 58 44.2 (19.3) 3.0 % -17.10 [ -22.79, -11.41 ]
Montgomery 2007 198 23.6 (15.1) 201 27.8 (14.6) 3.6 % -4.20 [ -7.12, -1.28 ]
Morgan 2000 86 27.5 (37.5) 94 27.5 (37.5) 1.8 % 0.0 [ -10.97, 10.97 ]
Murray 2001a 57 32.5 (10) 48 40 (12.5) 3.3 % -7.50 [ -11.89, -3.11 ]
Murray 2001b 94 37.5 (12.5) 96 45 (15) 3.4 % -7.50 [ -11.42, -3.58 ]
Nagle 2008 167 17.75 (12.25) 171 16.25 (13.75) 3.6 % 1.50 [ -1.27, 4.27 ]
Nassar 2007 98 4.6 (9) 98 13.5 (19.2) 3.3 % -8.90 [ -13.10, -4.70 ]
Protheroe 2007 69 23.4 (14.3) 69 40.5 (18.3) 3.0 % -17.10 [ -22.58, -11.62 ]
Sawka 2012 37 25.2 (13.4) 37 52.1 (21.9) 2.4 % -26.90 [ -35.17, -18.63 ]
Schwalm 2012 76 14.8 (10.5) 74 19.5 (16.7) 3.3 % -4.70 [ -9.18, -0.22 ]
Shorten 2005 99 23.5 (12.5) 88 29.5 (18.25) 3.3 % -6.00 [ -10.54, -1.46 ]
Shourie 2013 43 14.25 (17.25) 67 37.25 (21.5) 2.6 % -23.00 [ -30.29, -15.71 ]
Vandemheen 2009 70 11.6 (13.6) 79 20.4 (16.9) 3.2 % -8.80 [ -13.70, -3.90 ]
Vodermaier 2009 55 20.5 (14.75) 56 24.75 (15.5) 3.0 % -4.25 [ -9.88, 1.38 ]
Subtotal (95% CI) 4263 3787 100.0 % -7.32 [ -9.35, -5.28 ]
Heterogeneity: Tau2 = 27.77; Chi2 = 223.37, df = 32 (P<0.00001); I2 =86%
Test for overall effect: Z = 7.05 (P < 0.00001)
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Analysis 4.4. Comparison 4 Decisional conflict, Outcome 4 Decisional conflict - without studies having high
risk of bias.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 4 Decisional conflict
Outcome: 4 Decisional conflict - without studies having high risk of bias
Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Uncertainty subscale
Bekker 2004 50 45 (20.83) 56 45 (25.83) 3.1 % 0.0 [ -8.89, 8.89 ]
Chabrera 2015 61 32 (11.4) 61 43.8 (8.82) 5.1 % -11.80 [ -15.42, -8.18 ]
De Achaval 2012 69 33.4 (23.26) 69 35.9 (22.43) 3.6 % -2.50 [ -10.12, 5.12 ]
Dolan 2002 41 27 (19.25) 37 26 (24.25) 2.9 % 1.00 [ -8.79, 10.79 ]
Fagerlin 2011 690 37.4 (62.3) 160 73.2 (159.7) 0.8 % -35.80 [ -60.98, -10.62 ]
Gattellari 2003 106 42.5 (20) 108 42.5 (33.33) 3.7 % 0.0 [ -7.35, 7.35 ]
Gattellari 2005 131 30.83 (19.25) 136 29.17 (15) 4.9 % 1.66 [ -2.49, 5.81 ]
Hanson 2011 118 22 (20) 115 28.75 (20) 4.5 % -6.75 [ -11.89, -1.61 ]
Hess 2012 101 24.7 (23.33) 103 36.8 (23.59) 4.0 % -12.10 [ -18.54, -5.66 ]
Jibaja-Weiss 2011 44 15.38 (32.25) 39 12.83 (22.53) 2.3 % 2.55 [ -9.32, 14.42 ]
Laupacis 2006 54 20.5 (18.75) 55 23 (21) 3.6 % -2.50 [ -9.97, 4.97 ]
Legare 2008a 43 26.5 (23) 41 33.25 (25.25) 2.7 % -6.75 [ -17.09, 3.59 ]
Mathers 2012 95 20.1 (16.6) 80 29.4 (20.8) 4.3 % -9.30 [ -14.95, -3.65 ]
Mathieu 2007 315 22.23 (19.46) 295 22.65 (19.46) 5.2 % -0.42 [ -3.51, 2.67 ]
McAlister 2005 205 20 (20) 202 17.5 (17.5) 5.1 % 2.50 [ -1.15, 6.15 ]
Montgomery 2003 50 35.5 (20.47) 58 47.99 (25.14) 3.2 % -12.49 [ -21.10, -3.88 ]
Montgomery 2007 201 22.1 (18.4) 203 27.3 (18.8) 5.1 % -5.20 [ -8.83, -1.57 ]
Morgan 2000 86 35 (13) 94 32.5 (13) 5.0 % 2.50 [ -1.30, 6.30 ]
Murray 2001a 57 35 (20) 48 42.5 (20) 3.6 % -7.50 [ -15.18, 0.18 ]
Murray 2001b 94 52.5 (25) 96 60 (27.5) 3.6 % -7.50 [ -14.97, -0.03 ]
Nagle 2008 167 24 (19.75) 171 24.25 (21.5) 4.8 % -0.25 [ -4.65, 4.15 ]
Schwalm 2012 76 18 (18.8) 74 19.6 (19.9) 4.1 % -1.60 [ -7.80, 4.60 ]
Shourie 2013 44 16.25 (18.25) 68 38.25 (29.5) 3.2 % -22.00 [ -30.85, -13.15 ]
Vandemheen 2009 70 26.4 (25.9) 79 36.4 (27.8) 3.2 % -10.00 [ -18.63, -1.37 ]
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Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Vodermaier 2009 55 27 (24.25) 56 30 (10) 3.8 % -3.00 [ -9.92, 3.92 ]
Wong 2006 136 38.25 (22.5) 146 40 (20.83) 4.5 % -1.75 [ -6.82, 3.32 ]
Subtotal (95% CI) 3159 2650 100.0 % -4.53 [ -6.87, -2.18 ]
Heterogeneity: Tau2 = 24.77; Chi2 = 101.56, df = 25 (P<0.00001); I2 =75%
Test for overall effect: Z = 3.79 (P = 0.00015)
2 Uninformed subscale
Bekker 2004 50 32.5 (15) 56 31.67 (14.17) 4.2 % 0.83 [ -4.74, 6.40 ]
Chabrera 2015 61 39.7 (10.6) 61 61.1 (19.7) 4.2 % -21.40 [ -27.01, -15.79 ]
De Achaval 2012 69 15.9 (15.78) 69 27.3 (16.61) 4.2 % -11.40 [ -16.81, -5.99 ]
Dolan 2002 41 15.75 (13) 37 24.5 (21.25) 3.7 % -8.75 [ -16.67, -0.83 ]
Fagerlin 2011 690 8.7 (43.2) 160 57.4 (110.7) 2.0 % -48.70 [ -66.15, -31.25 ]
Hess 2012 101 22.8 (22.8) 103 40.6 (21.53) 4.1 % -17.80 [ -23.89, -11.71 ]
Jibaja-Weiss 2011 44 15 (22.26) 39 23.42 (28.72) 3.0 % -8.42 [ -19.58, 2.74 ]
Laupacis 2006 54 16.25 (13.75) 54 27.25 (15) 4.2 % -11.00 [ -16.43, -5.57 ]
Legare 2008a 43 29.75 (22.75) 41 34.25 (26) 3.2 % -4.50 [ -14.97, 5.97 ]
Mann D 2010 80 27.1 (17.6) 70 33.8 (17.6) 4.2 % -6.70 [ -12.35, -1.05 ]
Mathers 2012 95 18.1 (13.3) 80 26 (16.6) 4.4 % -7.90 [ -12.41, -3.39 ]
Mathieu 2007 315 20.78 (15.59) 295 23.26 (15.59) 4.7 % -2.48 [ -4.96, 0.00 ]
McAlister 2005 205 15 (12.5) 202 20 (15) 4.6 % -5.00 [ -7.68, -2.32 ]
Montgomery 2003 50 22.17 (9.47) 58 49.14 (25.4) 3.9 % -26.97 [ -34.01, -19.93 ]
Montgomery 2007 199 35.1 (25.6) 203 35.8 (22.7) 4.3 % -0.70 [ -5.43, 4.03 ]
Morgan 2000 86 20 (21.5) 94 27.5 (21.5) 4.0 % -7.50 [ -13.79, -1.21 ]
Mullan 2009 48 13.65 (19.84) 37 15.28 (15.49) 3.8 % -1.63 [ -9.14, 5.88 ]
Murray 2001a 52 27.56 (10.51) 45 38.88 (20.02) 4.0 % -11.32 [ -17.83, -4.81 ]
Murray 2001b 93 29.93 (17.26) 93 38.89 (22.53) 4.1 % -8.96 [ -14.73, -3.19 ]
Nagle 2008 167 15.25 (14.5) 171 12.75 (14.75) 4.6 % 2.50 [ -0.62, 5.62 ]
Schwalm 2012 76 15.7 (13.5) 74 22.3 (20.5) 4.2 % -6.60 [ -12.17, -1.03 ]
Shourie 2013 44 11.25 (15.25) 69 46.25 (26) 3.8 % -35.00 [ -42.61, -27.39 ]
Vandemheen 2009 70 4.5 (9.6) 79 17.2 (20.6) 4.3 % -12.70 [ -17.77, -7.63 ]
Vodermaier 2009 55 22 (15.75) 56 30 (22.5) 3.9 % -8.00 [ -15.21, -0.79 ]
Wong 2006 136 21.75 (15) 146 25.75 (15) 4.5 % -4.00 [ -7.50, -0.50 ]
Subtotal (95% CI) 2924 2392 100.0 % -9.96 [ -13.13, -6.78 ]
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Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 54.55; Chi2 = 223.82, df = 24 (P<0.00001); I2 =89%
Test for overall effect: Z = 6.15 (P < 0.00001)
3 Unclear values subscale
Chabrera 2015 61 28.1 (11.2) 61 53.2 (14.5) 5.3 % -25.10 [ -29.70, -20.50 ]
De Achaval 2012 69 17.9 (14.95) 69 26.1 (19.11) 5.0 % -8.20 [ -13.92, -2.48 ]
Dolan 2002 41 19.75 (15.75) 37 29.25 (24) 4.2 % -9.50 [ -18.61, -0.39 ]
Fagerlin 2011 690 12.6 (50.3) 160 47.7 (128.4) 2.0 % -35.10 [ -55.35, -14.85 ]
Hess 2012 101 24.2 (25.64) 103 41.4 (22.05) 4.8 % -17.20 [ -23.77, -10.63 ]
Jibaja-Weiss 2011 44 14.38 (27.08) 39 29.73 (41.6) 2.8 % -15.35 [ -30.66, -0.04 ]
Laupacis 2006 54 18.75 (16.5) 55 30 (17) 4.9 % -11.25 [ -17.54, -4.96 ]
Legare 2008a 43 19.75 (16.5) 41 23.25 (20) 4.5 % -3.50 [ -11.36, 4.36 ]
Mathers 2012 95 16.7 (13.9) 80 26.7 (18.2) 5.2 % -10.00 [ -14.87, -5.13 ]
Mathieu 2007 315 19.51 (16.3) 295 22.59 (80) 4.1 % -3.08 [ -12.38, 6.22 ]
McAlister 2005 205 15 (12.5) 202 17.5 (15) 5.6 % -2.50 [ -5.18, 0.18 ]
Montgomery 2003 50 28.5 (12.5) 58 51.29 (25.73) 4.6 % -22.79 [ -30.26, -15.32 ]
Montgomery 2007 201 17.6 (13.2) 203 24.1 (15.8) 5.6 % -6.50 [ -9.34, -3.66 ]
Morgan 2000 86 30 (3.25) 94 30 (3.25) 5.8 % 0.0 [ -0.95, 0.95 ]
Murray 2001a 53 35.38 (12.33) 45 40.56 (16.44) 5.0 % -5.18 [ -11.02, 0.66 ]
Murray 2001b 82 37.5 (15) 84 42.85 (16.57) 5.3 % -5.35 [ -10.16, -0.54 ]
Nagle 2008 167 19 (15.25) 171 15.5 (15.75) 5.5 % 3.50 [ 0.20, 6.80 ]
Schwalm 2012 76 18 (15.3) 74 26 (24.2) 4.9 % -8.00 [ -14.50, -1.50 ]
Shourie 2013 44 11.25 (13) 69 37.5 (24.25) 4.8 % -26.25 [ -33.14, -19.36 ]
Vandemheen 2009 70 9.9 (17.7) 79 16.8 (21) 4.9 % -6.90 [ -13.12, -0.68 ]
Vodermaier 2009 55 20.75 (15.5) 56 24.75 (15.5) 5.0 % -4.00 [ -9.77, 1.77 ]
Subtotal (95% CI) 2602 2075 100.0 % -9.55 [ -13.08, -6.02 ]
Heterogeneity: Tau2 = 55.88; Chi2 = 273.66, df = 20 (P<0.00001); I2 =93%
Test for overall effect: Z = 5.30 (P < 0.00001)
4 Unsupported subscale
Chabrera 2015 61 30.5 (11.6) 61 51.7 (15.3) 5.0 % -21.20 [ -26.02, -16.38 ]
De Achaval 2012 69 20.5 (14.95) 69 25 (15.78) 4.9 % -4.50 [ -9.63, 0.63 ]
Dolan 2002 41 21 (13.5) 37 23.25 (20) 4.0 % -2.25 [ -9.91, 5.41 ]
Fagerlin 2011 690 18.1 (46.9) 160 43.3 (119.4) 1.6 % -25.20 [ -44.03, -6.37 ]
Hess 2012 101 18.5 (22.56) 103 29.2 (22.56) 4.5 % -10.70 [ -16.89, -4.51 ]
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Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Jibaja-Weiss 2011 44 19.17 (26.3) 39 22.07 (28.88) 2.8 % -2.90 [ -14.84, 9.04 ]
Laupacis 2006 53 17.25 (15.75) 55 24 (17.25) 4.5 % -6.75 [ -12.98, -0.52 ]
Legare 2008a 43 24.25 (19.5) 41 23.5 (17.25) 4.0 % 0.75 [ -7.11, 8.61 ]
Mann D 2010 80 25.2 (13.72) 70 29.6 (13.72) 5.1 % -4.40 [ -8.80, 0.00 ]
Mathers 2012 95 17.4 (13.1) 80 20.8 (15.3) 5.1 % -3.40 [ -7.66, 0.86 ]
Mathieu 2007 315 20.9 (15.58) 295 22.98 (15.58) 5.6 % -2.08 [ -4.55, 0.39 ]
McAlister 2005 205 15 (15) 202 15 (15) 5.5 % 0.0 [ -2.91, 2.91 ]
Montgomery 2003 50 23.67 (10.96) 58 40.52 (19.83) 4.6 % -16.85 [ -22.79, -10.91 ]
Montgomery 2007 200 22.2 (16.5) 201 28.5 (18.7) 5.3 % -6.30 [ -9.75, -2.85 ]
Morgan 2000 86 30 (24.75) 94 32.5 (24.75) 4.2 % -2.50 [ -9.74, 4.74 ]
Murray 2001a 53 32.7 (12.75) 45 40.56 (17.1) 4.5 % -7.86 [ -13.92, -1.80 ]
Murray 2001b 85 36.47 (14.43) 82 48.68 (15.46) 5.0 % -12.21 [ -16.75, -7.67 ]
Nagle 2008 167 15.25 (13.75) 171 14.5 (15.75) 5.4 % 0.75 [ -2.40, 3.90 ]
Schwalm 2012 76 12.2 (15.2) 74 14.9 (16.9) 4.8 % -2.70 [ -7.85, 2.45 ]
Shourie 2013 43 13.25 (17.25) 69 38 (21.75) 4.1 % -24.75 [ -32.02, -17.48 ]
Vandemheen 2009 70 6.9 (12.3) 79 14.5 (17.7) 4.9 % -7.60 [ -12.45, -2.75 ]
Vodermaier 2009 55 16.25 (16.25) 56 21 (15.75) 4.6 % -4.75 [ -10.70, 1.20 ]
Subtotal (95% CI) 2682 2141 100.0 % -7.00 [ -9.76, -4.24 ]
Heterogeneity: Tau2 = 33.90; Chi2 = 141.02, df = 21 (P<0.00001); I2 =85%
Test for overall effect: Z = 4.98 (P < 0.00001)
5 Ineffective choice subscale
Bekker 2004 50 22.5 (13.75) 56 21.88 (14.38) 4.7 % 0.62 [ -4.74, 5.98 ]
Chabrera 2015 61 27.1 (11.7) 61 49.5 (14.3) 4.9 % -22.40 [ -27.04, -17.76 ]
De Achaval 2012 69 27.7 (18.27) 69 31.2 (19.11) 4.4 % -3.50 [ -9.74, 2.74 ]
Dolan 2002 41 20.5 (14.5) 37 25.75 (21) 3.8 % -5.25 [ -13.34, 2.84 ]
Fagerlin 2011 690 30 (52.3) 160 55.5 (133.9) 1.3 % -25.50 [ -46.61, -4.39 ]
Hanson 2011 118 14 (15.55) 115 19.25 (15.55) 5.1 % -5.25 [ -9.24, -1.26 ]
Laupacis 2006 53 15 (14.5) 55 21.25 (16) 4.6 % -6.25 [ -12.00, -0.50 ]
Legare 2008a 43 16.5 (14.75) 41 22.25 (19) 4.1 % -5.75 [ -13.05, 1.55 ]
Mathers 2012 95 16.1 (14.4) 80 23.3 (15.2) 5.0 % -7.20 [ -11.61, -2.79 ]
Mathieu 2007 315 18.41 (14.96) 295 19.19 (14.96) 5.4 % -0.78 [ -3.16, 1.60 ]
McAlister 2005 205 15 (12.5) 202 17.5 (15) 5.4 % -2.50 [ -5.18, 0.18 ]
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Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Montgomery 2003 50 26 (11.11) 58 35.13 (17.2) 4.7 % -9.13 [ -14.52, -3.74 ]
Morgan 2000 86 20 (32) 94 22.5 (32) 3.5 % -2.50 [ -11.86, 6.86 ]
Murray 2001a 57 25 (10) 48 30 (15) 4.8 % -5.00 [ -9.97, -0.03 ]
Murray 2001b 94 30 (15) 96 37.5 (17.5) 4.9 % -7.50 [ -12.13, -2.87 ]
Nagle 2008 167 16.25 (13.75) 171 15 (14.25) 5.3 % 1.25 [ -1.74, 4.24 ]
Schwalm 2012 76 11.3 (11.4) 74 15.9 (15.9) 4.9 % -4.60 [ -9.04, -0.16 ]
Shourie 2013 44 11 (12.25) 68 30.5 (19.5) 4.5 % -19.50 [ -25.38, -13.62 ]
Vandemheen 2009 70 10.4 (16.4) 79 17.9 (20.4) 4.5 % -7.50 [ -13.42, -1.58 ]
Vodermaier 2009 55 28.25 (20.75) 56 35 (20) 4.0 % -6.75 [ -14.33, 0.83 ]
Whelan 2004 94 12.5 (12) 107 17 (13) 5.2 % -4.50 [ -7.96, -1.04 ]
Wong 2006 136 19.38 (13.13) 159 36.67 (19.17) 5.1 % -17.29 [ -21.00, -13.58 ]
Subtotal (95% CI) 2669 2181 100.0 % -6.97 [ -9.76, -4.18 ]
Heterogeneity: Tau2 = 35.80; Chi2 = 164.67, df = 21 (P<0.00001); I2 =87%
Test for overall effect: Z = 4.90 (P < 0.00001)
6 Total decisional conflict score
Allen 2010 291 14 (34.29) 334 20 (37.83) 2.8 % -6.00 [ -11.66, -0.34 ]
Chabrera 2015 61 31.2 (10.2) 61 51.7 (13.3) 3.2 % -20.50 [ -24.71, -16.29 ]
De Achaval 2012 69 23.4 (14.95) 69 29.2 (16.61) 2.9 % -5.80 [ -11.07, -0.53 ]
Dolan 2002 41 20.75 (13) 37 25.75 (20.25) 2.4 % -5.00 [ -12.64, 2.64 ]
Evans 2010 89 38.08 (24.15) 103 49.58 (24.15) 2.6 % -11.50 [ -18.35, -4.65 ]
Fagerlin 2011 690 22 (42.2) 160 55.7 (108.4) 1.0 % -33.70 [ -50.79, -16.61 ]
Hanson 2011 118 16.25 (18.55) 115 24.25 (18.55) 3.0 % -8.00 [ -12.76, -3.24 ]
Hess 2012 101 23.3 (20.76) 103 43.3 (18.97) 2.9 % -20.00 [ -25.46, -14.54 ]
Jibaja-Weiss 2011 44 16.53 (19.9) 39 22.16 (25.29) 2.0 % -5.63 [ -15.51, 4.25 ]
Kuppermann 2014 357 12.9 (14.1) 353 13.8 (15.6) 3.5 % -0.90 [ -3.09, 1.29 ]
Lam 2013 113 15.8 (15.5) 112 19.9 (16.3) 3.2 % -4.10 [ -8.26, 0.06 ]
Laupacis 2006 53 17.5 (13.75) 54 25.25 (14.25) 2.9 % -7.75 [ -13.06, -2.44 ]
Legare 2008a 43 23 (14.25) 41 27 (15.25) 2.7 % -4.00 [ -10.32, 2.32 ]
Lepore 2012 215 34.15 (24.03) 216 39.85 (24.04) 3.1 % -5.70 [ -10.24, -1.16 ]
Mann D 2010 80 25.5 (11.14) 70 28.5 (11.14) 3.3 % -3.00 [ -6.57, 0.57 ]
Mathers 2012 95 17.4 (12.6) 80 25.2 (14.9) 3.2 % -7.80 [ -11.93, -3.67 ]
Mathieu 2007 315 20.06 (14.51) 295 21.89 (14.51) 3.5 % -1.83 [ -4.13, 0.47 ]
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Study or subgroup Decision Aid Usual Care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
McAlister 2005 205 15 (12.5) 202 17.5 (12.5) 3.5 % -2.50 [ -4.93, -0.07 ]
Montgomery 2003 50 27.1 (10) 58 44.2 (19.3) 2.8 % -17.10 [ -22.79, -11.41 ]
Montgomery 2007 198 23.6 (15.1) 201 27.8 (14.6) 3.4 % -4.20 [ -7.12, -1.28 ]
Montori 2011 49 14.4 (24.92) 46 16.2 (24.92) 1.9 % -1.80 [ -11.83, 8.23 ]
Morgan 2000 86 27.5 (37.5) 94 27.5 (37.5) 1.8 % 0.0 [ -10.97, 10.97 ]
Mullan 2009 48 14.1 (17.89) 37 14.95 (12.68) 2.7 % -0.85 [ -7.35, 5.65 ]
Murray 2001a 57 32.5 (10) 48 40 (12.5) 3.1 % -7.50 [ -11.89, -3.11 ]
Murray 2001b 94 37.5 (12.5) 96 45 (15) 3.2 % -7.50 [ -11.42, -3.58 ]
Nagle 2008 167 17.75 (12.25) 171 16.25 (13.75) 3.4 % 1.50 [ -1.27, 4.27 ]
Nassar 2007 98 4.6 (9) 98 13.5 (19.2) 3.2 % -8.90 [ -13.10, -4.70 ]
Protheroe 2007 69 23.4 (14.3) 69 40.5 (18.3) 2.9 % -17.10 [ -22.58, -11.62 ]
Sawka 2012 37 25.2 (13.4) 37 52.1 (21.9) 2.3 % -26.90 [ -35.17, -18.63 ]
Schwalm 2012 76 14.8 (10.5) 74 19.5 (16.7) 3.1 % -4.70 [ -9.18, -0.22 ]
Shorten 2005 99 23.5 (12.5) 88 29.5 (18.25) 3.1 % -6.00 [ -10.54, -1.46 ]
Shourie 2013 43 14.25 (17.25) 67 37.25 (21.5) 2.5 % -23.00 [ -30.29, -15.71 ]
Vandemheen 2009 70 11.6 (13.6) 79 20.4 (16.9) 3.0 % -8.80 [ -13.70, -3.90 ]
Vodermaier 2009 55 20.5 (14.75) 56 24.75 (15.5) 2.8 % -4.25 [ -9.88, 1.38 ]
Whelan 2004 94 10 (12) 107 15.5 (12.9) 3.3 % -5.50 [ -8.94, -2.06 ]
Subtotal (95% CI) 4370 3870 100.0 % -7.81 [ -9.84, -5.77 ]
Heterogeneity: Tau2 = 29.64; Chi2 = 243.60, df = 34 (P<0.00001); I2 =86%
Test for overall effect: Z = 7.51 (P < 0.00001)
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Analysis 5.1. Comparison 5 Participation in decision making, Outcome 1 Participation in decision making -
all studies.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 5 Participation in decision making
Outcome: 1 Participation in decision making - all studies
Study or subgroup Decision Aid Usual Care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Clinician-controlled decision making
Auvinen 2004 31/103 73/100 13.9 % 0.41 [ 0.30, 0.57 ]
Davison 1997 3/30 10/30 2.6 % 0.30 [ 0.09, 0.98 ]
Dolan 2002 7/43 6/43 3.5 % 1.17 [ 0.43, 3.19 ]
Kasper 2008 6/134 10/139 3.6 % 0.62 [ 0.23, 1.66 ]
Krist 2007 20/196 14/75 7.1 % 0.55 [ 0.29, 1.03 ]
Legare 2011 26/81 24/70 10.3 % 0.94 [ 0.59, 1.47 ]
Legare 2012 58/163 65/165 15.0 % 0.90 [ 0.68, 1.20 ]
Man-Son-Hing 1999 16/137 23/146 7.6 % 0.74 [ 0.41, 1.34 ]
Mathers 2012 8/92 16/77 5.1 % 0.42 [ 0.19, 0.92 ]
Morgan 2000 25/86 39/94 11.4 % 0.70 [ 0.47, 1.05 ]
Murray 2001a 5/57 4/48 2.4 % 1.05 [ 0.30, 3.70 ]
Murray 2001b 5/94 6/95 2.8 % 0.84 [ 0.27, 2.67 ]
Sawka 2012 4/37 9/37 3.1 % 0.44 [ 0.15, 1.32 ]
Smith 2010 3/357 0/173 0.5 % 3.40 [ 0.18, 65.50 ]
Vodermaier 2009 14/53 16/54 7.4 % 0.89 [ 0.48, 1.64 ]
Whelan 2003 6/80 12/91 3.9 % 0.57 [ 0.22, 1.45 ]
Subtotal (95% CI) 1743 1437 100.0 % 0.68 [ 0.55, 0.83 ]
Total events: 237 (Decision Aid), 327 (Usual Care)
Heterogeneity: Tau2 = 0.05; Chi2 = 23.59, df = 15 (P = 0.07); I2 =36%
Test for overall effect: Z = 3.74 (P = 0.00019)
2 Patient-controlled decision making
Auvinen 2004 44/103 9/100 4.8 % 4.75 [ 2.45, 9.20 ]
Davison 1997 17/30 5/30 3.5 % 3.40 [ 1.44, 8.03 ]
Dolan 2002 9/43 15/43 4.5 % 0.60 [ 0.29, 1.22 ]
Kasper 2008 109/134 103/139 10.4 % 1.10 [ 0.97, 1.25 ]
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Study or subgroup Decision Aid Usual Care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Krist 2007 106/196 35/75 9.0 % 1.16 [ 0.88, 1.52 ]
Legare 2011 39/81 30/70 8.1 % 1.12 [ 0.79, 1.60 ]
Legare 2012 52/163 57/165 8.6 % 0.92 [ 0.68, 1.26 ]
Man-Son-Hing 1999 85/137 80/146 9.8 % 1.13 [ 0.93, 1.38 ]
Mathers 2012 59/92 33/77 8.7 % 1.50 [ 1.11, 2.02 ]
Morgan 2000 17/86 14/94 5.0 % 1.33 [ 0.70, 2.53 ]
Murray 2001a 18/57 2/48 1.6 % 7.58 [ 1.85, 31.03 ]
Murray 2001b 49/94 53/95 9.1 % 0.93 [ 0.72, 1.22 ]
Sawka 2012 17/37 9/37 4.8 % 1.89 [ 0.97, 3.68 ]
Smith 2010 335/357 166/173 10.9 % 0.98 [ 0.94, 1.02 ]
Vodermaier 2009 4/53 2/54 1.2 % 2.04 [ 0.39, 10.66 ]
Subtotal (95% CI) 1663 1346 100.0 % 1.28 [ 1.05, 1.55 ]
Total events: 960 (Decision Aid), 613 (Usual Care)
Heterogeneity: Tau2 = 0.09; Chi2 = 109.06, df = 14 (P<0.00001); I2 =87%
Test for overall effect: Z = 2.47 (P = 0.013)
3 Shared decision making
Auvinen 2004 25/103 17/100 4.6 % 1.43 [ 0.82, 2.48 ]
Davison 1997 10/30 15/30 3.9 % 0.67 [ 0.36, 1.24 ]
Dolan 2002 27/43 22/43 7.6 % 1.23 [ 0.85, 1.78 ]
Kasper 2008 19/134 26/103 4.9 % 0.56 [ 0.33, 0.96 ]
Krist 2007 71/196 27/75 8.0 % 1.01 [ 0.71, 1.43 ]
Legare 2011 16/81 16/70 4.0 % 0.86 [ 0.47, 1.60 ]
Legare 2012 53/163 43/165 8.3 % 1.25 [ 0.89, 1.75 ]
Man-Son-Hing 1999 36/137 43/146 7.5 % 0.89 [ 0.61, 1.30 ]
Mathers 2012 25/92 28/77 6.2 % 0.75 [ 0.48, 1.17 ]
Morgan 2000 42/86 38/94 8.6 % 1.21 [ 0.87, 1.68 ]
Murray 2001a 34/57 42/48 11.0 % 0.68 [ 0.54, 0.87 ]
Murray 2001b 40/94 36/95 8.1 % 1.12 [ 0.79, 1.59 ]
Sawka 2012 15/37 19/37 5.3 % 0.79 [ 0.48, 1.30 ]
Smith 2010 17/357 5/173 1.8 % 1.65 [ 0.62, 4.39 ]
Vodermaier 2009 35/53 36/54 10.1 % 0.99 [ 0.76, 1.30 ]
Subtotal (95% CI) 1663 1310 100.0 % 0.95 [ 0.83, 1.10 ]
Total events: 465 (Decision Aid), 413 (Usual Care)
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Study or subgroup Decision Aid Usual Care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.03; Chi2 = 25.31, df = 14 (P = 0.03); I2 =45%
Test for overall effect: Z = 0.64 (P = 0.52)
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Analysis 5.2. Comparison 5 Participation in decision making, Outcome 2 Participation in decision making -
in consultation.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 5 Participation in decision making
Outcome: 2 Participation in decision making - in consultation
Study or subgroup Decision Aid Usual Care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Clinician-controlled decision making - in consultation
Legare 2011 26/81 24/70 25.9 % 0.94 [ 0.59, 1.47 ]
Legare 2012 58/163 65/165 67.9 % 0.90 [ 0.68, 1.20 ]
Whelan 2003 6/80 12/91 6.1 % 0.57 [ 0.22, 1.45 ]
Subtotal (95% CI) 324 326 100.0 % 0.89 [ 0.70, 1.12 ]
Total events: 90 (Decision Aid), 101 (Usual Care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.95, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.31)
2 Patient-controlled decision making - in consultation
Legare 2011 39/81 30/70 43.2 % 1.12 [ 0.79, 1.60 ]
Legare 2012 52/163 57/165 56.8 % 0.92 [ 0.68, 1.26 ]
Subtotal (95% CI) 244 235 100.0 % 1.01 [ 0.80, 1.27 ]
Total events: 91 (Decision Aid), 87 (Usual Care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
3 Shared decision making - in consultation
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Study or subgroup Decision Aid Usual Care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Legare 2011 16/81 16/70 24.7 % 0.86 [ 0.47, 1.60 ]
Legare 2012 53/163 43/165 75.3 % 1.25 [ 0.89, 1.75 ]
Subtotal (95% CI) 244 235 100.0 % 1.14 [ 0.84, 1.55 ]
Total events: 69 (Decision Aid), 59 (Usual Care)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.05, df = 1 (P = 0.30); I2 =5%
Test for overall effect: Z = 0.82 (P = 0.41)
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Analysis 5.3. Comparison 5 Participation in decision making, Outcome 3 Participation in decision making -
in preparation for consultation.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 5 Participation in decision making
Outcome: 3 Participation in decision making - in preparation for consultation
Study or subgroup Decision Aid Usual Care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Clinician-controlled decision making
Auvinen 2004 31/103 73/100 23.6 % 0.41 [ 0.30, 0.57 ]
Davison 1997 3/30 10/30 3.1 % 0.30 [ 0.09, 0.98 ]
Dolan 2002 7/43 6/43 4.3 % 1.17 [ 0.43, 3.19 ]
Kasper 2008 6/134 10/139 4.4 % 0.62 [ 0.23, 1.66 ]
Krist 2007 20/196 14/75 9.5 % 0.55 [ 0.29, 1.03 ]
Man-Son-Hing 1999 16/137 23/146 10.4 % 0.74 [ 0.41, 1.34 ]
Mathers 2012 8/92 16/77 6.5 % 0.42 [ 0.19, 0.92 ]
Morgan 2000 25/86 39/94 17.8 % 0.70 [ 0.47, 1.05 ]
Murray 2001a 5/57 4/48 2.8 % 1.05 [ 0.30, 3.70 ]
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Study or subgroup Decision Aid Usual Care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Murray 2001b 5/94 6/95 3.3 % 0.84 [ 0.27, 2.67 ]
Sawka 2012 4/37 9/37 3.7 % 0.44 [ 0.15, 1.32 ]
Smith 2010 3/357 0/173 0.5 % 3.40 [ 0.18, 65.50 ]
Vodermaier 2009 14/53 16/54 10.0 % 0.89 [ 0.48, 1.64 ]
Subtotal (95% CI) 1419 1111 100.0 % 0.60 [ 0.48, 0.75 ]
Total events: 147 (Decision Aid), 226 (Usual Care)
Heterogeneity: Tau2 = 0.03; Chi2 = 14.51, df = 12 (P = 0.27); I2 =17%
Test for overall effect: Z = 4.59 (P < 0.00001)
2 Patient-controlled decision making
Auvinen 2004 44/103 9/100 6.3 % 4.75 [ 2.45, 9.20 ]
Davison 1997 17/30 5/30 4.7 % 3.40 [ 1.44, 8.03 ]
Dolan 2002 9/43 15/43 5.8 % 0.60 [ 0.29, 1.22 ]
Kasper 2008 109/134 103/139 11.8 % 1.10 [ 0.97, 1.25 ]
Krist 2007 106/196 35/75 10.5 % 1.16 [ 0.88, 1.52 ]
Man-Son-Hing 1999 85/137 80/146 11.3 % 1.13 [ 0.93, 1.38 ]
Mathers 2012 59/92 33/77 10.2 % 1.50 [ 1.11, 2.02 ]
Morgan 2000 17/86 14/94 6.4 % 1.33 [ 0.70, 2.53 ]
Murray 2001a 18/57 2/48 2.3 % 7.58 [ 1.85, 31.03 ]
Murray 2001b 49/94 53/95 10.6 % 0.93 [ 0.72, 1.22 ]
Sawka 2012 17/37 9/37 6.2 % 1.89 [ 0.97, 3.68 ]
Smith 2010 335/357 166/173 12.2 % 0.98 [ 0.94, 1.02 ]
Vodermaier 2009 4/53 2/54 1.8 % 2.04 [ 0.39, 10.66 ]
Subtotal (95% CI) 1419 1111 100.0 % 1.37 [ 1.08, 1.73 ]
Total events: 869 (Decision Aid), 526 (Usual Care)
Heterogeneity: Tau2 = 0.12; Chi2 = 123.58, df = 12 (P<0.00001); I2 =90%
Test for overall effect: Z = 2.59 (P = 0.0096)
3 Shared decision making
Auvinen 2004 25/103 17/100 5.3 % 1.43 [ 0.82, 2.48 ]
Davison 1997 10/30 15/30 4.5 % 0.67 [ 0.36, 1.24 ]
Dolan 2002 27/43 22/43 8.7 % 1.23 [ 0.85, 1.78 ]
Kasper 2008 19/134 26/103 5.6 % 0.56 [ 0.33, 0.96 ]
Krist 2007 71/196 27/75 9.1 % 1.01 [ 0.71, 1.43 ]
Man-Son-Hing 1999 36/137 43/146 8.6 % 0.89 [ 0.61, 1.30 ]
Mathers 2012 25/92 28/77 7.0 % 0.75 [ 0.48, 1.17 ]
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Study or subgroup Decision Aid Usual Care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Morgan 2000 42/86 38/94 9.8 % 1.21 [ 0.87, 1.68 ]
Murray 2001a 34/57 42/48 12.5 % 0.68 [ 0.54, 0.87 ]
Murray 2001b 40/94 36/95 9.2 % 1.12 [ 0.79, 1.59 ]
Sawka 2012 15/37 19/37 6.1 % 0.79 [ 0.48, 1.30 ]
Smith 2010 17/357 5/173 2.1 % 1.65 [ 0.62, 4.39 ]
Vodermaier 2009 35/53 36/54 11.5 % 0.99 [ 0.76, 1.30 ]
Subtotal (95% CI) 1419 1075 100.0 % 0.94 [ 0.80, 1.09 ]
Total events: 396 (Decision Aid), 354 (Usual Care)
Heterogeneity: Tau2 = 0.03; Chi2 = 22.37, df = 12 (P = 0.03); I2 =46%
Test for overall effect: Z = 0.86 (P = 0.39)
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Analysis 6.1. Comparison 6 Proportion undecided, Outcome 1 Proportion undecided - all studies.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 6 Proportion undecided
Outcome: 1 Proportion undecided - all studies
Study or subgroup Decision Aid Usual Care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Nassar 2007 1/98 13/90 0.9 % 0.07 [ 0.01, 0.53 ]
Jibaja-Weiss 2011 0/44 4/39 0.5 % 0.10 [ 0.01, 1.78 ]
Man-Son-Hing 1999 1/139 9/148 0.9 % 0.12 [ 0.02, 0.92 ]
Miller 2011 22/132 72/132 6.5 % 0.31 [ 0.20, 0.46 ]
Protheroe 2007 7/56 18/56 3.9 % 0.39 [ 0.18, 0.86 ]
Vuorma 2003 8/184 20/179 3.8 % 0.39 [ 0.18, 0.86 ]
Chambers 2012 6/48 17/59 3.5 % 0.43 [ 0.19, 1.01 ]
Mathieu 2010 21/117 82/209 6.5 % 0.46 [ 0.30, 0.70 ]
Mathieu 2007 17/349 36/356 5.4 % 0.48 [ 0.28, 0.84 ]
Sawka 2012 4/37 8/37 2.5 % 0.50 [ 0.16, 1.52 ]
Murray 2001b 13/94 25/96 5.0 % 0.53 [ 0.29, 0.97 ]
Shorten 2005 14/99 20/93 4.9 % 0.66 [ 0.35, 1.22 ]
Schwartz 2009a 33/100 56/114 7.2 % 0.67 [ 0.48, 0.94 ]
Fagerlin 2011 171/383 67/102 8.3 % 0.68 [ 0.57, 0.81 ]
Mathers 2012 8/95 9/80 3.3 % 0.75 [ 0.30, 1.85 ]
Legare 2008a 16/44 18/41 5.7 % 0.83 [ 0.49, 1.40 ]
Bozic 2013 45/60 52/62 8.3 % 0.89 [ 0.75, 1.07 ]
Vandemheen 2009 13/70 16/78 4.7 % 0.91 [ 0.47, 1.75 ]
Berry 2013 14/120 12/107 4.2 % 1.04 [ 0.50, 2.15 ]
Allen 2010 34/291 36/334 6.3 % 1.08 [ 0.70, 1.69 ]
Arterburn 2011 10/75 8/77 3.4 % 1.28 [ 0.54, 3.07 ]
Stacey 2014a 20/66 9/66 4.3 % 2.22 [ 1.09, 4.51 ]
Total (95% CI) 2701 2555 100.0 % 0.64 [ 0.52, 0.79 ]
Total events: 478 (Decision Aid), 607 (Usual Care)
Heterogeneity: Tau2 = 0.13; Chi2 = 67.06, df = 21 (P<0.00001); I2 =69%
Test for overall effect: Z = 4.16 (P = 0.000031)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours decision aid Favours usual care
251Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.1. Comparison 7 Satisfaction, Outcome 1 Satisfaction with the choice - all studies.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 7 Satisfaction
Outcome: 1 Satisfaction with the choice - all studies
Study or subgroup Decision aid Usual care
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Barry 1997 104 75.89 (17.2) 117 73.9 (18) 1.99 [ -2.65, 6.63 ]
Bernstein 1998 61 73.1 (20.9) 48 77.7 (20.5) -4.60 [ -12.42, 3.22 ]
Chabrera 2015 61 95.7 (6.89) 61 79.3 (10.3) 16.40 [ 13.29, 19.51 ]
Hanson 2011 126 84.8 (15.19) 127 83.5 (16.19) 1.30 [ -2.57, 5.17 ]
Jibaja-Weiss 2011 43 93.5 (12) 38 92.5 (15) 1.00 [ -4.97, 6.97 ]
Laupacis 2006 54 73 (21.7) 56 61 (25.4) 12.00 [ 3.18, 20.82 ]
Montgomery 2007 212 85 (15) 209 80 (15) 5.00 [ 2.13, 7.87 ]
Morgan 2000 86 80 (26) 94 77.5 (26) 2.50 [ -5.10, 10.10 ]
Nassar 2007 86 87.9 (12.5) 84 84.2 (15) 3.70 [ -0.46, 7.86 ]
Ozanne 2007 15 82.5 (14.75) 15 80 (12.25) 2.50 [ -7.20, 12.20 ]
Smith 2010 357 80.25 (11) 173 80.25 (10.75) 0.0 [ -1.97, 1.97 ]
-100 -50 0 50 100
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Analysis 7.2. Comparison 7 Satisfaction, Outcome 2 Satisfaction with the choice - in consultation.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 7 Satisfaction
Outcome: 2 Satisfaction with the choice - in consultation
Study or subgroup Decision aid Usual care
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ozanne 2007 15 82.5 (14.75) 15 80 (12.25) 2.50 [ -7.20, 12.20 ]
-100 -50 0 50 100
Favours control Favours decision aid
Analysis 7.3. Comparison 7 Satisfaction, Outcome 3 Satisfaction with the choice - in preparation for
consultation.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 7 Satisfaction
Outcome: 3 Satisfaction with the choice - in preparation for consultation
Study or subgroup Decision aid Usual care
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Barry 1997 104 75.89 (17.2) 117 73.9 (18) 1.99 [ -2.65, 6.63 ]
Bernstein 1998 61 73.1 (20.9) 48 77.7 (20.5) -4.60 [ -12.42, 3.22 ]
Chabrera 2015 61 95.7 (6.89) 61 79.3 (10.3) 16.40 [ 13.29, 19.51 ]
Hanson 2011 126 15.25 (15.19) 127 16.5 (16.19) -1.25 [ -5.12, 2.62 ]
Jibaja-Weiss 2011 43 93.5 (12) 38 92.5 (15) 1.00 [ -4.97, 6.97 ]
Laupacis 2006 54 73 (21.7) 56 61 (25.4) 12.00 [ 3.18, 20.82 ]
Montgomery 2007 212 85 (15) 209 80 (15) 5.00 [ 2.13, 7.87 ]
Morgan 2000 86 80 (26) 94 77.5 (26) 2.50 [ -5.10, 10.10 ]
Nassar 2007 86 87.9 (12.5) 84 84.2 (15) 3.70 [ -0.46, 7.86 ]
Smith 2010 357 80.25 (11) 173 80.25 (10.75) 0.0 [ -1.97, 1.97 ]
-100 -50 0 50 100
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Analysis 7.4. Comparison 7 Satisfaction, Outcome 4 Satisfaction with the decision making process - all
studies.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 7 Satisfaction
Outcome: 4 Satisfaction with the decision making process - all studies
Study or subgroup Decision Aid Usual Care
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Barry 1997 104 76.38 (16.5) 117 71.07 (18.4) 5.31 [ 0.71, 9.91 ]
Bernstein 1998 61 73.1 (20.6) 48 76.5 (17.6) -3.40 [ -10.58, 3.78 ]
Bozic 2013 60 94.4 (10) 62 91.1 (14.4) 3.30 [ -1.09, 7.69 ]
Jibaja-Weiss 2011 43 94 (17) 38 92.5 (17) 1.50 [ -5.92, 8.92 ]
Knops 2014 74 74 (16) 80 73 (19) 1.00 [ -4.53, 6.53 ]
Kupke 2013 50 91.4 (12.5) 31 86.3 (18.6) 5.10 [ -2.31, 12.51 ]
Man-Son-Hing 1999 146 83.75 (14.79) 138 84.75 (13.04) -1.00 [ -4.24, 2.24 ]
Morgan 2000 86 72 (19.88) 94 70 (19.88) 2.00 [ -3.81, 7.81 ]
Schroy 2011 214 84.17 (10.33) 217 77.83 (13.17) 6.34 [ 4.11, 8.57 ]
-10 -5 0 5 10
Favours simple DA Favours detailed DA
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Analysis 7.5. Comparison 7 Satisfaction, Outcome 5 Satisfaction with the decision making process - in
consultation.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 7 Satisfaction
Outcome: 5 Satisfaction with the decision making process - in consultation
Study or subgroup Decision Aid Usual Care
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kupke 2013 50 91.4 (12.5) 31 86.3 (18.6) 5.10 [ -2.31, 12.51 ]
-10 -5 0 5 10
Favours simple DA Favours detailed DA
Analysis 7.6. Comparison 7 Satisfaction, Outcome 6 Satisfaction with the decision making process - in
preparation for consultation.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 7 Satisfaction
Outcome: 6 Satisfaction with the decision making process - in preparation for consultation
Study or subgroup Decision Aid Usual Care
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Barry 1997 104 76.38 (16.5) 117 71.07 (18.4) 5.31 [ 0.71, 9.91 ]
Bernstein 1998 61 73.1 (20.6) 48 76.5 (17.6) -3.40 [ -10.58, 3.78 ]
Bozic 2013 60 94.4 (10) 62 91.1 (14.4) 3.30 [ -1.09, 7.69 ]
Jibaja-Weiss 2011 43 94 (17) 38 92.5 (17) 1.50 [ -5.92, 8.92 ]
Knops 2014 74 74 (16) 80 73 (19) 1.00 [ -4.53, 6.53 ]
Man-Son-Hing 1999 146 83.75 (14.79) 138 84.75 (13.04) -1.00 [ -4.24, 2.24 ]
Morgan 2000 86 72 (19.88) 94 70 (19.88) 2.00 [ -3.81, 7.81 ]
Schroy 2011 214 84.17 (10.33) 217 77.83 (13.17) 6.34 [ 4.11, 8.57 ]
-10 -5 0 5 10
Favours simple DA Favours detailed DA
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Analysis 8.1. Comparison 8 Choice, Outcome 1 Choice: surgery over conservative option.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 8 Choice
Outcome: 1 Choice: surgery over conservative option
Study or subgroup Decision Aid Usual Care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Per-protocol analysis
Arterburn 2011 30/72 43/73 6.8 % 0.71 [ 0.51, 0.99 ]
Auvinen 2004 60/103 91/100 8.9 % 0.64 [ 0.54, 0.76 ]
Barry 1997 8/103 16/116 2.6 % 0.56 [ 0.25, 1.26 ]
Bernstein 1998 25/61 28/48 6.1 % 0.70 [ 0.48, 1.03 ]
Berry 2013 42/120 49/107 7.0 % 0.76 [ 0.56, 1.05 ]
Bozic 2013 38/61 43/62 7.8 % 0.90 [ 0.70, 1.16 ]
Jibaja-Weiss 2011 18/44 20/39 5.1 % 0.80 [ 0.50, 1.27 ]
Kennedy 2002 82/253 101/244 8.1 % 0.78 [ 0.62, 0.99 ]
Knops 2014 39/91 36/87 6.6 % 1.04 [ 0.73, 1.46 ]
Lam 2013 38/67 39/81 7.1 % 1.18 [ 0.87, 1.60 ]
Morgan 2000 45/86 63/95 7.9 % 0.79 [ 0.62, 1.01 ]
Murray 2001a 6/54 1/48 0.5 % 5.33 [ 0.67, 42.73 ]
Protheroe 2007 7/56 3/56 1.2 % 2.33 [ 0.64, 8.57 ]
Schwartz 2009a 18/64 15/114 3.8 % 2.14 [ 1.16, 3.95 ]
Stacey 2014a 55/69 48/68 8.6 % 1.13 [ 0.93, 1.37 ]
Vodermaier 2009 2/39 5/41 0.8 % 0.42 [ 0.09, 2.04 ]
Vuorma 2003 98/184 88/179 8.5 % 1.08 [ 0.89, 1.32 ]
Whelan 2004 6/94 26/107 2.4 % 0.26 [ 0.11, 0.61 ]
Subtotal (95% CI) 1621 1665 100.0 % 0.87 [ 0.75, 1.01 ]
Total events: 617 (Decision Aid), 715 (Usual Care)
Heterogeneity: Tau2 = 0.06; Chi2 = 55.99, df = 17 (P<0.00001); I2 =70%
0.1 0.2 0.5 1 2 5 10
Favours decision aid Favours usual care
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(. . . Continued)
Study or subgroup Decision Aid Usual Care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.79 (P = 0.074)
2 Intention-to-treat analysis
Arterburn 2011 30/75 43/77 6.8 % 0.72 [ 0.51, 1.01 ]
Auvinen 2004 60/104 91/106 9.4 % 0.67 [ 0.56, 0.81 ]
Barry 1997 8/104 16/123 2.4 % 0.59 [ 0.26, 1.33 ]
Bernstein 1998 25/65 28/53 5.9 % 0.73 [ 0.49, 1.09 ]
Berry 2013 42/266 49/228 6.3 % 0.73 [ 0.51, 1.07 ]
Bozic 2013 38/61 43/62 8.2 % 0.90 [ 0.70, 1.16 ]
Jibaja-Weiss 2011 18/51 20/49 4.7 % 0.86 [ 0.52, 1.43 ]
Kennedy 2002 82/300 101/298 8.4 % 0.81 [ 0.63, 1.03 ]
Knops 2014 39/91 36/87 6.7 % 1.04 [ 0.73, 1.46 ]
Lam 2013 38/67 39/81 7.3 % 1.18 [ 0.87, 1.60 ]
Morgan 2000 45/120 63/120 7.7 % 0.71 [ 0.54, 0.95 ]
Murray 2001a 6/57 1/55 0.5 % 5.79 [ 0.72, 46.54 ]
Protheroe 2007 7/72 3/72 1.1 % 2.33 [ 0.63, 8.67 ]
Schwartz 2009a 18/100 15/114 3.5 % 1.37 [ 0.73, 2.57 ]
Stacey 2014a 55/71 48/71 9.0 % 1.15 [ 0.93, 1.41 ]
Vodermaier 2009 2/39 5/41 0.8 % 0.42 [ 0.09, 2.04 ]
Vuorma 2003 98/184 88/179 9.1 % 1.08 [ 0.89, 1.32 ]
Whelan 2004 6/94 26/107 2.3 % 0.26 [ 0.11, 0.61 ]
Subtotal (95% CI) 1921 1923 100.0 % 0.86 [ 0.75, 1.00 ]
Total events: 617 (Decision Aid), 715 (Usual Care)
Heterogeneity: Tau2 = 0.05; Chi2 = 46.00, df = 17 (P = 0.00017); I2 =63%
Test for overall effect: Z = 2.00 (P = 0.046)
3 Per-protocol analysis without prophylactic mastectomy
Arterburn 2011 30/72 43/73 7.0 % 0.71 [ 0.51, 0.99 ]
Auvinen 2004 60/103 91/100 9.5 % 0.64 [ 0.54, 0.76 ]
Barry 1997 8/103 16/116 2.5 % 0.56 [ 0.25, 1.26 ]
Bernstein 1998 25/61 28/48 6.2 % 0.70 [ 0.48, 1.03 ]
Berry 2013 42/120 49/107 7.2 % 0.76 [ 0.56, 1.05 ]
Bozic 2013 38/61 43/62 8.2 % 0.90 [ 0.70, 1.16 ]
Jibaja-Weiss 2011 18/44 20/39 5.1 % 0.80 [ 0.50, 1.27 ]
Kennedy 2002 82/253 101/244 8.6 % 0.78 [ 0.62, 0.99 ]
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(. . . Continued)
Study or subgroup Decision Aid Usual Care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Knops 2014 39/91 36/87 6.8 % 1.04 [ 0.73, 1.46 ]
Lam 2013 38/67 39/81 7.4 % 1.18 [ 0.87, 1.60 ]
Morgan 2000 45/86 63/95 8.4 % 0.79 [ 0.62, 1.01 ]
Murray 2001a 6/54 1/48 0.5 % 5.33 [ 0.67, 42.73 ]
Protheroe 2007 7/56 3/56 1.1 % 2.33 [ 0.64, 8.57 ]
Stacey 2014a 55/69 48/68 9.2 % 1.13 [ 0.93, 1.37 ]
Vodermaier 2009 2/39 5/41 0.8 % 0.42 [ 0.09, 2.04 ]
Vuorma 2003 98/184 88/179 9.1 % 1.08 [ 0.89, 1.32 ]
Whelan 2004 6/94 26/107 2.3 % 0.26 [ 0.11, 0.61 ]
Subtotal (95% CI) 1557 1551 100.0 % 0.84 [ 0.73, 0.97 ]
Total events: 599 (Decision Aid), 700 (Usual Care)
Heterogeneity: Tau2 = 0.05; Chi2 = 47.70, df = 16 (P = 0.00005); I2 =66%
Test for overall effect: Z = 2.32 (P = 0.020)
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Analysis 8.2. Comparison 8 Choice, Outcome 2 Choice for screening.
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 8 Choice
Outcome: 2 Choice for screening
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 PSA screening
Allen 2010 225/291 264/334 19.0 % 0.98 [ 0.90, 1.06 ]
Evans 2010 4/127 11/123 0.8 % 0.35 [ 0.12, 1.08 ]
Gattellari 2003 27/106 25/108 4.0 % 1.10 [ 0.69, 1.77 ]
Gattellari 2005 37/131 42/136 5.8 % 0.91 [ 0.63, 1.33 ]
Krist 2007 163/196 64/75 17.3 % 0.97 [ 0.87, 1.09 ]
Lepore 2012 97/215 99/216 11.7 % 0.98 [ 0.80, 1.21 ]
Partin 2004 83/308 87/290 9.5 % 0.90 [ 0.70, 1.16 ]
Volk 1999 48/78 64/80 11.7 % 0.77 [ 0.63, 0.95 ]
Watson 2006 119/465 149/512 11.8 % 0.88 [ 0.72, 1.08 ]
Wolf 1996 40/103 68/102 8.5 % 0.58 [ 0.44, 0.77 ]
Subtotal (95% CI) 2020 1976 100.0 % 0.88 [ 0.80, 0.98 ]
Total events: 843 (Experimental), 873 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 21.43, df = 9 (P = 0.01); I2 =58%
Test for overall effect: Z = 2.30 (P = 0.021)
2 Colorectal cancer screening
Dolan 2002 2/45 7/43 1.0 % 0.27 [ 0.06, 1.24 ]
Lewis 2010 71/207 70/226 10.6 % 1.11 [ 0.84, 1.45 ]
Miller 2011 25/132 18/132 5.3 % 1.39 [ 0.80, 2.42 ]
Pignone 2000 46/124 28/124 7.8 % 1.64 [ 1.10, 2.45 ]
Ruffin 2007 56/87 33/87 9.6 % 1.70 [ 1.24, 2.32 ]
Schroy 2011 116/269 96/276 12.0 % 1.24 [ 1.00, 1.53 ]
Smith 2010 211/357 130/173 14.0 % 0.79 [ 0.70, 0.89 ]
Steckelberg 2011 141/785 134/792 11.9 % 1.06 [ 0.86, 1.32 ]
Trevena 2008 117/134 124/137 14.7 % 0.96 [ 0.89, 1.05 ]
Wolf 2000 173/266 79/133 13.1 % 1.09 [ 0.93, 1.29 ]
Subtotal (95% CI) 2406 2123 100.0 % 1.12 [ 0.95, 1.31 ]
0.2 0.5 1 2 5
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(. . . Continued)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 958 (Experimental), 719 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 48.11, df = 9 (P<0.00001); I2 =81%
Test for overall effect: Z = 1.37 (P = 0.17)
3 Breast cancer genetic testing
Green 2001 13/29 16/42 21.9 % 1.18 [ 0.67, 2.06 ]
Lerman 1997 74/122 87/164 46.0 % 1.14 [ 0.93, 1.40 ]
Schwartz 2001 35/191 49/190 32.1 % 0.71 [ 0.48, 1.04 ]
Subtotal (95% CI) 342 396 100.0 % 0.99 [ 0.71, 1.38 ]
Total events: 122 (Experimental), 152 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 5.15, df = 2 (P = 0.08); I2 =61%
Test for overall effect: Z = 0.07 (P = 0.94)
4 Prenatal diagnostic testing
Bjorklund 2012 92/184 111/206 21.8 % 0.93 [ 0.77, 1.12 ]
Kuppermann 2014 244/357 238/353 78.2 % 1.01 [ 0.92, 1.12 ]
Subtotal (95% CI) 541 559 100.0 % 0.99 [ 0.91, 1.09 ]
Total events: 336 (Experimental), 349 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
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Analysis 8.3. Comparison 8 Choice, Outcome 3 Choice: diabetes medication (uptake new medication).
Review: Decision aids for people facing health treatment or screening decisions
Comparison: 8 Choice
Outcome: 3 Choice: diabetes medication (uptake new medication)
Study or subgroup Decision Aid Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Mann D 2010 9/80 3/70 12.1 % 2.63 [ 0.74, 9.32 ]
Mathers 2012 17/92 9/78 34.6 % 1.60 [ 0.76, 3.39 ]
Mullan 2009 16/48 8/37 36.2 % 1.54 [ 0.74, 3.21 ]
Weymiller 2007 7/23 4/19 17.1 % 1.45 [ 0.50, 4.20 ]
Total (95% CI) 243 204 100.0 % 1.65 [ 1.06, 2.56 ]
Total events: 49 (Decision Aid), 24 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.62, df = 3 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.22 (P = 0.026)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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A D D I T I O N A L T A B L E S
Table 1. Decision aids evaluated in the trials
Study Topic Availability Source Contact Information
Allen 2010 Prostate cancer screening No Allen,
Center for Community-
Based Research, Dana-
Farber Cancer Institute,
Boston, MA, USA, 2010
Requested access
Arterburn 2011 Bariatric surgery Yes Informed Medical Deci-
sions Foundation, MA,
USA, 2010
informedmedicaldecisions.org/
imdf˙decision˙aid/
making-decisions-about-
weight-loss-surgery/
Auvinen 2004 Prostate cancer
treatment
Yes Auvinen, Helsinki, Fin-
land, 1993
Included in publication
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Table 1. Decision aids evaluated in the trials (Continued)
Barry 1997 Benign prostate disease
treatment
Yes Informed Medical Deci-
sions Foundation, MA,
USA, 2001
informedmedicaldecisions.org/
imdf˙decision˙aid/
treatment-options-
for-benign-prostatic-
hyperplasia/
Bekker 2004 Prenatal screening Yes Bekker, Leeds, UK, 2003 Included in publication
Bernstein 1998 Ischaemic heart disease
treatment
Yes Informed Medical Deci-
sions Foundation, MA,
USA, 2002
informedmedicaldecisions.org/
imdf˙decision˙aid/
treatment-choices-for-
carotid-artery-disease/
Berry 2013 Prostate cancer
treatment
No Berry, Phyllis F. Cantor
Center, MA, USA, 2011
donna berry@dfci.
harvard.edu
Bjorklund 2012 Antenatal Down syn-
drome screening
Yes Södersjukhuset, Depart-
ment of Obstetrics and
Gynecology, Stockholm,
Sweden
vimeo.com/34600615/
Bozic 2013 Osteoarthritis of the
knee or hip
No Informed Medical De-
cisions Foundation and
Health Dialog; USA
www.healthdialog.com
Brazell 2014 Pelvic Organ Prolapse Yes Healthwise, USA decisionaid.ohri.ca
Chabrera 2015 Prostate cancer
treatment
No C Chabrera. School of
Health Sciences, Depart-
ment of Nursing. Mataro,
Spain
cchabrera@tecnocampus.
cat
Chambers 2012 Healthcare personnel’s
influenza immunization
Yes A McCarthy. Ottawa In-
fluenza Decision
Aid Planning Group, CA,
2008
decisionaid.ohri.ca/
decaids.html#oida
Clancy 1988 Hepatitis B Vaccine No Clancy, Richmond VA,
USA, 1983
-
Davison 1997 Prostate cancer
treatment
No Davison, Manitoba CA,
1992-1996
-
De Achaval 2012 Total
knee arthroplasty treat-
ment
Yes Informed Medical Deci-
sions Foundation, MA,
USA
informedmedicaldecisions.org/
imdf˙decision˙aid/
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Table 1. Decision aids evaluated in the trials (Continued)
treatment-choices-for-
knee-osteoarthritis/
Dolan 2002 Colon cancer screening No Dolan, Rochester NY,
USA, 1999
-
Evans 2010 Prostate cancer screening Yes Elwyn, Cardiff, UK www.prosdex.com
Fagerlin 2011 Breast cancer prevention Yes Fagerlin, Ann Arbor, MI,
USA
-
Fraenkel 2007 Osteoarthritis knee treat-
ment
No Fraenkel, New Haven
CT, USA
Author said DA never
fully developed, all info in
paper
Fraenkel 2012 Atrial fibrillation No Vet-
erans Affairs Connecticut
Healthcare System, USA
Obtained from author
terri.fried@yale.edu
Frosch 2008a Prostate cancer screening No Frosch, Los Angeles, USA Screenshots from author
Gattellari 2003 Prostate cancer screening Yes Gatellari, Sydney, AU,
2003
included in publication
Gattellari 2005 Prostate cancer screening Yes Gatellari, Sydney, AU,
2003
Included in publication
Green 2001 Breast cancer genetic
testing
Yes Green,Hershey PA,USA,
2000
1-800-757-4868
dwc@mavc.com
Hamann 2006 Schizophrenia treatment Yes Hamann, Munich, GER Emailed by author (in
German)
Hanson 2011 Feeding options in ad-
vanced
dementia
Yes Mitchell,
Tetroe, O’Connor; 2001
(updated 2008)
decisionaid.ohri.ca/
decaids.html#feedingtube
Heller 2008 Breast reconstruction Yes University of Texas MD
Anderson Cancer Center,
Houston TX, USA, 2003
Disc mailed
Hess 2012 Stress testing for chest
pain
Yes Hess, Rochester, MN,
USA, 2012
Included in publication
Jibaja-Weiss 2011 Breast cancer treatment Yes Jibaja-Weiss, Baylor Col-
lege of Medicine, 2010
www.bcm.edu/
patchworkoflife
Johnson 2006 Endodontic treatment Yes Johnson, Chicago, USA,
2004
Included in publication
263Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Decision aids evaluated in the trials (Continued)
Kasper 2008 Multiple sclerosis No Jürgen Kasper -
Kennedy 2002 Abnormal uterine bleed-
ing treatment
No Kennedy/Coulter,
London UK, 1996
-
Knops 2014 Asymptomatic Abdom-
inal Aortic Aneurysm
treatment
Yes Amsterdam, The Nether-
lands
www.keuzehulp.info/
amc/AAA/landing-page
Krist 2007 Prostate cancer screening Yes Krist, Fairfax VA, USA
www.familymedicine.vcu.edu/
research/misc/psa/
index.html
Kupke 2013 Dental - posterior tooth
decay
Yes University of Cologne,
Cologne, Germany
jana.kupke@uk-koeln.de
Kuppermann 2014 Prenatal screening No Kuppermann, San Fran-
cisco CA, USA
Interactive web-based de-
cision aid
Lam 2013 Breast cancer treatment Yes Kwong Wah Hospital,
Hong Kong, China
Obtained from author.
wwtlam@hku.hk
Langston 2010 Contraceptive method
choice
Yes World Health Organiza-
tion, 2005
www.who.int/
reproductivehealth/
publications/
family˙planning/
9241593229index/en/
index.html
Laupacis 2006 Pre-operative autologous
blood donation
No Laupacis, Ottawa, CA,
2001
Decisionaid.ohri.ca/
decaids-archive.html
LeBlanc 2015 Treatment for osteoporo-
sis
Yes Mayo Clinic -
Legare 2008a Natural health products No Legare, Quebec City, CA,
2006
-
Legare 2011 Use of antibiotics for
acute
respiratory infections
Yes Legare, Quebec City, CA,
2007 www.decision.chaire.fmed.ulaval.ca/
index.php?id=192&L=2
Legare 2012 Antibiotics for acute res-
piratory infections
Yes Legare, Quebec City, CA
www.decision.chaire.fmed.ulaval.ca/
index.php?
Leighl 2011 Advanced colorectal can-
cer chemotherapy
Yes Princess Margaret Hospi-
tal, Toronto, 2011
Natasha.Leighl@uhn.on.
ca
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Table 1. Decision aids evaluated in the trials (Continued)
Lepore 2012 Prostate cancer screening Yes Sally Weinrich University
of Louisville, USA
Obtained from author
slepore@temple.edu
Lerman 1997 Breast cancer genetic
testing
No Lerman/Schwartz, Wash-
ington DC, USA, 1997
-
Lewis 2010 Colorectal cancer
screening
Yes Lewis,
University of North Car-
olina, Chapel Hill, NC,
USA, 2010
decisionsupport.unc.edu/
CHOICE6/
Loh 2007 Depression treatment Yes Loh, Freiburg, GER Emailed to us by author -
in German
Man-Son-Hing 1999 Atrial fibrillation treat-
ment
No McAlister/Laupacis, Ot-
tawa CA, 2000
decisionaid.ohri.ca/
decaids-archive.html
Mann D 2010 Diabetes treatment -
statins
Yes Montori, Rochester MN,
USA
mayoresearch.mayo.edu/
mayo/research/ker˙unit/
form.cfm
Mann E 2010 Diabetes
screening
Yes Marteau, King’s College
London, London, Eng-
land, 2010
Additional file 2 of publi-
cation
Marteau 2010 Diabetes
screening
Yes Marteau, King’s College
London, London, Eng-
land, 2010
Provided by author, same
DA as Mann E 2010
Mathieu 2007 Mammography Yes Mathieu, Sydney, AU DA emailed by author
Mathers 2012 Diabetes treatment Yes The Univer-
sity of Sheffield, Sheffield,
UK, 2008
Obtained from author
C.Ng@sheffield.ac.uk
Mathieu 2010 Mammography Yes Mathieu, University of
Sydney, AUS, 2010
www.psych.usyd.edu.au/
cemped/
com˙decision˙aids.shtml
McAlister 2005 Atrial fibrillation treat-
ment
No McAlister/Laupacis, Ot-
tawa CAN, 2000
decisionaid.ohri.ca/
decaids-archive.html
McBride 2002 Hormone replacement
therapy
Yes, update in progress Sigler/Bastien, Durham
NC, USA, 1998
basti001@mc.duke.edu
McCaffery 2010 Screening after mildly
abnormal pap smear
Yes Screening & test evalua-
tion program, School of
public health, University
of Sydney 2007
kirstenm@health.usyd.
edu.au
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Table 1. Decision aids evaluated in the trials (Continued)
Miller 2005 BRCA1/BRCA2 gene
testing
No Miller, Fox Chase PA,
USA
-
Miller 2011 Colorectal
cancer screening
Yes University of North Car-
olina, Chapel Hill, NC,
USA, 2007
intmedweb.wakehealth.edu/
choice/choice.html (no
longer available)
Montgomery 2003 Hypertension treatment No Montgomery, UK, 2000 -
Montgomery 2007 Birthing options after
caesarean
Yes Montgomery, Bristol,
UK, last update 2004 www.computing.dundee.ac.uk/
acstaff/cjones/diamond/
Information.html
Montori 2011 Osteoporosis treatment Yes Montori, Mayo Founda-
tion for Medical Educa-
tion and Research, 2007
shareddecisions.mayoclinic.org/
decision-aids-for-
diabetes/other-decision-
aids/
Morgan 2000 Ischaemic heart disease
treatment
Yes Informed Medical Deci-
sions Foundation, MA,
USA, 2002
informedmedicaldecisions.org/
imdf˙decision˙aid/
treatment-choices-for-
carotid-artery-disease/
Mott 2014 PTSD treatment Yes Michael E DeBakey Vet-
erans Affairs Medical
Center, Houston, USA
Obtained from author
juliette.mott@va.gov
Mullan 2009 Diabetes treatment Yes Montori or Mayo Foun-
dation(?) Rochester MN,
USA,
Included in publication
Murray 2001a Benign prostate disease
treatment
Yes Informed Medical Deci-
sions Foundation, MA,
USA, 2001
informedmedicaldecisions.org/
imdf˙decision˙aid/
treatment-options-
for-benign-prostatic-
hyperplasia/
Murray 2001b Hormone replacement
therapy
No, update in progress Informed Medical Deci-
sions Foundation, MA,
USA
informedmedicaldecisions.org/
imdf˙decision˙aid/
treatment-choices-for-
managing-menopause/
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Table 1. Decision aids evaluated in the trials (Continued)
Nagle 2008 Prenatal screening Yes Nagle, Victoria, AU www.mcri.edu.au/
Downloads/
PrenatalTestingDecisionAid.pdf
Nassar 2007 Birth breech presenta-
tion
Yes Nassar, West Perth WA,
AU
sydney.edu.au/medicine/
public-health/shdg/
resources/
decision˙aids.php
Oakley 2006 Osteoporosis treatment No Cranney, Ottawa CA,
2002
decisionaid.ohri.ca/
decaids-archive.html
Ozanne 2007 Breast cancer prevention No Ozanne, Boston MA,
USA
-
Partin 2004 Prostate cancer screening Yes Informed Medical Deci-
sions Foundation, MA,
USA, 2001
informedmedicaldecisions.org/
imdf˙decision˙aid/
deciding-if-the-psa-test-
is-right-for-you/
Pignone 2000 Colon cancer screening Yes Pignone, Chapel Hill
NC, USA, 1999
www.med.unc.edu/
medicine/edusrc/
colon.htm
Protheroe 2007 Menorrhagia treatment No Protheroe, Manchester,
UK
Computer-
ized decision aid, Clinical
Guidance Tree - no longer
in existence, author sent
chapter in thesis
Rubel 2010 Prostate cancer screening No Centers for Disease Con-
trol and Prevention
(CDC), USA, 2010
No longer available
Ruffin 2007 Colorectal cancer screen-
ing
Yes Regents of the Univer-
sity of Michigan (copy-
right info), Ann Arbor
MI, USA, 2006
colorectalweb.org
Sawka 2012 Adjuvant radioactive io-
dine treatment for pa-
tients with early-stage
papillary thyroid cancer
No University Health Net-
work, Toronto, Canada,
2009
-
Schroy 2011 Colorectal
cancer screening
Yes Schroy III, Boston, USA Paul.schroy@bmc.org
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Table 1. Decision aids evaluated in the trials (Continued)
Schwalm 2012 Coronary angiogram ac-
cess site
Yes Schwalm, Hamilton,
ON, Canada, 2009
www.phri.ca/workfiles/
studies/presentations/
PtDA%20Vascular%20Access%2023-
May−2012.pdf
Schwartz 2001 Breast cancer genetic
testing
No Schwartz/Lerman, Wash-
ington DC, USA, 1997
-
Schwartz 2009a BRCAmutation prophy-
lactic surgery
No Schwartz, Washington
DC, USA
-
Sheridan 2006 Cardiovascular preven-
tion
Yes Sheridan, Chapel Hill,
NC, USA
www.med-
decisions.com/cvtool/
Sheridan 2011 Coronary heart
disease prevention
Yes Sheridan, University of
North Carolina at Chapel
Hill, Division of General
Internal Medicine, North
Carolina, USA, 2011
www.med-
decisions.com/h2hv3/
Shorten 2005 Birthing options after
previous caesarean
Yes (updated 2006) Shorten, Wollongong,
AU, 2000
ashorten@uow.edu.au or
www.capersbookstore.com.au/
product.asp?id=301
Shourie 2013 Measles mumps and
rubella vaccination
Yes University of Leeds, UK
& NSIRS Australia
www.leedsmmr.co.uk
Smith 2010 Bowel
cancer screening
Yes Smith, Sydney, AU 2008 sydney.edu.au/medicine/
public-health/shdg/
resources/
decision˙aids.php
Stacey 2014a Osteoarthritis of the hip
and knee
No Informed Medical De-
cisions Foundation and
Health Dialog; USA
www.healthdialog.com
Steckelberg 2011 Colorectal cancer screen-
ing
Yes Steckelberg, Hamburg,
Germany
-
Taylor 2006 Prostate cancer screening Yes George-
town University Medical
Center, Washington DC,
USA, 2000
Obtained from author
taylorkl@georgetown.
edu
Thomson 2007 Atrial fibrillation treat-
ment
Yes Thomson, Newcastle
Upon Thyne, UK
Disc sent by mail
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Table 1. Decision aids evaluated in the trials (Continued)
Trevena 2008 Colorectal cancer screen Yes Trevena, Sydney, AU sydney.edu.au/medicine/
public-health/shdg/
resources/
decision˙aids.php
Van Peperstraten 2010 Embryos transplant Yes Radboud University Ni-
jmegen Medical Centre;
2006
www.umcn.nl/ivfda-en
Vandemheen 2009 Cystic Fibrosis referral
transplant
Yes Aaron, Ottawa ON, CA,
2009 (last update 2011)
decisionaid.ohri.ca/
decaids.html#cfda
Vodermaier 2009 Breast cancer surgery Yes Vodermaier, Vancouver
BC, CA
Received by email (in
German)
Volk 1999 Prostate cancer screening Yes Informed Medical Deci-
sions Foundation, MA,
USA, 1999
informedmedicaldecisions.org/
imdf˙decision˙aid/
deciding-if-the-psa-test-
is-right-for-you/
Vuorma 2003 Menorrhagia treatment No Vuorma, Helsinki Fin-
land, 1996
-
Watson 2006 Prostate cancer screening Yes Oxford, UK Included in publication
Weymiller 2007 Diabetes mellitus type 2
treatment
Yes Montori, Rochester MN,
USA
mayoresearch.mayo.edu/
mayo/research/ker˙unit/
form.cfm
Williams 2013 Prostate cancer screening Yes Georgetown University,
Washington, DC, USA
Obtained from author
taylorkl@georgetown.
edu
Whelan 2003 Breast cancer chemo-
therapy
Yes Whelan, Hamilton CA,
1995
Included in publication
Whelan 2004 Breast cancer surgery Yes Whelan, Hamilton CA,
1997
Included in publication
Wolf 1996 Prostate cancer screening Yes Wolf, Charlottesville VA,
USA, 1996
Script in publication
Wolf 2000 Colon cancer screening Yes Wolf, Charlottesville VA,
USA, 2000
Script in publication
Wong 2006 Pregnancy termination No Bekker, Leeds, UK, 2002 -
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Table 2. Knowledge
Study Scale used Timing N decision
aid
Decision aid -
mean
N
comparison
Comparison -
mean
Notes
Bozic 2013 Decision qual-
ity in-
strument, 19
items re
knowledge (>
50%)
After 1st con-
sultation with
surgeon
60 58.3% 60 33.3% P = 0.01
Evans 2010 12 true or false
questions;
scores ranging
from −12 to
12
Immediately
post
89 4.9 103 2.17 P < 0.001
Fagerlin 2011 Insuffi-
cient (≤ 50%
correct)
Immediately
post
383 31.8% 102 93.1% P < 0.001
Sufficient Immediately
post
383 61.9% 102 6.9% -
Fraenkel 2012 Open-ended
questions
about medica-
tion options to
reduce stroke
- knows medi-
cations
Postinterven-
tion
66 61% 62 31% OR 3.5 (95%
CI: 1.6 to 7.7,
P = 0.001)
Open-ended
questions
about side ef-
fects of medi-
cations -
knows side ef-
fects
Postinterven-
tion
53 49% 46 37% OR 1.
9 (95%CI: 0.9
to 4.0; P = 0.
07)
Hamann
2006
7-
item multiple
choice knowl-
edge
test (unable to
standardize re-
sults)
On discharge
(~ 1 month)
49 15 (4.4 SD) 58 10.9 (5.4 SD) P = 0.01
Heller 2008 12-item mul-
tiple choice
Pre-
operatively
66 14%* 67 8%* *mean
increase from
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Table 2. Knowledge (Continued)
baseline
P = 0.02
LeBlanc 2015
(in consulta-
tion)
13-item ques-
tionnaire (me-
dian, IQR) to-
tal score
Immediately
post
32 7 (4.5 to 9.0) 45 5.5 (2.5 to 8.
0)
P = 0.11
9-
items knowl-
edge based on
decision aid
Immediately
post
32 6 (3.5 to 6.5) 45 4 (2.0 to 8.0) P = 0.01
Legare 2008a 10-item yes/
no/
unsure general
knowledge
test about nat-
ural health
products (not
specific to out-
comes of op-
tions)
Change scores
from baseline
to 2 weeks
43 0.86 ± 1.77
P = 0.002
41 0.51 ± 1.47 P
= 0.031
No difference
between
groups (P = 0.
162)
Mann D 2010
(in consulta-
tion)
14-item
survey
Immediately
post
- - - - No differ-
ence in level of
knowledge be-
tween groups
Mathers 2012 Correctly an-
swers question
about best op-
tion to lower
blood sugar
6 months
postinterven-
tion
95 51.6% 80 28.8% P < 0.001
Correctly an-
swers question
about best op-
tion to lower
complications
6 months
postinterven-
tion
95 31.0% 80 29% P = 0.90
Mathieu 2007 9-item - 4 con-
cept questions
and 5 numeric
questions
- 351 - 357 - Signif-
icantly higher
mean increase
for the inter-
vention group
(2.62 ) com-
pared to con-
trol group (0.
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Table 2. Knowledge (Continued)
68) from base-
line, P < 0.001
Miller 2005 8-item survey 2-week, 2-
month, and 6-
month follow-
ups
- - - - Interven-
tion type had
no impact on
gen-
eral or specific
knowledge
Nagle 2008 Good level
knowledge
was
scored higher
than the mid
point of
the knowledge
scale (greater
than 4)
- - - - - 88% (147/
167) in DA
group com-
pared to 72%
(123/171)
pamphlet
group. OR 3.
43 (95% CI 1.
79 to 6.58)
Ozanne 2007
(in consulta-
tion)
Change
in knowledge
from baseline
Post-test 15 48% to 64% 15 45% to 57% change
in knowledge
score was sig-
nificant for de-
cision aid (P =
0.01) but not
control (P = 0.
13)
Partin 2004 10-item
knowledge in-
dex score
2 weeks 308 7.44 290 6.9 P = 0.001
Rubel 2010 24-
items adapted
from existing
prostate can-
cer knowledge
measures
Immediately
post
100 - 100 - The to-
tal mean stan-
dardized
knowl-
edge score was
84.38 (SD 12.
38)
Trevena 2008 Ad-
equate knowl-
edge (positive
score: under-
standing ben-
efits/harms)
1 month 134 28/134 137 8/137 P = 0.0001
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Table 2. Knowledge (Continued)
Watson 2006 12-item true/
false/don’t
know
Post-test 468 75% (range 0
to 100)
522 25% (range 0
to 100)
P < 0.0001
Weymiller
2007 (in con-
sultation)
14-item - 9 ad-
dressed by de-
cision aid; 5
were not
Immediately
post
52 46 - Mean differ-
ence between
groups 2.
4 (95% CI 1.5
to 3.3) P < 0.
05 (when de-
cision aid ad-
min-
istered during
the consulta-
tion only - not
if prior to the
consultation)
CI: confidence interval; DA: decision aid; OR: odds ratio; SD: standard deviation.
Table 3. Accurate risk perceptions
Study Scale used Timing N decision
aid
Decision aid -
mean
N
comparison
Comparison -
mean
Notes
Fraenkel 2012 Accuracy of
stroke risk
(reported
by taking the
absolute value
of the differ-
ence between
the partic-
ipant’s risk as
es-
timated by the
DA and the
estimate pro-
vided by the
par-
ticipant - out
of 100; lower
score indicates
more accurate
estimation of
risk)
Postinterven-
tion
69 9.1 (SD 13.3) 66 14.2 (SD 13) P = 0.002
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Table 3. Accurate risk perceptions (Continued)
Accuracy of
bleeding risk
(reported
same as above)
Postinterven-
tion
69 8.7 (SD 12.5) 66 13.1 (SD 12.
2)
P = 0.004
Hanson 2011 Expectation of
benefit index
11 items score
from 1 to 4
with
lower score in-
dicating better
knowledge
Post (after re-
viewing DA)
127 2.3 129 2.6 P = 0.001
Kuppermann
2014
Correct es-
timate of am-
niocente-
sis miscarriage
risk
3-6 months
postinterven-
tion
357 263 (73.8%) 353 208 (59.0%) P < 0.001
Correct esti-
mate of Down
syndrome risk
3-6 months
postinterven-
tion
357 210 (58.7%) 353 163 (46.1%) P = 0.001
Mann E 2010 3 of 8multiple
choice items
in the knowl-
edge test
(question 4, 5,
7)
2 weeks post - - - - Total knowl-
edge reported
only
Mathieu 2010 5 item numer-
ical questions
(max = 5)
Post 113 3.02 189 2.45 P < 0.001
Miller 2005 - 2-week, 2-
month, and 6-
month follow-
ups
- - - - Intervention
type had no
impact on risk
perceptions
Smith 2010 8 numer-
ical questions
(max = 8)
- 357 2.93 (SD 2.
91)
173 0.58 (SD 1.
28)
P < 0.001
Weymiller
2007 (in con-
sultation)
- Immediately 52 - 46 - Difference be-
tween group
OR
22.4 (95% CI
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Table 3. Accurate risk perceptions (Continued)
5.9 to 85.8)
when decision
aid admin-
istered during
the consulta-
tion only (not
if prior to)
OR 6.7 (95%
CI 2.2 to 19.
7)
when the de-
cision aid ad-
min-
istered prior to
or during the
consultation
CI: confidence interval; DA: decision aid; OR: odds ratio; SD: standard deviation.
Table 4. Values congruent with chosen option
Study Scale used Timing N decision
aid
Decision aid -
mean
N
comparison
Comparison -
mean
Notes
Arterburn
2011
Percent match
procedures de-
scribed by
Sepucha et al
(2007; 2008).
For val-
ues items were
most predic-
tive and used
to specify lo-
gis-
tic models to
estimate pre-
dicted proba-
bility of select-
ing surgery >
0.5
Postinterven-
tion
75 - 77 - The interven-
tion group ex-
pe-
rienced amore
rapid early im-
provement in
value concor-
dance imme-
diately
after the inter-
vention com-
pared to con-
trol
Berry 2013 Con-
cordant when
men reported:
a) sexual func-
tion influ-
enced decision
6 months
postinterven-
tion
239 - 209 - No difference
OR = 0.82;
95% CI 0.56
to 1.2
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Table 4. Values congruent with chosen option (Continued)
and they had
radiation ther-
apy; b) bowel
function in-
fluenced deci-
sion and they
had surgery; c)
all effects in-
fluenced deci-
sion and they
had
surveillance
Frosch 2008a Concordance
between par-
ticipant’s pref-
erences
and values for
potential out-
comes related
to the decision
and the choice
made
within weeks 155 - 151 - Men assigned
to the decision
aid who chose
not to have a
PSA test rated
their concern
about prostate
cancer
lower than did
men who re-
quested a PSA
test. Men as-
signed to usual
care provided
similar ratings
of concern
about prostate
cancer regard-
less of
their PSA de-
cision. There
was no statis-
tically signifi-
cant difference
between
groups
Legare 2008a - - - - - - Women valu-
ing
of non-chem-
ical aspect of
natural health
products was
positively as-
sociated with
their choice of
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Table 4. Values congruent with chosen option (Continued)
nature health
products, P =
0.006. No dif-
ference be-
tween groups
Lerman 1997 Association
between val-
ues and choice
- - - - - No difference;
between-
group differ-
ences were not
reported
Vandemheen
2009
Congru-
ence between
personal val-
ues and deci-
sion
3 weeks 70 - 70 - Patient
choices were
consis-
tent with their
values across
both random-
ized groups
DA: decision aid; SD: standard deviation.
Table 5. Decisional Conflict Score
Study Scale used Timing N decision
aid
Decision aid -
mean
N
comparison
Comparison -
mean
Notes
Arterburn
2011
Total de-
cisional con-
flict- change
from base-
line (standard-
ised values)
Immediately
post
75 Mean−20SD
19.44
77 Mean −11.8
SD 22.83
P = 0.03
Berry 2013 Decisional
conflict scale
Uncertainty - −3.61 units - - P = 0.04
Uninformed - - - - No significant
difference
Unclear values - −3.57 units - - P = 0.002
Unsupported - - - - No significant
difference
Ineffective de-
cision
- - - - No significant
difference
Total - −1.75 units - - P = 0.07
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Table 5. Decisional Conflict Score (Continued)
Fagerlin 2011 Decisional
conflict scale
Immediately
post
- - - - DCS
was higher in
the inter-
vention group
compared to
control, P < 0.
001
Frosch 2008a Decisional
conflict - sub-
scales only
Feeling unin-
formed
155 23.37 151 29.68 P < 0.05
Feeling
unclear values
155 32.25 151 37.93 P < 0.05
Feeling
supported
155 30.51 151 35.21 P < 0.05
Feeling uncer-
tain
155 - 151 - No difference
Effective deci-
sions
155 - 151 - No difference
Knops 2014 Deci-
sional conflict
(total score)
4 months 73 19 SD 14 81 22 SD 17 No difference
10 months 73 21 SD 17 81 18 SD 17 No difference
Krist 2007 Decisional
conflict
Immedi-
ately after of-
fice visit
196 1.54 75 1.58 No difference
LeBlanc 2015
(in consult)
Decision con-
flict (overall)
median, IQR
Immediately
post
28 10.9 (95% CI
1.6 to 26.6)
36 22.7 (95% CI
7.8 to 28.5)
P = 0.18
Informed sub-
scale
Immediately
post
28 4.2 (95% CI 0
to 25)
36 20.8 (95% CI
0 to 33.3)
P = 0.14
Values
subscale
Immediately
post
28 16.7 (95% CI
0 to 25)
36 25.0 (95% CI
8.3 to 33.3)
P = 0.25
Support sub-
scale
Immediately
post
28 8.3 (95% CI 0
to 25)
36 16.7 (95% CI
0 to 25)
P = 0.35
Certainty sub-
scale
Immediately
post
28 8.3 (95% CI 0
to 25)
36 25 (95% CI 0
to 25)
P = 0.3
Effectiveness
subscale
Immediately
post
28 12.5 (95% CI
0 to 25)
36 18.8 (95% CI
0 to 25)
P = 0.15
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Table 5. Decisional Conflict Score (Continued)
Legare 2012
(in consult)
De-
cisional con-
flict - propor-
tion who had
a value of 2.5
or more on the
1−5 DCS. (n,
%)
Immediately
post
163 4.6% (95%
CI 2.6 to 7.4)
165 6.3% (95%
CI 0 to 12.8)
Absolute
difference 1.7;
RR 0.8 (95%
CI 0.2 to 2.4)
Leighl 2011 Decisional
conflict scale
median
(range)
1-2
weeks postin-
tervention
107 26 (range 0-
79)
100 26 (range 0-
67)
No difference
Mathieu 2010 Based on ap-
proaches sug-
gested
by Marteau et
al. (informed
choice)
Immediately
after interven-
tion
91 71% 110 64% P = 0.24
Ozanne 2007
(in consult)
Decisional
conflict
Postconsulta-
tion
15 - 15 - Both groups
showed lower
de-
cisional con-
flict postcon-
sultation (P <
0.001) but no
difference be-
tween groups
Rubel 2010 Decisional
conflict
Immediately
post
- - - - The to-
tal mean score
was 24.5 with
a SD of 15.25
(N = 200)
Schwartz
2009a
Decisional
conflict
12 of 16 items
of the original
scale
- - - - Sig-
nificant longi-
tudinal im-
pact of the de-
cision aid was
moderated by
baseline deci-
sion status; de-
ci-
sion aid led to
significant de-
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Table 5. Decisional Conflict Score (Continued)
creases in de-
cisional con-
flict for those
who were un-
decided at the
time of ran-
domisation
Thomson
2007 (in con-
sult)
Decisional
conflict
Postconsulta-
tion
53 - 56 - Difference be-
tween de-
cision aid and
control group
were −0.18
(95% CI −0.
34 to −0.01).
P = 0.036
3-months post 51 - 55 - Difference be-
tween de-
cision aid and
control group
were −0.15
(95% CI −0.
37 to 0.06), no
significant dif-
ference
Van
Peperstraten
2010
15 item ques-
tionnaire (1-
5)
- satisfaction-
uncertainty
Postinterven-
tion, pre IVF
124 72.5 128 75 P = 0.76
15 item ques-
tionnaire (1-
5) - informed
(includes
some items
from DCS)
Postinterven-
tion, pre IVF
124 77.5 128 87.5 P = 0.001
Weymiller
2007 (in con-
sult)
Decisional
conflict
Immediately
post
52 - 46 - Mean
difference in-
dicates statis-
tically signif-
icantly lower
de-
cisional con-
flict for deci-
sion aid com-
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Table 5. Decisional Conflict Score (Continued)
pared to usual
care
Total DCS
−10.6 (95%
CI −15.4 to
−5.9)
Un-
certain −12.8
(95%CI−18.
4 to −7.3)
In-
formed−17.3
(95%CI−22.
6 to −12.0) if
administered
during consult
−6.6 (95%CI
−14.3 to −1.
1) if adminis-
tered prior to
consult
Values clarity
−8.5
(95% CI−15.
7 to −1.3)
Support −9.4
(95%CI−14.
8 to −3.9)
Effective deci-
sion −10.0
(95%CI−15.
0 to −5.0)
CI: confidence interval; DA: decision aid; DCS: decisional conflict scale; IVF: in vitro fertilisation; SD: standard deviation.
Table 6. Decisional Conflict Score - low literacy version
Study Scale used Timing Ndecision aid Decision aid -
mean
N comparison Comparison -
mean
Notes
Fraenkel 2012 Informed Immediately
post
69 13.0 66 24.8 P = 0.01
Values Immediately
post
69 6.4 66 21.0 P <.001
Smith 2010 Total DCS 2 week follow-
up
357 13.63 (SD 20.
55)
173 14.91 (SD 18.
34)
P = 0.02
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Table 6. Decisional Conflict Score - low literacy version (Continued)
Taylor 2006 Total DCS Used 8 of 10
items only
1 month post
80 24.1% high 74 41.9% high Results were
dichotomized
(items re-
moved choos-
ing without
pressure from
others;
know what op-
tions are avail-
able to you)
Williams
2013
Total DCS 2 months post 153 27.5% 136 38.2% Significant de-
crease
for DA group
compared
to usual care in
the home con-
dition site
13 months
post
153 38.6% 136 31.6% No difference
DA: decision aid; DCS: decisional conflict scale; SD: standard deviation.
Table 7. Decisional Conflict Score - SURE test
Study Scale used Timing N decision
aid
Decision aid -
mean
N
comparison
Comparison -
mean
Notes
Stacey 2014a SURE tool
Item: ’Feels
sure about the
best choice’
Postinterven-
tion; prior to
surgical con-
sult
65 72.3% 66 80.3% No difference
’Knows the
benefits and
harms . . .’
Postinterven-
tion; prior to
surgical con-
sult
65 92.3% 66 66.7% No difference
’Clear about
which benefits
and harms . . .
’
Postinterven-
tion; prior to
surgical con-
sult
65 87.7% 66 74.2% No difference
’Has enough
support and
advice . . .’
Postinterven-
tion; prior to
surgical con-
sult
65 76.9% 66 77.3% No difference
282Decision aids for people facing health treatment or screening decisions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 7. Decisional Conflict Score - SURE test (Continued)
Total SURE
score
Postinterven-
tion; prior to
surgical con-
sult
65 69.2% 66 57.6% No difference
Table 8. Patient-clinician communication
Study Scale used Timing N decision
aid
Decision aid -
mean
N
comparison
Comparison -
mean
Notes
Fraenkel 2012 Discussed risk
of stroke
Immediately
post
69 71% 66 12% P < 0.001
Discussed risk
of major
bleeding
Immediately
post
69 69% 66 20% P < 0.001
Hanson 2011 Discussed
feeding with
physician,
nurse clini-
cian, or physi-
cian’s assistant
3 months 126 46% 127 33% P = 0.04
Dis-
cussed feeding
with other
nursing home
staff
3 months 126 64% 127 71% P = 0.42
Hess 2012 (in
consult)
OPTION
scale
Analysis of the
consultation
using video-
recordings
101 Mean 26.6%
(95% CI 24.9
to 8.2)
103 Mean
7% (95% CI
5.9 to 8.1)
Signif-
icantly greater
in the inter-
vention arm
LeBlanc 2015
(in consult)
OPTION
scale
Analysis of the
consultation
using video-
recordings
25 Mean
57% (95% CI
50 to 64)
13 Mean
43% (95% CI
37 to 48)
P = 0.001
Lepore 2012 Discussed
PSA testing
with physician
postinterven-
tion
8 months
postinterven-
tion
215 15.8% 216 8.3% P < 0.001
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Table 8. Patient-clinician communication (Continued)
Montori 2011
(in consult)
OPTION
100-point
scale
Analysis of the
consultation
using video-
recorded con-
sultations
38 49.8 32 27.3 P < 0.001
Mullan 2009
(in consult)
OPTION
scale
Analysis of the
consultation
using video-
recorded con-
sultations
48 used deci-
sion aid
within consul-
tation
Mean 49.7%
(SD 17.74)
37 usual care Mean 27.7%
(SD 11.75)
MD 21.
8 (95% CI 13.
0 to 30.5) for
decision aid vs
usual care. All
but 2 of the
12 items sig-
nificantly
favoured the
decision aid
Sheridan2006 Dis-
cussed CHD
with doctor
Patient re-
ported Imme-
diately post
16/41 de-
cision aid pre-
consult
with summary
report to bring
to consult
- 8/34 usual
care
- Abso-
lute difference
16% (95% CI
−4 to 37)
Plan to reduce
CHD risk and
discussed with
doctor
Patient re-
ported Imme-
diately post
15/41 de-
cision aid pre-
consult
with summary
report to bring
to consult
- 8/34 usual
care
- Abso-
lute difference
13% (95% CI
−7 to 34).
Plan to reduce
CHD risk and
not discussed
with doctor
Patient re-
ported Imme-
diately post
37/41 de-
cision aid pre-
consult
with summary
report to bring
to consult
- 25/34 usual
care
- Abso-
lute difference
16% (95% CI
−1 to 33)
Sheridan2011 Had CHD
discussion
with provider
Patient
reported
Immediately
post
79 89% 78 58% Abso-
lute difference
31% (95% CI
15 to 45; P <
0.001)
Patient-raised
discussion
Patient
reported
Immediately
post
79 63% 78 35% Abso-
lute difference
28% (95% CI
9 to 45; P = 0.
02)
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Table 8. Patient-clinician communication (Continued)
Mod-
ified Health-
care Climate
Question-
naire: 1. “My
provider pro-
vided me with
choices and
options about
lowering
my chances of
heart disease”
Patient
reported
Immediately
post
79 91% 78 76% Abso-
lute difference
15% (95% CI
−0.1 to 31; P
= 0.02)
2.
“My provider
under-
stands how I
see things with
respect to low-
ering
my chances of
heart disease.”
Patient
reported
Immediately
post
79 95% 78 86% Abso-
lute difference
9% (95% CI
−7 to 25; P =
0.21)
3.
“My provider
conveyed con-
fidence in my
ability tomake
changes
regarding low-
ering
my chances of
heart disease”
patient
reported
Immediately
post
79 88% 78 77% Abso-
lute difference
11% (95% CI
−5 to 27; P =
0.15)
4.
“My provider
encour-
aged me to ask
questions”
Patient
reported
Immediately
post
79 78% 78 67% Abso-
lute difference
11% (95% CI
−4% to 27%;
P = 0.13)
5. “My
provider lis-
tened to how I
would like to
do things”
Patient
reported
Immediately
post
79 92% 78 71% Abso-
lute difference
21% (CI 95%
6 to 37; P < 0.
01)
6.
“My provider
tried to under-
Patient
reported
Immediately
79 84% 78 69% Abso-
lute difference
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Table 8. Patient-clinician communication (Continued)
standing how
I see things be-
fore suggest-
ing new
ways to lower
my chances of
heart disease.”
post 15% (CI 95%
−0.3 to 31; P
= 0.05)
Weymiller
2007 (in con-
sult)
OPTION
Scale
Analysis of the
consultation
using video-
recorded con-
sultations
1/2 used deci-
sion aid prior
to consult and
1/2
used it during
consult
- Usual care - Greater
patient partic-
ipation MD 4.
4 (95% CI 2.9
to 6.0) in deci-
sion aid com-
pared to usual
care
CHD: coronary heart disease;CI: confidence interval; DA: decision aid; DCS: decisional conflict scale; ICC: intraclass correlation
coefficient;MD: mean difference; OPTION scale: observing patient involvement scale; RR: risk ratio; SD: standard deviation
Table 9. Participation in decision making
Study Scale used Timing Ndecisionaid Decision aid -
mean
N
comparison
Comparison -
mean
Notes
Allen 2010 Control pref-
erences - pa-
tients choos-
ing active/col-
laborative de-
cision making
Postinterven-
tion
291 95% 334 92% No difference
Control pref-
erences did
not change
Postinterven-
tion
291 92% 334 87% No difference
Control pref-
er-
ences changed
to passive
Postinterven-
tion
291 3% 334 5% No difference
Control pref-
er-
ences changed
to active/ col-
laborative
Postinterven-
tion
291 3% 334 7% No difference
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Table 9. Participation in decision making (Continued)
Hamann
2006
COMRADE
used to mea-
sure patients’
perceived in-
volvement in
decisions
Postconsulta-
tion
49 79.5 (SD 18.
6)
76.8 (SD 20.
9)
58 69.7 (SD 20.
0)
73.5 (SD 19.
3)
Increased pa-
tient involve-
ment in deci-
sion aid group
postinterven-
tion compared
to usual care
at baseline. At
discharge
there was no
difference be-
tween groups
Hanson 2011 Surrogates
feeling some-
what or very
in-
volved in deci-
sion making
Postinterven-
tion
- 83% - 77% P = 0.18
Leighl 2011 Achieved de-
cision involve-
ment
Postinterven-
tion
- 32% - 35% No difference
Loh 2007 (in
consult)
Patients’ per-
ceived in-
volvement in
decision mak-
ing
Postconsulta-
tion
191 26.3 pre 28.0
post
96 24.5 pre
25.5 post
Im-
proved patient
participation
from baseline
to post expo-
sure to the de-
cision aid (P =
0.010) and in
comparison to
the usual care
group (P = 0.
003) but there
was no change
in the control
group for the
pre-post com-
parison
Rubel 2010 Adapted from
the
Control Pref-
erences Scale
Postinterven-
tion
- - - - The total
mean
scores were: 2.
74 (SD 1.25)
(N = 99) pre
and 2.83 (SD
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Table 9. Participation in decision making (Continued)
1.
16) (N = 199)
post, no statis-
tically signifi-
cant difference
Sheridan2011 Patient partic-
ipation:
’Any’
Immediately
post
79 79% 78 51% Abso-
lute difference
28% (95% CI
9 to 45; P = 0.
01)
’None’ Immediately
post
79 21% 78 49% Absolute dif-
ference−28%
(95% CI −45
to −9)
Van
Peperstraten
2010
Decision Eval-
uation scale
(15 item ques-
tionnaire) De-
cision control
subscale
Postconsulta-
tion
124 85 128 87.5 P = 0.33
DA: decision aid; SD: standard deviation.
Table 10. Proportion undecided
Study Scale used Timing N decisionaid Decision aid -
mean
N
comparison
Comparison -
mean
Notes
Kasper 2008 Single
item - ranging
from ’0 = com-
pletely unde-
cided’ to ’100
=made my de-
cision’
- - - - - No difference
Sawka 2012 Answer “I
don’t know” to
question “I fa-
vor taking ad-
juvant
radioactive io-
dine”
Im-
mediately post
- treatment
preference
37 10.8% 37 21.6% -
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Table 10. Proportion undecided (Continued)
6.3 months
(mean) post -
actual decision
37 13.5% 37 8.1% -
Answer “I
don’t know” to
question “I fa-
vor not taking
adjuvant
radioactive io-
dine”
Im-
mediately post
- treatment
preference
37 43.2% 37 37.8% -
6.3 months
(mean) post -
actual decision
37 40.5% 37 51.4% -
DA: decision aid
Table 11. Satisfaction with the choice
Study Scale used Timing Ndecisionaid Decision aid -
mean
N
comparison
Comparison -
mean
Notes
Heller 2008 1-
item; pleased
with treat-
ment choice
1 month post-
surgery
62/66 - 55/67 - P = 0.03
Legare 2012
(in consult)
Single
question Lik-
ert scale to as-
sess the qual-
ity of the deci-
sion made (0 =
very low qual-
ity; 10 = very
high quality)
Immediately
post
162 8.54 (SD 1.
56)
159 8.53 (SD 1.
51)
No difference;
MD 0.0 (95%
CI −0.4 to 0.
4)
Leighl 2011 Satisfac-
tion with deci-
sion scale:
median
(range)
1
month postin-
tervention
107 22 (13-25) 100 21(15-25) No difference
Marteau 2010 Scale: ranging
from 1−7 and
standardized
out 100
4 weeks - 91.17 (SD 14) - 91.33 (SD 14.
50)
No difference
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Table 11. Satisfaction with the choice (Continued)
Schwartz
2009b
6-item 1, 6, 12
months
100 - 114 - Over-
all, no differ-
ence between
groups; deci-
sion aid led to
significantly
increased sat-
isfaction com-
pared to usual
care
among those
who were un-
decided at ran-
dom-
ization but not
among those
who hadmade
a decision be-
fore random-
ization; (only
graph in paper
with no raw
data)
Taylor 2006 Single item -
”Are you satis-
fied with your
decision about
prostate can-
cer testing?
1 month 80 79.7% 74 75.7% -
Trevena 2008 Satisfaction
with the deci-
sion
Immediately
post
134 - 137 - No difference
(P = 0.56)
Williams
2013
6-item Sat-
isfaction with
Decision Scale
Baseline - > 95% - > 95% -
DA: decision aid.
Table 12. Satisfaction with the decision-making process
Study Scale used Timing Ndecisionaid Decision aid -
mean
N
comparison
Comparison -
mean
Notes
Satisfaction with the decision-making process Satisfaction with
sion-making process
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Table 12. Satisfaction with the decision-making process (Continued)
Hess 2012 (in
consult)
Satisfac-
tion with de-
cision process
(0 for strongly
agree to 5 for
strongly
disagree)
- 101 - 103 - Patients in DA
group re-
ported greater
sat-
isfaction with
the DM pro-
cess (strongly
agree, 61%
DA vs 40%
usual care)
Vodermaier
2009
Satisfied with
process
1 week follow-
up
53 42 56 50 High satisfac-
tion with no
difference by
group
Satisfaction with participating in decision making Satisfaction with
ing in decision making
Kennedy
2002
Measured sat-
isfaction
with opportu-
nities to par-
ticipate in de-
cision making
using a single
item
- - - - - Com-
pared to usual
care, women
who re-
ceived the de-
cision aid fol-
lowed by
nurse
coaching were
significantly
more satisfied
with the op-
portunities to
participate in
decision mak-
ing (OR 1.5,
95% CI 1.1 to
2.0)
Satisfaction with the information provided Satisfaction with
mation provided
LeBlanc 2015
(in consult)
Amount of in-
formation was
just right
Postconsulta-
tion
29 25 (86%) 37 34 (92%) P = 0.69
Informa-
tion received
was clear
Postconsulta-
tion
27 17 (63%) 36 26 (72%) P = 0.43
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Table 12. Satisfaction with the decision-making process (Continued)
Informa-
tion received
was helpful
Postconsulta-
tion
28 21 (75%) 34 23 (68%) P = 0.53
Would recom-
mend method
to others
Postconsulta-
tion
28 24 (86%) 35 27 (77%) P = 0.52
Laupacis 2006 Satisfac-
tion with in-
formation re-
ceived sub-
scale 4-item (0
to 100; low to
high)
Average 10
days
54 76 (15.5 SD) 56 59 (23.3 SD) P = 0.001
Montori 2011
(in consult)
(7 point
scales)
Participants’
satisfaction
with knowl-
edge transfer
• Amount
of
information
• Clarity
of
information
• Helpfulness
of the
information
• Would
want other
decisions
• Recommend
to others
Postinterven-
tion
49 6.6
6
6
6.1
6.4
46 6.3
6
5.8
5.8
6.2
P = 0.798
P = 0.296
P = 0.624
P = 0.248
P = 0.435
Clinicians’ sat-
isfaction with
knowledge
transfer
• Helpfulness
of the
information
• Would
want other
Postinterven-
tion
39 5.8
6.1
5.9
33 5.2
4.9
4.8
P = 0.006
P < 0.001
P < 0.001
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Table 12. Satisfaction with the decision-making process (Continued)
decisions
• Recommend
to others
Oakley 2006 Satisfaction
with informa-
tion about
medicines
4 months post 16 10.4 (SD 2.9) 17 10.1 (SD 2.2) No difference
Satisfaction with the clinician Satisfaction with
cian
Laupacis 2006 Satisfac-
tionwith prac-
titioner treat-
ment during
decision pro-
cess sub-
scale 4-item (0
to 100; low to
high)
Average 10
days
54 69 (25.3 SD) 56 54 (26.7 SD) P = 0.004
Miller 2005 Sat-
isfaction with
cancer infor-
mation service
1-item (1 to 5;
low to high)
2 weeks - 4.37 (0.84
SD)
- 4.38 (0.86
SD)
No difference
6 months - 4.51 (0.75
SD)
- 4.51 (0.64
SD)
No difference
Vodermaier
2009 • Physician
helped me
understand
• Physician
understood
important to
me
• Physician
answered
questions
• Satisfied
with
involvement
• Satisfied
with
physician’s
involvement
1 week follow-
up
53 49 (92.5%)
47
47
44
36
56 53 (94.6%)
50
51
45
36
High satisfac-
tion with no
difference by
group
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DA: decision aid; SD: standard deviation.
Table 13. Preparation for decision making
Study Scale used Timing Ndecisionaid Decision aid -
mean
N
comparison
Comparison -
mean
Notes
Fraenkel 2007 Prepa-
ration for De-
cision Making
Scale
Pre-
consultation
43 35 (median) 40 20.5 (median) P < 0.001
Stacey 2014a Prepa-
ration for De-
cision Making
Scale item (5-
point scale
from: 1 not at
all to 5 a great
deal)
’Help
recognize de-
cision to be
made’
Postinterven-
tion; pre-con-
sultation
66 4.12 (SD 1.
21)
64 3.78 (SD 1.
25)
No difference
Prepa-
ration for De-
cision Making
Scale item
’Help know
decision de-
pends on what
matters most’
Postinterven-
tion; pre-con-
sultation
66 4.48 (SD 0.
85)
64 4.14 (SD 1.
10)
No difference
Prepa-
ration for De-
cision Making
Scale item
’Help think
about how in-
volved
you want to be
in decision’
Postinterven-
tion; pre-con-
sultation
66 4.48 (SD 0.
81)
64 4.25 (SD 1.
05)
No difference
Prepa-
ration for De-
cision Making
Scale item
’Prepare you
Postinterven-
tion; pre-con-
sultation
66 4.36 (SD 0.
91)
64 4.23 (SD 1.
04)
No difference
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